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Approximately	   50%	   of	   Acute	   Myeloid	   Leukaemia	   (AML)	   patients	   relapse	   within	   5	   years	   of	   diagnosis.	  
Allogeneic	  haematopoietic	  stem	  cell	   transplantation	   (HSCT)	  has	  curative	  potential,	  partly	  mediated	  by	  a	  
Graft-­‐versus-­‐Leukaemia	   (GvL)	   effect.	   GvL	   activity	  may	   be	   boosted	   by	   donor	   lymphocyte	   infusions	   (DLI)	  
after	   HSCT,	   given	   pre-­‐emptively	   (pDLI),	   to	   prevent	   relapse	   in	   mixed	   donor	   chimeric	   recipients,	   or	  
therapeutically	  (tDLI)	  following	  disease	  recurrence.	  	  Few	  publications	  report	  efficacy	  of	  these	  approaches,	  
therefore	   a	   retrospective	   analysis	   of	   outcomes	   after	   DLI	   at	   our	   institution,	   following	   lymphodepleted,	  
reduced	   intensity	   conditioned	   HSCT	   for	   AML/myelodysplastic	   syndromes	   (MDS),	   was	   performed.	  
Encouraging	  estimated	  5-­‐year	  overall	  survival	  rates	  following	  DLI	  of	  80%	  for	  pDLI	  recipients	  and	  40%	  for	  
tDLI	   recipients	  were	   observed.	   Incidence	   of	   GvHD	  was	   only	  moderate,	   suggesting	   delayed	   add-­‐back	   of	  
immune	  cells	  can	  boost	  GvL	  reactions	  in	  AML/MDS	  patients	  without	  excessive	  toxicity.	  However,	  despite	  
association	  of	  DLI	  with	  reduced	  relapse,	  leukaemia	  recurrence	  in	  a	  proportion	  of	  patients	  highlights	  that	  
GvL	  activity	  is	  neither	  guaranteed	  nor	  universally	  sustained.	  
Two	   forms	   of	   vaccination	   are	   described	   in	   this	   thesis,	   aiming	   to	   enhance	   priming	   and	   activity	   of	  
leukaemia-­‐reactive	  T-­‐cells.	  Both	  offer	  broad	  applicability	  across	  all	  human	  leucocyte	  antigen	  (HLA)-­‐types.	  
T-­‐cell	   responses	   to	   peptide	   vaccinations	   targeting	   the	   leukaemia-­‐associated	   antigen	   Wilms’	   Tumour	  
protein	  (WT1)	  were	  enhanced	  by	  exploration	  of	  novel	  adjuvants	  for	  induction	  of	  cell-­‐mediated	  immunity.	  
Vaccinations	  comprising	  these	  adjuvants	  and	  single	  peptides	  or	  overlapping	  peptides	  spanning	  the	  whole	  
WT1	  protein,	  induced	  functional	  T-­‐cell	  responses	  (antigen-­‐specific	  in	  vivo	  cytolytic	  activity	  and	  interferon-­‐
gamma	  production)	   in	   C57BL/6	  mice.	   Secondly,	   autologous	   AML	   blasts,	   genetically	  modified	   to	   express	  
the	  immunostimulatory	  molecules	  CD80	  and	  IL-­‐2,	  were	  co-­‐administered	  as	  a	  vaccine	  with	  tDLI	  in	  a	  Phase	  I	  
clinical	   trial.	   Preliminary	   data	   supporting	   safety	   of	   this	   approach	   and	   possible	   induction	   of	   immune	  
responses	   to	   vaccination,	   evidenced	   by	   development	   of	   a	   delayed-­‐type	   hypersensitivity	   reaction	   in	   a	  
subject,	  are	  presented.	  
This	  thesis	  describes	  broad-­‐based	  immunotherapeutic	  strategies	  in	  AML	  patients	  for	  prevention	  of	  disease	  
recurrence	  by	  enhancement	  of	  anti-­‐leukaemic	  immune	  responses.	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List	  of	  Abbreviations	  
1-­‐MT	   	   1-­‐methyl	  trytophan	  
ABL1	   	   Abelson	  murine	  leukemia	  viral	  oncogene	  homolog	  1	  
ACV	   	   AML	  Cell	  Vaccine	  
Ag	   	   Antigen	  
ALC	   	   Absolute	  Lymphocyte	  Count	  
ALL	   	   Acute	  Lymphoblastic	  Leukaemia	  
AML	   	   Acute	  Myeloid	  Leukaemia	  
ANOVA	   	   Analysis	  of	  variance	  between	  groups	  
APC	   	   Allophycocyanin	  
APC	   	   Antigen	  Presenting	  Cell	  	  
ANN	   	   Artificial	  Neural	  Network	  
ASC	   	   Apoptosis-­‐associated	  speck-­‐like	  protein	  containing	  a	  CARD	  	  
(caspase-­‐recruitment	  domain)	  
AST	   	   Aspartate	  aminotransferase	  
ATCC	  	   	   American	  Type	  Culture	  Collection	  
ATG	   	   Anti-­‐thymocyte	  Globulin	  
ATP	   	   Adenosine	  triphosphate	  
BAGE	   	   B-­‐Melanoma	  antigen	  
BCG-­‐CWS	   Bacille	  Calmette	  Guerin	  –	  Cell	  Wall	  Skeleton	  
BCL-­‐2	   	   B-­‐Cell	  Lymphoma	  2	  
BD	   	   Beckton	  Dickinson	  
BLCL	   	   B-­‐lymphoblastoid	  Cell	  Line	  
BM	   	   Bone	  Marrow	  
BMI1	   	   B	  lymphoma	  Mo-­‐MLV	  insertion	  region	  1	  homolog	  
BSU	   	   Biological	  Services	  Unit	  
CAR	   	   Chimeric	  Antigen	  Receptor	  
CASAC	   	   Combined	  Adjuvants	  for	  Synergistic	  Activation	  of	  Cellular	  	  
Immunity	  
CCR/CXCR	   Chemokine	  receptor	  
CD	   	   Cluster	  of	  differentiation	  
CD40L	   	   CD40	  Ligand	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cDNA	   	   Complementary	  deoxyribonucleic	  acid	  
CFA	   	   Complete	  Freund’s	  Adjuvant	  
CFSE	  	   	   Carboxyfluorescein	  diacetate,	  succinimidyl	  ester	  
CI	   	   Confidence	  Interval	  
CLIP	   	   Class	  II-­‐associated	  invariant	  chain	  self-­‐peptide	  
CLS	   	   Capillary	  Leak	  Syndrome	  
CML	   	   Chronic	  Myeloid	  Leukaemia	  
CMV	   	   Cytomegalovirus	  
CpG	  ODN	   2’-­‐deoxyribocytidine-­‐phosphate-­‐guanosine	  oligodeoxynucleotides	  
cppt	   	   Central	  polypurine	  tract	  
CR	   	   Complete	  Remission	  
CRS	   	   Cytokine	  release	  syndrome	  
cts	   	   Central	  termination	  sequence	  
CTCAE	   	   Common	  Toxicity	  Criteria	  of	  Adverse	  Events	  
CTL	   	   Cytotoxic	  T-­‐Lymphocyte	  
CTLA-­‐4	   	   Cytotoxic	  T-­‐Lymphocyte	  Antigen	  4	  
DEAE	  	   	   Diethylaminoethyl	  	  
DC	   	   Dendritic	  cell	  (pDC,	  plasmacytoid;	  cDC,	  conventional)	  
dH20	   	   Distilled	  water	  	  
DLI	   	   Donor	  Lymphocyte	  Infusion	  
DLT	   	   Dose-­‐limiting	  toxicity	  
DMEM	   	   Dulbecco’s	  Modified	  Eagle’s	  Medium	  
DMSO	   	   Dimethyl	  Sulfoxide	  
DNAM1	   	   DNAX	  accessory	  Molecule-­‐1	  
DTH	   	   Delayed	  Type	  Hypersensitivity	  
EBV	   	   Epstein-­‐Barr	  Virus	  
ECOG	   	   Eastern	  Cooperative	  Oncology	  Group	  
EDTA	   	   Ethylenediaminetetraacetic	  acid	  
eGFR	   	   Estimated	  Glomerular	  Filtration	  Rate	  
EGR	   	   Early	  Growth	  Response	  Receptor	  
eh/pr	   	   Enhancer/promoter	  
ELISA	   	   Enzyme-­‐linked	  Immunosorbent	  Assay	  
ELISpot	   	   Enzyme-­‐linked	  Immunosorbent	  spot	  assay	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ER	   	   Endoplasmic	  Reticulum	  
ERAAP	   	   ER	  aminopeptidase	  associated	  with	  antigen	  presentation	  
FACS	   	   Fluorescence-­‐activated	  cell	  sorting	  
FBC	   	   Fludarabine-­‐Busulphan-­‐Campath	  (Alemtuzumab)	  	  
FBL-­‐3	   	   Friend’s	  Leukaemia	  Virus-­‐induced	  Leukaemia	  
FBS	   	   Fetal	  Bovine	  Serum	  
FDC	   	   Full	  donor	  chimerism	  
FITC	   	   Fluorescein	  isothiocyanate	  
Flt-­‐3	   	   Fms-­‐like	  tyrosine	  kinase	  receptor-­‐3	  
FoxP3	   	   Forkhead	  box	  P3	  
FSC	   	   Forward	  scatter	  
FU	   	   Follow-­‐up	  
G250	   	   Renal	  Cell	  Carcinoma-­‐Associated	  Antigen	  G250,	  also	  known	  as	  Carbonic	  Anhydrase	  IX	  
GAG	   	   Group-­‐specific	  antigen	  
gDNA	   	   Genomic	  DNA	  
GITRL	   	   Glucocorticoid-­‐induced-­‐TNFR-­‐related	  protein	  ligand	  
GM-­‐CSF	   	   Granulocyte-­‐Macrophage	  Colony-­‐Stimulating	  Factor	  
GMP	   	   Good	  Manufacturing	  Practice	  
GvH	   	   Graft-­‐versus-­‐Host	  
GvHD	   	   Graft-­‐versus-­‐Host	  Disease	  (aGvHD,	  acute	  GvHD;	  cGvHD,	  chronic	  GvHD)	  
GvL	   	   Graft	  versus	  Leukaemia	  
h-­‐TERT	   	   Human	  Telomerase	  Reverse	  Transcriptase	  
HAGE	   	   Helicase	  antigen	  
her2	   	   Human	  Epidermal	  Growth	  Factor	  Receptor	  2	  
HLA	   	   Human	  leukocyte	  Antigen	  
HOX	   	   Homeobox	  
HSCT	   	   Haematopoietic	  Stem	  Cell	  Transplant/Transplantation	  
HPV	   	   Human	  Papilloma	  Virus	  
HTLV	   	   Human	  T-­‐lymphotropic	  Virus	  	  
HTS	   	   High-­‐throughput	  sampler	  	  
ICAM-­‐1	   	   Intercellular	  Adhesion	  Molecule-­‐1	  
i.d.	  	   	   Intra-­‐dermal	  
IDO	   	   Indoleamine	  2,3	  dioxygenase	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IEDB	   	   Immune	  epitope	  database	  
IFA	   	   Incomplete	  Freund’s	  Adjuvant	  
IFN	   	   Interferon	  
Ig	   	   Immunoglobulin	  
IGF®	   	   Insulin-­‐like	  Growth	  Factor	  (Receptor)	  
IκB	  	   	   inhibitor	  of	  NF-­‐κB	  
IL	   	   Interleukin	  
IMPD	  	   	   Investigational	  Medicinal	  Product	  Dossier	  	  
i.p.	   	   intraperitoneal	  
IPAF	   	   ICE-­‐protease-­‐activating	  factor	  
IRF	   	   IFN-­‐regulatory	  factor	  
i.v.	   	   Intravenous	  
KIR	   	   Killer-­‐cell	  Immunoglobulin-­‐like	  Receptor	  
KLH	   	   Keyhole	  Limpet	  Haemocyanin	  
LAA	   	   Leukaemia	  Associated	  Antigen	  
LCMV	   	   Lymphochoriomeningitis	  Virus	  
LPS	   	   Lipopolysaccharide	  
LSA	   	   Leukaemia-­‐specific	  antigen	  
LSC	   	   Leukaemic	  Stem	  Cell	  
LTR	   	   Long	  terminal	  repeat	  
LV_AML	  	   Lentiviral-­‐modified	  AML	  
MA	   	   Myeloablative	  
MAGE	   	   Melanoma-­‐associated	  Antigen	  
MAIMP	  	   	   Manufacturer’s	  Authorisation	  for	  Investigational	  Medicinal	  Products	  	  
MAP	   	   Mitogen	  activated	  protein	  
MCB	  	   	   Master	  Cell	  Bank	  	  
Mcl-­‐1	   	   Myeloid	  cell	  leukemia	  sequence	  1	  
MDA5	   	   Melanoma-­‐differentiation-­‐associated	  Gene	  5	  
MDC	   	   Mixed	  Donor	  Chimerism	  
MDS	   	   Myelodysplastic	  Syndrome	  
MDSC	   	   Myeloid	  Derived	  Suppressor	  Cells	  
MFI	   	   Mean	  fluorescence	  intensity	  
mHag	   	   Minor	  histocompatibility	  antigen	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MHC	   	   Major	  Histocompatibility	  Complex	  
MICA/B	   	   MHC	  Class	  I	  chain-­‐related	  gene	  A/B	  products	  
MNC	   	   Mononuclear	  cell	  
MOI	   	   Multiplicity	  of	  Infection	  
MPL	   	   Monophosphoryl	  Lipid	  A	  
MPN	   	   Myeloproliferative	  neoplasm	  
MPP11	   	   M-­‐phase	  phosphoprotein	  11	  
mRNA	   	   Messenger	  ribonucleic	  acid	  
MRD	   	   Minimal	  residual	  disease	  
MSC	   	   Mesenchymal	  Stem	  Cell	  
MTD	   	   Maximum	  Tolerated	  Dose	  	  
MUC1	   	   Mucin1	  
MyD88	   	   Myeloid	  differentiation	  primary-­‐response	  gene	  88	  
NALP	   	   NACHT-­‐,	  LRR-­‐	  and	  pyrin-­‐domain-­‐containing	  protein	  
NCI	   	   National	  Cancer	  Institute	  
NCR	   	   Natural	  Cytotoxicity	  Receptor	  
NCBI	   	   National	  Centre	  for	  Biotechnology	  Information	  
NF-­‐κB	   	   Nuclear	  Factor	  kappa	  B	  
NH4Cl	  	   	   Ammonium	  chloride	  
NK	   	   Natural	  Killer	  
NKG2D	   	   Natural	  killer	  group	  2,	  member	  D	  
NOD	   	   Non-­‐obese	  diabetic	  
NOD	   	   nucleotide-­‐binding	  oligomerization	  domain	  
NPM1	   	   Nucleophosmin	  1	  
NRM	   	   Non-­‐relapse	  mortality	  
NUP214	  	   Nucleoporin	  214	  kDa	  
ODN	   	   Oligodeoxynucleotide	  
OS	   	   Overall	  Survival	  
O/W	   	   Oil-­‐in-­‐water	  
OFA-­‐iLRP	   Oncofetal	  antigen/immature	  laminin	  receptor	  protein	  
OVA	   	   Ovalbumin	  
OVA-­‐ISQ	  	   ISQAVHAAHAEINEAGR	  
OVA-­‐SIINF	   SIINFEKL	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PADRE	   	   Pan-­‐HLA-­‐DR-­‐epitope	  
PAMP	   	   Pathogen	  associated	  molecular	  pattern	  
PB	   	   Peripheral	  blood	  
PBL	   	   Peripheral	  Blood	  Lymphocyte	  
PBMC	   	   Peripheral	  Blood	  Mononuclear	  Cell	  
PBS	   	   Phosphate	  Buffered	  Saline	  
PCR	   	   Polymerase	  Chain	  Reaction	  
PD1/PDL1	   Programmed	  Death	  receptor	  1/Programmed	  Death	  Receptor	  1	  	  
Ligand	  
PDGF(R)	  	   Platelet-­‐derived	  Growth	  Factor	  (Receptor)	  
pDLI	   	   Pre-­‐emptive	  donor	  lymphocyte	  infusions	  
PE	   	   Phycoerythin	  
PerCP	   	   Peridinin-­‐chlorophyll-­‐protein	  complex	  
PFS	   	   Progression-­‐free	  survival	  
PI	   	   Principal	  investigator	  
PI3	   	   Phosphoinositide-­‐3	  kinase	  
PMA	  	   	   Phorbol	  12-­‐myristate	  13-­‐acetate	  
pMHC	   	   peptide/MHC	  
PML	   	   promyelocytic	  leukaemia	  
Poly	  I:C	   	   Polyinosinic–polycytidylic	  acid	  
PR1	   	   Proteinase-­‐3	  (PR3)	  derived	  antigen	  
PRAME	   	   Preferentially	  expressed	  antigen	  in	  melanoma	  
PRR	   	   Pattern	  recognition	  receptor	  
qPCR	   	   Quantitative	  PCR	  
RA(RS)	   	   Refractory	  anaemia	  (with	  ring	  sideroblasts)	  
RAEB	   	   Refractory	  anaemia	  with	  excess	  of	  blasts	  
RAG2	   	   Recombinase	  Activating	  Gene	  2	  
RARA	   	   Retinoic	  acid	  receptor	  alpha	  
RBC	   	   Red	  Blood	  Cell	  
RCL	   	   Replication	  Competent	  Lentivirus	  
REV	   	   Regulator	  of	  virion	  expression	  
RHAMM	  	   Hyaluronan-­‐mediated	  motility	  receptor	  
rHu	   	   Recombinant	  Human	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RIC	   	   Reduced	  Intensity	  Conditioning	  
RICK	   	   Receptor-­‐interacting	  serine/threonine	  kinase	  	  
RIG-­‐I	   	   Retinoic-­‐acid-­‐inducible	  gene	  I	  
RRE	   	   Rev	  response	  element	  
RT	   	   Reverse	  transcriptase	  
RT-­‐qPCR	  	   Real-­‐time	  qPCR	  
RPM	   	   Revolutions	  per	  minute	  
RPMI	   	   Roswell	  Park	  Memorial	  Institute	  
RRE	   	   Rev-­‐responsive	  element	  
RS	   	   Ring	  sideroblasts	  
RUNX1	   	   Runt-­‐related	  transcription	  factor	  1	  
RUNX1T1	   Runt-­‐related	  transcription	  factor	  1;	  translocated	  to	  1,	  (cyclin	  D-­‐related)	  
s.c.	   	   Sub-­‐cutaneous	  
SCF	   	   Stem	  Cell	  Factor	  
SCID	   	   Severe	  Combined	  Immunodeficiency	  
SD	   	   Standard	  deviation	  
SFFV	   	   Spleen	  focus-­‐forming	  virus	  
SLP	   	   Synthetic	  Long	  Peptide	  
SSC	   	   Side	  scatter	  
STR	   	   Short	  tandem	  repeat	  
SYK	   	   Spleen	  tyrosine	  kinase	  
TAA	   	   Tumour-­‐associated	  antigen	  
TAP	   	   Transporter	  associated	  with	  antigen	  processing	  
TBK1	   	   TANK-­‐binding	  kinase	  1	  
TCD	   	   T-­‐cell	  depletion	  
TCR	   	   T-­‐cell	  Receptor	  
tDLI	   	   Therapeutic	  donor	  lymphocyte	  infusions	  
TGF	   	   Transforming	  Growth	  Factor	  
Th	   	   T-­‐helper	  
TIR	   	   Toll/IL-­‐1R	  domain	  
TIRAP	   	   TIR	  domain-­‐containing	  adaptor	  protein	  
TIL	   	   Tumour-­‐infiltrating	  lymphocyte	  
TLR	   	   Toll-­‐like	  Receptor	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TNF	   	   Tumour	  Necrosis	  Factor	  
TRAIL	   	   TNF-­‐related	  apoptosis	  inducing	  ligand	  
TRAM	   	   TRIF-­‐related	  adaptor	  molecule	  	  
Treg	   	   Regulatory	  T-­‐cell	  
TRIF	   	   TIR-­‐domain-­‐containing	  adaptor	  protein	  inducing	  IFNβ	  	  
TRP-­‐2	   	   Tyrosinase	  protein	  2	  
UPN	   	   Unique	  patient	  number	  
v/v	   	   Volume	  per	  volume	   	   	  
VIN	   	   Vulval	  intra-­‐epithelial	  neoplasia	  
VSV-­‐G	   	   Vesicular	  stomatitis	  virus	  glycoprotein	  	  
VUD	   	   Volunteer	  unrelated	  donor	  
WCBP	  	   	   Women	  of	  childbearing	  potential	  	  
W/T	   	   Wild	  type	  
WT1	   	   Wilms’	  Tumour	  1	  	  
WT1-­‐PGC	   PGCNKRYFKLSHLQMHSRKHTG	  
WT1-­‐RMF	   RMFPNAPYL	  




Chapter	  1 Introduction	  
1.1 Current	  outcomes	  for	  patients	  diagnosed	  with	  Acute	  Myeloid	  Leukaemia	  
Acute	   Myeloid	   Leukaemia	   (AML)	   is	   a	   haematological	   neoplasm	   with	   an	   age-­‐adjusted	   incidence	   of	  
approximately	  3	  per	  100,000	  persons/year,	  the	  median	  age	  at	  diagnosis	  being	  65.	  It	  is	  characterised	  by	  an	  
abnormal	   clonal	   proliferation	   of	   primitive	   myeloid	   cells1.	   Typical	   morphologic	   appearances,	  
immunophenotypic	  marker	   expression	  and	   recurrent	   genetic	   changes	   allow	   the	  disease	   to	  be	   classified	  
into	  defined	  subtypes	  (Appendix	  A)1.	  	  
	  
Currently,	   therapy	   for	   AML	   is	   limited	   to	   chemotherapy	   to	   induce	   remission,	   followed	   by	   further	  
chemotherapy	  or	  allogeneic	  haematopoietic	  stem	  cell	  transplantation	  (HSCT)	  as	  consolidation	  to	  prevent	  
relapse.	   Prognostic	   variables,	   such	   as	   increasing	   age,	   history	   of	   antecedent	   bone	  marrow	   disorder	   and	  
presence	   (as	  well	   as	   number)	   of	   specific	   karyotypic	   and	  molecular	   abnormalities,	   allow	   stratification	  of	  
patients	   according	   to	   the	   risk	   of	   relapse2.	   Large	   randomised	   controlled	   studies	   have	   identified	   those	  
patients	  with	  good	  cytogenetic/molecular	   risk	  profiles	   suitable	   for	   treatment	  with	  chemotherapy	  alone,	  
versus	  those	  with	  adverse	  cytogenetic/molecular	  risk	  profiles	  for	  whom	  allogeneic	  HSCT	  as	  consolidation	  
offers	   the	   only	   chance	   of	   long-­‐term	   cure2.	   The	   greatest	   difficulty	   in	   deciding	   the	   optimal	   consolidation	  
strategy	   after	   first	   remission	   applies	   to	   the	   large	   population	   of	   patients	  with	   normal	   karyotype	  AML2,3.	  
Recent	  advances	   in	  understanding	   the	  prognostic	   implications	  of	  AML-­‐associated	  genetic	  aberrations	   in	  
the	   context	   of	   normal	   karyotype	   AML,	   such	   as	   mutations	   in	   nucleophosmin	   1	   (NPM1)	   and	   FMS-­‐like	  
tyrosine	  kinase	  3	  (Flt-­‐3)	  genes,	  have	  improved	  risk	  stratification	  in	  these	  patients4.	  Prognostication	  for	  this	  
cohort	  of	  patients	  with	  heterogeneous	  outcomes	   is	   likely	   to	   improve	  as	  genomic	   sequencing	  data	   from	  
large	  cohorts	  of	  AML	  patients,	  combining	  details	  of	  additional	  gene	  mutations,	  accumulates5.	  
	  
In	  recent	  decades	  there	  has	  been	  an	  overall	  improvement	  in	  survival	  principally	  for	  patients	  under	  the	  age	  
of	  60	  at	  diagnosis	  of	  AML	  (see	  Figure	  1-­‐1)2,6.	  Better	  outcomes	  have	  been	  attributed	  to	  superior	  supportive	  
care	  strategies,	  such	  as	  infection	  prophylaxis,	  and	  the	  selected	  use	  of	  allogeneic	  haematopoietic	  stem	  cell	  
transplantation	  (HSCT)	  in	  appropriate	  patients.	  By	  contrast,	  there	  have	  been	  few	  advances	  in	  the	  cytotoxic	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agents	   used	   for	   remission	   induction	   and	   consolidation,	  which	   have	   remained	   largely	   unchanged	  during	  





















Figure	  1-­‐1	  Changes	  in	  survival	  for	  AML	  patients	  aged	  15-­‐59	  years	  (A)	  or	  over	  60	  (B)	  at	  diagnosis	  over	  the	  
last	  four	  decades.	  Taken	  from	  Burnett	  et	  al,6.	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In	   spite	   of	   these	   improvements,	   while	   up	   to	   80%	   of	   AML	   patients	   may	   enter	   a	   period	   of	   remission	  
following	  initial	  induction	  chemotherapy,	  the	  risk	  of	  relapse	  overall	  is	  greater	  than	  50%	  within	  the	  first	  2	  
years3,7,8.	   The	   poorest	   outcomes	   are	   observed	   in	   the	   large	   proportion	   of	   patients	   aged	   over	   60	   at	  
diagnosis	  of	  AML,	  with	  less	  than	  a	  quarter	  of	  these	  patients	  surviving	  to	  5	  years	  (Figure	  1-­‐1)6.	  	  This	  adverse	  
prognosis	  reflects	  both	  disease	  biology	  (higher	  incidence	  of	  adverse	  prognostic	  factors	   in	  older	  patients)	  
and	  also	   increased	  comorbidity,	   limiting	  the	   intensity	  (and	  efficacy)	  of	  cytotoxic	  agents	  used9.	  Given	  the	  
higher	  risk	  of	  relapse	  in	  older	  patients,	  HSCT	  offers	  the	  best	  chance	  of	  cure	  for	  this	  group.	  However,	  the	  
organ	   toxicity	   of	   standard	  myeloablative	   (MA)	   transplant	   conditioning	   regimens,	   arising	   from	   both	   the	  
cytotoxic	  drugs	  and	  early,	  severe	  Graft-­‐versus-­‐Host	  (GvH)	  reactions,	  has	  been	  associated	  with	  prohibitive	  
non-­‐relapse	   mortality	   (NRM)	   in	   these	   patients.	   Demonstration	   of	   the	   dominant	   role	   that	   donor	  
lymphocytes	   play	   in	   mediating	   a	   graft-­‐versus-­‐leukaemic	   (GvL)	   effect	   that	   maintains	   remissions	   post-­‐
HSCT10-­‐12	   led	  to	  the	  development	  of	  reduced	  intensity	  conditioning	  (RIC)	  regimens.	  These	  regimens	  have	  
an	  acceptable	  NRM	  in	  older	  patients	  (approximately	  20-­‐30%	  at	  5	  years)	  due	  to	  the	  less	  cytotoxic	  and	  more	  
immunosuppressive	  nature	  of	  the	  agents	  used	  for	  conditioning,	  reducing	  organ	  damage	  and	  incidence	  of	  
severe	  acute	  graft-­‐versus-­‐host	  disease	  (GvHD)13,14.	  RIC	  aims	  to	  exploit	  GvL	  activity	  due	  to	  allorecognition	  
of	   tumour	   cells	   by	   donor-­‐derived	   lymphocytes	   as	   the	   principal	  means	   of	   disease	   control.	   Furthermore,	  
HSCT	  has	  the	  potential	  to	  serve	  as	  an	  immunotherapeutic	  platform,	  whereby	  the	  GvL	  effect	  arising	  from	  
the	  graft	  can	  be	  subsequently	  enhanced,	   for	  example	  by	  add-­‐back	  of	  donor	   lymphocytes.	  However,	   the	  
weaker	  cytotoxicity	  of	  RIC	  regimens,	  combined	  with	  delayed	  immune	  reconstitution	  observed	  in	  athymic	  
older	  HSCT	  recipients	  has	  been	  associated	  with	  a	  persisting	  risk	  of	  relapse	  in	  retrospective	  comparisons15-­‐
17.	   The	   additional	   use	   of	   T-­‐cell	   depletion	   (TCD)	   in	   conditioning	   regimens	   to	   prevent	   graft	   rejection	   and	  
attenuate	  GvHD	  may	  also	  hinder	  immune	  reconstitution,	  with	  an	  attendant	  risk	  of	  relapse18,19.	  Once	  AML	  
recurs	  post-­‐HSCT,	  salvage	  using	  chemotherapy	  alone	  or	  in	  combination	  with	  donor	  lymphocyte	  infusions	  
(DLI)	  has	  been	  associated	  with	  dismal	  rates	  of	  overall	  survival	  approximating	  20%	  or	  less	  at	  2	  years20,21.	  
	  
Clearly	   newer	   treatment	   strategies	   to	   advance	   the	   therapy	   of	   AML	   are	   desperately	   required.	   Despite	  
many	  years	  of	  research,	  front-­‐line	  cytotoxics	  used	  to	  treat	  AML	  have	  not	  changed,	  highlighting	  the	  limited	  
impact	  of	  novel	  agents2,6.	  Immunotherapeutic	  approaches	  to	  the	  treatment	  of	  AML	  are	  highly	  attractive,	  
offering	   the	   possibility	   of	   targeted	   eradication	   of	   leukaemic	   cells	   not	   only	   in	   HSCT	   patients	   but	   also	   in	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those	  patients	  deemed	  unsuitable	   for	  HSCT22,23.	  Adjuvant	   immunotherapy	  may	  be	  one	  means	  to	   induce	  
and	   maintain	   GvL	   responses	   after	   stem	   cell	   transplantation24,25.	   The	   following	   sections	   describe	   the	  
evidence	   for	   immune	  mediated-­‐eradication	  of	  AML,	   providing	   a	   rationale	   for	  AML	   immunotherapy	   and	  
discussing	   barriers	   to	   the	   success	   of	   such	   treatment.	   Active	   (immunisation)	   and	   passive	   (adoptive	   cell	  
transfer,	  e.g.	  DLI)	  strategies	  promoting	  anti-­‐leukaemic	   immune	  responses	  within	  patients	  are	  described.	  
Vaccination	   approaches	   receive	   a	   particular	   emphasis	   as	   a	   background	   to	   the	   presented	   work	   in	   this	  
thesis	  evaluating	  peptide	  and	  whole	  cell	  immunisation	  targeting	  AML.	  	  
	  
1.2 Evidence	  for	  immune	  surveillance	  of	  AML	  
Scientists	  such	  as	  Ehrlich,	  Burnet	  and	  Thomas	  originally	  hypothesised	  that	  the	  immune	  system	  is	  capable	  
of	   recognising	   and	   specifically	   eliminating	   tumour	   cells	   arising	  within	   an	   organism.	   They	   proposed	   that	  
immune	   cells	   constantly	   survey	   for	   malignant	   cells	   and	   act	   to	   either	   repress	   their	   growth	   or	   induce	  
death26.	   The	   development	   of	   sophisticated	   immunodeficient	   mouse	   models	   delineated	   relative	  
contributions	   of	   different	   components	   of	   the	   immune	   system	   to	   this	   process.	   Mice	   lacking	   interferon	  
gamma	   (IFNγ)	   responsiveness	   (due	   to	   absent/non-­‐functional	   IFNγ	   receptor	   or	   downstream	   signalling	  
components)	  or	  deficient	   in	  B,	  T	  and	  NKT-­‐cells	   (recombination	  activating	  gene	  2	   [RAG2]	  knockout	  mice)	  
demonstrate	  greater	  susceptibility	  to	  spontaneous	  and	  induced	  solid	  tumours26-­‐29.	  Other	  cell	  types,	  such	  
as	  γδ	  T-­‐cells30,31	  and	  Natural	  Killer	  (NK	  cells)32,	  and	  molecules,	  such	  as	  perforin33,	  tumour	  necrosis	  factor	  
(TNF)-­‐related	   apoptosis	   inducing	   ligand	   (TRAIL)34,	   have	   all	   been	   shown	   to	   restrict	   tumour	   growth	  when	  
present	  and	  functional.	  Similarly,	  in	  human	  pathology,	  immunosuppressive	  therapy	  or	  inherited	  defects	  of	  
the	  immune	  system	  are	  associated	  with	  increased	  risk	  of	  malignancies28.	  
	  
In	   the	   specific	   setting	  of	  AML,	   several	   lines	  of	   evidence	   support	   the	   role	  of	   various	   components	  of	   the	  
immune	  system	  in	  surveillance	  and	  eradication	  of	  leukaemic	  blasts.	  Multivariate	  analysis	  has	  shown	  that	  
superior	  absolute	  lymphocyte	  count	  (ALC)	  recovery	  at	  specific	  time	  points	  post	  induction	  chemotherapy	  is	  
significantly	  associated	  with	   improved	  overall	  and	  leukaemia-­‐free	  survival	   in	  patients	  with	  AML	  or	  acute	  
lymphoblastic	   leukaemia	   (ALL)35,36.	   Furthermore,	   studies	   have	   demonstrated	   that	   NK-­‐37,38,	   T39-­‐cells	   and	  
more	  recently,	  NKT40	  and	  γδ	  T-­‐cells41	  isolated	  from	  patients	  in	  remission	  post	  chemotherapy	  for	  AML	  can	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lyse	  autologous	  primary	  blasts.	  The	  ability	  of	  DLI	   to	   induce	   remission	   in	  patients	  with	   recurrent	  chronic	  
myeloid	   leukaemia	  (CML)	  following	  allogeneic	  HSCT	  has	  provided	  some	  of	  the	  strongest	  evidence	  for	  an	  
immune-­‐mediated	   destruction	   of	   leukaemic	   cells	   in	   vivo10,11.	   In	   the	   context	   of	   fully	   Human	   Leukocyte	  
Antigen	   (HLA)-­‐matched	  allogeneic	  HSCT,	   these	  GvL	   reactions	  have	  been	  demonstrated	   to	   arise	   through	  
donor	   T-­‐cell	   allorecognition	   of	   epitopes	   from	   mismatched	   minor	   histocompatibility	   antigens	   (mHags),	  
presented	   in	   the	   context	   of	   major	   histocompatibility	   complex	   (MHC)	   molecules	   and	   showing	   higher	  
expression	   on	   leukaemic	   cells	   than	   healthy	   tissue.	   Responses	   against	  mismatched	  mHags	   expressed	   by	  
healthy	  recipient	  tissues	  may	  however	  result	  in	  unwanted	  GvHD42.	  	  
	  
Leukaemia-­‐specific	  T-­‐cell	  responses	  also	  occur	  in	  the	  autologous,	  non-­‐HSCT	  setting,	  whereby	  lymphocytes	  
recognise	   epitopes	   derived	   typically	   from	   self	   antigens	   showing	   aberrantly	   high	   expression	   in	   tumour	  
cells.	   Peptide	   elution	   studies	   to	   isolate	   epitopes	   bound	   to	   MHC	   molecules	   on	   tumour	   targets	   and	  
complementary	   deoxyribonucleic	   acid	   (cDNA)	   screening	   libraries	   produced	   from	   tumour	   cells	   provided	  
the	   initial	  means	  to	   identify	   immunogenic	   tumour-­‐associated	  antigens	   (TAAs)	   in	   the	  context	  of	   tumours	  
such	  as	  melanoma43.	  As	  knowledge	  of	  peptide/MHC	  (pMHC)	  binding	  and	  T-­‐cell	  receptor	  (TCR)	  recognition	  
has	   advanced,	   in	   silico	   prediction	   tools	   have	   accelerated	   the	   identification	   of	   immune	   epitopes	   from	   a	  
wide	  range	  of	  TAAs44.	  	  
A	  number	  of	  leukaemia-­‐associated	  antigens	  (LAAs)	  expressed	  by	  primary	  AML	  blasts	  are	  recognised	  (Table	  
1).	  Cytotoxic	   T	   lymphocytes	   (CTLs)	  have	  been	   isolated	   from	  AML	  patients	   and	  demonstrated	   in	   vitro	   to	  
respond	  to	  the	  specific	  LAA-­‐derived	  peptide	  in	  an	  MHC-­‐restricted	  manner,	  resulting	  in	  IFNγ	  production	  or	  
target	  cell	  lysis45,46.	  In	  addition,	  serological	  responses	  to	  LAAs	  have	  been	  detected	  in	  patients	  with	  myeloid	  
diseases	  whilst	  remaining	  undetectable	  in	  healthy	  volunteers,	  suggesting	  activation	  of	  B-­‐cells	  and	  helper	  
T-­‐cells46.	  	  Occasionally,	  uniquely	  expressed	  leukaemia-­‐specific	  antigens	  (LSA)	  may	  be	  the	  targets	  of	  T-­‐cell	  
responses.	   Examples	   include	   epitopes	   arising	   from	   fusion	   proteins	   such	   as	   RUNX1-­‐RUNX1T147,	   PML-­‐
RARA48	   or	   DEK-­‐NUP214 * 49	   resulting	   from	   specific	   gene	   translocations	   [t(8;21),	   t(15;17)	   and	   t(6;9)	  
respectively].	  The	  low	  frequency	  of	  these	  specific	  translocations	  within	  AML	  patients	  (5%,	  5-­‐8%	  and	  <2%	  
respectively)	  restricts	  their	  potential	  as	  therapeutic	  targets1.	  Mutations	  in	  Flt-­‐3	  and	  NPM1	  genes,	  in	  up	  to	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
* RUNX1, Runt-­‐related	  transcription	  factor	  1;	  RUNX1T1,	  Runt-­‐related	  transcription	  factor	  1,	  translocated	  
to	  1,	  (cyclin	  D-­‐related);	  PML,	  promyelocytic	  leukaemia;	  RARA,	  retinoic	  acid	  receptor	  alpha;	  NUP214,	  
nucleoporin	  214kDa 
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40%	   and	   approximately	   30%	   of	   patients	   with	   AML	   respectively,	   are	   more	   frequently	   observed1.	   T-­‐cell	  
responses	  directed	  at	  epitopes	  derived	  from	  these	  mutant	  proteins	  have	  also	  been	  documented50-­‐52.	  	  
The	   role	   that	   chemotherapy	   plays	   in	   the	   induction	   of	   tumour-­‐specific	   immune	   responses	   is	   also	  
noteworthy53,54.	   Chemotherapy	   reduces	   tumour	   bulk,	   but	   in	   some	   experimental	   models,	   it	   has	   been	  
shown	  that	  apoptosing	  neoplastic	  cells	  stimulate	   immune	  cells54,55.	   In	  combination,	  reduction	  of	  tumour	  
load	   and	   activation	  of	   tumour-­‐reactive	   immunity	  may	   allow	   the	   immune	   system	   to	   regain	   control	   over	  
neoplastic	   expansion53,54.	   Lymphodepleting	   chemotherapy	   agents,	   such	   as	   fludarabine	   and	  
cyclophosphamide	   may	   be	   used	   to	   influence	   adaptive	   immunity	   through	   different	   mechanisms53.	  
Lymphopenia-­‐induced	  homeostatic	  expansion	  of	  adoptively	   transferred	   tumour-­‐specific	  cytotoxic	  T-­‐cells	  
occurs	   after	   fludarabine	   and	   cyclophosphamide	   treatment56.	   Immunomodulating	   low	   doses	   of	  
cyclophosphamide	  deplete	  regulatory	  T-­‐cells	   (Tregs)	  that	  normally	  act	  to	   limit	  expansion	  of	  high	  avidity,	  
self-­‐antigen	   recognising	   T-­‐cells.	   Depletion	   of	   Tregs	   by	   prior	   low	   dose	   cyclophosphamide	   treatment	   has	  
been	  shown	  to	  allow	  effective	  induction	  and	  expansion	  of	  tumour-­‐specific	  	  (self-­‐reactive)	  T-­‐cell	  responses	  
following	   peptide	   vaccination	   against	   a	   particular	   TAA57.	   	   Newer	   treatments	   for	   AML,	  which	   also	   show	  
immunomodulatory	  activity,	  such	  as	  the	  demethylating	  agent	  5-­‐azacytidine,	  have	  been	  reported	  to	  induce	  
tumour-­‐specific	   T-­‐cell	   responses.	   Evidence	   from	   in	   vitro	   studies	   suggested	   that	   5-­‐azacytidine	   promotes	  
upregulation	   of	   epigenetically	   silenced	   tumour	   associated	   antigens	   (TAAs)	   by	   tumour	   cells,	   allowing	  
enhanced	  antigen	  presentation	  and	  activation	  of	  tumour	  specific	  CTLs58.	  	  
	  
Another	   area	   of	   emerging	   interest	   is	   that	   anti-­‐leukaemic	   immune	   responses	   may	   be	   effective	   against	  
leukaemic	  stem	  cells	   (LSC)59.	  Chemotherapy	  resistance	  of	  LSCs	  has	  been	  postulated	  as	  a	  mechanism	  for	  
leukaemic	   relapse60.	   The	   largely	   quiescent	   nature	   of	   these	   cells	   may	   protect	   them	   from	   apoptosis	  
induction	   upon	   exposure	   to	   cytotoxics60.	   Whether	   long-­‐term	   disease	   control	   may	   arise	   from	   antigen-­‐
specific	  T-­‐cells	  targeting	  chemotherapy-­‐resistant	  LSCs	  directly,	  or	  rather	  their	  progeny,	  is	  an	  area	  of	  active	  
research	  interest22,60.	  Immune	  therapies	  may	  be	  more	  effective	  than	  cytotoxic	  agents	  against	  LSCs,	  due	  to	  
their	  cell-­‐cycle	  independent	  mechanism	  of	  action.	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The	  evidence	  above	  supports	  the	  role	  of	  the	  immune	  system	  in	  detecting	  and	  eradicating	  AML.	  However,	  
this	   is	  clearly	   failing	  at	  the	  time	  of	  disease	  presentation	  or	  relapse.	  Strategies	  by	  which	  AML	  may	  evade	  
the	  immune	  system	  are	  described	  in	  the	  next	  section.	  
27	  
Table	  1-­‐1	  Expression	  of	  candidate	  leukaemia	  associated	  antigens	  in	  AML,	  normal	  tissues	  and	  normal	  


























































































































































































































































































































































































































































































































































































































































































*For	  a	  full	  explanation	  of	  abbreviations,	  please	  refer	  to	  the	  main	  Abbreviations	  section.
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1.3 Immune	  evasion	  by	  AML	  
Despite	  the	  potential	  for	  the	  immune	  system	  to	  detect	  and	  destroy	  leukaemic	  cells,	  the	  neoplastic	  process	  
ultimately	   subverts	   this,	   allowing	   disease	   progression	   or	   recurrence.	   A	   process	   of	   dynamic	   shaping	   of	  
immune	   responses	   and	   tumour	   immunogenicity	   favours	   disease	   control	   or	   relapse,	   according	   to	   the	  
immunoediting	   hypothesis	   proposed	   by	   Schreiber.	   Three	   distinct	   phases	   in	   the	   relationship	   between	   a	  
tumour	  and	  the	  immune	  system	  have	  been	  suggested,	  namely	  elimination,	  equilibrium	  and	  escape	  (Figure	  
1-­‐2)29.	   In	   the	   earliest	   stages	   of	   malignant	   disease,	   immunogenic	   tumour	   cells	   are	   highly	   vulnerable	   to	  
destruction	  by	   the	   innate	   and	   adaptive	   immune	   systems,	   preventing	   clinically	   evident	  malignancy.	   Less	  
immunogenic	   tumour	   cells	   survive	   the	   elimination	   phase	   and	   persist	   during	   equilibrium,	   ultimately	  
leading	  to	  clinically	  evident	  disease	  (escape).	  A	  long-­‐term	  equilibrium	  on	  the	  other	  hand	  is	  manifested	  by	  













Taken	  from	  Schreiber	  et	  al,29.	  See	  the	  main	  Abbreviations	  list	  for	  a	  full	  explanation	  of	  abbreviations.	  
Figure	  1-­‐2	  The	  cancer	  immunoediting	  hypothesis	  
or from damaged tissues (such as hyaluronan
fragments) as solid tumors begin to grow in-
vasively (30). A third potential mechanism may
involve stress ligands such as RAE-1 and H60
(mouse) or MICA/B (human) that are frequently
expressed on the surface of tumor cells. Such lig-
ands bind to activating receptors on innate im-
mune cells, leading to release of pro-inflammatory
and immunomodulatory cytokines, which in turn
establish a microenvironment that facilitates the
development of a tumor-specific adaptive im-
mune response (31). Although in some experi-
mental systems, activation of innate immunity
can protect against tumor development, in most
systems effective cancer immunosurveillance re-
sponses require the additional expression of tu-
mor antigens capable of propagating the expansion
of effector CD4+ and CD8+ Tcells. Thus, coordi-
nated and balanced activation of both innate and
adaptive immunity is needed to protect the host
against a developing tumor. If tumor cell destruc-
tion goes to completion, the elimination phase
represents an endpoint of the cancer immunoedit-
ing process.
The elimination phase has not yet been di-
rectly observed in vivo, but its existence has been
inferred from the earlier onset or greater pene-
trance of neoplasia in mice lacking certain im-
mune cell subsets, recognition molecules, effector
pathways, or cytokines and by studies comparing
tumor initiation, growth, and metastases in wild-
type versus immunodeficient mice [reviewed in
(18)]. These studies have revealed that the im-
mune components required for effective elimina-
tion of any given tumor are dependent on specific
characteristics of the tumor, such as how it orig-
inated (spontaneous versus carcinogen-induced),
its anatomic location, and its rate of growth.
Equilibrium. Rare tumor cell variants may
survive the elimination phase and enter the equi-
librium phase, in which the adaptive immune
system prevents tumor cell outgrowth and also
sculpts the immunogenicity of the tumor cells.
We envisage equilibrium to be the longest phase
of the cancer immunoediting process—perhaps
extending throughout the life of the host. As
such, it may represent a second stable endpoint
of cancer immunoediting. In equilibrium, the im-
mune system maintains residual tumor cells in
a functional state of dormancy, a term used to
describe latent tumor cells that may reside in
patients for decades before eventually resuming
growth as either recurrent primary tumors or dis-
tant metastases (32). Equilibrium thus represents
a type of tumor dormancy in which outgrowth
of occult tumors is specifically controlled by
immunity.
An early suggestion that the immune system
couldmaintain tumor cells in a dormant/equilibrium
state came from tumor transplantation experi-
ments in which mice were primed with a trans-
plantable tumor and then rechallenged with the
same tumor in order to induce tumor latency (33).
However, stronger evidence for the existence of
an immunologically mediated equilibrium phase
came from primary tumorigenesis experiments
showing that immunocompetent mice treated
with low-dose carcinogen [3′-methylcholanthrene
(MCA)] harbored occult cancer cells for an ex-
tended time period even when the mice did not
develop any apparent tumors (34). When the
immune system of these mice was ablated [by














































































Fig. 3. The cancer immunoediting concept. Cancer immunoediting is an extrinsic tumor suppressor
mechanism that engages only after cellular transformation has occurred and intrinsic tumor suppressor
mechanisms have failed. In its most complex form, cancer immunoediting consists of three sequential
phases: elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity
work together to destroy developing tumors long before they become clinically apparent. Many of the
immunemolecules and cells that participate in the elimination phase have been identified, but more work
is needed to determine their exact sequence of action. If this phase goes to completion, then the host
remains free of cancer, and elimination thus represents the full extent of the process. If, however, a rare
cancer cell variant is not destroyed in the elimination phase, it may then enter the equilibrium phase, in
which its outgrowth is prevented by immunologic mechanisms. T cells, IL-12, and IFN-g are required to
maintain tumor cells in a state of functional dormancy, whereas NK cells and molecules that participate in
the recognition or effector function of cells of innate immunity are not required; this indicates that
equilibrium is a function of adaptive immunity only. Editing of tumor immunogenicity occurs in the
equilibrium phase. Equilibriummay also represent an end stage of the cancer immunoediting process and
may restrain outgrowth of occult cancers for the lifetime of the host. However, as a consequence of
constant immune selection pressure placed on genetically unstable tumor cells held in equilibrium, tumor
cell variants may emerge that (i) are no longer recognized by adaptive immunity (antigen loss variants or
tumors cells that develop defects in antigen processing or presentation), (ii) become insensitive to
immune effector mechanisms, or (iii) induce an immunosuppressive state within the tumor microenvi-
ronment. These tumor cells may then enter the escape phase, in which their outgrowth is no longer blocked
by immunity. These tumor cells emerge to cause clinically apparent disease. [Figure adapted from (18)]



























MΦ:	  	   Macrophage	  
DC:	  	   Dendritic	  cell	  
MDSC:	  	   Myeloid	  derived	  
suppressor	  cell	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AML	  cells	  have	  been	  observed	  to	  employ	  a	  number	  of	  mechanisms	  in	  order	  to	  evade	  immune	  recognition	  










Taken	  from	  Barrett	  and	  Le	  Blanc	  22.	  See	  the	  main	  Abbreviations	  list	  for	  a	  full	  explanation	  of	  abbreviations.	  
	  
Immune	   evasion	   may	   involve	   avoidance	   of	   T-­‐	   or	   NK-­‐cell	   recognition,	   or	   promotion	   of	  
dysfunctional/inhibitory	   immune	   responses	   by	   AML	   blasts.	   NK	   cells	   express	   a	   number	   of	   activating	  
receptors,	   including	   the	   natural	   cytotoxicity	   receptors	   (NCRs,	   NKp44,	   NKp46	   and	   NKp30)	   or	   DNAX	  
accessory	  Molecule-­‐1	   (DNAM-­‐1)	   and	   Natural	   killer	   group	   2,	   member	   D	   (NKG2D)94.	   Down-­‐regulation	   of	  
NCRs	  on	  NK-­‐cells	   from	  AML	  patients95	   or	   their	   ligands	  on	  AML	  blasts	   has	  been	  observed95,96.	   Inhibitory	  
interactions	   between	   AML	   blasts	   and	   NK-­‐cells	   may	   also	   occur.	   Cell	   surface	   molecules	   such	   as	  
glucocorticoid-­‐induced	  TNFR-­‐related	  protein	  ligand	  (GITRL)97	  and	  CD137L98	  expressed	  by	  AML	  blasts	  bind	  
ligands	   on	   NK	   cells,	   inhibiting	   NK	   cell	   cytotoxicity	   and	   cytokine	   production.	   T-­‐cell	   activation	   may	   be	  
avoided	  by	   reduced	  expression	  of	   co-­‐stimulatory	  molecules	   such	  as	  CD80,	   resulting	   in	   failure	   to	  deliver	  
necessary	  co-­‐stimulatory	  signals	  and	  promotion	  of	  anergy99.	  Down-­‐regulation	  of	  certain	  HLA	  Class	  I	  alleles	  
by	  AML	  blasts,	  such	  as	  those	  belonging	  to	  the	  HLA	  Bw6	  group	  that	  are	  not	  sensed	  by	  NK	  cells	  but	  present	  
tumour	  antigens	  to	  CTLs,	  provides	  another	  means	  to	  specifically	  evade	  attack	  by	  T-­‐cells100.	  	  
	  
immune pressure to select variants that evade immune
surveillance. AML can express the ligand for the
glucocorticoid-induced tumour necrosis factor-related
protein (GITRL), which can block NK function through
triggering GITR on the NK cell directly or through soluble
GITRL [32]. AML blasts often weakly express o-stimulatory
molecules which may favour their escape from T cell-
mediated killing, and the probability of remaining in remis-
sion is greatest in patients who express both CD80 and CD86
[4]. AML cells can shed ligands for co-stimulatory molecules
such as the 4-1BB ligand, which may allow the leukaemia to
block T cell attack by the binding of soluble ligand to the T
cell [33]. The class II-associated invariant chain self-peptide
(CLIP) is expressed variably in AML. CLIP down-regulation
can increase antigenicity of AML cells (by unblocking MHC
class II loading with self-antigen) and increase CD4
responses. Patients whose AML blasts have less CLIP bound
to HLA-DRmolecules have prolonged remissions [34]. AML
cells secrete soluble factors which may be responsible for a
variety of defects observed in T cell a d NK cell function
[35,36]. Through their myeloid-lineage affinity, AML cells
can generate leukaemic dendritic cells (DC) in vitro and in
vivo which function as antigen-presenting cells (APC).
However, AML DC are distinctly abnormal [37]. They can
inhibit the induction of CTL, inducing T cell anergy [38–40]
and favouring the generation of regulatory T cells [41] which
are increased in AML [42]. Probably as a consequence of the
leukaemia, T cells in AML show several abnormalities: recent
thymic emigrants are reduced, suggesting defective thymic
function [43]. In a detailed study of T cells in AML Le Dieu
and colleagues found T cells with abnormal phenotypes and
genotypes that formed defective immune synapses with
AML blasts [44]. Finally, the AML microenvironment may
favour AML survival – mesenchymal stromal cells in leu-
kaemias can provide an immunosuppressive milieu [45] and
the protective endosteal region of the marrow favours the
survival of leukaemic stem cells [46].
Developments in immunotherapy of AML
Treatment strategies
Whether the goal of immunotherapy in AML is to boost the
patient’s immune system or to conf r immunity with T cells,
NK cells or monoclonal antibodies, immune treatment is
usually planned as a means of sustaining remission once the
disease has been bulk-reduced with chemotherapy. Animal
models of AML have proved useful in providing the basis for
adoptive T cell and NK cell therapy [47], exploring the com-
bination of immunotherapy with chemotherapy [48] and
defining the role of regulatory T cells in preventing full effi-
cacy of leukaemia-specific cytotoxic T cells in a mouse AML
model [49]. The development of robust human leukaemia
models in immune deficient mice has helped to identify
MHag, CD44 and WT1 as targets for immune attack that
result in the elimination of human AML transferred into
non-obese diabetic (NOD)-SCID or the more permissive
NOD/LtSz-scid IL2Rgammac null (NSG) mice [50–53].
These studies have helped to pinpoint treatments and factors
which improve elimination of AML progenitor cells, but are
limited by the artificial environment of the mouse which,
despite immune deficiency, may not represent a sufficiently
permissive environment for human AML to proliferate. In
man, clinical immunotherapy trials have variously explored
cytokines, vaccines to boost T cell immunity, treatments to
increase susceptibility of the target as well as strategies to
directly attack AML cells with antibodies, or lymphocytes
(Fig. 2).
Cytokines
The availability of the lymphokine interleukin (IL)-2 for
clinical use in the 1980s precipitated a number of clinical
trials exploring its potential to boost both T cell and NK cell
function to prevent relapse after induction therapy for AML.
Fig. 1. Interactions between acute myeloid
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Figure	  1-­‐3	  Mechanisms	  of	  immune	  evasion	  by	  AML	  blasts	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Secretion	   of	   immunosuppressive	   factors	   by	   human	   AML	   cell	   lines	   or	   primary	   AML	   blasts,	   resulting	   in	  
inhibition	  of	  NK	  and	  T-­‐cell	  proliferation101	  or	  T-­‐cell	  function102	  has	  been	  previously	  demonstrated.	  Elegant	  
studies	   have	   demonstrated	   that	   T-­‐cells	   from	   AML	   patients	   at	   diagnosis	   were	   unable	   to	   form	   effective	  
immune	   synapses	  with	   autologous	   blasts.	   Further	   analysis	   revealed	   this	  was	   due	   to	   dysfunction	  within	  
both	  the	  AML	  blasts	  and	  the	  patients’	  T-­‐cells103.	  Furthermore,	  AML	  blasts	  derive	  from	  myeloid	  progenitors	  
and	   therefore	   may	   differentiate	   into	   dendritic	   cells	   (DCs).	   Studies	   in	   vitro	   have	   suggested	   that	   AML-­‐
derived	  DCs	  show	  abnormal	  maturation104	  and	  promote	  the	  generation	  of	  suppressive	  T-­‐regulatory	  cells	  
(Tregs)	   through	   increased	   expression	   of	   indoleamine	   2,3-­‐dioxygenase	   (IDO)105.	   Activated	   Tregs	   in	   turn	  
suppress	  effector	  T-­‐cell	  responses	  to	  the	  tumour.	  	  
	  
Natural	   regulatory	  mechanisms	   that	  operate	   to	   terminate	  T-­‐cell	   responses	  may	  also	  hinder	   tumour	   cell	  
killing.	   Following	   engagement	   of	   the	   T-­‐cell	   receptor	   (TCR)	   with	   a	   cognate	   peptide	   bound	   to	   a	   major	  
histocompatibility	   complex	  molecule	   (pMHC),	   costimulatory	   signals	  are	  delivered	  by	  binding	  of	  CD28	   to	  
CD80/86	   on	   antigen	   presenting	   cells	   (APCs).	   Subsequent	   cytotoxic	   T-­‐lymphocyte-­‐associated	   antigen	   4	  
(CTLA-­‐4)	   upregulation	   by	   T-­‐cells	   acts	   to	   outcompete	   CD28	   for	   binding	   to	   CD80/86	   to	   terminate	   the	  
costimulatory	   signal106,107.	   This	   results	   in	   delivery	   of	   inhibitory	   signals	   to	   the	   T-­‐cells,	   modulating	   the	  
amplitude	  of	   the	   response	   in	   proportion	   to	   the	   strength	  of	   the	   T-­‐cell	   activating	   signal106,107.	   Ligation	  of	  
constitutively	  expressed	  CTLA-­‐4	  on	  Tregs	  also	  has	  a	  vital	  physiologic	  role	  to	  allow	  suppressive	  control	  of	  
effector	   T-­‐cell	   function108.	   Accordingly,	   inhibition	   of	   CTLA-­‐4	   signalling	   via	   blocking	   antibodies	   has	   been	  
shown	  to	   improve	  endogenous	  anti-­‐tumour	  T-­‐cell	  responses109.	  Programmed	  cell	  death	  protein	  1	  (PD-­‐1)	  
acts	   at	   a	   later	   phase	   of	   the	   T-­‐cell	   response,	   to	   limit	   effector	   T-­‐cell	   activity	   in	   the	   periphery	   and	   avoid	  
collateral	   inflammatory	   damage	   to	   local	   tissue106.	   Increased	   expression	   of	   PD-­‐1	   on	   tumour	  
infiltrating/specific	   lymphocytes	   has	   been	   demonstrated110,111.	   Some	   tumours	   (including	   AML112)	   have	  
been	   shown	   to	   up-­‐regulate	   the	   PD-­‐1	   ligands,	   PDL1	   and	   PDL2106,113.	   	   Therefore	   malignant	   cells	   may	  
negatively	  modulate	  anti-­‐tumour	  T-­‐cell	  (and	  also	  PD1-­‐expressing	  B-­‐	  and	  NK-­‐cell)	  responses,	  providing	  an	  
additional	  means	  whereby	  they	  can	  evade	  adaptive	  immune	  responses.	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There	   is	   substantial	  evidence	   that	   immune	  eradication	  of	   leukaemic	  blasts	  may	  contribute	   to	   long-­‐term	  
control/cure	   of	   the	   disease.	   Disease	   may	   recur	   due	   to	   the	   persistence	   of	   chemotherapy-­‐resistant	  
leukaemic	   stem	   cells	   within	   the	   host.	   Manipulation	   of	   immune	   responses	   may	   be	   used	   to	   enhance	  
eradication	  of	  leukaemic	  blasts	  as	  an	  adjunct	  to	  tumour	  debulking	  by	  chemotherapy.	  Increasing	  evidence	  
suggests	  that	  certain	  chemotherapeutics	  may	  exert	  some	  of	  their	  effects	  by	  eliciting	  immune	  responses.	  
Replacement	  of	  a	   “tumour-­‐edited”	  host	   immune	  system	   in	   the	  context	  of	  allogeneic	   transplantation	  by	  
healthy	  donor	  cells	  capable	  of	  GvL	  activity	  has	  curative	  potential.	  Boosting	  of	   immune	  responses	  during	  
clinical	  remission,	  within	  or	  outside	  the	  setting	  of	  HSCT,	  has	  the	  potential	  to	  target	  LSCs	  or	  their	  progeny	  
and	   prevent	   disease	   recurrence.	   Knowledge	   of	   the	   interactions	   between	   the	   immune	   system	   and	  
leukaemic	   cells/progenitors	   and	   the	   mechanisms	   used	   to	   escape	   from	   immune	   surveillance	   is	  
accumulating.	   As	   a	   result,	   strategies	   to	   beneficially	   enhance	   and	   maintain	   immune	   activity	   against	  
leukaemia	  and	  overcome	  immune	  escape	  mechanisms	  are	  being	  explored.	  
	  
1.4 Immunotherapeutic	  strategies	  in	  AML	  
A	  number	  of	  approaches	  have	  undergone	  pre-­‐clinical	  or	  early	  phase	  study	  to	  either	  directly	  stimulate	  or	  
passively	  confer	  anti-­‐leukaemic	  immune	  activity	  in	  subjects.	  Passive	  mechanisms	  include	  adoptive	  transfer	  
of	  lymphocytes.	  At	  its	  most	  basic,	  this	  includes	  the	  use	  of	  donor	  lymphocyte	  infusions,	  described	  in	  more	  
detail	  in	  section	  1.5.	  Selected	  lymphocyte	  subsets	  may	  also	  be	  transferred,	  including	  CD8-­‐depleted	  DLI114	  
or	  NK	  cells,	  derived	  from	  haploidentical	  donors115.	  The	  development	  of	  more	  sophisticated	  gene	  therapy	  
approaches	  has	  allowed	  the	  generation	  of	  antigen-­‐specific	  T-­‐cells,	  directed	  against	  target	  LAAs	  (e.g.	  TCR	  
gene	   therapy	   resulting	   in	   the	   production	   of	  WT1-­‐specific	   T-­‐cells116)	   or	   T-­‐cells	   bearing	   chimeric	   antigen	  
receptors	   (CARs)	   which	   are	   not	   reliant	   on	   recognition	   of	   pMHC	   complexes	   but	   rather	   bind	   to	   non-­‐
polymorphic	  targets,	  such	  as	  CD123	  on	  AML	  cells117.	  	  
	  
Active	   leukaemia-­‐specific	   immunity	   is	  principally	   induced	  by	  vaccination	  approaches	   such	  as	  whole	   cell,	  
antigen-­‐loaded	  DCs,	  DNA	  or	  peptide	  vaccines	  targeting	  the	  LAAs	  listed	  in	  Table	  1-­‐1.	  Peptide	  vaccination	  in	  
a	  Phase	  I/II	  study	  using	  the	  proteinase	  3	  derived	  PR1	  peptide	  induced	  at	  least	  a	  2-­‐fold	  expansion	  in	  PR1-­‐
specific	   T-­‐cells	   in	   nearly	   half	   of	   AML	   patients	   vaccinated,	   with	   a	   4-­‐month	   increase	   in	   progression-­‐free	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survival	   (PFS)	   in	   immune	   responders118.	   	   Following	   high	   dose	   Hyaluronan-­‐mediated	   motility	   receptor	  
(RHAMM)	  peptide	  vaccination,	  Greiner	  et	  al	  demonstrated	   transient	   immunological	  and	  haematological	  
responses	   in	   a	   mixed	   cohort	   of	   patients	   with	   haematological	   malignancies119.	   Peptide	   vaccination	  
targeting	  WT1	  has	  been	  studied	  in	  both	  pre-­‐clinical	  and	  clinical	  settings	  and	  serves	  as	  a	  paradigm	  of	  active	  
vaccination	   approaches	   to	   AML;	   this	   area	   is	   explored	   in	   section	   1.6.	   Whole	   cell	   vaccination	   using	  
genetically	  modified	   tumour	   cells	   (leukaemia	   cells120,121	   or	   a	   leukaemia	   cell	   line122	   modified	   to	   express	  
granulocyte-­‐macrophage	   colony-­‐stimulating	   factor	   [GM-­‐CSF122]	   or	   CD80	   and	   IL-­‐2120,121)	   and	   Phase	   I/II	  
studies	   have	   either	   been	   reported122	   or	   are	   in	   progress	   (RFUSIN2-­‐AML1	   vaccine	   trial,	   EudraCT	  Number	  
2005-­‐000806-­‐29).	  	  Whole	  cell	  vaccination	  for	  AML	  is	  described	  in	  further	  detail	  in	  section	  1.7.	  
	  
1.5 Donor	  lymphocyte	  infusions:	  adoptive	  immunotherapy	  to	  prevent	  and	  treat	  
myeloid	  malignancies	  
One	  of	  the	  earliest	  forms	  of	  immunotherapy	  employed	  in	  patients	  with	  haematological	  malignancies	  has	  
been	  the	  use	  of	  unmanipulated	  infusions	  of	  donor	  lymphocytes	  to	  treat	  or	  prevent	  recurrent	  disease	  post-­‐
HSCT.	  	  A	  major	  breakthrough	  in	  the	  therapy	  of	  patients	  with	  recurrent	  chronic	  myeloid	  leukaemia	  (CML)	  
post-­‐allogeneic	   HSCT	   was	   the	   demonstration	   by	   Kolb	   and	   co-­‐workers	   that	   DLI	   combined	   with	   IFNα	  
therapy	  could	  be	  used	  to	  re-­‐induce	  sustained	  remissions	   in	  these	  patients123.	  A	  number	  of	  other	  groups	  
reported	   efficacy	   of	  DLI	   for	   therapy	   of	   recurrent	   CML,	  with	   high	   rates	   of	   remission	   seen	  particularly	   in	  
patients	  in	  early,	  chronic	  phase	  disease	  at	  relapse124-­‐129.	  Responses	  to	  DLI	  reported	  in	  original	  case	  series	  
appeared	  to	  coincide	  in	  some	  instances	  with	  an	  increase	  in	  donor-­‐derived	  haemopoiesis	  and/or	  the	  onset	  
of	   GvHD,	   or	   cytopenias	   due	   to	   marrow	   aplasia,	   suggesting	   the	   induction	   of	   alloreactive	   GvL	  
responses128,129.	  Larger	  retrospective	  registry	  studies	  evaluated	  outcomes	  following	  therapeutic	  DLI	  (tDLI)	  
in	  a	  range	  of	  other	  haematological	  malignancies,	  including	  acute	  and	  chronic	  leukaemias,	  lymphoma	  and	  
myeloma.	   The	   best	   responses	   to	   tDLI	  were	   frequently	   observed	   in	   patients	  with	   recurrent	   early	   phase	  
CML,	   with	   detectable	   but	   often	   curtailed	   responses	   in	   the	   context	   of	   relapsed	   acute	   leukaemias	   or	  
accelerated	  phase	  CML11,130.	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Specifically	   in	   the	   context	   of	   AML	   and	   myelodysplastic	   syndrome	   (MDS),	   variable	   results	   from	  
retrospective	  registry	  studies	  have	  been	  described	  (Table	  1-­‐2).	  Comparisons	  between	  different	  studies	  are	  
difficult	  for	  a	  number	  of	  reasons.	  These	  include	  the	  retrospective	  nature	  of	  most	  studies,	  use	  of	  registry	  
data	  sourced	  from	  multiple	  institutions,	  varied	  reporting	  of	  infusion	  cell	  type	  and	  dose	  (total	  nucleated	  or	  
mononucleated	   cells,	   or	   CD3+	   cells,	   per	   kg)	   and	   the	   inclusion	   of	   heterogeneous	   disease	   cohorts	  
comprising	   small	   numbers	   of	   patients.	   Further	   factors	   confounding	   the	   interpretation	  of	   results	   of	   tDLI	  
have	   included	   the	   treatment	   of	   patients	   with	   varying	   pre-­‐therapy	   levels	   of	   disease	   burden	   (usually	  
described	  in	  terms	  of	  leukaemic	  blast	  percentage)	  or	  the	  use	  of	  an	  immunomodulatory	  drug	  such	  as	  IFNα	  
or	  chemotherapy	  to	  reduce	  disease	  bulk	  prior	  to	  DLI.	  Overall,	  rates	  of	  remission	  induction	  with	  tDLI	  have	  
ranged	   from	   14-­‐47%	   in	   the	   studies	   listed	   in	   Table	   1-­‐2	   but	   dismal	   2	   year	   overall	   survival	   (OS)	   rates,	  
generally	   less	   than	  20%	  at	   2	   years,	   have	   repeatedly	  been	  described,	   largely	  due	   to	   subsequent	  disease	  
recurrence.	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19%	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   Not	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*Patients	  in	  complete	  remission	  (CR)	  following	  chemotherapy	  were	  not	  considered	  evaluable	  for	  response	  
to	  DLI	  	  
§Some	   of	   the	   recipients	   of	   DLI	   without	   chemotherapy	   underwent	   second	   HSCT,	   which	   may	   also	   have	  
contributed	  to	  the	  %	  achieving	  CR	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NRM	   due	   to	   complications	   such	   as	   GvHD	   (with	   a	   reported	   incidence	   of	   acute	   and/or	   chronic	   GvHD	   in	  
between	   20-­‐60%	   of	   patients,	   Table	   1-­‐2)	   also	   contributes	   to	   reduced	   overall	   survival	   (OS).	   The	   largest	  
report	  of	  tDLI	  administration	  for	  relapsed	  AML	  post-­‐HSCT	  by	  Schmid	  et	  al.,	  a	  retrospective	  registry	  study	  
of	   171	   recipients,	   identified	   factors	   that	  were	   predictive	   of	   improved	   survival	   response	   by	  multivariate	  
analysis.	   These	   included	   presence	   of	   fewer	   than	   35%	   bone	   marrow	   blasts	   at	   relapse,	   female	   gender,	  
favourable	  cytogenetic	  disease	  risk	  profile	  and	  morphological	  remission	  at	  the	  time	  of	  DLI.	  Overall,	  2-­‐year	  
survival	  following	  DLI	  was	  estimated	  at	  21%	  ±	  3%.	  This	  study	  also	  reported	  the	  outcomes	  of	  228	  patients	  
who	  did	  not	  receive	  any	  cellular	  therapy	  to	  treat	  their	  recurrent	  disease.	  Their	  OS	  was	  worse,	  at	  9%	  ±	  2%	  
at	   2	   years,	   again	   suggesting	   greater	   prospects	   for	   disease	   control	   where	   GvL	   can	   be	   boosted.	   For	   the	  
whole	  cohort	  studied,	  relapse	  beyond	  5	  months	  post-­‐HSCT	  was	  associated	  with	  a	  superior	  2-­‐year	  OS	  (27%	  
vs.	  13%	  for	   those	  relapsing	  within	  5	  months	  post-­‐HSCT,	  p=0.0007)136.	  This	  particular	   finding	  may	  reflect	  
variation	  in	  the	  disease	  biology	  between	  individual	  patients,	  influencing	  the	  tempo	  of	  disease	  recurrence.	  
It	  is	  also	  possible	  that	  those	  patients	  who	  experienced	  longer	  remissions	  post-­‐HSCT	  had	  developed	  some	  
GvL	  activity,	  albeit	  of	  lessened	  efficacy	  around	  the	  time	  of	  disease	  recurrence,	  which	  could	  be	  boosted	  by	  
fresh	  infusions	  of	  lymphocytes.	  	  
	  
Most	  of	  the	  patients	  described	  in	  this	  study	  and	  the	  others	  listed	  in	  Table	  1-­‐2	  had	  received	  a	  full	  intensity	  
and/or	  T-­‐replete	  HSCT.	  There	  are	  very	  few	  reports	  of	  the	  response	  to	  tDLI	   in	  patients	  with	  AML	  or	  MDS	  
following	  T-­‐cell-­‐depleted,	  reduced	  intensity	  conditioned	  (TCD	  RIC)	  regimens	  and	  in	  general,	  these	  patients	  
have	  been	  grouped	  in	  studies	  including	  subjects	  with	  myeloid	  and	  lymphoid	  malignancies137,138.	  Shaw	  and	  
colleagues	  reported	  on	  outcomes	  for	  a	  mixed	  cohort	  of	  patients	  following	  TCD	  RIC	  HSCT,	  given	  DLI	  for	  a	  
variety	  of	   indications,	   including	   recurrent	  disease139.	   They	  demonstrated	  a	  42%	  complete	   response	  and	  
19%	   partial	   response	   to	   DLI	   in	   36	   recipients	  with	   persistent	   or	   relapsed	   disease	   post-­‐TCD	   RIC	   HSCT139.	  
Early	  reports	  of	  outcomes	  from	  our	  institution	  of	  tDLI	  for	  morphologic	  or	  cytogenetic	  relapse	  of	  MDS/AML	  
post	  fludarabine,	  busulphan	  and	  Campath®	  (alemtuzumab)	  (FBC)-­‐conditioned	  allograft	  in	  small	  numbers	  
of	  patients	  demonstrated	  limited	  response	  to	  DLI	  following	  morphological	  evidence	  of	  disease	  recurrence,	  
but	  complete	  remissions	  in	  over	  half	  of	  patients	  treated	  for	  cytogenetic	  relapse	  only13,140.	  Given	  the	  lack	  
of	  data	  to	  demonstrate	  efficacy	  for	  the	  use	  of	  tDLI	  for	  relapsed	  MDS/AML	  post-­‐TCD	  RIC	  allografts,	  one	  aim	  
of	  this	  thesis	  was	  to	  examine	  outcome	  data	  from	  our	  institution	  in	  more	  detail.	  This	  is	  especially	  relevant	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in	  the	  context	  of	  our	  Phase	  I	  clinical	  trial	  of	  whole	  cell	  vaccination	  using	  CD80/IL-­‐2	  modified	  AML	  blasts,	  
which	  combines	  vaccination	  with	  administration	  of	  tDLI	  to	   improve	  the	  efficacy	  of	  this	  form	  of	  adoptive	  
immunotherapy.	  
	  
The	  use	  of	  pre-­‐emptive	  DLI	  (pDLI)	  to	  prevent	  relapse	  following	  TCD	  RIC	  HSCT	  for	  AML/MDS	  is	  another	  area	  
where	   there	   are	   limited	   data.	   Furthermore,	   centres	   may	   report	   outcomes	   following	   more	   than	   one	  
indication	  for	  administration	  of	  DLI	  in	  the	  absence	  of	  overt	  relapse:	  planned,	  prophylactic	  administration	  
of	  DLI	  early	  post-­‐HSCT	  in	  high-­‐risk	  patients,	  versus	  administration	  guided	  by	  a	  persistently	  low,	  or	  falling,	  
donor	   T-­‐cell	   chimerism.	   Within	   our	   institution,	   pDLI	   has	   been	   given	   to	   patients	   with	   persistent	  
predominant	   recipient	   T-­‐cell	   chimerism	   or	   a	   progressive	   fall	   in	   donor	   CD3+	   percentage	   on	   successive	  
readings13,140,141.	  Therefore,	  the	  term	  pDLI	  will	  be	  used	  in	  this	  thesis	  to	  describe	  only	  this	  indication.	  	  
	  
Mixed	   donor	   chimerism	   (MDC)	   is	   often	   reported	   following	   TCD	   and/or	   RIC	   HSCT,	   in	   contrast	   to	  
myeloablative,	  non	  T-­‐cell	  depleted	  HSCT139,142-­‐146.	  The	  prognostic	  significance	  of	  persistent	  MDC	  following	  
TCD	   RIC	   HSCT	   remains	   an	   area	   of	   ongoing	   debate.	   Whilst	   some	   studies	   have	   reported	   MDC	   to	   be	  
associated	  with	  an	   increased	   risk	  of	   relapse139,	  others	  have	   linked	  MDC	   to	   lower	   rates	  of	  GvHD	  and	  no	  
demonstration	  of	  higher	  disease	  recurrence	  rates147.	  In	  part,	  these	  differences	  arise	  due	  to	  the	  variety	  of	  
diseases,	  HSCT	  conditioning	  regimens	  and	  choice	  (as	  well	  as	  dose)	  of	  T-­‐cell	  depleting	  antibody	  used	  in	  the	  
studies.	  Furthermore	  changes	  over	  time	  in	  the	  technologies	  used	  to	  measure	  chimerism	  (e.g.	  karyotyping	  
versus	  quantitative	  polymerase	  chain	  reaction	  (qPCR)	  of	  short	  tandem	  repeat	  (STR)	  sequences),	  the	  use	  of	  
whole	   bone	   marrow	   or	   blood,	   or	   lineage-­‐specific	   analyses	   of	   peripheral	   blood	   subsets,	   and	   a	   lack	   of	  
uniform	  criteria	  to	  define	  MDC,	  confound	  comparisons	  between	  groups.	  To	  counter	  some	  of	  these	  issues,	  
consensus	  definitions	  and	  approaches	  to	  measurement	  of	  chimerism	  have	  been	  suggested148,149.	  	  
	  
Specifically,	   whether	   reduced	   donor	   T-­‐cell	   chimerism	   predicts	   increased	   likelihood	   of	   relapse	   in	   the	   T-­‐
deplete	   transplant	   setting	   is	   controversial.	   Van	   Besien	   et	   al143	   and	   Nikolousis	   et	   al150	   studied	  
heterogeneous	   cohorts	   of	   patients	   who	   underwent	   RIC	   HSCT	   incorporating	   the	   lymphocyte-­‐depleting	  
anti-­‐CD52	  antibody	  alemtuzumab.	  Neither	   reported	  a	  significant	   impact	  of	   the	  presence	  of	  mixed	  T-­‐cell	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chimerism	  before	  day	  180	  on	   relapse	   risk.	  However,	  Van	  Besien	  and	  colleagues	  did	  demonstrate	   that	  a	  
successive	  decline	  in	  CD3	  chimerism	  of	  more	  than	  15%	  between	  days	  30-­‐180	  was	  predictive	  of	  a	  40%	  risk	  
of	  relapse,	  in	  comparison	  with	  a	  10%	  risk	  of	  relapse	  amongst	  those	  with	  stable	  CD3%	  between	  these	  time	  
points143.	   Where	   anti-­‐thymocyte	   globulin	   (ATG)	   was	   used	   for	   T-­‐cell	   depletion,	   Mohty	   and	   colleagues	  
reported	   a	   significantly	   higher	   risk	   of	   relapse	   in	   patients	   following	   RIC	   HSCT	   for	   myeloid	   malignancies	  
showing	   predominant	   recipient	   T-­‐cell	   chimerism	   at	   day	   90151.	   Mattsson	   and	   colleagues	   included	   a	  
selection	  of	  patients	   in	  their	  report	  who	  received	  ATG	  as	  part	  of	  RIC	  and	  found	  no	  association	  between	  
relapse	   risk	   and	   mixed	   T-­‐cell	   chimerism,	   although	   this	   study	   included	   children	   and	   adults	   with	   both	  
malignant	  and	  non-­‐malignant	  diseases146.	  
	  
Given	   indications	   that	  declining	  donor	  T-­‐cell	   chimerism	  may	  portend	   relapse,	   a	  number	  of	   groups	  have	  
sought	  to	  explore	  the	  ability	  of	  pDLI	  to	  convert	  mixed	  to	  full	  donor	  T-­‐cell	  chimerism	  and	  assess	  impact	  on	  
disease-­‐free	   survival	   and	   measure	   toxicity,	   such	   as	   development	   of	   GvHD.	   Pre-­‐emptive	   DLI	   has	   been	  
shown	   to	  effectively	   restore	   full	   donor	   chimerism	   (FDC)	   following	  alemtuzumab-­‐containing	  RIC	   in	  more	  
than	   half	   of	  mixed	   chimeric	   patients	  with	   Hodgkin’s144	   and	   non-­‐Hodgkin’s	   lymphoma152	   patients	   and	   a	  
range	  of	  other	  haematological	  malignancies142,153.	  Peggs	  et	  al	  were	  also	  able	  to	  demonstrate	  a	  very	   low	  
rate	  of	  recurrent	  Hodgkin’s	  disease	  and	  survival	  advantage	  for	  recipients	  of	  pDLI	  for	  mixed	  chimerism	  over	  
patients	   spontaneously	   achieving	   FDC144.	   Rates	   of	   acute	   and/or	   chronic	   GvHD	   following	   pDLI	   in	   these	  
studies	   ranged	   from	  20-­‐40%	  with	  DLI-­‐related	  mortality	   approaching	  10%	  of	   recipients	   at	  worst142,144,153.	  
pDLI	  was	  not	  administered	  to	  these	  patients	  before	  6	  months	  post-­‐HSCT,	  based	  on	  earlier	  retrospective	  
studies	  suggesting	  a	  >50%	  chance	  of	  acute	  or	  chronic	  GvHD	  induction	  where	  DLI	  was	  administered	  earlier	  
than	  6	  months	  post-­‐HSCT137.	  Furthermore,	  an	  escalating	  rather	  than	  bulk	  dose	  schedule	  for	  administration	  
of	   donor	   lymphocytes	   was	   used	   as	   a	  means	   to	   attenuate	   toxicity153,154,	   although	   dose	   increments	   and	  
intervals	  have	  not	  been	  evaluated	  prospectively	  in	  a	  randomised	  manner.	  
	  
These	  studies	  have	  therefore	  shown	  effective	  and	  durable	  response	  to	  pDLI	  particularly	  in	  the	  context	  of	  
lymphoma.	   Importantly,	   conversion	   to	   FDC	   and	   durable	   remissions	   were	   not	   always	   accompanied	   by	  
clinical	   evidence	   of	   GvHD,	   suggesting	   that	   it	   is	   possible	   to	   modulate	   chimerism	   in	   such	   a	   way	   as	   to	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promote	   alloreactive	   graft-­‐versus-­‐lymphoma	   responses	   without	   toxicity.	   The	   efficacy	   of	   pDLI	   for	  
haematological	  malignancies	  that	  tend	  to	  show	  a	  more	  rapid	  pace	  of	  recurrence,	  such	  as	  AML,	  has	  been	  
less	   clearly	  documented.	  Given	   that	  AML	   frequently	   recurs	  during	   the	   first	  6	  months	   following	  TCD	  RIC	  
HSCT155,	   there	   is	   also	   a	   rationale	   for	   earlier	   intervention	  with	   pDLI	   to	   prevent	   relapse.	   A	   retrospective	  
analysis	   from	  our	   institution	  has	   shown	   that	   around	  half	   of	   patients	  who	  underwent	   TCD	  RIC	  HSCT	   for	  
MDS,	  or	  AML	  secondary	  to	  MDS,	  have	  mixed	  donor	  T-­‐cell	  chimerism	  at	  6	  months	  to	  1	  year141.	  Lim	  et	  al	  
demonstrated	   that	  17/28	   (61%)	  patients	   following	  FBC	  RIC	  HSCT	   for	  MDS/AML	  converted	   from	  MDC	  to	  
FDC	   after	   receiving	   pDLI.	   Of	   the	   28	   recipients	   of	   pDLI,	   10	   (36%)	   subsequently	   developed	  GvHD156.	   The	  
median	  time	  to	  pDLI	  post-­‐HSCT	  was	  196	  days	  (range	  76–469	  days)	  and	  a	  median	  of	  2	  doses	  of	  escalating	  
dose	  pDLI	  were	  given	  (range	  1-­‐7).	  In	  the	  small	  cohort	  of	  pDLI	  recipients	  patients	  described,	  median	  OS	  and	  
disease-­‐free	  survival	  (DFS)	  of	  80%	  and	  77%	  respectively	  at	  2	  years	  were	  observed.	  Thus	  these	  encouraging	  
findings	  support	  potential	  efficacy	  of	  pDLI	  in	  patients	  with	  predominant	  recipient	  or	  declining	  donor	  T-­‐cell	  
chimerism	  but	  an	  assessment	  of	  efficacy	  and	  toxicity	  in	  a	  larger	  cohort	  of	  patients	  is	  warranted	  and	  forms	  




1.6 WT1	  peptide	  vaccination	  targeting	  AML	  
A	  recent	  pilot	  project	  by	  the	  National	  Cancer	   Institute	   identified	  the	  WT1	  protein	  as	  the	  highest	  priority	  
TAA	  to	  be	  considered	  when	  designing	  studies	  of	  immunotherapy	  for	  malignant	  disease157.	  This	  was	  based	  
on	   a	   number	   of	   criteria,	   including	   (1)	   specificity	   of	   expression	  by	   cancer	   cells,	   (2)	   expression	   levels,	   (3)	  
surface	  or	  intracellular	  localization	  within	  tumour	  cells,	  (4)	  frequency	  of	  over-­‐expression	  within	  patients,	  
(5)	  oncogenicity	  and	  (6)	  evidence	  of	  immunogenicity	  in	  vivo157.	  Although	  no	  candidate	  TAA	  possessed	  all	  
desirable	   characteristics,	  WT1	   surpassed	  other	   LAAs	  according	   to	   these	   criteria.	  WT1	   remains	   the	  most	  
extensively	  studied	  LAA	  to	  date	  in	  the	  context	  of	  leukaemia	  immunotherapy.	  Its	  suitability	  as	  a	  target	  and	  
utility	   in	   peptide	   vaccines	   for	   leukaemia	   immunotherapy	   is	   outlined	   below,	  with	   detailed	   discussion	   of	  
peptide	  vaccination	  studies	  targeting	  WT1	  to	  date.	  
	  
1.6.1 Suitability	  of	  WT1	  as	  a	  target	  for	  immunotherapy	  of	  AML	  
The	  Wilms’	  Tumour	  (WT1)	  gene,	  located	  on	  chromosome	  11p13,	  was	  identified	  as	  a	  tumour	  suppressor	  in	  
cases	  of	  sporadic	  and	  hereditary	  paediatric	  nephroblastoma158.	  The	  gene	  spans	  50Kb	  and	  is	  comprised	  of	  
10	   exons	   containing	   alternative	   splice	   sites	   resulting	   in	   the	   production	   of	   4	   protein	   isoforms159,160.	   The	  
protein	   product	   is	   a	   member	   of	   the	   Early	   Growth	   Response	   (EGR)	   family	   of	   transcription	   factors,	  
possessing	  four	  zinc	  finger	  motifs	  for	  binding	  to	  EGR-­‐1	  consensus	  sequences	  in	  promoters	  of	  genes	  such	  
as	  Insulin-­‐like	  Growth	  Factor	  (IGF)-­‐II	  and	  Platelet	  Derived	  Growth	  Factor	  (PDGF)	  –	  A	  chain158-­‐160.	  The	  WT1	  
protein	   is	   normally	   expressed	   at	   its	   highest	   level	   during	   embryonic	   development.	   	   It	   shows	   low-­‐level	  
expression	   in	   adulthood,	   when	   it	   is	   confined	   to	   the	   nuclei	   of	   normal	   tissues	   such	   as	   thymus,	   spleen,	  
haematopoietic	  progenitor	  cells,	  renal	  and	  gonadal	  cells74,159.	  	  	  
	  
Increased	  expression	  of	  WT1	  messenger	  ribonucleic	  acid	  (mRNA)	  and/or	  protein	  has	  been	  demonstrated	  
in	   various	   haematopoietic	   malignancies	   (AML,	   CML,	   ALL	   and	   MDS)161-­‐164.	   	   Whilst	   data	   are	   conflicting	  
regarding	  the	  prognostic	  implication	  of	  the	  level	  of	  WT1	  expression	  in	  AML	  patients	  at	  diagnosis74,165-­‐168,	  it	  
is	   recognized	   that	  WT1	   is	   frequently	   overexpressed	   in	   their	   abnormal	  mononuclear	   cells.	   Studies	   have	  
reported	   that	  WT1	   is	   highly	   expressed	   (as	  measured	   by	   quantitation	   of	  mRNA	   transcripts)	   in	   the	   AML	  
blasts	  of	  at	  least	  70%	  of	  newly	  diagnosed	  patients163.	  	  Expression	  of	  WT1	  mRNA	  by	  AML	  blasts	  at	  diagnosis	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has	   been	   shown	   to	   be	   300-­‐400	   fold	   higher	   than	   that	   in	   normal	   bone	   marrow	   in	   one	   study169.	   More	  
recently,	   data	   from	   a	   European	   LeukaemiaNet	   study	   using	   a	   standardized	   assay	   for	   WT1	   mRNA	  
measurement,	   identified	  median	   expression	   of	  WT1	  mRNA	   by	   real-­‐time	   quantitative	   polymerase	   chain	  
reaction	   (RT-­‐qPCR)	   in	   the	   peripheral	   blood	   (PB)	   and	   bone	  marrow	   (BM)	   of	   healthy	   controls	   to	   be	   0.01	  
copies	   /104	  ABL	   copies	   (range,	   0.01-­‐47.6)	   and	  19.8	   copies/104	  ABL	   copies	   (range,	   0-­‐213)	   respectively	   in	  
204	  healthy	  donor	  specimens.	  By	  contrast,	  analysis	  of	  504	  pre-­‐treatment	  AML	  samples	  revealed	  median	  
WT1	  expression	   in	  PB	  and	  BM	  to	  be	  3107	   (range	  0-­‐1.13x106)	  copies/104	  ABL	  copies	  and	  2505	   (range	  0-­‐
7.5x105)	  copies/104	  ABL	  copies67.	  Far	  less	  frequently,	  mutations	  in	  WT1	  (usually	  insertions	  or	  deletions	  in	  
exons	  7	  and	  9)	  have	  been	  observed	  in	  paediatric	  and	  adult	  AML	  patients,	  particularly	  in	  normal	  karyotype	  
AML	  or	   in	   association	  with	  Flt-­‐3	  mutation74.	   In	   one	   study,	   10%	  of	   cytogenetically	   normal	   AML	  patients	  
harboured	  WT1	  mutations	  at	  diagnosis170,	  however	  data	  are	  contradictory	  as	  to	  whether	  these	  mutations	  
predict	  adverse	  outcomes6.	  
	  
The	   frequent	   overexpression	   of	  WT1	   gene	   products	   in	   AML	   patients	   renders	   it	   an	   attractive	   target	   for	  
AML	   immunotherapy.	  However,	  WT1	   expression	  by	  healthy	   tissues	   is	  an	   important	  consideration,	   since	  
the	   induction	  of	  WT1-­‐specific	   immune	   responses	  could	   result	   in	  autoimmunity	  against	   renal	   glomerular	  
podocytes	   or	   haematopoietic	   cells.	   During	   myeloid	   differentiation	   there	   is	   up-­‐regulation	   of	   WT1	  
expression	   by	   common	  myeloid,	   granulocyte-­‐monocyte	   and	   megakaryocyte-­‐erythroid	   progenitors	   (4%,	  
2%	   and	   17%	   of	   cells	   respectively)	   but	   <1%	   of	   fully	   differentiated	   myeloid	   cells	   have	   detectable	  WT1	  
expression74,171.	  WT1	   has	   been	   shown	   to	   be	   detectable	   in	   ~1%	   of	   CD34+	   pluripotent	   haematopoietic	  
progenitor	   cells	   (both	   in	   the	   committed	   (proliferating)	   CD38+	   and	   uncommitted	   (quiescent)	   CD38-­‐	  
fractions)	  but	  not	  in	  long-­‐term	  bone	  marrow	  haematopoietic	  stem	  cells74.	  Additionally,	  overexpression	  of	  
WT1	   in	   CD34+	   CD38-­‐	   LSCs	   relative	   to	   healthy	   haematopoietic	   stem	   cells	   has	   been	   demonstrated171,172.	  
Such	  endosteal	  BM	  resident	  CD34+	  CD38-­‐	  LSCs	  are	  non-­‐cycling	  and	  therefore	  resistant	  to	  cytotoxic	  agents,	  
but	  may	  be	  sensitive	  to	  targeting	  of	  WT160.	  	  
	  
These	  findings	  collectively	  suggest	  that	  immunotherapeutic	  targeting	  of	  WT1	  should	  predominantly	  affect	  
malignant	  cells	  with	  abnormally	  high	  levels	  of	  WT1	  expression,	  rather	  than	  normal	  tissues	  showing	  much	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lower	  expression.	  Indeed,	  studies	  of	  the	  lytic	  function	  of	  WT1-­‐specific	  CTLs	  have	  demonstrated	  selective	  
elimination	  of	  leukaemic	  over	  healthy	  CD34+	  cells.	  A	  high-­‐avidity	  WT1-­‐specific	  CTL	  line	  killed	  CD34+	  cells	  
isolated	  from	  CML	  patients	  but	  not	  healthy	  donor	  CD34+	  cells.	  The	  difference	  in	  lysis	  was	  attributed	  to	  the	  
much	   lower	   expression	   of	  WT1	   (determined	   by	   RT-­‐PCR	   of	   extracted	   mRNA	   and	   Western	   Blotting)	   by	  
healthy	  CD34+	  cells	   in	  comparison	  with	  CD34+	  cells	  from	  CML	  patients173.	   In	  addition,	  these	  researchers	  
and	   a	   separate	   group	   showed	   no	   inhibition	   of	   colony	   formation	   by	   healthy	   donor	   bone	   marrow	   cells	  
following	  co-­‐culture	  with	  WT1-­‐specific	  CTLs173,174.	  	  
	  
An	  additional	  feature	  rendering	  WT1	  an	  attractive	  candidate	  for	   immunotherapeutic	  targeting	   in	  AML	  is	  
its	  putative	  role	  in	  maintenance	  of	  the	  malignant	  phenotype.	  This	  has	  been	  proposed	  by	  the	  observation	  
of	  reduced	  proliferation	  of	  leukaemic	  cells	  exposed	  to	  WT1	  antisense	  oligonucleotides	  and	  suggests	  that	  
WT1	  represents	  a	  persistent	  target	  in	  AML	  cells	  during	  the	  disease	  course164.	  Finally,	  WT1	  expression	  may	  
serve	   as	   a	   marker	   of	   minimal	   residual	   disease	   (MRD)	   and	   early	   predictor	   of	   disease	   recurrence.	  
Immunotherapeutic	  targeting	  of	  WT1	  during	  a	  period	  of	  low	  disease	  burden,	  detected	  through	  monitoring	  
of	  WT1	  mRNA	  in	  patients’	  PBMCs,	  could	  therefore	  represent	  an	  efficacious	  strategy175.	  
	  
1.6.2 Immunogenicity	  of	  WT1:	  vaccine-­‐induced	  and	  spontaneous	  T-­‐cell	  responses	  directed	  at	  WT1	  
epitopes	  in	  mice	  and	  humans	  
	  
1.6.2.1 Induction	  of	  WT1-­‐specific	  T-­‐cell	  responses	  in	  murine	  models	  
Early	  studies	  exploited	  murine	  models	  to	   investigate	  putative	   immunogenic	  WT1	  epitopes	  using	  peptide	  
vaccinations.	  The	  DNA	  coding	   sequence	  of	  WT1	   shows	  a	  high	   level	  of	   conservation:	  approximately	  81%	  
sequence	   homology	   between	   murine	   and	   human	   cDNA	   with	   a	   92%	   homology	   between	   the	   protein-­‐
encoding	   regions	   (Figure	   1-­‐4)160,176.	   Immunogenic	   epitopes	   from	   homologous	   sequences	   within	   both	  
murine	   and	   human	   WT1	   may	   therefore	   be	   selected	   for	   studies	   in	   murine	   models	   of	   WT1	   peptide	  
vaccination.	  WT1	  also	  shows	  a	  similar	  pattern	  of	  expression	  in	  adult	  murine	  and	  human	  tissues,	  therefore	  
autoimmune	   toxicity	   as	   a	   consequence	   of	   WT1	   peptide	   vaccination	   in	   mice	   may	   predict	   toxicities	   in	  
humans.	  Furthermore,	  successful	  induction	  of	  WT1-­‐specific	  T-­‐cell	  responses	  in	  mice	  suggests	  tolerance	  to	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this	  self-­‐antigen	  can	  be	  subverted,	  which	  is	  likely	  to	  be	  similarly	  required	  for	  effective	  induction	  of	  WT1-­‐













Alignment	  of	  murine	  and	  human	  amino	  acid	  sequences	  of	  WT1	  (accession	  numbers	  NP_659032.3	  and	  
NP_077744.3	  respectively)	  reveals	  92%	  sequence	  homology.	  	  Human	  and	  murine	  sequences	  are	  aligned	  
above;	  the	  intervening	  row	  outlines	  the	  homologous,	  missing	  and	  altered	  amino	  acids.	  Sequence	  
alignment	  was	  performed	  using	  the	  ExPasy	  Bioinformatics	  Resource	  Portal	  (http://www.expasy.org)177.	  	  
	  
One	  of	  the	  earliest	   identified	  HLA-­‐A*02:01	  restricted	  WT1	  epitopes,	  p126	  (RMFPNAPYL,	  WT1-­‐RMF),	  was	  
initially	  shown	  to	  stimulate	  human	  HLA-­‐A*02:01	  specific	  CTLs	  in	  vitro178	  and	  subsequently	  to	  promote	  H-­‐
2Db-­‐restricted	   T-­‐cell	   responses	   in	   C57BL/6	   mice179.	   Sugiyama’s	   group	   suggested	   comparable	   binding	  
affinity	  of	  WT1-­‐RMF	  to	  H-­‐2Db	  or	  HLA-­‐A*02:01,	  a	  finding	  since	  supported	  by	  in	  silico	  HLA	  binding	  prediction	  
software,	   such	   as	   SYFPEITHI	   (http://www.syfpeithi.de/index.html)180	   and	   the	   Immune	  Epitope	  Database	  
(IEDB)	   (http://www.immuneepitope.org/)181.	   These	   programmes	   analyse	   proteins	   for	   the	   presence	   of	  
sequence	  motifs	  (the	  set	  of	  anchor	  residues	  within	  the	  peptide	  which	  interact	  with	  the	  relevant	  binding	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Figure	  1-­‐4	  Protein	  sequence	  alignment	  of	  murine	  and	  human	  WT1	  protein	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points	  within	  a	  particular	  HLA	  molecule)	  to	  enable	  the	  identification	  of	  putative	  immunogenic	  epitopes.	  In	  
the	   case	   of	   SYFPEITHI,	   the	   top	   2%	   of	   listed	   peptides	   in	   the	   output	   are	   predicted	   to	   have	   the	   highest	  
binding	  affinity	  to	  a	  particular	  allele	  (generally	  scoring	  >20	  on	  the	  binding	  index)180.	  Using	  the	  SYFPEITHI	  
algorithm,	   binding	   scores	   for	   WT1-­‐RMF	   to	   H-­‐2Db	   and	   HLA-­‐A*02:01	   are	   comparable,	   at	   24	   and	   22	  
respectively180.	  	  
	  
Sugiyama’s	   group	   demonstrated	   that	   C57BL/6	   mice	   immunised	   with	   syngeneic,	   lipopolysaccharide-­‐
stimulated	  splenocytes	  loaded	  with	  WT1-­‐RMF	  resulted	  in	  rejection	  of	  the	  WT1	  over-­‐expressing,	  syngeneic	  
leukaemic	   cell	   line	   FBL-­‐3,	   without	   toxicity	   against	   healthy	   tissue,	   such	   as	   glomerular	   epithelium179.	  
Although	   other	   epitopes	   derived	   from	   WT1	   have	   been	   explored	   in	   peptide	   vaccination	   studies	   using	  
C57BL/6	  mice159,	  WT1-­‐RMF	  remains	  the	  most	  extensively	  studied	  to	  date.	  Whilst	   induction	  of	  WT1-­‐RMF	  
specific	   CTL	   responses	   in	   mice	   following	   repeated	   vaccinations	   has	   been	   demonstrated,	   in	   general,	  
vaccinations	   have	   been	   effective	   only	   in	   the	   prophylactic	   setting179,182	   (rejection	   of	   subsequent	   tumour	  
challenge),	   with	   diminished	   therapeutic	   efficacy	   for	   established	   tumours182-­‐184.	   This	   was	   most	   recently	  
described	  by	  Kohrt	  et	  al.,	  who	  vaccinated	  C57BL/6	  mice	  up	  to	  4	  times	  at	  weekly	  intervals	  with	  WT1-­‐RMF	  
peptide	  in	  combination	  with	  Incomplete	  Freund’s	  Adjuvant	  (IFA)	  and	  determined	  the	  frequency	  of	  WT1-­‐
RMF	  specific	  T-­‐cells	  in	  peripheral	  blood	  after	  each	  vaccination	  using	  fluorescence-­‐based	  tetramer	  analysis,	  
Figure	  1-­‐5.	  After	  4	  rounds	  of	  vaccination,	  approximately	  1-­‐1.5%	  of	  all	  CD8+	  T-­‐cells	  were	  WT1-­‐RMF	  specific.	  
Following	  in	  vitro	  cultures,	  the	  percentage	  of	  IFNγ+	  CD8+	  memory	  T-­‐	  cells	  responding	  specifically	  to	  WT1-­‐
expressing	   tumour	   cells	   was	   higher	   (at	   10-­‐15%),	   Figure	   1-­‐5.	   Mice	   immunized	   four	   times	   were	   able	   to	  
subsequently	   reject	   FBL-­‐3	   cells	   resulting	   in	   superior	   survival	   compared	   with	   mice	   immunized	   with	   IFA	  




















Taken	  from	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presence of disseminated tumor. In contrast, survival of prophy-
lactically vaccinated, FBL3-challenged mice was significantly
improved after 1 to 4 weekly WT1 peptide vaccinations before
FBL3 tumor inoculation; all mice in the group that received 4
weekly WT1 peptide vaccinations before FBL3 tumor challenge
survived beyond 50 days (P ! .001 vs IFA injected group),
between 75% and 80% of mice survived if 2 or 3 WT1
vaccinations preceded FBL3 tumor challenge (P ! .001), and
40% of mice survived if one WT1 vaccination preceded FBL3
tumor challenge (P " .002; Figure 1B). The evaluation of
2 other murine strains with the same MHC class I type, (H-2Db),
LP/J, and C3H.SW, confirmed protection of all prophylactically
vaccinated FBL3-challenged mice. Survival was significantly
improved after 4 weekly prophylactic WT1 peptide vaccinations
before FBL3 tumor challenge compared with mice that received
control IFA vaccination (P ! .001; Figure 1C-D).
We next determined if 4 therapeutic WT1 peptide vaccina-
tions beginning 24 hours after FBL3 tumor inoculation would
also inhibit tumor growth (Figure 1E). Figure 1F shows that
among the 3 murine strains, 4 weekly WT1 vaccinations
administered after FBL3 tumor inoculation prolonged median
survival by only 1 to 2 weeks compared with mice that received
control vaccination with IFA alone, and all therapeutically
vaccinated mice died by day 50.
WT1 peptide vaccination generates memory CD44hiCD8!
T cells that are WT1-tetramer! and can produce IFN-" after
tumor cell stimulation
We assessed whether WT1 peptide vaccination induced a WT1
antigen specific CD8# T-cell response. Figure 2A shows flow
cytometry plots staining for CD44 and WT1-tetramer among
gated CD8# T cells obtained from PBLs from C57BL/6 mice after
1-4 weekly WT1 vaccinations compared with 4 weekly control IFA
vaccinations. In all cases, PBLs were collected 28 days after the
first vaccination. Increased percentages of WT1-tetramer#CD44hi
cells were observed among gated CD8# T cells with each addi-
tional WT1 peptide vaccination. After 4 weekly WT1 peptide
vaccinations the WT1-tetramer#CD44hi cells rose to a mean of
0.75% among the gated CD8# T cells in the blood which was
significantly increased compared with mice that received fewer
peptide vaccinations (P ! .01), and compared with vaccination
with IFA alone (0.15%; P ! .01; Figure 2B).
We next determined if the CD8#CD44hi T-cell population was
specifically reactive to WT1 expressing tumor cells by stimulating
PBLs obtained from WT1 or IFA control vaccinated mice with an
equal number of irradiated FBL3 or H11 tumor cells for 24 hours.
Figure 2C shows a marked increase from 0.1 to 5 and 13.5% in
cells staining positively for CD44 and IFN-$ among gated CD8#
T cells in mice that received 2 and 4 WT1 peptide vaccinations,
respectively, after coculture with FBL3 tumor cells compared with
mice injected with IFA (P ! .01). In contrast, PBLs obtained from
similar groups of WT1 vaccinated mice revealed minimal IFN-$
production after incubation with irradiated WT1 nonexpressing,
H11 tumor cells (Figure 2C-D). The mean percentages of IFN-$
producing cells were significantly different when FBL3 and H11
stimulations were compared (P ! .001; Figure 2D).
Donor WT1 peptide vaccination combined with allogeneic BMT
enhances antileukemia activity against the FBL3 tumor
We next assessed whether the T-cell immune response induced by
WT1 vaccination could be efficiently transferred into irradiated
FBL3 tumor-inoculated recipients and inhibit tumor growth in
Figure 2. WT1 peptide vaccination induces memory CD8! T cells which are functional and WT1-specific. (A-D) Peripheral blood lymphocytes (PBLs) from C57BL/6
mice were isolated 28 days after the first vaccination. (A) Representative flow cytometry plots show percent of gated CD8 T cells staining positively for CD44 and WT1-tetramer
(box) after 1 to 4 vaccinations. Plots are representative of 5 mice per group. (B) Mean percentage of CD8# WT1-tetramer# cells among gated CD8# T cells (*P ! .001).
(C) Representative flow cytometry plots show percent of gated CD8# T cells stained positively for CD44 and intracellular IFN-$ (box) after 24-hour coculture with
irradiated FBL3 tumor cells or H11 tumor cells (negative control). Plots are representative of 5 mice per group. (D) Mean percentages of CD8#IFN-$# T cells among
gated CD8# T cells (*P ! .001).
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presence of disseminated tumor. In contrast, survival of prophy-
lactically vaccinated, FBL3-challenged mice was significantly
improved after 1 to 4 weekly WT1 peptide vaccin tions before
FBL3 tumor inoculation; all mice in th group that received 4
weekly WT1 peptide vaccinations before FBL3 tumor challenge
survived beyond 50 days (P ! .001 vs IFA injected group),
between 75% and 80% of mice survived if 2 or 3 WT1
vaccinations preceded FBL3 tumor challenge (P ! .001), and
40% of mice survived if one WT1 vaccination preceded FBL3
tumor challenge (P " .002; Figure 1B). The evaluation of
2 other murine strains with the sam MHC cl ss I type, (H-2Db),
LP/J, and C3H.SW, confirmed protection of all prophylactically
vaccinate FBL3-challenged mice. Survival was significantly
improved after 4 weekly prophylactic WT1 peptide vaccinations
before FBL3 tumor challenge compared with mice that received
control IFA vaccination (P ! .001; Figure 1C-D).
We next determined if 4 therapeutic WT1 peptide vaccina-
tions beginning 24 hours after FBL3 tumor inoculation would
also inhibit tumor growth (Figure 1E). Figure 1F shows that
among the 3 murine strains, 4 weekly WT1 vaccinations
administered after FBL3 tumor inoculation prolonged median
survival by only 1 to 2 weeks compared with mice that received
control vaccination with IFA alone, and all therapeutically
vaccinated mice died by day 50.
WT1 peptide vaccination generates memory CD44hiCD8!
T cells that are WT1-tetramer! and can produce IFN-" after
tumor cell stimulation
We assessed whether WT1 peptide vaccination induced a WT1
antigen specific CD8# T-cell response. Figure 2A shows flow
cytometry plots staining for CD44 and WT1-tetramer among
gated CD8# cells obtained from PBLs from C57BL/6 mice after
1-4 weekly WT1 vaccinations compared with 4 weekly control IFA
vaccinations. In all c s s, PBLs were collected 28 days after the
first vaccination. Increased percentages of WT1-tetramer#CD44hi
cells were observed amo g gated CD8# T c l s with each a di-
tional WT1 p ptide vaccination. After 4 weekly WT1 peptide
vaccinations the WT1-tetramer#CD44hi cells rose to a mean of
0.75% among the gated CD8# T cells in the blood which was
significantly increased compared with mic that received fewer
peptide vaccinations ( . ), and compared with vaccination
with IFA alone (0.15%; P ! .01; Figure 2B).
We next determined if the CD8#CD44hi T-cell population was
specifically reactive to WT1 expressing tumor cells by stimulating
PBLs obtained from WT1 or IFA control vaccinated mice with an
equal number of irradiated FBL3 or H11 tumor cells for 24 hours.
Figure 2C shows a marked increase from 0.1 to 5 and 13.5% in
cells staining positively for CD44 and IFN-$ among gated CD8#
T cells in mice that received 2 and 4 WT1 peptide vaccinations,
respectively, after coculture with FBL3 tumor cells compared with
mice injected with IFA (P ! .01). In contrast, PBLs obtained from
similar groups of WT1 vaccinated mice revealed minimal IFN-$
production after incubation with irradiated WT1 nonexpressing,
H11 tumor cells (Figure 2C-D). The mean percentages of IFN-$
producing cells were significantly different when FBL3 and H11
stimulations were compared (P ! .001; Figure 2D).
Donor WT1 peptide vaccination combined with allogeneic BMT
enhances antileukemia activity against the FBL3 tumor
We next assessed whether the T-cell immune response induced by
WT1 vaccination could be efficiently transferred into irradiated
FBL3 tumor-inoculated recipients and inhibit tumor growth in
Figure 2. WT1 p ptide vaccination indu es memory CD8! T cells which are functional and WT1-specific. (A-D) P ripheral blo d lymph cytes (PBLs) from C57BL/6
mice were isolated 28 days after the first vaccinatio . (A) Representative fl w cytometry plots show percent of gated CD8 T cells staining positiv ly for CD44 and WT1-tetramer
(box) after 1 to 4 vaccinations. Plots are representative of 5 mice per group. (B) Mean percentage f 8# WT1-tetramer# cells among g ted CD8# T cells (*P ! .001).
(C) Representative fl w cytometry plots show percent of gated CD8# T cells stai ed positively for CD44 and intracellula IFN-$ (b x) after 24 hour oculture with
irr diated FBL3 tumor cells or H11 tumor cells (negative control). Plots are representative of 5 mice per group. (D) Mean percentages of CD8#IFN-$# T cells among
gated CD8# T cells (*P ! .001).
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Figure	  1-­‐5	  WT1-­‐RMF	  specific	  T-­‐cell	  responses	  induced	  following	  repeated	  vaccination	  with	  WT1-­‐RMF	  and	  
Incomplete	  Freund’s	  Adjuvant	  can	  result	  in	  subsequent	  rejection	  of	  WT1-­‐expressing	  tumour	  but	  not	  
established	  tumour	  	  
Mice	  were	  immunized	  with	  IFA	  alone,	   r	  with	  IFA	  &	  WT1-­‐RMF,	  weekly	  for	  up	  to	  4	  vaccinations.	  Blood	  
samples	  were	  collected	  at	  day	  28	  fr m	  all	  mice	  and	  analysed	  for	  WT1-­‐RMF	  tetramer	  staining	  (A-­‐B)	   nd	  
IFNγ	  production	  following	  in	  vitro	  culture	  (C-­‐D).	  A.	  Percentages	  of	  CD44+	  (effector	  memory)	  WT1-­‐RMF	  
tetramer+	   CD8	   T-­‐cells	   at	   day	   28	   following	   1-­‐4	   vaccinations	   (rep esentative	   flow	   cytometry	   plot )	  B.	  
Mean	   percentage	   of	   WT1-­‐RMF-­‐tetramer+	   CD8+	   T	   cells,	   n=5	   per	   group.	   C.	   Peripheral	   blood	  
lymphocytes	  were	  isolated	  from	  mice	  after	  2	  rounds	  of	  vaccination	  with	  WT1-­‐RMF/IFA	  or	  4	  rounds	  of	  
vaccination	   with	   either	   IFA	   alone	   or	   WT1-­‐RMF&IFA.	   IFNγ	   production	   by	   CD8+	   CD44+	   T-­‐cells	   was	  
assessed	   aft r	   24-­‐hour	   co-­‐culture	   in	   vitro	   with	   WT1+	   FBL-­‐3	   or	   WT1-­‐	   H11	   tumour	   c ll	   lines	  
(repre entative	   flow	   cytometry	   l t	   from	   e ch	   group	   shown).	  D	  Me n	   percentage	   of	   IFNγ+	   CD8+	   T	  
cells	   in	  each	  group	   (n=5	  per	  group).	   (E-­‐F)	  Mice	  were	  challenged	  with	  1x105	  WT1+	  FBL-­‐3	  cells	  7	  days	  
after	  th 	  last	  of	  up	  to	  4	  immunizations	  (E)	  and	  survival	  was	  analysed.	  F	  Survival	  duration	  after	  tumour	  
challenge	   was	   significantly	   improved	   in	   mice	   immunized	   with	   WT1-­‐RMF	   and	   IFA	   relative	   to	   mice	  
receiving	  IFA	  alone	  (p<0.01	  for	  all	  WT1-­‐RMF	  immunized	  mice	  versus	  controls).	  Survival	  appeared	  to	  be	  
prolonged	  with	   increasing	  number	  of	   vaccinations	   received	   (no	   statistical	   comparisons	  between	   the	  
groups	  of	  WT1-­‐RMF	  immunized	  mice	  provided	  in	  this	  publication).	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These	   data	   suggest	   that	   despite	   induction	   of	   low	   frequencies	   of	   WT1-­‐specific	   T-­‐cells	   following	   4	  
vaccinations	   (determined	   by	   tetramer	   analyses),	   CTLs	   were	   of	   sufficient	   functional	   potency	   to	  
subsequently	  reject	  tumour	  cells.	  However,	  therapeutic	  vaccinations	  with	  4	  doses	  of	  WT1-­‐RMF	  and	  IFA,	  a	  
day	  after	  inoculation	  with	  FBL-­‐3,	  could	  not	  prevent	  death	  in	  any	  tumour-­‐bearing	  mice182.	  Therefore	  in	  the	  
context	   of	   active	   tumour	   growth,	   either	   the	   time	   taken	   to	   induce	   WT1-­‐RMF	   specific	   T-­‐cells	   or	   the	  
suppressive	   tumour	   microenvironment	   prevented	   immune-­‐mediated	   destruction	   of	   the	   tumour.	   Such	  
data	   highlights	   the	   requirement	   for	   more	   effective	   vaccination	   strategies	   to	   target	   WT1-­‐expressing	  
tumours,	  described	  in	  later	  sections.	  
	  
1.6.2.2 WT1-­‐specific	  T-­‐cell	  responses	  in	  healthy	  donors	  and	  patients	  
WT1-­‐RMF/A*02:01-­‐specific	   CTLs	   generated	   following	   prolonged	   cultures	   of	   healthy	   donor	   PBMCs	   have	  
demonstrated	  significant	  lytic	  activity	  against	  A*02:01+	  WT1-­‐expressing	  leukaemic	  cell	  lines	  (up	  to	  80%	  of	  
targets	  at	  the	  highest	  effector:	  target	  ratios)	  and	  primary	  leukaemic	  cells	  (up	  to	  60%	  of	  targets)	  in	  vitro173.	  	  
A	  number	  of	  other	  Class	   I174,185-­‐187	   and	   II188-­‐192	  epitopes	   from	  WT1	  have	  been	   identified	   through	   in	   vitro	  
cultures	  of	  healthy	  donor	  and	  patient	  PBMCs	  with	  candidate	  peptides.	  WT1-­‐specific	  CTLs	  generated	  from	  
such	  cultures	  have	  shown	  specific	  cytotoxicity	  against	  WT1-­‐expressing	  primary	  leukaemia	  cells	  or	  cell	  lines	  
in	  a	  HLA-­‐restricted	  manner,	  whilst	  sparing	  healthy	  CD34+	  cells173,186.	  Adoptive	   transfer	  of	  donor-­‐derived	  
WT1	   specific	   CTLs	   into	   non-­‐obese	   diabetic,	   severe	   combined	   immunodeficient	  mice	   (NOD	   SCID)	   led	   to	  
regression	   of	  WT1-­‐expressing	   human	   leukaemia173,186.	   Detection	   of	  WT1-­‐specific	   CTLs	   in	   the	   peripheral	  
blood	   of	   patients	   with	   myeloid	   malignancies	   has	   provided	   evidence	   that	   WT1	   is	   immunogenic	   in	   the	  
setting	   of	   active	   disease193,194.	   In	   the	   context	   of	   allogeneic	   HSCT,	   detectable	   WT1-­‐specific	   immune	  
responses	  in	  donors	  and	  HSCT	  recipients	  have	  been	  associated	  with	  GvL	  activity195-­‐197.	  	  
	  
Given	   this	   evidence	   supporting	   immunogenicity	   of	   selected	  WT1	   epitopes,	   investigators	   have	   explored	  
WT1	   peptide	   vaccination	   as	   a	   means	   to	   induce	   WT1-­‐specific	   cytotoxic	   T-­‐cell	   responses	   against	   WT1-­‐
expressing	   tumours.	   A	   number	   of	   Phase	   I/II	   trials	   of	   WT1	   peptide	   vaccination	   in	   patients	   with	  
haematological	  malignancies	  have	  been	  carried	  out,	  a	  selection	  of	  which	  are	  described	  in	  more	  detail	   in	  
Table	  1-­‐3.	  The	  majority	  of	  these	  studies	  (and	  also	  those	  in	  the	  setting	  of	  solid	  tumour)	  have	  used	  a	  single	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Class	  I	  peptide	  derived	  from	  WT1	  for	  vaccination.	  Patient	  cohorts	  have	  frequently	  comprised	  those	  with	  
myeloid	   malignancies,	   specifically	   AML,	   MDS	   or	   CML.	   Subjects	   usually	   had	   detectable	   disease	   burden	  
(morphological	  evidence	  of	  >5%	  leukaemic	  blasts	  on	  bone	  marrow	  examination	  or	  detectable	  WT1	  mRNA	  
transcripts	   in	   blood/bone	   marrow).	   Reductions	   in	   WT1	   mRNA	   burden	   have	   followed	   WT1	   peptide	  
vaccination	  in	  case	  series	  or	  in	  clinical	  trials198-­‐202.	  Similarly,	  withdrawal	  of	  vaccination	  was	  associated	  with	  
recrudescence	   of	   WT1	   mRNA	   transcripts	   in	   blood/bone	   marrow175,202.	   Immunological	   responses	   were	  
detectable	   in	   some	   patients	   following	   vaccination,	   including	   increased	   frequencies	   of	   WT1	   tetramer+	  
CD8+	  T-­‐cells	  and	  greater	  cytokine	  production	  (IFNγ	  or	  TNFα)	  by	  patient	  T-­‐cells	  upon	  re-­‐exposure	  to	  WT1	  
peptide	   in	   vitro173,198-­‐200.	   In	  one	   study,	   delayed	   type	  hypersensitivity	   reactions	  were	  detected	   in	   a	   small	  
number	  of	  patients	  who	  showed	  a	  sustained	  remission	  following	  vaccination201.	  Only	  one	  study,	  using	  a	  
single	  Class	   I	  HLA-­‐A*24:02	  restricted	  peptide	  to	  vaccinate	  Japanese	  patients	  demonstrated	  a	  correlation	  
between	   the	   induction	   of	   increased	   frequencies	   of	   WT1	   tetramer+	   T-­‐cells	   following	   vaccination	   to	  
reduction	   in	   tumour	   burden	   (percentage	   of	   BM	   leukaemic	   blasts	   and/or	   WT	   expression	   levels	   in	  
BM/blood)202.	   The	   proportion	   of	   patients	   demonstrating	   immunological	   responses	   to	   WT1	   peptide	  
vaccination	   has	   varied	   between	   44-­‐86%	   in	   these	   studies.	   Overall,	   the	  magnitude	   of	   the	   induced	  WT1-­‐
specific	  T-­‐cell	  responses	  has	  been	  small,	  with	  duration	  limited	  to	  weeks175,198-­‐200,202.	  
	  
One	  approach	  to	  enhancing	   immune	  response	   induction	   to	   the	  well-­‐studied	  epitope	  WT1-­‐RMF	  that	  has	  
been	  explored	  in	  pre-­‐clinical	  and	  now	  clinical	  studies	  has	  been	  heteroclitic	  modification	  of	  this	  peptide	  to	  
enhance	  binding	  to	  the	  HLA	  Class	  I	  binding	  groove.	  Scheinberg’s	  group	  substituted	  the	  arginine	  at	  position	  
one	  (a	  secondary	  anchor	  residue	  for	  MHC	  Class	  I	  binding)	  for	  a	  tyrosine	  residue	  (WT1-­‐YMFPNAPYL,	  WT1-­‐
YMF)203.	  WT1-­‐YMF	  was	  predicted	  in	  silico	  to	  have	  higher	  binding	  affinity	  for	  HLA-­‐A*02:01	  (SYFPEITHI	  score	  
24	  versus	  22	  for	  the	  native	  WT1-­‐RMF).	  Greater	  binding	  of	  WT1-­‐YMF	  to	  the	  Class	  I	  peptide-­‐binding	  groove	  
may	  result	  in	  a	  higher	  density	  of	  WT1-­‐YMF/A*02:01	  complexes	  on	  APCs	  and	  more	  sustained	  presentation	  
to	  CD8+	  T-­‐cells	  that	  cross-­‐react	  with	  the	  native	  WT1-­‐RMF/A*02:01	  complex203,204.	  T-­‐cell	  clones	  generated	  
in	  vitro	  against	  WT1-­‐YMF	  showed	  greater	  IFNγ	  production	  when	  re-­‐exposed	  to	  the	  native	  or	  heteroclitic	  
peptide	   in	  comparison	  to	  WT1-­‐RMF-­‐specific	  CTLs,	  but	  did	  not	  show	  superior	   lysis	  of	  primary	  WT1+	  CML	  
cells203.	   The	   group	   used	  WT1-­‐YMF	   as	   part	   of	   their	   multi-­‐epitope	   vaccine	   against	   WT1	   (Table	   1-­‐3)	   and	  
demonstrated	   cross-­‐reactivity	   of	   CD8+	   T-­‐cells	   isolated	   from	   vaccinated	   patients	   against	   the	   native	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peptide,	  by	  virtue	  of	  proliferative	  responses,	  cytokine	  production	  and	  lysis	  of	  WT1-­‐expressing	  targets201.	  
Overall,	  the	  use	  of	  heteroclitic	  peptides	  in	  cancer	  vaccines	  has	  shown	  variable	  efficacy,	  enhancing	  antigen-­‐
specific	   immune	   responses	   against	   some	   targets205	   or	   priming	   CTLs	   with	   inferior	   anti-­‐tumour	   activity	  
compared	   to	   CTLs	   stimulated	  with	   the	   native	   peptide206.	   As	   yet	   it	   is	   uncertain	  whether	   immunisations	  
using	  WT1-­‐YMF	  afford	  superior	  efficacy	  over	  WT1-­‐RMF	  for	  induction	  of	  WT1-­‐RMF-­‐specific	  responses.	  This	  
approach	  warrants	  further	  investigation	  in	  vaccination	  studies.	  
	  
These	  early	  phase	  studies	  of	  WT1	  peptide	  vaccination	  have	  primarily	  been	  designed	  to	  assess	  safety	  and	  
feasibility	   of	   peptide	   vaccination	   targeting	  WT1.	  Minor	   toxicity	   has	   been	   reported	   despite	   evidence	   of	  
WT1-­‐specific	   immune	   responses	   being	   induced	   (Table	   1-­‐3).	   Indeed	   a	   handful	   of	   patients	   have	   been	  
vaccinated	  over	  100	  times	  during	  an	  approximately	  8	  year	  treatment	  period	  with	  the	  only	  adverse	  events	  
described	   being	   local	   injection	   site	   induration175.	   In	   summary,	   substantial	   in	   vitro	   and	   in	   vivo	   evidence	  
from	  murine	  and	  human	  studies	  have	  suggested	  potential	  efficacy	  of	  peptide	  vaccination	  targeting	  WT1	  
as	  immunotherapy	  against	  myeloid	  leukaemia.	  Whilst	  clinical	  trial	  data	  supports	  induction	  of	  WT1-­‐specific	  
immune	  responses	  by	  vaccination,	  in	  some	  instances	  associated	  with	  a	  reduction	  in	  tumour	  burden,	  clear	  
objective	  evidence	  of	  sustained	  and	  efficacious	  anti-­‐leukaemic	  responses	  are	  lacking.	  In	  the	  next	  section,	  
methods	  to	  enhance	  induction	  of	  WT1-­‐specific	  immune	  responses	  are	  discussed.	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Table	  1-­‐3	  Clinical	  trials	  of	  WT1	  peptide	  vaccination	  in	  patients	  with	  myeloid	  malignancies	  	  





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.6.3 Limitations	  of	  vaccine	  approaches	  to	  date	  
While	  clinical	  studies	   indicate	  that	  WT1	  peptide	  vaccination	  appears	  safe,	   it	   is	  difficult	   to	  gauge	  efficacy	  
due	  to	  the	  inclusion	  of	  select	  patients,	  often	  with	  advanced	  stage	  disease,	  in	  uncontrolled	  Phase	  I-­‐II	  trials.	  
In	  such	  early	  phase	  studies,	  assessment	  of	   immune	  response	  induction	  has	  frequently	  been	  a	  secondary	  
endpoint.	  There	  are	  likely	  to	  be	  inherent	  obstacles	  to	  the	  induction	  of	   immune	  responses	  against	  a	  self-­‐
antigen	   in	   cancer	  patients,	  namely	   the	   requirement	   to	  overcome	  peripheral	   tolerance	  mechanisms	  and	  
the	   immune	   suppressive	  milieu	   within	   the	   tumour-­‐bearing	   host.	   There	   are	   specific	   limitations	   to	  WT1	  
peptide	   vaccination	   approaches	   reported	   to	   date	   that	   should	   be	   considered	   when	   designing	   new	  
vaccination	  strategies.	  Broadly,	  these	  can	  be	  divided	  into	  the	  choice	  of	  peptide(s)	  and	  adjuvants	  used	  for	  
vaccination.	  
	  
Choice	  of	  immunising	  WT1	  peptides	  
The	   majority	   of	   early	   studies	   of	   WT1	   peptide	   vaccination	   in	   both	   solid	   tumour	   and	   haematological	  
malignancies	  have	  used	  a	  single	  HLA	  Class	  I	  peptide	  for	  vaccination198-­‐200,202,208.	  Thus	  far,	  few	  studies	  have	  
included	   Class	   II	   epitopes	   within	   WT1	   peptide	   vaccines201,209.	   Incorporation	   of	   Class	   II	   epitopes	   is	  
attractive,	   as	  activation	  of	  CD4+	  helper	  T-­‐cells	  may	   increase	   the	   likelihood	  of	   generating	  memory	  T-­‐cell	  
responses210,211.	   One	   reported	   trial	   of	   WT1	   peptide	   vaccination	   not	   incorporating	   a	   helper	   epitope	  
demonstrated	   short-­‐lived	  WT1-­‐specific	   CD8+	   T-­‐cell	   responses,	   suggesting	   poor	  memory	   T-­‐cell	   response	  
induction200.	   Furthermore,	   activated	   CD4+	   T-­‐cells	   may	   be	   capable	   of	   directly	   mediating	   tumour	  
cytotoxicity212.	   AML	   and	   MDS	   patients	   with	   advanced	   phase	   disease	   have	   been	   shown	   to	   have	  
significantly	   elevated	  WT1-­‐specific	   Immunoglobulin-­‐gamma	   (IgG)	   antibodies	   in	   their	   sera	   in	   comparison	  
with	  early	  phase	  MDS	  patients	  and	  healthy	  volunteers213.	  This	  suggests	  a	  functional	  role	  for	  CD4+	  helper	  
T-­‐cells	   in	  supporting	  WT1-­‐specific	  adaptive	   immunity	  and	  taking	  these	  findings	  together,	  there	   is	  a	  clear	  
rationale	  for	  the	  inclusion	  of	  epitopes	  to	  stimulate	  helper	  responses.	  
	  
Synthetic	  long	  peptides	  (SLP)	  have	  been	  favoured	  over	  shorter	  Class	  II	  epitopes	  for	  inclusion	  in	  vaccines	  by	  
some	  researchers214.	  Proposed	  benefits	   include	  a	  greater	   likelihood	   that	  CD4+	  and	  CD8+	  epitopes,	  both	  
embedded	  within	  a	  carefully	  chosen	  SLP,	  will	  be	  processed	  by	  the	  same	  professional	  APC.	  This	  APC	  would	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present	  appropriate	  epitopes	  simultaneously	  to	  CD4+	  and	  CD8+	  T-­‐cells	  in	  close	  proximity.	  By	  contrast,	  use	  
of	   shorter	   peptides	   could	   result	   in	   exogenous	   loading	   of	   minimal	   length	   determinants	   onto	   MHC	  
molecules	  belonging	  to	  non-­‐professional	  APCs,	  including	  B	  and	  T	  cells,	  which	  may	  travel	  to	  draining	  lymph	  
nodes	   and	   drive	   transient	   or	   anergic	   responses	   in	   cognate	   T	   cells	   or	   perhaps	   even	   fratricide214.	  	  
Scheinberg’s	  group	  explored	  this	  approach	  by	  developing	  a	  multi-­‐epitope	  WT1	  vaccine	  including	  a	  Class	  I-­‐
binding	  nonamer,	  two	  Class	  II	  peptides	  and	  a	  SLP.	  The	  longer	  peptides	  were	  chosen	  for	  binding	  across	  a	  
range	  of	  Class	  II	  molecules	  and	  had	  shown	  induction	  of	  both	  CD4+	  and	  CD8+	  T	  cell	  responses	  following	  in	  
vitro	  cultures	  of	  healthy	  donor	  PBMCs190.	  This	  cocktail	  of	  WT1	  peptides	  has	  demonstrated	  safety	   in	  two	  
separate	  pilot	  studies	  of	  vaccination	  in	  AML201	  and	  lung	  cancer	  patients209.	  After	   in	  vitro	  culture	  of	  CD4+	  
and	  CD8+	  T-­‐cells	  isolated	  from	  vaccinated	  patients,	  IFNγ	  production,	  proliferative	  and	  lytic	  responses	  were	  
observed	  upon	  exposure	  to	  targets	  presenting	  the	  immunising	  peptides201,209.	  
	  
A	   further	   advance	   would	   be	   the	   inclusion	   of	   multiple	   epitopes	   covering	   the	   whole	   target	   antigen	  
sequence.	   By	   including	   several	   peptides	   spanning	   WT1,	   all	   known	   and	   as	   yet	   undiscovered	   immune	  
epitopes	   are	   included	   within	   a	   single	   “off-­‐the-­‐shelf”	   vaccine	   product.	   Indeed,	   recent	   detailed	   in	   vitro	  
studies	  by	  Doubrovina	  et	  al	  have	  identified	  41	  previously	  unreported	  immunogenic	  Class	  I	  and	  II	  epitopes	  
within	   WT1,	   capable	   of	   binding	   across	   a	   broad	   range	   of	   HLA	   types215.	   The	   advantage	   of	   using	   an	  
overlapping	  peptide	  pool	  rather	  than	  whole	  protein	  is	  that	  immunogenic	  epitopes	  would	  be	  more	  readily	  
accessible	  for	  processing	  and	  presentation	  by	  professional	  APCs.	  Use	  of	  the	  whole	  protein	  for	  vaccination	  
might	   increase	   the	   likelihood	  of	  generating	  a	  humoral	   rather	   than	  a	  cell-­‐mediated	   response.	  Given	   that	  
data	  is	  still	  accumulating	  regarding	  the	  identity	  of	   immunodominant	  epitopes	  within	  WT1	  for	  a	  range	  of	  
HLA	   types	   in	   vivo,	   vaccinating	   with	   a	   pool	   of	   overlapping	   WT1	   peptides	   encompassing	   all	   potential	  
epitopes	   is	   attractive.	   Overlapping	   peptide	   pools	   have	   been	   used	   in	   Phase	   II	   trials	   of	   therapeutic	  
vaccination	   against	   E6	   and	   E7	   oncoproteins	   expressed	   by	   Human	   Papilloma	   Virus	   (HPV)-­‐16–associated	  
gynaecological	   malignancies216,217.	   Whilst	   it	   is	   acknowledged	   that	   the	   responses	   generated	   in	   these	  
settings	   are	   against	   a	   foreign,	   tumour-­‐specific,	   virus-­‐derived	   antigen,	   nevertheless,	   therapeutic	   efficacy	  
and	   detectable	   immune	   responses	   in	   vaccinated	   patients	   have	   been	   observed.	   Vaccinating	   with	   more	  
than	  one	  immunogenic	  peptide	  may	  also	  prevent	  clonal	  deletion	  of	  T-­‐cells	  following	  repeated	  vaccination	  
against	  a	  single	  epitope200.	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Choice	  of	  adjuvant	  
A	  further	  explanation	  for	  the	  reported	  low	  magnitude	  and/or	  unsustained	  WT1-­‐specific	  T-­‐cell	  response	  to	  
vaccination	  so	  far	  may	  be	  the	  choice	  of	  adjuvant	  used.	  Until	  recently,	  few	  adjuvants	  capable	  of	  promoting	  
T-­‐cell	  responses	  have	  been	  considered	  clinically	  safe	  enough	  to	  be	  used	  in	  trials.	  The	  majority	  of	  clinical	  
studies	   of	  WT1	   peptide	   vaccination	   have	   used	   adjuvants	   with	   well	   established	   safety	   records,	   such	   as	  
Montanide	   (a	   derivative	   of	   incomplete	   Freund’s	   adjuvant)	   and	   GM-­‐CSF,	   Table	   1-­‐3218.	   Montanide	  
formulations	  comprise	  mineral	  or	  non-­‐mineral	  oil	  based	  adjuvants	  possessing	  surfactant	  properties	   that	  
act	  as	  vehicles	  for	  vaccine	  delivery	  as	  well	  as	  inducing	  a	  local	  inflammatory	  reaction219.	  GM-­‐CSF	  stimulates	  
and	  matures	  DCs	   and	   it	   is	   suggested	   that	   this	   quality	   facilitates	   induction	   of	   T-­‐cell	   responses	   following	  
peptide	  vaccination	  against	  a	  self-­‐antigen220.	  Such	  adjuvants	  have	  been	  widely	  used	   in	  clinical	   trials	  and	  
shown	   to	   be	   safe,	   however	   their	   efficacy	   remains	   uncertain.	   In	   part,	   this	   is	   due	   to	   incomplete	  
understanding	   of	   their	   modes	   of	   action.	   Some	   groups	   have	   raised	   concerns	   that	   vaccinations	   using	  
Montanide-­‐based	   emulsions	   containing	   Class	   I	   peptides	   were	   associated	   with	   induction	   of	   short-­‐lived	  
CD8+	  T-­‐cell	  activity	  and	  lack	  of	  memory	  response	  generation200,221.	  One	  explanation	  for	  this	  may	  be	  that	  
slow,	   sustained	   release	   of	   the	   Class	   I	   peptide	   from	   the	  Montanide	   depot	   in	   the	   absence	   of	   helper	   or	  
danger	   signals	   has	   a	   tolerising	   effect221.	   With	   regards	   to	   GM-­‐CSF,	   two	   clinical	   trials	   of	   vaccination	   in	  
melanoma,	  where	  patients	  were	  randomised	  to	  receive	  GM-­‐CSF	  (or	  not)	  with	  their	  vaccine,	  demonstrated	  
a	   statistically	   significant	   reduction	   in	   immunological	   responses	   for	   those	   patients	   who	   received	   GM-­‐
CSF222,223.	  It	  is	  possible	  that	  the	  local	  GM-­‐CSF	  injection	  favoured	  activation	  of	  myeloid-­‐derived	  suppressor	  
cells	  that	  prevented	  an	  effective	  immune	  response	  from	  being	  generated.	  Whilst	  this	  observation	  may	  be	  
vaccination	  dose	  or	  route	  dependent,	   it	  suggests	  that	   identification	  of	  more	  potent	  adjuvants	  for	  use	   in	  
vaccinations	  is	  desirable224.	  
	  
Most	   clinical	   trials	   of	   peptide	   vaccination	   reported	   to	   date	   have	   employed	   the	   limited	   selection	   of	  
adjuvants	  licensed	  for	  clinical	  use,	  generally	  adopted	  from	  the	  field	  of	  microbial	  vaccinology.	  Incomplete	  
understanding	  of	  the	  mechanism	  of	  action	  of	  the	  earliest	  adjuvant	  formulations	  and	  concerns	  about	  the	  
potential	   for	   induction	   of	   autoimmunity	   have	   contributed	   to	   delays	   in	   the	   development	   of	   the	   next	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generation	   of	   compounds	   designed	   to	   promote	   cell-­‐mediated	   immunity.	  Whilst	   the	  mode	   of	   action	   of	  
some	   of	   the	   earliest	   identified	   adjuvants	   has	   only	   recently	   been	   appreciated,	   it	   is	   clear	   that	   many	  
adjuvants	  exert	   their	  effects	  on	  B	  and	  T-­‐cells	  via	  cells	  of	   the	   innate	   immune	  system.	  As	  such,	   there	  has	  
been	  interest	  in	  exploiting	  vital	  players	  within	  the	  innate	  immune	  system,	  such	  as	  professional	  APCs	  that	  
act	   as	   gatekeepers	   to	   effective	   T-­‐cell	   priming	   and	   induction	   of	   adaptive	   immunity.	   Identification	   of	  
compounds	  mimicking	  danger	   signals	  arising	   from	   infectious	   stimuli	  has	  driven	   the	  exploration	  of	  more	  
potent	  mediators	  of	  cellular	  immunity,	  such	  as	  toll-­‐like	  receptor	  (TLR)	  agonists,	  as	  vaccine	  adjuvants.	  The	  
evidence	  and	  rationale	  to	  support	  this	  approach	  is	  discussed	  in	  the	  following	  section.	  
	  
1.6.4 Novel	  adjuvants	  for	  induction	  of	  cell-­‐mediated	  immunity	  
The	  importance	  of	  the	  innate	  immune	  system	  for	  priming	  adaptive	  immune	  responses	  has	  prompted	  the	  
investigation	   of	   ligands	   known	   collectively	   as	   pathogen	   associated	   molecular	   patterns	   (PAMPs)	   as	  
adjuvants.	  These	   ligands	  bind	  pattern	  recognition	  receptors	   (PRRs)	  on	  DCs	   to	  deliver	  a	  powerful	  danger	  
signal	   that	  provokes	   their	  maturation	   into	   fully	   functional,	   professional	  APCs.	  Hijacking	   such	   ligands	   for	  
use	  as	  adjuvants	   is	  one	  means	  to	  enhance	  response	  to	  vaccination.	  TLR	  agonists	  have	  been	  a	  particular	  
focus	   of	   interest	  with	   selected	   agonists	   now	   licensed	   for	   clinical	   use	   as	   adjuvants	  whilst	   others	   remain	  
under	  clinical	  trial	  investigation	  (Table	  1-­‐4).	  	  
	  
TLRs	   are	   among	   the	   best-­‐characterised	   PRRs	   (others	   include	   Nod-­‐like	   receptors,	   retinoic-­‐acid-­‐inducible	  
gene	   I	   (RIG-­‐I)-­‐like	   receptors,	   and	   C-­‐type	   lectin	   receptors),	   having	   initially	   been	   identified	   in	  Drosophila.	  
Thirteen	   TLRs	   have	   been	   identified,	   of	   which	   10	   are	   expressed	   in	   humans225.	   TLR	   function	   has	   been	  
studied	  to	  greatest	  depth	  in	  the	  context	  of	  expression	  by	  DCs,	  but	  a	  range	  of	  cell	  types,	  including	  epithelial	  
and	  endothelial	  cells,	  monocytes	  and	  lymphocytes	  express	  TLRs225.	  TLRs	  may	  be	  located	  at	  the	  cell-­‐surface	  
or	   internally	   located	   within	   endosomes	   and	   this	   spatial	   separation	   in	   part	   reflects	   the	   nature	   of	   the	  
ligands	  binding	  these	  different	  receptors226.	   	  TLRs-­‐1,	   -­‐2,	   -­‐4,	   -­‐5,	   -­‐6	  and	  -­‐11	  are	   located	  at	   the	  cell-­‐surface	  
and	  primarily	   recognize	   lipid	  and/or	  protein-­‐based	  components	  deriving	   from	  microbial	  walls226.	  One	  of	  
the	  most	  well	  defined	  agonists	  binding	  to	  a	  cell-­‐surface	  receptor	  is	  lipopolysaccharide	  (LPS),	  which	  binds	  
to	  TLR-­‐4	  on	  macrophages.	   TLRs	  3,	   -­‐7,	   -­‐8	  and	   -­‐9	  are	  exclusively	   found	  within	   compartments	   such	  as	   the	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endoplasmic	   reticulum	   (ER),	   endosomes,	   lysosomes	   and	   endolysosomes226.	   These	   receptors	   specifically	  










Ab,	  antibody;	  Th,	  T-­‐helper	  1/2/17.	  Taken	  from	  Coffman	  et	  al227.	  
	  
	  
They	   are	   in	   this	  way	   segregated	   from	   the	   rest	   of	   the	   cell	   to	   avoid	   activation	  by	   the	  host’s	   own	  nucleic	  
acids.	  TLR3	  was	  originally	  recognized	  to	  bind	  double-­‐stranded	  RNA	  (dsRNA,	  typically	  derived	  from	  viruses)	  
such	  as	  a	  synthetic	  analogue,	  polyinosinic-­‐polycytidylic	  acid	  (poly	  I:C).	  TLR9	  binds	  synthetic	  unmethylated	  
2’-­‐deoxyribocytidine-­‐phosphate-­‐guanosine	   oligodeoxynucleotides	   (CpG	   ODN),	   based	   on	   DNA	   motifs	  
present	   in	  microbes	  but	   infrequently	   found	   in	  mammalian	  cells226.	  Binding	  of	  CpG	  ODN	  to	  TLR9	  directly	  
activates	   DCs,	   macrophages	   and	   B-­‐cells	   and	   is	   involved	   in	   skewing	   towards	   a	   T-­‐helper	   (Th)	   1-­‐type	   of	  
immune	  response228,	  a	  function	  that	  may	  be	  appropriated	  for	  induction	  of	  cell-­‐mediated	  response	  against	  
tumours,	  described	  later.	  
	  
TLR	  ligation	  leads	  to	  the	  recruitment	  and	  activation	  of	  a	  number	  of	  signalling	  proteins,	  including	  Mitogen	  
activated	   protein	   (MAP)	   and	   Phosphoinositide-­‐3	   (PI3)	   kinases.	   Two	   major	   signalling	   pathways	   are	  
activated	  following	  TLR	  ligation:	  a	  myeloid	  differentiation	  primary	  response	  gene	  88	  (MyD88)-­‐dependent	  
Challenges for Vaccine Adjuvant Development: Humoral
Versus Cellular Immunity
Most current vaccines confer protection primarily through
humoral immunity (Plotkin, 2010). Responses are elicited by
a variety of vaccine platforms that include live attenuated,
recombinant protein, toxoids, or polysaccharide-protein conju-
gates. Antibody responses to many current vaccines are
long-lived and require infrequent or no additional boosting to
sustain protection (Amanna et al., 2007). Despite the impressive
success of such vaccines, there are substantial groups of people
for which current vaccines, even those using alum adjuvant, do
not achieve adequate seroconversion rates or protective anti-
body titers. Moreover, responses to vaccines begin to decline
in healthy adults after 40–50 years of age (Chen et al., 2009)
and as a result of health conditions such as chronic kidney
disease (Beran, 2008). The addition of an adjuvant to an existing
vaccine, as has been done for influenza (Podda, 2001), or
a witch fro alum to a more effective adjuvant, as for hepatitis
B virus (HBV) (Beran, 2008; Halperin et al., 2006), represents
a substantial benefit for these groups.
For polarization of helper T cell, there are striking differences in
the type of response preferentially stimulated by different adju-
vants. Adjuvants uch as MF59 and ISCOMs (Table 1), as well
as Toll-like receptor 2 (TLR2) and TLR5 ligands, enhance T cell
and antibody responses without altering their Th1/Th2 cell
balance of the specific antigens. In contrast, more polarized
Th1 cell responses are elicited by adjuvants that incorporate
agonists of TLR3, TLR4, TLR7-TLR8, and TLR9. Complete
Freund’s adjuvant (CFA) and CAF01 induce mixed Th1 and
Th17 cell responses. Thus, selection of an appropriate adjuvant
is influenced by the type of CD4+ T cell response required for
protection.
A more daunting challenge is developing adjuvants that will
generate protective CD8+ T cell responses to soluble proteins.
Here, the type of vaccine is dictated by the particular processing
pathway of MHC class I presentation. Vaccines that lead to
direct infection of cells, such as viral vectors or DNA, induce
CD8+ T cell immunity through the endogenous class I presenta-
tion pathway; however, exogenous protein vaccines require
cross-presentation. To promote differentiation of functional
CD8+ T cells, a successful adjuvant must be given with a protein
formulated in a manner that facilitates entry into the MHC class I
processing pathway, trigger dendritic cell (DC) activation, and
induce type-I interferon (IFN) production.
The difficulty in generating potent and durable T cell immunity
with current vaccines and adjuvants has profound clinical impli-
cations for a variety of diseases. There are still no fully effective
vaccines against many widespread infectious diseases,
including HIV-AIDS, malaria, and tuberculosis. Although humoral
immunity has a clear role in preventing infection by HIV (Mascola
et al., 2000) and can influence certain stages of malaria infection
(Moorthy and Ball u, 2009), ther is compelling evidence that
Th1 cells, CD8+ T cells, or both also have a critical role in prevent-
ing or controlling these infections. More challenging still is the
task of developing adjuvants for therapeutic treatment of
cancers and chronic viral infections, where it will be necessary
to generate potent and perhaps multifunctional T cell responses
in patients who respond poorly to the relevant tumor or viral









Alum aluminum salts NLRP3 inflammasome (?) Ab, Th2 (+ Th1 in humans)




Ab, Th1 + Th2
AS04 MPL plus alum TLR4 and inflammasome (?) Ab, Th1
Adjuvants in Widespread Experimental Use or in Late Stage Clinical Development
Poly-IC (also Poly-ICLC) synthetic derivatives of dsRNA TLR3, MDA5 Ab, Th1, CD8+ T cells
MPL and formulations
(AS01, AS02)
MPL and QS-21 TLR4 (MPL), ? (QS21) Ab, Th1
Flagellin, flagellin-Ag
fusion proteins
Flagellin from S. typhimurium TLR5 Ab, Th1 + Th2
Imiquimods imidazoquinoline derivatives TLR7, TLR8 or both Ab, Th1, CD8+ T cells (when conjugated)
CpG oligodeoxynuceotides
and formulations (IC31, QB10)
synthetic phophorothioate-linked DNA
oligonucleotides with optimized CpG
motifs
TLR9 Ab, Th1, CD8+ T cells (when conjugated)
CAF01 trehalose dimycolate (cord factor) Mincle Ab, Th1, Th17
ISCOMS and ISCOMATRIX saponins mechanism undefined Ab, Th1+ Th2, CD8+ T cells
IFA (and Montanide
formulations)
mineral or paraffin oil + surfactant mechanism undefined Ab, Th1 + Th2





The principal immune response stimulated is based on results from human and mouse studies, although it may be limited to one species in some
cases. Where indicated, conjugation of TLR ligand to antigen is necessary to obtain significant CD8+ T cell responses.
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Table	  1-­‐4	  Licensed	  adjuvants	  in	  clinical	  use	  and	  adjuvants	  in	  experimental	  phase	  or	  late	  stage	  clinical	  
development	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and	   a	  MyD88-­‐independent	   pathway	   (Figure	   1-­‐6)229.	   Signalling	   via	   these	   pathways	   results	   in	   distinctive	  
biological	   consequences.	   TLRs	  3	   and	  4	   signal	   via	   the	   Toll/IL-­‐1R	   (TIR)-­‐domain-­‐containing	   adaptor	  protein	  
inducing	  IFNβ	  (TRIF),	  resulting	  in	  activation	  of	  the	  transcription	  factors	  Interferon	  regulatory	  factor	  (IRF)	  3	  
Nuclear	   Factor	   kappa	   B	   and	   (NFκB).	   This	   leads	   to	   secretion	   of	   type	   I	   IFNs	   as	   well	   as	   inflammatory	  
cytokines,	  whereas	  other	  TLRs	  (1,2,5	  and	  6)	  induce	  predominantly	  inflammatory	  cytokines	  via	  the	  MyD88-­‐
dependent	   pathway	   and	   activation	   of	   NFκB226.	   Intracellular	   TLRs	   7	   and	   9	   are	   primarily	   expressed	   by	  
plasmacytoid	  DCs	  in	  humans,	  responding	  to	  microbial	  nucleic	  acids.	  	  These	  receptors	  signal	  via	  a	  MyD88-­‐
dependent	  pathway	  to	  trigger	   inflammatory	  cytokine	  and	  Type	  I	   IFN	  release,	  vital	   for	  the	  destruction	  of	  
targets	  such	  as	  viruses226.	  The	  different	  cellular	  locations	  and	  signalling	  pathways	  used	  by	  TLRs	  direct	  the	  
nature	  of	  the	  immune	  response	  which	  will	  be	  orchestrated	  by	  DCs,	  monocytes	  and	  other	  innate	  immune	  
cells226.	  	  
	  
Ligation	   of	   TLRs	   on	   immature	  DCs	   provides	   a	   powerful	   stimulus	   for	  maturation	   into	   professional	   APCs.	  
Binding	  of	  poly	  I:C	  to	  TLR3	  within	  DCs	  results	  in	  enhanced	  MHC	  molecule	  expression,	  production	  of	  pro-­‐
inflammatory	   cytokines	   such	   as	   IL-­‐12	   and	   Type	   I	   IFN	   and	  enhanced	   cross-­‐priming.	   Cross-­‐priming	   allows	  
induction	   of	   a	   cytotoxic	   CD8+	   T-­‐cell	   response	   to	   epitopes	   from	   endocytosed	   microbes,	   predominantly	  
occurring	   via	   a	   retrograde	   pathway	   that	   delivers	   endocytosed	   pathogens	   to	   the	   cytosol.	   Following	  
proteasomal	  degradation,	  peptides	  are	  delivered	  by	  transporter	  associated	  with	  antigen	  processing	  (TAP)	  
transporters	   to	  MHC	   Class	   I	   molecules	   in	   the	   ER230.	   This	   is	   an	   important	  mechanism	   in	   the	   context	   of	  
immunisation,	   as	   long	   peptides	   delivered	   into	   the	   dermal	   tissues	   must	   be	   endocytosed	   by	   DCs	   and	  
transferred	  to	  the	  Class	  I	  pathway	  if	  presentation	  to	  CD8+	  T-­‐cells	  is	  to	  be	  possible.	  TLR9	  ligation	  on	  murine	  
plasmacytoid	   DCs	   has	   also	   been	   associated	   with	   enhanced	   cross-­‐priming231	   and	   there	   is	   accumulating	  
evidence	   that	   human	   DC	   subsets	   show	   increased	   cross-­‐priming	   following	   exposure	   to	   selected	   TLR	  
agonists232,233.	   Additionally,	   selected	   TLR	   agonists	   may	   stimulate	   innate/bystander	   cells	   (pDCs,	   non-­‐
haematopoietic	   cells)	   to	   secrete	   pro-­‐inflammatory	   cytokines	   that	   act	   indirectly	   to	   promote	  myeloid	  DC	  


























































































The crystalline product 
resulting from digestion of 
haemoglobin by the 
intraerythrocytic replicative 
stage of malaria parasites 
(Plasmodium spp.).
C-type lectins
Animal receptor proteins that 
bind carbohydrates in a 
calcium-dependent manner. 
The binding activity of C-type 
lectins is based on the 
structure of the carbohydrate-
recognition domain (CRD), 
which is highly conserved 
between members of this 
family.
they induce cytokine production and cell activation1,5. 
These cytosolic receptors are grouped in two main fami-
lies: the NLR family (nucleotide-binding oligomerization 
domain (NOD)-like receptor family), which includes 
at least 23 members that are either NOD receptors or 
NALPs (NACHT-, LRR- and pyrin-domain-containing 
proteins); and a family of receptors that have an RNA-
helicase domain joined to two caspase-recruitment 
domains (CARDs), such as retinoic-acid-inducible 
gene I (RIG-I) and melanoma-differentiation-associated 
gene 5 (MDA5). The name RIG-I-like receptor (RLR) 
family has been proposed by Creagh and O’Neill10 for the 
latter family of receptors, for consistency in nomenclature 
with the TLR and NLR families.
There is growing evidence that these additional 
PRRs can cooperate with TLRs in the innate immune 
response to pathogens. The main sentinel cells of 
innate immunity (epithelial cells, phagocytic cells and 
dendritic-cell (DC) subsets) simultaneously express 
overlapping but not identical combinations of TLRs 
Figure 1 | Schematic representation of the structure and main signalling pathways of the PRR families. Only the 
adaptor molecules and the main signalling pathways that differentiate the different classes of pattern-recognition 
receptor (PRR) are shown. In reality, the pathways that are activated by the different receptors are multiple and 
complex (BOXES 1,2). For example, Toll-like receptor (TLR) signalling involves not only nuclear factor-κB (NF-κB) 
activation, but also mitogen-activated protein kinases, phosphatidylinositol 3-kinase and several other pathways 
that markedly affect the overall biological response to the activation of TLRs. Dectin-1 (a β-glucan receptor) is shown 
as an example of various cell-surface PRRs, some belonging to the lectin-like family and some linked with the 
immunoreceptor tyrosine-based activation motif (ITAM)-containing adaptor Fc receptor γ-chain (FcRγ), the activation 
of which, as described in the text, can markedly affect TLR signalling. ASC, apoptosis-associated speck-like protein 
containing a CARD (caspase-recruitment domain); ds, double-stranded; IFN, interferon; IκB, inhibitor of 
NF-κB; IL, interleukin; IPAF, ICE-protease-activating factor; IRF, IFN-regulatory factor; LPS, lipopolysaccharide; 
MDA5, melanoma-differentiation-associated gene 5; MyD88, myeloid differentiation primary-response gene 88; 
NALP, NACHT-, LRR- and pyrin-domain-containing protein; NOD, nucleotide-binding oligomerization domain; 
RICK, receptor-interacting serine/threonine kinase; RIG-I, retinoic-acid-inducible gene I; ss, single-stranded; 
TBK1, TANK-binding kinase 1; TIRAP, Toll/IL-1R (TIR)-domain-containing adaptor protein; TRAM, TRIF-related 
adaptor molecule; TRIF, TIR-domain-containing adaptor protein inducing IFNβ; SYK, spleen tyrosine kinase.
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Figure	  1-­‐6	  Schematic	  representation	  of	  selected	  TLR	  signalling	  pathways.	  
Diagrammatic	  representation	  of	  signalling	  pathways	  used	  by	  selected	  TLR .	  Cell-­‐ urfac 	  TLRs	  
such	  as	  TLRs	  1,	  2,	  4-­‐6	  signal	  via	  a	  MyD88	  dependent	  pathway,	  as	  do	  the	  endosomally	  located	  
TLRs	  7-­‐9.	  TLRs	  3-­‐4	  utilise	  a	  MyD88	  independent	  pathway	  that	  requires	  Toll/IL-­‐1R	  (TIR)-­‐domain-­‐
containing	  adaptor	  prot in	   duci g	  IFNβ	  (TRIF).	  Signalling	  via	  TLRs	  3-­‐4	  a d	  7-­‐9	  leads	  to	  
increased	  production	  of	  Type	  I	  IFN	  by	  the	  DC	  as	  well	  as	  secretion	  of	  pro-­‐inflammatory	  cytokines.	  
Signalling	  via	  the	  other	  receptors	  predominantly	  results	  in	  secretion	  of	  pro-­‐inflammatory	  
cytokines	  such	  as	  IL-­‐12,	  IL-­‐10,	  IL-­‐6,	  IL-­‐1β	  and	  TNF.	  	  
	  
Abbreviations:	  ASC,	  apoptosis-­‐associated	  speck-­‐like	  protein	  containing	  a	  CARD	  (caspase-­‐
recruitment	  domain);	  ds,	  double-­‐stranded;	  IFN,	  interferon;	  IκB,	  inhibitor	  of	  
NF-­‐κB;	  IL,	  interleukin;	  IPAF,	  ICE-­‐protease-­‐activating	  factor;	  I F,	  IFN-­‐r gula ory	  factor;	  LPS,	  
lipopolysaccharide;	  MDA5,	  melanoma-­‐differentiation-­‐associated	  gene	  5;	  MyD88,	  myeloid	  
differentiation	  primary-­‐response	  gene	  88;	  NALP,	  NACHT-­‐,	  LRR-­‐	  and	  pyrin-­‐domain-­‐co taining	  
protein;	  NOD,	  nucleotide-­‐binding	  oligomerization	  domain;	  RICK,	  receptor-­‐interacting	  
serine/threonine	  kinase;	  RIG-­‐I,	  retinoic-­‐acid-­‐inducible	  gene	  I;	  ss,	  single-­‐stranded;	  TBK1,	  TANK-­‐
binding	  kinase	  1;	  TIRAP,	  Toll/IL-­‐1R	  (TIR)-­‐domain-­‐containing	  adaptor	  protein;	  TRAM,	  TRIF-­‐related	  
adaptor	  molecule;	  SYK,	  spleen	  tyrosine	  kinase.	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Ligation	  of	  TLRs	  on	   tissue-­‐resident	  DCs	   in	   the	  presence	  of	  an	   inflammatory	  milieu	  and	  signals	  e.g.	   from	  
phagocytic	  receptors,	  induce	  their	  maturation	  and	  activation.	  As	  well	  as	  enhanced	  antigen	  processing	  and	  
presentation,	   activated	  DCs	  up-­‐regulate	   the	   chemokine	   receptor	   CCR7,	   enabling	  migration	   to	   the	   T-­‐cell	  
rich	   areas	   of	   lymphoid	   tissue.	   Local	   chemokines	   induce	   DCs	   to	   express	   high	   levels	   of	   co-­‐stimulatory	  
molecules	   (such	   as	   CD80,	   CD86	   and	   CD40)	   and	   adhesion	   molecules	   such	   as	   Intercellular	   Adhesion	  
Molecule-­‐1	   (ICAM-­‐1)	   to	   increase	   the	   likelihood	   of	   successful	   interactions	  with	   naïve	   CD8+	   and	   CD4+	   T-­‐
cells.	   Secretion	   of	   IL-­‐12	   by	   activated	   DCs	   delivers	   the	   powerful	   “third	   signal”	   required	   to	   drive	   a	   Th1	  
immune	  response	  involving	  activated	  cytotoxic	  T-­‐cells234.	  	  
	  
Researchers	   have	   demonstrated	   that	   a	   single	   TLR	   agonist	   or	   inflammatory	   cytokine	   alone	   is	   usually	  
insufficient	   to	  optimally	   induce	   IL-­‐12	  production	   (specifically	   IL-­‐12p70,	   the	  biologically	  active	   form	  of	   IL-­‐
12)	  by	  DCs.	  This	  suggests	  that	  similarly	  to	  T-­‐cells,	  DCs	  also	  require	  two	  signals	  for	  high	  level	  secretion	  of	  
this	   potent	   cytokine	   capable	   of	   inducing	   cytotoxic	   T-­‐cell	   responses229,234.	   Indeed,	   ligation	   of	   certain	  
combinations	  of	  TLRs	  has	  a	  cooperative	  effect	  on	  cytokine	  production	  (including	  TNF,	  IL-­‐1β,	  IL-­‐6,	  IL-­‐10,	  IL-­‐
12	   and	   IL-­‐23)	   by	   DCs229.	   In	   one	   study	   of	   mouse	   macrophages,	   the	   use	   of	   two	   TLR	   agonists	   (poly	   I:C,	  
targeting	  TLR-­‐3	  and	  CpG	  ODN,	  targeting	  TLR-­‐9)	  resulted	  in	  supra-­‐additive	  production	  of	  TNF,	  IL-­‐6	  and	  IL-­‐
12p40235.	  One	  explanation	  underlying	  this	  synergism	  is	  the	  activation	  of	  both	  the	  MyD88	  dependent	  and	  
independent	  signalling	  pathways	  using	  this	  combination	  of	  TLR	  agonists.	  Combined	  triggering	  of	  selected	  
TLRs	   on	   mouse	   and	   human	   DCs	   also	   increases	   IL-­‐12p70,	   promoting	   Th1	   responses,	   enhanced	   IFNγ	  
production	  and	  cytolytic	  activity	  in	  CD8+	  T	  cells	  and	  NK	  cells236,237.	  	  
	  
These	  observations	  have	  led	  to	  the	  exploration	  of	  TLR	  agonists	  for	  use	  as	  adjuvants	  in	  vaccinations	  against	  
both	  microbial	   targets	   and	  also	   tumours.	  A	  number	  of	  Phase	   I-­‐III	   clinical	   trials	   to	  evaluate	   individual	  or	  
combined	   TLR	   agonists	   as	   adjuvants	   in	   therapeutic	   vaccines	   for	   solid	   organ	   and	   haematological	  
malignancies	  are	  ongoing.	  A	  Phase	  III	  trial	  of	  a	  Glaxo-­‐Smith-­‐Kline	  developed	  vaccine	  targeting	  melanoma-­‐
associated	   antigen	   (MAGE),	   in	   combination	  with	   TLR	   4	   and	   9	   agonists	   in	  melanoma	  patients,	   is	   due	   to	  
report	   in	   the	   near	   future.	   It	   is	   hoped	   that	   regulatory	   approval	   for	   clinical	   use	   for	  many	  more	   of	   these	  
adjuvants	  will	  be	  forthcoming	  as	  a	  result	  of	  such	  studies.	  A	  specific	  focus	  of	  our	  research	  group	  has	  been	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to	   determine	   whether	   combining	   TLR	   agonists	   with	   other	   pro-­‐inflammatory	   signals	   could	   further	  
potentiate	  induction	  of	  antigen-­‐specific	  T-­‐cell	  responses.	  Our	  findings	  led	  to	  the	  development	  of	  a	  multi-­‐
adjuvant	  system	  known	  as	  CASAC	  –	  Combined	  Adjuvants	  for	  Synergistic	  Activation	  of	  Cellular	  immunity.	  A	  
description	   of	   the	   relevant	   previously	   described	   studies	   of	   CASAC	   follows,	   as	   investigation	   of	   CASAC	   in	  
combination	  with	  WT1	  peptide	  vaccination	  forms	  a	  major	  portion	  of	  this	  thesis.	  
	  
1.6.5 Combined	  Adjuvants	  for	  Synergistic	  Activation	  of	  Cellular	  Immunity	  (CASAC)	  
Work	   from	   our	   group	   investigated	   the	   potential	   for	   using	   novel	   adjuvant	   combinations	   in	   peptide	  
vaccinations	   targeting	   both	   foreign	   and	   self-­‐antigens238.	   In	   these	   studies	   C57BL/6	  mice	   underwent	   two	  
rounds	  of	   intra-­‐dermal	  vaccination	  using	  an	  oil-­‐in-­‐water	  emulsion	  admixed	   in	  a	  50:50	  ratio	  with	  vaccine	  
components.	  The	  vaccine	  consisted	  of	  combinations	  of	  up	  to	  two	  TLR	  agonists,	  IFNγ	  and	  agonist	  anti-­‐CD40	  
antibody	  or	  a	  Class	  II	  helper	  peptide	  along	  with	  the	  target	  Class	  I	  peptide.	  Exogenous	  IFNγ (derived	  from	  
activated	  NK	  and	  T-­‐cells	   in	  vivo)	  or	   ligation	  of	  CD40	  on	  DCs	   (via	  agonistic	  anti-­‐CD40	  antibody	   in	  vitro	  or	  
activated	  T-­‐cells	  expressing	  CD40L	  in	  vivo)	  have	  both	  been	  shown	  to	  combine	  with	  TLR	  ligation	  to	  increase	  
IL-­‐12p70	  production,	  providing	  a	   rationale	   for	   their	   inclusion	   in	   the	  vaccine239,240.	   Fluorescent	  pentamer	  
staining	  of	  CD8+	  T-­‐cells,	  IFNγ	  production	  and	   in	  vivo	  cytotoxic	  lysis	  assay	  were	  used	  to	  assess	  magnitude	  
and	  functional	  efficacy	  of	  antigen-­‐specific	  responses238.	  	  
	  
Following	   vaccinations	   against	   the	   chicken	   ovalbumin-­‐derived	   OVA-­‐SIINFEKL257-­‐264	   (OVA-­‐SIINF)	   peptide,	  
fluorescently	   labelled	   H-­‐2Kb-­‐OVA-­‐SIINF	   pentamers	  were	   used	   to	   identify	   cognate	   CD8+	   T-­‐cells.	  Massive	  
clonal	   expansion	   of	   CD8+	   T-­‐cells	   specific	   for	   OVA-­‐SIINF,	   up	   to	   80%	   of	   all	   CD8+	   T-­‐cells,	   was	   observed	  
following	   2	   vaccinations	   using	   the	  most	   potent	   combination	   of	   components:	   2	   TLR	   agonists	   (CpG	  ODN	  
(TLR9	   agonist)	   and	  monophosphoryl	   lipid	   A,	  MPL	   (TLR4	   agonist)),	   agonist	   anti-­‐CD40	   antibody,	   IFNγ	   and	  
100	   µg	   OVA-­‐SIINF	   peptide,	   in	   emulsion.	   This	   combination	   of	   components	   was	   termed	   CASAC,	   or	  
Combined	  Adjuvants	  for	  Synergistic	  Activation	  of	  Cellular	  Immunity238.	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These	  expansions	  of	  CD8+	  OVA-­‐SIINF-­‐specific	  T-­‐cells	  were	  capable	  of	  highly	  significant	  in	  vivo	  lytic	  activity,	  
as	  measured	  by	  specific	  lysis	  of	  90-­‐100%	  of	  syngeneic	  splenocytes	  loaded	  with	  the	  immunising	  peptide.	  A	  
functional,	   long-­‐lived	  memory	   response	  was	   also	   observed	   using	  OVA-­‐SIINF-­‐specific	   pentamer	   analyses	  
following	  re-­‐challenge	  with	  OVA-­‐SIINF	  peptide	  alone	  at	  >100	  days	  post	  initial	  vaccination238.	  
	  
Different	  elements	  of	  the	  vaccination	  were	  assessed	  and	  optimised	  in	  this	  study.	  The	  major	  findings	  were	  
as	  follows:	  
1. Relevant	  (derived	  from	  the	  same	  target	  protein	  as	  the	  Class	   I	  peptide)	  or	   irrelevant	  (unrelated)	  
Class	   II	   helper	   peptides	   could	   substitute	   for	   agonist	   anti-­‐CD40	   antibody	   in	   CASAC	   to	   induce	  
effective	   antigen-­‐specific	   CD8+	   T-­‐cell	   responses.	   This	   suggests	   that	   ligation	   of	   CD40	   on	  DCs	   by	  
CD40L	  on	  activated	  helper	  T-­‐cells	  may	  be	  one	  of	  the	  functions	  of	  these	  cells	  in	  driving	  cytotoxic	  T-­‐
cell	  responses,	  as	  has	  been	  reported	  previously241,242.	  	  
2. Use	  of	  whole	  ovalbumin	  (OVA)	  protein	  for	   immunisation	  resulted	   in	  OVA-­‐SIINF-­‐specific	  CD8+	  T-­‐
cell	  responses.	  This	  suggests	  that	  processing	  and	  cross-­‐presentation	  of	  this	  class	   I	  epitope	  from	  
OVA	  by	  CASAC-­‐activated	  DCs	  occurred.	  
3. Presence	  of	   two	  TLR	  agonists	   in	   the	  vaccine	  was	  critical	   to	  efficacy.	  Some	  combinations	  of	  TLR	  
agonists	   were	   more	   potent	   than	   others,	   e.g.	   CpG	   ODN	   and	   poly	   I:C	   were	   a	   more	   effective	  
combination	  than	  CpG	  ODN	  plus	  Pam3CSK4	  (TLR	  1/2	  agonist)	  and	  similar	  in	  potency	  to	  CpG	  ODN	  
and	  MPL.	  
4. Analysis	   of	   cytokine	  production	  by	  CD4+	  T	   cells	   isolated	   from	  draining	   lymph	  nodes	   suggested	  
that	  Th1-­‐type	  immune	  responses	  had	  been	  induced.	  
5. CASAC	  showed	  superior	  efficacy	  in	  generating	  OVA-­‐SIINF-­‐specific	  CD8+	  T-­‐cell	  responses	  over	  the	  
most	  commonly	  used	  experimental	  adjuvant,	  Complete	  Freund’s	  Adjuvant	  (CFA)	  and	  Incomplete	  
Freund’s	  Adjuvant	  (IFA)238.	  
Another	  key	  finding	  was	  that	  CD8+	  T-­‐cell	  responses	  could	  also	  be	  generated	  against	  a	  self-­‐peptide	  derived	  
from	   the	  melanoma	  associated	   antigen	   tyrosinase-­‐related	  peptide	   2	   (TRP-­‐2),	   SVYDFFVWL	  180-­‐188.	   A	   dose	  
dependent	  increase	  in	  vaccination	  efficacy	  (frequency	  of	  TRP-­‐2-­‐specific	  CD8+	  T-­‐cells	  and	  antigen-­‐specific	  
in	  vivo	  lysis)	  was	  observed	  with	  up	  to	  400µg	  of	  Class	  I	  peptide	  per	  vaccination.	  Furthermore,	  C57BL/6	  mice	  
inoculated	   with	   the	   TRP-­‐2-­‐expressing	   B16	   syngeneic	   melanoma	   cell	   line	   showed	   significantly	   superior	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survival	   following	   therapeutic	   vaccination	   with	   CASAC	   and	   TRP2	   in	   comparison	   with	   control,	   non-­‐
immunised	  mice	  (Figure	  1-­‐7).	  This	  survival	  advantage	  was	  decreased	  by	  pre-­‐treatment	  with	  depleting	  anti-­‐
CD8β	   antibodies,	   suggesting	  an	   important	  protective	   role	   for	  CD8+	  T-­‐cells	   in	   the	  anti-­‐tumour	   response.	  
Importantly,	   while	   there	   was	   some	   demonstrable	   evidence	   of	   autoimmunity	   in	   these	   animals	  
(development	   of	   white	   hairs	   at	   the	   vaccination	   sites)	   there	   was	   no	   evidence	   of	   epitope	   spreading	   or	  
















Taken	  from	  Wells	  et	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anti-CD40 plus CpG. Tumors grew rapidly in mice not receiving
vaccine. Mice were killed when tumor diameter reached !15 mm,
and all control mice were killed by day 30. TRP-2/CASAC
immunization completely prevented the appearance of tumors
until day 45, when only one of eight mice developed a tumor.
Anti-CD40 plus CpG alone induced significantly weaker pro-
tection, with only one of six mice surviving to day 72. CD8
depletion significantly reduced protection induced by TRP-2/
CASAC, although the appearance of tumors was much delayed
even in the absence of CD8 T cells. Surviving TRP-2/CASAC-
immunized animals were resistant to further tumor cell chal-
lenge with twice as many B16 cells (not shown). We also de-
tected specific staining of CD8 cells in the blood of these mice
with a TRP-2180 –188/H-2Kb MHC pentamer (Fig. 6c). Pentamer
staining cells were only detected in TRP-2/CASAC-immunized
mice and were not significantly altered by the challenge with
live B16 cells. TRP-2-specific CD8s were undetectable in anti-
CD40/CpG-immunized or CD8-depleted animals.
Because it was possible that the potency of CASAC could pos-
sibly induce epitope spreading for the recognition of other self-Ags
present in surrounding tissue or dying tumor cells, anti-DNA
IgG2a autoantibodies were measured in TRP-2/CASAC-immu-
nized mice (Fig. 6d). Serum from mice in which chronic graft-vs-
host disease had been induced was used as a positive control (27).
We did not observe significant anti-DNA IgG2a in TRP-2/
CASAC-immunized mice, indicating that CASAC does not trigger
generalized autoimmunity. However, low but significant levels of
anti-DNA IgG2a were detected in B16 tumor-bearing mice immu-
nized with TRP-2180–188 self-peptide. We therefore tested whether
responses to the gp100 epitope expressed by B16 cells had oc-
curred by using IFN-! analysis (Fig. 6e). The results showed that
gp100 stimulation induced no detectable IFN-!" cells in the
spleen; the response was TRP-2180–188-specific and confined to the
effector memory (CD44highCD62L#) compartment. Furthermore,
we observed white hairs at the injection sites of TRP-2/CASAC-
immunized mice but not elsewhere (not shown), suggesting by-
stander killing of melanin-producing cells where vaccine was in-
jected, but without widespread autoimmunity.
Discussion
Development of subunit vaccines consisting of defined Ags
derived from infectious organisms or tumors has been greatly ham-
pered by the lack of effective CD8 T cell and Th1-inducing adju-
vants. These responses collaborate to mediate effective cell-medi-
ated immunity, resulting in the elimination of infected or
malignant host cells. Indeed, most vaccines in current use still
consist of live attenuated organisms, which can be difficult to man-
ufacture and have potential safety and storage issues. Adjuvants
such as mineral oil, mycobacteria, and alum are frequently re-
quired to amplify acquired immunity. The most effective is gen-
erally considered to be CFA, which can only be used in animals
and can cause damaging skin inflammation. In experimental mu-
rine studies with molecular adjuvants, the combination of a peptide
with anti-CD40 Ab and a TLR agonist is currently the most ef-
fective published strategy, with CD8 responses to SIINFEKL re-
ported to be as high as 16% of total CD8 cells in C57BL/6 mice
(34).
In this report we have described a novel approach that is much
more effective than CFA in the models studied, consists only of
defined molecules that have been tested in humans, and can be
formulated without oil, making it suitable for use as an aqueous
mucosal adjuvant. The levels of Ag-specific CD8 cell responses
we induced were higher than those reported in any previous work
to our knowledge, and these large clonal expansions consisted of
fully functional T cells as indicated by rapid IFN-! production and
CTL activity. Furthermore, we showed that responses could be
FIGURE 6. CASAC induces potent tumor protection in a melanoma treatment model mediated partly but not entirely by tumor-Ag specific CD8 T cells.
a and b, B16 tumors were induced in naive mice with 105 cells s.c. After 3, 11, and 19 days (arrows in b) mice were immunized with 400 "g of
TRP-2180–188/CASAC, TRP-2180–188/anti-CD40 plus CpG only, or PBS (no vaccine). A further group was depleted of CD8 T cells before TRP-2180–188/
CASAC vaccination (#CD8$, anti-CD8$). Animals were killed when tumors reached 15 mm. Tumor size (a) and mouse survival (b) in groups of 6–8
mice are shown. Statistical comparisons indicated are all against the TRP-2/CASAC group. Similar protection was observed in two independent experi-
ments. c, Staining of TRP-2-specific CD8 T cells in blood of mice as in a on day 22 using TRP-2180–188/H-2Kb pentamer. SIINFEKL pentamer was used
for the negative control stain. Mean percentage $ SEM from 6–8 mice is shown. d, Analysis of anti-DNA IgG2a autoantibody levels in sera of mice given
TRP-2/CASAC or B16 cells alone or in combination (n % 5–7, similar results were seen in a further experiment). GVHD, Positive control serum from
chronic graft-vs-host disease. e, IFN-! responses in spleen cells of mice given TRP-2/CASAC vaccine alone (upper panels) or challenged with B16 cells
and vaccinated (lower panels) on day 72. Data are CD8-gated events in samples stimulated with TRP-2 or gp100 peptide and costained with CD62L. Mean
percentage $ SEM from 5- 7 mice is shown.
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anti-CD40 plus CpG. Tumors grew rapidly in mice not receiving
vaccine. Mice were killed when tumor diameter reached !15 mm,
and all control mice were killed by day 30. TRP-2/CASAC
immunization completely prevented the appearance of tumors
until day 45, when only one of eight mice developed a tumor.
Anti-CD40 plus CpG alone induced significantly weaker pro-
tection, with only one of six mice surviving to day 72. CD8
depletion significantly reduced protection induced by TRP-2/
CASAC, although the appearance of tumors was much delayed
even in the absence of CD8 T cells. Surviving TRP-2/CASAC-
immunized animals were resistant to further tumor cell chal-
lenge with twice as many B16 cells (not shown). We also de-
tected specific staining of CD8 cells in the blood of these mice
with a TRP-2180 –188/H-2Kb MHC pentamer (Fig. 6c). Pentamer
staining cells were only detected in TRP-2/CASAC-immunized
mice and were not significantly altered by the challenge with
live B16 cells. TRP-2-specific CD8s were undetectable in anti-
CD40/CpG-immunized or CD8-depleted animals.
Because it was possible that the potency of CASAC could pos-
sibly induce epitope spreading for the recognition of other self-Ags
present in surrounding tissue or dying tumor cells, anti-DNA
IgG2a autoantibodies were measured in TRP-2/CASAC-immu-
nized mice (Fig. 6d). Serum from mice in which chronic graft-vs-
host disease had been induced was used as a positive control (27).
We did not observe significant anti-DNA IgG2a in TRP-2/
CASAC-immunized mice, indicating that CASAC does not trigger
generalized autoimmunity. However, low but significant levels of
anti-DNA IgG2a were detected in B16 tumor-bearing mice immu-
nized with TRP-2180–188 self-peptide. We therefore tested whether
responses to the gp100 epitope expressed by B16 cells had oc-
curred by using IFN-! analysis (Fig. 6e). The results showed that
gp100 stimulation induced no detectable IFN-!" cells in the
spleen; the response was TRP-2180–188-specific and confined to the
effector memory (CD44highCD62L#) compartment. Further ore,
we observed white hairs at the injection sites f TRP-2/CASAC-
immunized mice but not else here (not shown), suggesting by-
stander killing of melanin-producing cells where vaccine was in-
jected, but without widespread autoimmunity.
Discussion
Development of subunit vaccines consisting of defined Ags
derived from infectious organisms or tumors has been gr atly ham-
pered by the lack of effective CD8 T cell and Th1-inducing adju-
vants. These responses collaborate to mediate effective cell-medi-
ated immunity, resulting in the elimination of infected or
malignant host cells. Indeed, most vaccines in current use still
consist of live attenuated organisms, which can be difficult to man-
ufacture and have potential safety and storage issues. Adjuvants
such as mineral oil, mycobacteria, and alum are frequently re-
quired to amplify acquired immunity. The most effective is gen-
erally considered to be CFA, which can only be used in animals
and can cause damaging skin inflammation. In experimental mu-
rine studies with molecular adjuvants, the combination of a peptide
with anti-CD40 Ab and a TLR agonist is currently the most ef-
fective published strategy, with CD8 responses to SIINFEKL re-
ported to be as high as 16% of total CD8 cells in C57BL/6 mice
(34).
In this report we have described a novel approach that is much
more effective than CFA in the models studied, consists only of
defined molecules that have been tested in humans, and can be
formulated without oil, making it suitable for use as an aqueous
mucosal adjuvant. The levels of Ag-specific CD8 cell responses
we induced were higher tha those reported in any pr viou work
to our knowledge, and these large clonal expansions consisted of
fully functional T cells as indicated by rapid IFN-! production and
CTL activity. Furthermore, we showed that responses could be
FIGURE 6. CASAC induces potent tumor protection in a melanoma treatment model mediated partly but not entirely by tumor-Ag specific CD8 T cells.
a and b, B16 tumors were induced in naive mice with 105 cells s.c. After 3, 11, and 19 days (arrows in b) mice were immunized with 400 "g of
TRP-2180–188/CASAC, TRP-2180–188/anti-CD40 plus CpG only, or PBS (no vaccine). A further group was depleted of CD8 T cells before TRP-2180–188/
CASAC vaccination (#CD8$, anti-CD8$). Animals were killed when tumors reached 15 mm. Tumor size (a) a d mouse survival (b) in groups of 6–8
mice are shown. Statistical comparisons indicated are all against the TRP-2/CASAC group. Similar protectio was observed in two independent experi-
ments. c, Staining of TRP-2-specific CD8 T cells in blood of mice as in a on day 22 using TRP-2180–188/H-2Kb pentamer. SIINFEKL pentamer was used
for the negative control stain. Mean percentage $ SEM from 6–8 mice is shown. d, Analysis of anti-DNA IgG2a autoantibody levels in sera of mice given
TRP-2/CASAC or B16 cells alone or in combination (n % 5–7, similar results were seen in a further experiment). GVHD, Positive control serum from
chronic graft-vs-host disease. e, IFN-! responses in spleen cells of mice given TRP-2/CASAC vaccine alone (upper panels) or challenged with B16 cells
and vaccinated (lower panels) on day 72. Data are CD8-gated events in samples stimulated with TRP-2 or gp100 peptide and costained with CD62L. Mean
percentage $ SEM from 5- 7 mice is shown.
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Figure	  1-­‐7	  Vaccinations	  combining	  CASAC	  with	  a	  self-­‐peptide	  can	  improve	  survival	  from	  melanoma	  
in	  a	  mouse	  model	  
C57BL/6	  mice	  	  (n=5-­‐7	  per	  group)	  were	  inoculated	  subcutaneously	  with	  105	  B16	  melanoma	  cells	  
per	  mouse.	  Mice	  were	  vaccinated	  at	  days	  3,	  11	  and	  19	  with	  PBS	  only,	  or	  the	  class	  I	  TRP-­‐2	  peptide	  
along	  with	  CASAC	  (comprising	  poly	  I:C,	  CpG	  ODN,	  IFNγ and	  anti-­‐CD40	  antibody)	  or	  agonist	  anti-­‐
D40	  antibody	  and	  CpG	  ODN	  .	  One	  group	  of	  CASAC	  immunised	  mice	  als 	  rec ived	  a	  depleting	  
anti-­‐CD8	  antibody.	  (a,b).	  Reduced	  tumour	  diameter	   nd	  improved	  survival	  were	  observed	  for	  
mice	  immunised	  with	  TRP-­‐2/CASAC,	  the	  effects	  of	  which	  were	  diminished	  by	  pre-­‐treatment	  with	  
depleting	  anti-­‐CD8	  antibody.	  	  
(c)	  The	  high st	  percentages	  of	  TRP-­‐2	  specific	  CD8+	  T-­‐cells	  by	  pentamer	  studies	  are	  detected	  in	  
mice	  exposed	  to	  TRP-­‐2	  and	  CASAC.	  TRP-­‐2	  specific	  T-­‐cells	  are	  detected	  even	  in	  tumour-­‐bearing	  
mice	  after	  immuni ation.	  Th 	  frequency	  of	  antigen-­‐sp cific	  T-­‐cells	  is	  reduced	  by	  depletion	  of	  
CD8β+cells	  or	  use	  of	  only	  one	  TLR	  agonist	  (CpG	  O N)	  along	  with	  agonist	  anti-­‐CD40	  antibody.	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This	  work	  extended	   the	   findings	  of	  others	  who	  had	  explored	   combinations	  of	   a	   single	  TLR	  agonist	  with	  
anti-­‐CD40	  antibody	  for	  vaccinations	  and	  demonstrated	  significant	  expansions	  of	  antigen-­‐specific	  CD8+	  T-­‐
cells	   showing	   lytic	   activity243,244.	   Direct	   comparisons	   between	   groups	   are	   difficult	   due	   to	   variations	   in	  
methodology,	   for	   example	   the	   use	   of	   whole	   antigen	   versus	   peptide,	   and	   the	   number	   and	   interval	   of	  
vaccinations.	   However,	   within	   the	   data	   presented	   by	  Wells,	   when	   a	   single	   TLR	   agonist	   and	   anti-­‐CD40	  
antibody	  were	  used	  for	  vaccination,	  this	  appeared	  to	  be	  less	  efficient	  than	  CASAC	  in	  vaccinations	  against	  
both	  foreign	  and	  self	  peptides.	  This	  suggests	  that	  the	  combination	  of	  multiple	  different	  signals	  may	  still	  
have	  an	  additive	  effect	  upon	  immune	  response	  generation.	  
	  
Previous	  work	  from	  our	  group	  has	  demonstrated	  the	  ability	  to	  use	  a	  novel	  adjuvant	  combination	  (CASAC)	  
to	   induce	   highly	   potent	   immune	   responses	   against	   a	   xenoantigen.	   Additionally,	   effective	   anti-­‐tumour	  
responses	  were	  demonstrated	  following	  CASAC/self-­‐peptide	  vaccination	  targeting	  a	  melanoma-­‐associated	  
tumour	  antigen.	  Given	  the	  apparent	   low	  magnitude	  and	  efficacy	  of	   immune	  responses	  activated	  against	  
WT1	  peptides	  using	   common	  adjuvants	   such	  as	  Montanide	  or	  GM-­‐CSF,	   the	  potential	   efficacy	  of	  CASAC	  
warrants	  exploration	  in	  the	  context	  of	  WT1	  peptide	  vaccination	  and	  forms	  part	  of	  the	  data	  presented	  in	  
this	  thesis.	  
	  
1.7 Whole	  tumour	  cell	  vaccination	  using	  CD80/IL-­‐2	  gene	  modified	  blasts	  for	  
immunotherapy	  of	  AML	  
Peptide	   vaccination	   targeting	   a	   single	   or	   few	   LAAs	   is	   an	   attractive	   immunotherapeutic	   strategy	   where	  
immunogenic	  LAA	  epitopes	  have	  been	  identified.	  Furthermore,	  synthesis	  of	  peptides	  is	  a	  straightforward	  
procedure	  culminating	   in	   the	  production	  of	  an	  “off	   the	  shelf”	  vaccine.	  There	  are	  however	   limitations	  to	  
targeting	  a	  single	  antigen,	  namely	  that	  this	  may	  lead	  to	   immune	  escape	  by	  the	  tumour	  down	  regulating	  
expression	  of	  the	  LAA.	  Furthermore,	  although	  certain	  LAAs	  are	  immunogenic	  and	  highly	  expressed	  by	  the	  
tumour,	   there	   remains	   a	   lack	   of	   understanding	   regarding	   which	   LAA(s)	   is/are	   the	   crucial	   target(s)	   for	  
therapy.	  It	  is	  likely	  that	  there	  are	  other	  as	  yet	  unidentified	  LAAs	  that	  are	  immunogenic.	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One	  means	   to	  circumvent	   these	   issues	   is	   to	  use	  whole	   tumour	   (cell	   line	  or	  primary	   leukaemia	  cells)	   for	  
vaccination.	  This	  has	  the	  benefit	  of	   including	  all	  potential	  target	  LAAs	  (known	  and	  unknown)	  and	  where	  
primary	   leukaemic	  cells	  are	  used,	  results	   in	  the	  production	  of	  a	  vaccine	  that	   is	  tailored	  to	  the	   individual	  
patient.	  Leukaemic	  blasts	  are	  particularly	  suitable	  as	  substrates	  for	  use	  in	  whole	  tumour	  cell	  vaccination.	  
They	  are	  easily	  collected	  from	  peripheral	  blood	  and/or	  bone	  marrow	  for	  vaccine	  production.	  As	  described	  
in	  section	  1,	  AML	  cells	  may	  stimulate	  cognate	  T-­‐cells	  and	  NK-­‐cells	  through	  expression	  of	  MHC	  molecules	  
and	   ligands	  for	  NK	  recognition,	  as	  well	  as	  adhesion	  molecules	  permitting	   interaction	  with	   immune	  cells.	  
Due	   to	   their	   lineage	   origins,	   AML	   blasts	   come	   into	   close	   contact	  with	   cells	   of	   the	   innate	   and	   adaptive	  
immune	  systems	  within	  haematopoietic	  tissues.	  Despite	  such	  qualities,	  they	  frequently	  fail	  to	  effectively	  
activate	   responses	   in	   T-­‐	   and	   NK-­‐cells,	   due,	   for	   example,	   to	   secretion	   of	   soluble	   factors	   that	   adversely	  
modulate	   the	   immune	   environment101,102	   or	   induction	   of	   anergy	   through	   insufficient	   expression	   of	   co-­‐
stimulatory	  molecules99,245.	  Therefore,	  genetic	  modification	  of	  AML	  cells	  to	  directly	  increase	  their	  antigen	  
presentation	  function	  may	  increase	  their	  immunogenicity	  at	  vaccination.	  Immune	  responses	  may	  also	  be	  
induced	  indirectly,	  as	  irradiated	  AML	  cells	  administered	  at	  vaccination	  will	  ultimately	  be	  engulfed	  by	  DCs,	  
allowing	  presentation	  of	  tumour-­‐derived	  antigens	  to	  lymphoid	  cells	  in	  draining	  lymph	  nodes.	  
	  
Genetic	  modifications	   to	   induce	   expression	   of	   pro-­‐inflammatory	   cytokines	   (such	   as	  GM-­‐CSF122,246,247,	   IL-­‐
4248,	  IL-­‐12249	  and	  TNFα250),	  some	  of	  which	  may	  aid	  maturation	  of	  AML	  cells	  into	  APCs,	  have	  been	  explored	  
by	  investigators.	  Leukaemic	  cells	  modified	  to	  express	  GM-­‐CSF	  have	  been	  evaluated	  in	  early	  phase	  clinical	  
trials	   of	  whole	   cell	   vaccination.	   Researchers	   have	   carried	   out	   genetic	  modification	   of	   the	   CML	   cell	   line	  
K562	   to	   express	   GM-­‐CSF,	   for	   use	   as	   a	   whole	   cell	   vaccine	   known	   as	   GVAX251.	   In	   a	   pilot	   study	   of	   GVAX	  
vaccination	  in	  19	  CML	  patients	  not	  fully	  responsive	  to	  the	  tyrosine	  kinase	  inihibitor	  Imatinib,	  13	  patients	  
experienced	   a	   reduction	   in	   disease	   burden.	   However,	   clear	   evidence	   of	   vaccine-­‐specific	   immune	  
responses	  was	  not	  described247.	  A	  mixture	  of	  GVAX	  and	   irradiated	  autologous	   leukaemia	  cells	   formed	  a	  
patient-­‐specific	   vaccine	   that	  was	  administered	   to	  AML	  patients	  undergoing	  autologous	  HSCT	   in	  a	   single	  
arm,	  Phase	  II	  study.	  An	  immune	  readout	  in	  this	  study	  was	  development	  of	  a	  delayed	  type	  hypersensitivity	  
(DTH)	   reaction	   following	   re-­‐challenge	   with	   vaccine	   components	   (defined	   in	   general	   as	   persisting	  
induration	   >10mm	  diameter	   after	   48-­‐72	   hours	   and	   frequently	   associated	  with	   histologic	   characteristics	  
including	   T-­‐cell	   infiltration)252.	  A	   significant	   increase	   in	   3y-­‐relapse-­‐free	   survival	   (100%	  vs.	   48%,	  p=0.029)	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was	   reported	   for	   7/19	   vaccine	   recipients	  who	   developed	   a	  DTH	   response	   versus	   those	  who	   did	   not122.	  
Primary	  leukaemia	  cells	  modified	  by	  an	  adenoviral	  vector	  to	  express	  GM-­‐CSF	  have	  been	  used	  to	  vaccinate	  
AML	  and	  MDS	  patients	  at	  high	   risk	  of	   relapse	   following	  non-­‐myeloablative	  allogeneic	  HSCT	   in	  a	  Phase	   I	  
Clinical	  trial.	  DTH	  reactions	  were	  observed	  in	  7	  of	  8	  subjects	  who	  received	  5	  vaccinations,	  all	  of	  whom	  had	  
experienced	  durable	  remissions	  at	  the	  time	  of	  reporting246.	  	  
	  
AML	  blasts	  express	  some	  immune	  stimulatory	  molecules,	  such	  as	  CD86,	  but	  reduced	  or	  absent	  expression	  
of	   others,	   such	   as	   CD8099.	   In	   early	   studies	   of	   genetic	  modification	   of	   primary	   AML	   blasts,	   investigators	  
developed	  vectors	  to	   introduce	  CD80	  alone	  into	  AML	  cells	   in	  order	  to	  demonstrate	   induction	  of	  tumour	  
specific	   immune	   responses	   in	   vitro	   and	   in	   animal	  models.	   CD80-­‐modified	   AML	   blasts	   induced	   vigorous	  
proliferative	  allogeneic	  CD4+	  and	  CD8+	  T-­‐cell	  responses	  that	  were	  not	  seen	  in	  control	  cultures253,254.	  Mice	  
immunised	   with	   AML	   cells	   modified	   to	   express	   CD80	   subsequently	   rejected	   challenge	   with	   wild	   type,	  
unmodified	  AML,	  which	  was	  not	  observed	  in	  unimmunised	  mice255.	  	  
	  
Latterly,	   researchers	   demonstrated	   that	   anti-­‐leukaemic	   responses	   could	   be	   further	   enhanced	   by	  
combined	  genetic	  modification	  of	  AML	  cells	  to	  express	  CD80	  and	  pro-­‐inflammatory	  cytokines.	   In	  murine	  
models,	  superior	  survival	  and	  subsequent	  rejection	  of	  wild	  type	  tumour	  challenge	  was	  observed	  in	  mice	  
immunised	   with	   leukaemic	   cells	   modified	   to	   express	   CD80	   and	   GM-­‐CSF	   compared	   with	   recipients	   of	  
vaccine	   expressing	   either	  molecule	   alone256.	   Given	   demonstration	   of	   therapeutic	   efficacy	   in	   the	   in	   vivo	  
setting,	   additional	   focus	   was	   placed	   on	   designing	   vectors	   likely	   to	   offer	   the	   greatest	   safety	   when	  
administered	  to	  patients.	  Stripecke’s	  group	  combined	  introduction	  of	  CD80	  and	  GM-­‐CSF	  expression	   into	  
primary	  AML	  blasts	  using	  an	  HIV-­‐based,	  self-­‐inactivating	  lentiviral	  vector	  capable	  of	  effective	  induction	  of	  
autologous	  and	  allogeneic	  T-­‐cell	  responses257.	  
	  
Work	   in	  our	   laboratory	  over	   the	   last	  20	  years	  has	   focused	  on	  the	  generation	  of	   lentiviral-­‐modified	  AML	  
blasts	  (LV_AML)	  to	  induce	  expression	  of	  CD80	  and	  secretion	  of	  IL-­‐2258.	  IL-­‐2	  was	  chosen	  for	  inclusion	  in	  the	  
vector	  given	  its	  ability	  to	  reverse	  T-­‐cell	  clonal	  anergy	  and	  induce	  T	  and	  NK	  cell	  proliferation259.	  Lentiviral	  
vectors	   show	   a	   number	   of	   advantages	   over	   the	   adenoviral	   and	   retroviral	   vectors	   for	   this	   application.	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Firstly,	  they	  are	  able	  to	  efficiently	  transduce	  cells	  dividing	  even	  at	  a	  slow	  rate,	  such	  as	  AML	  cells	  in	  culture,	  
contrasting	  with	  the	  other	  vector	  types.	  Secondly,	  lentiviral	  vectors	  can	  be	  pseudotyped	  by	  using	  vesicular	  
stomatitis	  virus	  glycoprotein	  (VSV-­‐G)	  envelope	  gene	  instead	  of	  the	  Human	  Immunodeficiency	  Virus	  (HIV)-­‐
1	  envelope	  gene,	  permitting	  infection	  of	  a	  range	  of	  tissue	  types260.	  The	  lentiviral	  vector	  designed	  by	  Chan	  
et	  al	  (RFUSIN2,	  Figure	  1-­‐8)	  incorporates	  a	  number	  of	  safety	  features,	  including	  the	  elimination	  of	  any	  viral	  
gene-­‐encoded	  proteins	  within	   a	   4-­‐plasmid	   system,	   suggesting	   a	   very	   low	   risk	   of	   generating	   replication-­‐
competent	  lentivirus258.	  	  Deletion	  in	  the	  3’	  long	  terminal	  repeat	  (LTR)	  U3	  region	  of	  the	  vector	  removes	  all	  





Taken	  from	  the	  Investigational	  Medicinal	  Product	  Dossier	  (IMPD)	  for	  the	  RFUSIN2-­‐AML1	  trial	  (EudraCT	  
Number	  2005-­‐000806-­‐29).	  See	  the	  main	  Abbreviations	  section	  for	  full	  explanation	  of	  terms.	  
	  
Unpublished	  data	  from	  our	  department	  has	  demonstrated	  that	  survival	  of	  C3H	  mice	  inoculated	  with	  32D	  
leukaemia	   cells	   could	   be	   prolonged	   significantly	   following	   vaccination	   with	   irradiated	   RFUSIN2-­‐
transduced,	  CD80/IL-­‐2	  expressing	  32D	  cells,	  administered	  between	  10-­‐20	  days	  after	  tumour	   inoculation.	  
Survival	  was	  greatest	   (80%	  at	  100	  days)	   for	  mice	  vaccinated	  with	  CD80/IL-­‐2	  modified	   cells,	   followed	  by	  
those	  immunised	  with	  singly	  CD80	  or	  IL-­‐2	  –modified	  blasts,	  with	  no	  mice	  surviving	  after	  vaccination	  with	  
irradiated	   unmodified	   cells.	   These	   data	   confirmed	   the	   therapeutic	   potential	   of	   immunisation	   using	  
CD80/IL-­‐2	  modified	  cancer	  cells	  and	  underlined	  the	  possible	  added	  benefit	  of	  combining	  both	  CD80	  and	  
IL-­‐2	  genes	  in	  the	  vector.	  
	  
RFUSIN2	  has	  been	  shown	  to	  efficiently	   transduce	  primary	  AML	  cells	   from	  a	  range	  of	  morphological	  and	  
karyotypic	  subtypes.	  In	  published	  data,	  following	  RFUSIN2	  transduction,	  between	  41-­‐98%	  of	  primary	  AML	  
blasts	  expressed	  CD80,	  with	   IL-­‐2	   secretion	   ranging	   from	  2-­‐17ng/106	   cells	   in	  24	  hours.	  As	  a	   comparator,	  
transduction	   of	   AML	   cell	   lines	   resulted	   in	   97-­‐99%	   of	   cells	   expressing	   CD80	   and	   IL-­‐2	   production	   was	  
Figure	  1-­‐8	  RFUSIN2	  lentiviral	  construct	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between	  9-­‐11ng/106	  cells	  in	  24	  hours258.	  Transduced	  primary	  AML	  cells	  (LV_AML)	  or	  unmodified	  AML	  cells	  
isolated	  from	  patients	  at	  AML	  presentation	  were	  co-­‐cultured	  in	  vitro	  with	  their	  matched	  remission	  PBMCs	  
post-­‐HSCT.	  Following	  co-­‐culture,	  PBMCs	  were	  re-­‐challenged	  with	  autologous	  wild-­‐type	  AML	  or	  remission	  
BM	   cells.	   PBMCs	   from	   a	   patient	   that	   had	   been	   co-­‐cultured	   with	   LV_AML	   showed	   greater	   proliferative	  
responses	  upon	  re-­‐challenge	  with	  their	  wild	  type	  AML	  than	  PBMCs	  derived	  from	  cultures	  with	  unmodified	  
blasts.	   Those	   PBMCs	   that	   had	   been	   previously	   stimulated	   by	   LV_AML	   showed	   less	   proliferation	   on	  
exposure	  to	  healthy	  BM	  cells,	  suggesting	  leukaemia	  specificity	  of	  immune	  responses258.	  	  
	  
More	  detailed	  studies	  of	  patient	  T-­‐	  and	  NK-­‐cell	  responses	  following	  in	  vitro	  exposure	  to	  LV_AML	  cells	  have	  
subsequently	  been	  published.	  PBMCs	  from	  patients,	  or	  T-­‐cells	  from	  healthy	  donors	  were	  co-­‐cultured	  with	  
unrelated	   patients’	   CD80/IL-­‐2	   modified	   or	   wild-­‐type	   AML	   blasts	   (“allogeneic”	   co-­‐cultures).	   Upon	  
subsequent	   challenge	  with	   the	   same	  blasts	   (wild-­‐type),	   superior	   lysis	  was	  observed	  where	  PBMCs	  or	  T-­‐
cells	   had	   been	   previously	   co-­‐cultured	   with	   LV_AML120,121.	   An	   additive	   effect	   on	   lytic	   response	   was	  
observed	  where	  the	  vector	  conferred	  both	  CD80	  and	  IL-­‐2	  expression,	  relative	  to	  vectors	  containing	  either	  
component	  alone120,121.	   T-­‐cells	   isolated	  post	   co-­‐culture	  with	   LV_AML	  were	   shown	   to	   specifically	   secrete	  
IFNγ	  following	  challenge	  with	  primary	  AML	  blasts	  rather	  than	  normal	  CD14+	  bone	  marrow	  cells120.	  	  This	  is	  
suggestive	  of	  some	  specificity	  of	  the	  T-­‐cell	  response	  against	  abnormal,	  malignant	  cells	  rather	  than	  healthy	  
bone	   marrow	   cells.	   Not	   only	   allogeneic/healthy	   donor	   T-­‐	   and	   NK-­‐cells	   but	   also	   patient-­‐derived,	  
autologous,	   remission	   T-­‐	   and	   NK-­‐cells	   could	   be	   stimulated	   by	   LV_AML	   to	   show	   anti-­‐leukaemic	  
cytotoxicity120,121.	   One	   important	   concern	   had	   been	   that	   IL-­‐2	   secretion	   by	   LV_AML	   cells	   might	   induce	  
expansion	  of	  Tregs	  with	  potentially	  immunosuppressive	  effects	  on	  effector	  T-­‐cell	  function.	  Studies	  carried	  
out	   to	   specifically	   address	   this	   important	   issue	  demonstrated	   that	   despite	   evidence	  of	   Tregs	   in	   the	   co-­‐
cultures,	   subsequent	   lysis	   of	   primary	   AML	   blasts	   was	   preserved.	   There	   was	   no	   evidence	   of	   consistent	  
expansion	   of	   Tregs	   following	   co-­‐culture	   of	   PBMCs	   from	   healthy	   donors	   or	   patients	   with	   LV_AML261.	  
Significantly,	  these	  studies	  confirmed	  that	  primary	  leukaemic	  blasts	  retained	  sensitivity	  to	  lysis	  in	  vitro	  by	  
LV_AML	  stimulated	  donor-­‐derived	  T-­‐	  and	  NK-­‐cells.	   This	   suggests	   that	   LV_AML	  can	   stimulate	   leukaemia-­‐
specific	  cytotoxic	  responses	  in	  lymphocytes	  post-­‐allogeneic	  HSCT.	  Given	  that	  current	  reports	  describe	  low	  
rates	  of	   response	   to	   tDLI,	  our	  pre-­‐clinical	  data	   support	  use	  of	   LV_AML	  blasts	  as	  a	  whole	  cell	   vaccine	   to	  
combine	  with	  freshly	  infused	  donor	  lymphocytes	  in	  order	  boost	  the	  induction	  of	  GvL	  activity.	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These	  data	  allowed	  the	  approval	  of	  a	  Phase	  I	  trial	  of	  therapy	  of	  CD80/IL-­‐2	  modified	  AML	  blasts	  in	  patients	  
with	  relapsed	  AML	  post	  allogeneic	  HSCT	  (RFUSIN2-­‐AML1	  vaccine	  trial,	  EudraCT	  Number	  2005-­‐000806-­‐29).	  
Blasts	   collected	   at	   the	   time	   of	   disease	   relapse	   are	   cryopreserved	   under	   Good	  Manufacturing	   Practice	  
(GMP)	   conditions.	   Following	   salvage	   chemotherapy,	   patients	   showing	  morphological	   remission	   of	   AML	  
(<5%	  BM	  blasts)	  and	  meeting	  eligibility	   criteria	  are	  allocated	   to	   treatment	  either	  with	  a	  patient-­‐specific	  
vaccine	  produced	  by	  RFUSIN2	  transduction	  of	  the	  patient’s	  stored	  AML	  blasts	  and	  escalating	  doses	  of	  DLI	  








































































Figure	  1-­‐9	  Schematic	  depiction	  of	  treatment	  schedules	  in	  each	  arm	  of	  the	  
RFUSIN2-­‐AML1	  trial	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The	   primary	   endpoint	   of	   the	   study	   is	   to	   demonstrate	   safety	   of	   vaccination.	   One	   aspect	   of	   the	   safety	  
investigations	  is	  to	  exclude	  any	  generation	  of	  replication	  competent	  lentivirus	  (RCL)	  by	  screening	  for	  the	  
presence	  of	  HIV	  following	  vaccination.	  The	  specific	  vector-­‐related	  safety	  questions	  that	  will	  be	  addressed	  
are	  as	  follows:	  
1. Exclusion	  of	   viral	   genetic	   integration	   into	   the	  host	   genome.	  PCR	   studies	  will	   ascertain	  whether	  
patient	  PBMCs	  show	  evidence	  of	  integrated	  viral	  genes	  in	  genomic	  DNA	  and	  RNA	  
2. Exclusion	   of	   RCL	   generation.	  Measurement	   of	   serum	   p24	  will	   determine	  whether	   a	   functional	  
lentivirus	  has	  been	  generated.	  
3. Exclusion	  of	   systemically	  elevated	   levels	  of	   IL-­‐2.	  Detection	  of	  elevated	  systemic	   IL-­‐2	   in	  patients	  
would	  be	  an	  unexpected	  and	  unwanted	  side	  effect	  of	  vaccination.	  
	  
Patients	  will	  also	  be	  evaluated	  for	  evidence	  of	  exaggerated,	  systemic,	  immune	  stimulatory	  consequences	  
of	  CD80	  and	  IL-­‐2	  expression	  by	  LV_AML	  blasts,	  including:	  
1. Graft-­‐versus-­‐Host	   Disease.	   The	   use	   of	   donor	   lymphocyte	   infusions	   is	   associated	   with	   a	   risk	   of	  
triggering	  either	  acute	  or	  chronic	  GvHD262.	  Given	  that	  CD80/IL-­‐2	  modified	  AML	  blasts	  are	  able	  to	  
activate	  donor	  T-­‐cells	  in	  vitro,	  it	  is	  possible	  that	  the	  risk	  of	  GvHD	  inherent	  to	  administration	  of	  DLI	  
may	  be	  further	  exacerbated	  by	  the	  use	  of	  an	  immunostimulatory	  vaccine	  that	  may	  bear	  disparate	  
mHags.	   Not	   only	   could	   this	   result	   in	   exacerbation	   of	   GvHD	   (and	   GvL)	   but	   this	  may	   also	   cause	  
immune	   responses	   to	   be	   directed	   against	   normal	   haematopoietic	   precursors	   bearing	   such	  
antigens.	  
2. Capillary	  Leak	  Syndrome	  and	  Cytokine	  Storm.	  The	  effective	  use	  of	  systemic	  IL-­‐2	  at	  high	  doses	  is	  
often	  hampered	  by	  limited	  tolerability	  of	  this	  therapy263.	  Whilst	  some	  of	  the	  side	  effects	  result	  in	  
poor	   tolerability	   of	   the	   treatment	   (e.g.	   due	   to	   fevers,	   chills,	   rigors),	   others	   are	   potentially	   life-­‐
threatening263.	   One	   such	   severe	   toxicity	   is	   capillary	   leak	   syndrome,	   where	   extravasation	   of	  
vascular	   fluids	   and	  proteins	   into	  extravascular	   tissues	   results	   in	   fluid	   shift	   and	  accumulation	  of	  
oedema263.	  This	  results	  in	  hypotension	  and	  poor	  organ	  perfusion	  and	  subsequent	  organ	  damage.	  
The	   mechanisms	   underlying	   this	   include	   increased	   expression	   of	   endothelial	   cell	   adhesion	  
molecules	  due	  to	  exposure	  to	  IL-­‐2	  and	  increased	  trafficking	  of	  recruited	  neutrophils,	  monocytes	  
and	   lymphocytes	   across	   the	   endothelial	   wall.	   Damage	   to	   endothelial	   cell	   walls	   by	   activated	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transmigrating	   cells	   may	   result	   in	   increased	   vascular	   permeability	   and	   fluid	   leak264.	   With	   the	  
intra-­‐dermal	  introduction	  of	  a	  very	  low	  dose	  of	  IL-­‐2	  associated	  with	  the	  CD80/IL-­‐2	  modified	  AML	  
blasts	  (predicted	  to	  be	  <2.5	  µg/24	  hours),	  the	  likelihood	  of	  such	  an	  occurrence	  is	  small	  but	  will	  be	  
monitored	  in	  this	  study.	  
The	   use	   of	   systemic	   immune	   activating	   agents	   has	   the	   potential	   to	   trigger	   an	   overwhelming	  
immune	   response	   resulting	   in	   massive	   cytokine	   release	   with	   sequelae	   including	   multi-­‐organ	  
damage.	   This	   was	   observed	   in	   stark	   reality	   in	   the	   clinical	   trial	   of	   a	   super	   agonist	   anti-­‐CD28	  
monoclonal	   antibody	   that	   resulted	   in	   massive	   stimulation	   of	   T-­‐cells	   in	   the	   absence	   of	   TCR	  
ligation265.	   Such	  a	   response	  would	   seem	  unlikely	   to	  occur	   in	   the	   context	  of	   the	   current	   clinical	  
trial,	   as	   the	   CD80	   protein	   should	   remain	   fixed	   to	   the	   cell-­‐surface	   of	   the	   irradiated	   AML	   blast	  
rather	  than	  freely	  circulate.	  The	  very	  low	  levels	  of	  IL-­‐2	  produced	  by	  the	  vaccine	  would	  suggest	  a	  
low	  risk	  of	  hyperstimulation	  of	  the	  immune	  system	  due	  to	  IL-­‐2,	  but	  this	  remains	  a	  focus	  of	  safety	  
monitoring.	  
3. Off-­‐target	   “autoimmune”	   reactivity.	   In	   vitro	   studies	   have	   suggested	   that	   there	   is	   little	  
responsiveness	  of	   LV_AML	  primed	  T-­‐cells	   against	   healthy	  bone	  marrow-­‐derived	  CD14+	   cells120.	  
However,	  as	  AML	  blasts	  will	  share	  antigens	  with	  healthy	  tissues,	  induction	  of	  autoreactive	  T-­‐cell	  
responses	   remains	   a	   possibility.	   Furthermore,	   target	   cell	   destruction	   and	   local	   inflammation	  
could	  result	  in	  other	  tissue-­‐derived	  antigens	  being	  presented,	  resulting	  in	  off-­‐target	  alloreactivity	  
manifesting	   as	   autoimmune	   disease.	   During	   the	   course	   of	   treatment,	   clinical	   evaluation	   and	  
autoantibody	  screening	  will	  be	  performed	  to	  identify	  evidence	  of	  autoimmune	  reactivity.	  
	  
The	  above	  complications	  form	  the	  basis	  for	  characterising	  dose-­‐limiting	  toxicity	  (DLT),	  which	  is	  defined	  by	  
the	   development	   of	   vaccine-­‐related	   Grade	   3	   or	   higher	   non-­‐haematological	   toxicity,	   Grade	   3	   or	   higher	  
GvHD	   or	  Grade	   4	   or	   higher	   haematological	   toxicity	   (graded	   according	   to	   the	   Common	   Terminology	   for	  
Criteria	   for	   Adverse	   Events	   (CTCAE)	   version	   3.0).	   Any	   patient	   that	   develops	   a	   DLT	   receives	   no	   further	  
treatment	  on	  trial.	  Within	  each	  arm,	  the	  development	  of	  DLT	   in	  3	  patients	  terminates	  treatment	  within	  
that	   arm	   and	   the	   lowest	   tolerated	   dose	   by	   those	   3	   patients	   that	   did	   not	   result	   in	   DLT	   becomes	   the	  
maximum	   tolerated	   dose.	   Secondary	   endpoints	   include	   leukaemia-­‐free	   and	   overall	   survival	   as	   well	   as	  
analyses	   of	   immunological	   responses.	   Monitoring	   for	   disease	   recurrence	   will	   assess	   leukaemia-­‐free	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survival.	   Routine	   bone	  marrow	  and	  peripheral	   blood	   studies	   to	   assess	   remission	   status	   (morphological,	  
flow	   cytometric,	   cytogenetic	   and	   molecular	   where	   there	   is	   a	   marker	   of	   residual	   disease)	   and	   donor	  
chimerism	   are	   regularly	   evaluated	   according	   to	   the	   trial	   follow-­‐up	   protocol.	   Immunological	   studies	  will	  
include	  assessment	  of	  lymphoid	  subset	  composition	  and	  T-­‐cell	  repertoire	  analyses	  prior	  to	  and	  following	  
therapy	  as	  well	  as	  planned	  functional	  evaluation	  of	  in	  vitro	  lysis	  of	  AML	  target	  cells	  and	  leukaemia-­‐specific	  
cytokine	  production	  (IFNγ	  ELISpot	  assay).	  	  
	  
The	  RFUSIN2-­‐AML1	  trial	  has	  been	  open	  since	  2007,	  although	  recruitment	  occurred	  in	  earnest	  after	  2010	  
due	   to	   initial	   tight	   restrictions	   on	   eligibility	   (e.g.	   inclusion	   of	   patients	   undergoing	   matched	   related	  
Fludarabine-­‐Busulphan-­‐Campath	  conditioned	  allografts	  only)	  in	  the	  earliest	  versions	  of	  the	  protocol.	  In	  my	  
role	  as	  co-­‐investigator	  for	  this	  study,	  and	  following	  successful	  applications	  for	  amendments	  to	  the	  original	  
protocol,	  I	  had	  recruited	  4	  patients	  to	  the	  study,	  2	  allocated	  to	  the	  DLI	  only	  arm	  and	  2	  to	  the	  vaccine	  and	  
DLI	   arm	   by	   March	   2013.	   Preliminary	   results	   from	   these	   patients	   (safety	   data,	   adverse	   events,	   clinical	  
response	  and	  evaluation)	  along	  with	   lymphoid	   subset	  and	  TCR	   repertoire	  analyses	  will	   be	  presented	  as	  
part	  of	  this	  thesis.	  	  
	  
1.8 Aims	  of	  this	  thesis	  
The	  aims	  of	  this	  thesis	  are:	  
1. To	   review	   disease	   response	   and	   toxicity	   following	   therapeutic	   and	   pre-­‐emptive	   DLI	  
administration	  according	  to	  an	  escalating	  dose	  schedule	  in	  patients	  who	  have	  undergone	  TCD	  RIC	  
HSCT	  for	  myeloid	  malignancies	  at	  our	  institution.	  
2. To	  determine	  whether	  CASAC	  in	  combination	  with	  WT1	  peptide	  vaccination	  induces	  WT1-­‐specific	  
T-­‐cell	  expansion	  and	  cytotoxic	  responses	  in	  a	  murine	  model.	  
3. To	  examine	  the	   feasibility	  and	  clinical	  safety	  profile	  of	  RFUSIN2-­‐transduced	  primary	  AML	  blasts	  
expressing	  CD80	  and	  IL-­‐2,	  administered	  as	  a	  whole	  cell	  vaccine	  in	  combination	  with	  DLI,	  following	  
recurrent	   AML	   post-­‐TCD	   RIC	   HSCT.	   Preliminary	   analyses	   of	   lymphocyte	   subsets	   and	   TCR	  
repertoire	  following	  vaccine	  administration	  and/or	  DLI	  will	  also	  be	  described.	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Chapter	  2 Materials	  and	  Methods	  
2.1 Materials	  
	  Peptides	  
The	   following	  were	  purchased	   from	  Peptide	  Protein	  Research	  Ltd	   (Farnham,	  UK)	  at	  >95%	  purity	   in	  5mg	  
aliquots:	  
• RMFPNAPYL126-­‐134	  (Class	  I	  peptide	  from	  WT1	  protein,	  WT1-­‐RMF)	  
• YMFPNAPYL126-­‐134	  (Heteroclitic	  modification	  of	  the	  RMFPNAPYL	  peptide,	  WT1-­‐YMF)	  
• SIINFEKL257-­‐264	  (Class	  I	  peptide	  from	  Ovalbumin	  protein,	  OVA-­‐SIINF)	  
• ISQAVHAAHAEINEAGR323-­‐339	  (Class	  II	  peptide	  from	  Ovalbumin	  protein,	  OVA-­‐ISQ)	  
• KSSAKXVAAWTLKAAA	  (PADRE 965.10,	  pan-­‐HLA-­‐DR	  epitope)266	  	  
• PGCNKRYFKLSHLQMHSRKHTG396-­‐417	  (Long	  (22	  amino	  acid)	  Class	  II	  peptide	  from	  WT1	  protein,	  
WT1-­‐PGC)	  
The	  following	  Class	  I	  peptides	  were	  kind	  gifts	  from	  Dr	  Linda	  Barber,	  the	  Rayne	  Institute,	  Coldharbour	  Lane,	  
London	  
• YLLPAIVHI148-­‐156	  (ATP-­‐dependent	  RNA	  helicase)	  
• NLVPMVATVQ495-­‐504	  (Cytomegalovirus	  (CMV)	  pp65	  peptide)	  
The	   overlapping	   peptide	   pool	   was	   acquired	   from	  Miltenyi	   Biotec	   (Cologne,	   Germany).	   The	   non-­‐clinical	  
grade	  product	  was	  used	  in	  experiments	  although	  a	  clinical	  grade	  product	  is	  available:	  
• PepTivator®	  WT1	  peptide	  pool,	  comprising	  113	  x	  15-­‐mer	  sequences,	  with	  11	  amino	  acids	  overlap,	  
covering	  the	  complete	  sequence	  of	  the	  human	  WT1	  protein.	  
Information	  provided	  by	  Miltenyi	  Biotec	  on	  this	  product	  was	  limited.	  The	  60nmol	  vial	  of	  PepTivator®	  WT1	  
peptide	  pool	  contained	  100µg	  of	  each	  peptide	  according	  to	  the	  datasheet.	  There	  are	  approximately	  113	  
peptides	  in	  the	  pool	  giving	  a	  total	  weight	  of	  11300µg/11.3mg	  of	  peptide	  in	  1	  vial	  of	  60nmol	  PepTivator®	  
WT1	   peptide	   pool.	   This	   calculation	   was	   used	   to	   determine	   the	   volume	   in	   which	   to	   re-­‐suspend	   the	  
peptides	  for	  dosing	  (Tables	  2-­‐4	  and	  2-­‐5).	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Antibodies	  &	  Pentamers	  
Table	  2-­‐1	  Anti-­‐mouse	  antibodies	  used	  in	  murine	  studies	  
Test	  Antibody	   Clone	   Isotype	  Control	   Manufacturer	  








αCD19	  PE-­‐Cy7	   1D3	   Rat	  IgG2a	  Κ	  Isotype	  Control	  PE-­‐Cy7	   eBioscience,	  San	  
Diego,	  USA	  




αCD4	  FITC	   GK1.5	   Rat	  IgG2b Κ	  Isotype	  Control	  FITC eBioscience,	  San	  
Diego,	  USA 
α IFNγ  PE XMG1.2	   Rat	  IgG1	  Κ	  Isotype	  Control	  PE	   eBioscience,	  San	  
Diego,	  USA	  /BD*	  
biosciences,	  Franklin	  
Lakes,	  USA	  




37.51	   Not	  applicable	   eBioscience,	  San	  




free	  αCD40	  antibody	  
(stimulating)	  
HM40-­‐3	   Not	  applicable	   BioLegend,	  San	  Diego,	  
USA	  
*BD,	  Beckton	  Dickinson	  
74	  
The	   following	   anti-­‐human	   antibodies	   were	   used	   during	   AML	   cell	   vaccine	   production	   and	   in	   follow-­‐up	  
immunophenotyping	  studies	  on	  the	  RFUSIN2	  clinical	  trial.	  Internal	  controls	  (gating	  on	  cells	  known	  not	  to	  
express	  the	  marker	  of	  interest)	  were	  used	  rather	  than	  isotype	  control	  stains	  in	  these	  particular	  studies.	  
	  
Table	  2-­‐2	  Anti-­‐human	  antibodies	  used	  in	  the	  course	  of	  vaccine	  preparation	  and	  for	  immunophenotyping	  
studies	  during	  follow-­‐up	  on	  the	  RFUSIN1-­‐AML1	  clinical	  trial	  
Test	  Antibody	   Clone	   Manufacturer	  
αCD80	  PE L307.4	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD3	  V500	   UCHT1	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD56	  PE	  Cy5.5	   CMSSB	   eBioscience,	  San	  Diego,	  USA	  
αCD19	  APC	   HIB19	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD16	  eFluor®	  450	   CB16	   eBioscience,	  San	  Diego,	  USA	  
αCD4	  eFluor®	  450	   RPA-­‐T4	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD45RO	  APC UCHL1	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD27	  FITC	   M-­‐T271	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD69	  PE FN50	   eBioscience,	  San	  Diego,	  USA	  
α 	  HLA-­‐DR	  PerCP	  Cy5.5 G46-­‐6	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αCD25	  APC M-­‐A251	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
α 	  FoxP3	  PerCP	  Cy5.5 PCH101	   eBioscience,	  San	  Diego,	  USA	  
α 	  NKG2D	  APC 1D11	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  
αDNAM-­‐1	  FITC DX11	   BD	   biosciences,	   Franklin	   Lakes,	  
USA	  






The	  following	  pentamers	  were	  purchased	  from	  Proimmune	  Ltd	  (Oxford,	  UK)	  for	  use	  in	  the	  murine	  peptide	  
vaccination	  studies:	  
• Control	   pentamer	   –	   specific	   for	   the	   Lymphochoriomeningitis	   virus	   (LCMV)	   nucleoprotein	   396-­‐
404,	  (R-­‐PE-­‐	  FQPQNGQFI/Db)	  	  
• OVA-­‐SIINFEKL	  pentamer	  (R-­‐PE-­‐SIINFEKL/Kb)	  	  
• WT1-­‐RMFPNAPYL	  pentamer	  (R-­‐PE-­‐RMFPNAPYL/Db)	  
	  
2.1.1 	  Adjuvant	  components	  
Complete	  Freund's	  Adjuvant	  (CFA)	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
CpG	  ODN	  1826	  	   	   	   	   	   	   SIGMA-­‐Genosys,	  Sigma-­‐Aldrich,	  St	  Louis,	  	  
(5'-­‐t*c*c*a*t*g*a*c*g*t*t*c*c*t*g*a*c*g*t*t-­‐3')	   	   USA	   	  
	  (*Phosphothiorate	  modified	  bases)	  
Polyinosinic–polycytidylic	  acid	  sodium	  salt	  (Poly	  I:C)	  	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Recombinant	  mouse	  Interferon	  Gamma	  (IFN-­‐γ)	   	   Peprotech,	  Rocky	  Hill,	  USA	  
	  
2.1.2 Cell	  lines	  
293T/17	   American	  Type	  Culture	  Collection,	  (ATCC)	  
Virginia,	  USA	  
T2	  (TAP	  deficient)	  cells	   Kind	  gift,	  Dr	  Linda	  Barber	  
U937	   ATCC,	  Virginia,	  USA	  
	  
2.1.3 Primer	  sequences	  
IL-­‐2/CD80	  junction	  FORWARD	  primer:	  
5’TGTGAATATGCTGATGAGACAGCAACC	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
IL-­‐2/CD80	  junction	  REVERSE	  primer:	  
5’TGCGAGTTTGTGCCAGCTCTTCA	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
CD80	  FORWARD	  primer:	  
5’GGCAACGCTGTCCTGTGGTCA	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
CD80	  REVERSE	  primer:	  
5’CCTCGTCAGATGGCGCAGA	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
	  
2.1.4 Media	  and	  solutions	  
BD	  GolgiStopTM	  (containing	  Monensin)	   	   	   BD	  Biosciences,	  Oxford,	  UK	  	  
76	  
Cryosure-­‐DMSO	  (for	  GMP	  procedures)	  	   Wak-­‐Chemie	  Medical	  GmbH,	  Steinbach	  T/s,	  
Germany)	  	  
Dimethyl	  sulfoxide	  -­‐	  Hybri-­‐MaxTM,	  sterile-­‐filtered	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
(DMSO)	  
Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM)	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Phosphate	  buffered	  saline	  (PBS)	  	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Ethylenediaminetetraacetic	  acid	  (EDTA)	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Fetal	  bovine	  serum	  (FBS)	   	   	   	   	   Life	  Technologies,	  Carlsbad,	  USA	  
Ficoll-­‐Paque	  Premium	  	   GE	  Healthcare	  Bio-­‐Sciences,	  Piscataway,USA	  
FoxP3	  Fixation	  and	  Permeabilisation	  Concentrate	  and	  	   eBiosciences,	  San	  Diego,	  USA	  
Diluent	  kit	  
Human	  albumin	  	   Bio	  Products	  Laboratory	  Limited,	  Herts,	  UK	  
Intracellular	  fixation	  buffer	  	   eBiosciences,	  San	  Diego,	  USA	  
Isoflo®	  Isofluorane	   	   	   	   	   Abbot	  Animal	  Health,	  Maidenhead,	  UK	  
Penicillin	  &	  streptomycin	  solution	  	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
(10,000	  units	  penicillin	  and	  10	  mg	  streptomycin/mL)	  
Permeabilization	  Buffer	  (10x)	   	   	   	   eBiosciences,	  San	  Diego,	  USA	  
Roswell	  Park	  Memorial	  Institute	  medium	  (RPMI-­‐1640)	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Sodium	  citrate	  pH	  3;	  0.05M	  12%	  (v/v)	  solution	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Sodium	  hydroxide	  1.0N	  solution	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Squalene,	  ≥	  98%	  purity	   	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Trypan	  Blue	  solution	  (0.4%)	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Tween®	  80	  -­‐	  Cell	  culture	  tested	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
	  X-­‐VIVO	  15	  media	  	   	   	   	   	   Lonza	  Biologics,	  Walkersville,	  USA	  
	  
2.1.5 	  All	  other	  kits	  and	  reagents	  
Ammonium	  chloride	  (NH4Cl)	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Annexin	  V	  APC	   	   	   	   	   	   BD	  Biosciences,	  Franklin	  Lakes,	  USA	  
Anti-­‐Human	  HLA-­‐A2-­‐PE	  antibody,	  clone	  BB7.2,	   	   BD	  Biosciences,	  Franklin	  Lakes,	  USA	  
mouse	  IgG2bκ	  
Anti-­‐Rat	  Igκ/Negative	  Control	  (FBS)	  Compensation	  	   	   BD	  Biosciences,	  Franklin	  Lakes,	  USA	  
particles	  Set	   	  
Cell	  TraceTM	  (Carboxyfluorescein	  diacetate	   	   	   Invitrogen,	  Carlsbad,	  USA	  
succinimidyl	  ester,	  CFSE)	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Diethylaminoethyl	  (DEAE)-­‐dextran	  viral	  complexing	  agent	  	   GE	  Healthcare,	  Amersham,	  UK	  
Gentamicin	  sulphate	   Beacon	   Pharmaceuticals	   Ltd,	   East	   Sussex,	  
UK	  
HIV-­‐1	  p24	  Enzyme-­‐Linked	  Immunosorbent	  Assay	  (ELISA)	  kit	   PerkinElmer	  Life	  Sciences	  Inc.,	  Boston,	  USA	  
Interleukin-­‐2	  Duo	  Set	  ELISA	  kit	   R&D	  systems,	  Minneapolis,	  USA	  
Ionomycin	  calcium	  salt	  from	  Streptomyces	  conglobatus,	  	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
≥98%	  purity	  
Methanol	  (99.8%)	   	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	   	  	  
Monensin	  sodium	  salt,	  90-­‐95%	  purity	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  	  
Nuclease-­‐free	  water	  	   	   	   	   	   Promega,	  Wisconsin,	  USA	  	  
Phorbol	  12-­‐myristate	  13-­‐acetate,	  (PMA)	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  	  
Potassium	  bicarbonate	  (KHCO3)	   	   	   	   Sigma-­‐Aldrich,	  St	  Louis,	  USA	  
Power	  SYBR	  Green	  Master	  Mix	   	   	   	   Life	  Technologies,	  Carlsbad,	  USA	  
QIAamp	  DNA	  Mini	  Kit	  	   	   	   	   	   QIAGEN,	  Hilden,	  Germany	  
QIAamp®	  MinElute®	  Virus	  Spin	  Kit	  	   	   	   	   QIAGEN,	  Hilden,	  Germany	  
QuantiTect®	  Reverse	  Transcription	  Kit	  	   	   	   QIAGEN,	  Hilden,	  Germany	  
Recombinant	  human	  interleukin	  3	  (rhuIL-­‐3)	   	   	   CellGenix,	  Freiburg,	  Germany	  
Recombinant	  human	  Stem	  Cell	  Factor	  (rhuSCF)	   	   Amgen,	  Thousand	  Oaks,	  USA	  
	  
2.1.6 Solutions	  prepared	  in-­‐house	  
	  
1. Red	  Blood	  Cell	  (RBC)	  Lysis	  Buffer:	  
• 8.26g	  Ammonium	  Chloride	  (NH4CL)	  
• 1	  g	  potassium	  bicarbonate	  (KHCO3)	  
• 0.037	  g	  EDTA	  
The	   above	  were	   dissolved	   in	   1	   litre	   of	   distilled	  water.	   The	   resulting	   solution	  was	   then	   passed	  
through	  a	  0.2µM	  filter	  (Millipore,	  Massachusetts,	  USA)	  and	  stored	  at	  room	  temperature.	  
2. Monensin	  solution:	  
• Reconstituted	  monensin	  salt	  in	  99.8%	  methanol	  to	  a	  concentration	  of	  10mM	  with	  
subsequent	  dilution	  for	  use	  in	  assays	  (final	  concentration	  3µM	  per	  well)	  
• Alternatively,	  BD	  GolgiStopTM	  was	  used	  in	  some	  experiments	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2.2 Methods	  
2.2.1 Retrospective	  analysis	  of	  outcomes	  following	  Donor	  Lymphocyte	  Infusions	  (Chapter	  3)	  
The	  methodology	  for	  this	  chapter	  is	  described	  within	  the	  publication	  included	  in	  Chapter	  3.	  
	  
2.2.2 WT1	  peptide	  vaccination	  using	  combined	  adjuvants	  for	  synergistic	  activation	  of	  cellular	  immunity	  
(Chapter	  4)	  
2.2.2.1 	  Mice	  
C57BL/6	  mice	  were	  obtained	  from	  Harlan	  (Indianapolis,	  USA)	  and	  housed	  in	  a	  pathogen-­‐free	  facility	  at	  the	  
Biological	  Sciences	  Unit	  (BSU),	  Denmark	  Hill	  campus,	  according	  to	  Home	  Office	  Regulations.	  Female	  mice,	  
H-­‐2Kb/H-­‐2Db	  MHC	  haplotypes,	  6-­‐8	  weeks	  of	  age,	  were	  used	  in	  all	  experiments.	  Upon	  arrival	  at	  the	  facility,	  
mice	   were	   allowed	   to	   acclimatise	   to	   the	   new	   environment	   for	   1	   week	   before	   proceeding	   with	   an	  
experiment	   (unless	  being	  culled).	  Experiments	  were	  carried	  out	  according	   to	  protocols	   stated	   in	  Project	  
License	   70/6950.	   Any	   mice	   not	   culled	   at	   termination	   of	   an	   experiment	   were	   subsequently	   culled	   in	   a	  
timely	  manner	  using	  a	  Schedule	  1	  approved	  humane	  method.	  
	  
2.2.2.2 	  Assessment	  of	  peptide	  binding	  to	  MHC	  molecules	  using	  the	  Immune	  Epitope	  Database	  
As	   described	   in	   Chapter	   1,	   section	   1.6.2	   and	   Table	   1-­‐3,	   a	   number	   of	  WT1	   epitopes	   have	   been	   used	   in	  
peptide	   vaccinations	   targeting	   WT1	   in	   mice	   and	   in	   human	   clinical	   trials.	   WT1-­‐RMF	   has	   been	   used	  
extensively	  in	  both	  mouse	  and	  human	  studies	  due	  to	  good	  binding	  affinity	  for	  both	  HLA*02:01	  and	  H-­‐2Db	  
(section	   1.6.2).	   The	   longer	   Class	   II	   peptide	   PGCNKRYFKLSHLQMHSRKHTG,	   used	   in	   the	   multi-­‐epitope	  
vaccine	   studies	   described	   by	   Scheinberg’s	   group190,203,	   had	   not	   been	   evaluated	   in	   mice,	   although	   the	  
sequence	   is	   identical	   in	   the	  mouse	  and	  human	  WT1	  proteins.	   To	   assess	  whether	   sequences	  within	   this	  
peptide	  might	   bind	   the	  mouse	   class	   II	  molecule	   (I-­‐Ab	   in	   C57BL/6),	   the	   peptide	  was	   analysed	   using	   the	  
Immune	   Epitope	   Database	   (IEDB)181.	   This	   software	   uses	   a	   combination	   of	   approaches	   to	   assess	   the	  
binding	   potential	   for	   epitopes	   deriving	   from	   a	   particular	   sequence	   to	   bind	   to	   candidate	   Class	   I	   and	   II	  
molecules.	  The	  analysis	  demonstrated	  8	  sequences	  deriving	  from	  the	  longer	  peptide	  with	  percentile	  rank	  
between	  29-­‐53	  using	   the	  consensus	  method,	  suggesting	  moderate	  binding	  affinities	   for	   I-­‐Ab	   (Table	  2-­‐3).	  
Notably,	  within	   this	   long	  WT1	  peptide,	  54	  potential	  Class	   I	  peptides,	   ranging	   in	   length	   from	  8-­‐11	  amino	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acids	  and	  binding	  H-­‐2Kb	  or	  H-­‐2Db	  were	  identified.	  Each	  of	  these	  represents	  candidate	  epitopes	  that	  could	  
be	   processed	   and	   presented	   via	   cross-­‐presentation	   mechanisms	   to	   responder	   CD8+	   T-­‐cells	   (data	   not	  
shown).	  
	  	  
Table	  2-­‐3	  Peptides	  from	  within	  the	  long	  WT1	  peptide	  showing	  binding	  to	  the	  C57BL/6	  Class	  II	  molecule	  I-­‐
Ab	  and	  as	  an	  example,	  one	  of	  the	  more	  common	  HLA	  Class	  II	  alleles,	  HLA	  DRB1*04	  
Peptide	  sequence	   Class	  II	  allele	   Percentile	   rank*	   by	   consensus	  
method	  (IEDB)181	  
CNKRYFKLSHLQMHS	   I-­‐Ab	   27.91	  
GCNKRYFKLSHLQMH	  
	  
I-­‐Ab	   29.44	  
NKRYFKLSHLQMHSR	  
	  
I-­‐Ab	   30.59	  
	  




I-­‐Ab	   40.95	  
PGCNKRYFKLSHLQM	   I-­‐Ab	  	  	   45.09	  
YFKLSHLQMHSRKHT	   I-­‐Ab	   51.13	  
FKLSHLQMHSRKHTG	   I-­‐Ab	   53.2	  
	   	   	  
CNKRYFKLSHLQMHS	   DRB1*04:01	   2.53	  
NKRYFKLSHLQMHSR	   DRB1*04:01	   2.53	  
KRYFKLSHLQMHSRK	   DRB1*04:01	   2.53	  
GCNKRYFKLSHLQMH	   DRB1*04:01	   2.63	  
RYFKLSHLQMHSRKH	   DRB1*04:01	   2.66	  
YFKLSHLQMHSRKHT	   DRB1*04:01	   5.15	  
PGCNKRYFKLSHLQM	  
	  
DRB1*04:01	   6.65	  
FKLSHLQMHSRKHTG	   DRB1*04:01	   9.11	  
	  
*Top	  (low)	  percentile	  binders	  are	  deemed	  good	  binders.	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However,	  whilst	  such	  algorithms	  are	  extremely	  useful	  as	  a	  starting	  point	  to	  assess	  immunogenicity	  of	  
candidate	  peptides,	  all	  studies	  must	  be	  backed	  up	  by	  functional	  assessments	  for	  a	  true	  evaluation	  of	  
candidate	  epitopes	  with	  immunizing	  potential.	  
2.2.2.3 Vaccine	  preparation	  
Vaccine	   components	   were	   prepared	   as	   listed	   in	   Table	   2-­‐4	   under	   sterile	   conditions,	   in	   a	   Class	   II	  
microbiological	   safety	   cabinet	   (Howorth	   Airtech	   Ltd.)	   Peptides	   from	   Peptide	   Protein	   Research	   were	  
supplied	  in	  vials	  containing	  5mg	  of	  the	  particular	  peptide.	  Following	  dissolution	  in	  the	  relevant	  solvent	  to	  
achieve	  the	  desired	  concentration,	  components	  were	  evenly	  mixed	  by	  vortexing.	  Peptides	  were	  dissolved	  
until	  a	  clear	  solution	  was	  obtained;	  up	  to	  1µl	  of	  sodium	  hydroxide	  (1.0N	  solution)	  was	  added	  to	  achieve	  
this	   where	   required.	   Peptides	   were	   then	   aliquotted	   and	   stored	   in	   0.5ml	   tubes	   (Eppendorf,	   Hamburg,	  
Germany)	  at	  -­‐20oC	  (Leibherr	  Freezer).	  Repeated	  freeze-­‐thaw	  cycles	  of	  aliquots	  were	  avoided	  (maximum	  3	  
per	  vial).	  Emulsion	  was	  prepared,	  giving	  a	  final	  concentration	  of	  0.4%	  v/v	  Tween	  80	  and	  4.4%	  v/v	  Squalene	  
in	   PBS	   (e.g.	   16µl	   Tween	   80,	   176	  µl	   Squalene	   and	   3808	  µl	   PBS	   for	   final	   volume	   of	   4ml).	   Tween	   80	  was	  
pipetted	  into	  a	  15ml	  Falcon	  tube	  followed	  by	  Squalene	  and	  PBS.	  Following	  decontamination	  of	  the	  Sonics	  
Vibra	  Cell	  sonicator	  using	  70%	  Ethanol,	  the	  mixture	  was	  sonicated	  for	  5	  seconds	  at	  100%	  amplitude	  before	  
repeating,	  with	  30	  seconds	  rest	  between	  sonications.	  Sonication	  was	  repeated	  up	  to	  4	  times	  until	  a	  milky	  
white,	   even	  emulsion	  was	   formed	   that	  did	  not	   stick	   to	   the	   sides	  of	   the	   Falcon	   tube.	   The	  emulsion	  was	  
transferred	  to	  ice	  immediately	  and	  then	  stored	  in	  a	  water	  bath	  at	  37oC	  (Clifton	  unstirred	  water	  bath)	  until	  
use	  (within	  4	  hours	  of	  preparation).	  
	  
Sufficient	  vaccine	  was	  prepared	  in	  one	  1ml	  tube	  (Eppendorf,	  Hamburg,	  Germany)	  to	  vaccinate	  one	  more	  
than	  the	  total	  number	  of	  mice	  within	  a	  group,	  i.e.	  for	  a	  group	  of	  5	  mice,	  sufficient	  vaccine	  was	  prepared	  
for	  6	  mice,	  to	  allow	  for	  any	  pipetting/syringing	  errors.	  Each	  frozen	  vaccine	  component	  was	  allowed	  to	  
thaw	  to	  room	  temperature	  and	  then	  pipetted	  into	  each	  1ml	  tube	  to	  give	  the	  correct	  amount	  of	  each	  
constituent	  per	  vaccine	  (Table	  2-­‐5).	  An	  equal	  volume	  of	  emulsion	  was	  added	  to	  each	  1ml	  tube	  and	  then	  
mixed	  thoroughly	  by	  vortexing	  (Labinco	  L46	  vortex)	  for	  60	  seconds	  per	  tube.	  Where	  Complete	  Freund’s	  
adjuvant	  (CFA)	  was	  used	  instead	  of	  CASAC,	  this	  was	  required	  only	  for	  the	  first	  vaccination.	  The	  glass	  vial	  
containing	  CFA	  was	  vortexed	  thoroughly	  and	  the	  required	  volume	  of	  adjuvant	  was	  then	  removed	  using	  a	  
pipette	  and	  transferred	  into	  the	  1ml	  tube	  already	  containing	  the	  target	  peptide(s)	  in	  PBS.	  This	  was	  then	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vortexed	  thoroughly	  to	  ensure	  an	  even,	  milky	  emulsion	  was	  formed.	  For	  all	  subsequent	  vaccinations	  in	  
mice	  primed	  at	  first	  vaccination	  using	  CFA,	  emulsion	  (0.4%	  v/v	  Tween	  80,	  4.4%	  v/v	  squalene	  in	  PBS)	  was	  
used	  instead	  of	  CFA	  and	  combined	  with	  target	  peptide(s)	  in	  PBS.	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  Table	  2-­‐4	  Preparation	  of	  peptides	  and	  CASAC	  components	  	  
Component	   Preparation	  &	  storage	   Stock	  concentration	  	  








Each	  dissolved	  in	  10%	  
DMSO	  and	  PBS.	  1.0N	  
Sodium	  Hydroxide	  1µl	  used	  
to	  aid	  solubility	  where	  
required	  
Aliquotted	  into	  0.5ml	  tubes	  
(Eppendorf,	  Hamburg,	  
Germany)	  and	  stored	  at	  	  




WT1	  PepTivator®	  	   Dissolved	  in	  500µl	  PBS	  	  
Aliquotted	   into	   100µl	  
volumes	  in	  0.5ml	  tubes	  and	  
stored	  at	  -­‐20oC	  
22.6mg/ml	  
Anti-­‐CD40	  Antibody	   Used	  neat	  from	  stock	  	   1mg/ml	  
CpG	   Dissolved	   in	   nuclease-­‐free	  
water	  
Aliquotted	   into	   100µl	  
volumes	  in	  0.5ml	  tubes	  and	  
stored	  at	  -­‐20oC	  
5mg/ml	  
Poly	  I:C	   Dissolved	  in	  PBS	  
Aliquotted	   into	   250µl	  
volumes	  in	  0.5ml	  tubes	  and	  
stored	  at	  -­‐20oC	  
10mg/ml	  
Mouse	  IFNγ 	   Dissolved	  in	  PBS	  
Aliquotted	   into	   25µl	  




Tween	  80	  0.4%	  
PBS	  
	  
Components	   added	   and	  
mixed	   by	   sonication	   (see	  





Table	  2-­‐5	  Quantity	  of	  each	  CASAC	  vaccine	  component	  per	  vaccine,	  with	  example	  volumes	  for	  6	  mice	  
Vaccine	  
component	  
Stock	  concentration	   Amount	   per	  
vaccine	  
Volume	   for	   1	  
mouse	  
Volume	   for	   6	  
mice	  
Class	  I	  peptide	   8mg/ml	   100µg	   12.5	  µl	   75	  µl	  
Class	  II	  peptide	   8mg/ml	   100µg	   12.5	  µl	   75	  µl	  
WT1	  PepTivator®	  	   22.6mg/ml*	   282.5µg	   12.5	  µl	   75	  µl	  
Anti-­‐CD40	  
Antibody	  
1mg/ml	   25µg	   25	  µl	   150	  µl	  
CpG	   5mg/ml	   25µg	   5	  µl	   30	  µl	  
Poly	  I:C	   10mg/ml	   50µg	   5	  µl	   30	  µl	  
Mouse	  IFNγ 	   100µg/ml	   1	  ng	   1	  µl	   6	  µl	  










*	  approximate,	  based	  on	  available	  information	  from	  Miltenyi	  Biotec	  
2.2.2.4 Vaccination	  protocol	  
Vaccinations	  were	  performed	  at	  7-­‐10	  day	   intervals	  up	   to	  4	   times.	  Mice	  underwent	  general	   anaesthesia	  
using	   isofluorane	   inhalation.	   Up	   to	   5	   mice	   were	   placed	   in	   the	   anaesthetic	   chamber	   and	   anaesthesia	  
induced	   using	   an	   oxygen	   flow	   rate	   of	   2l/min,	   containing	   up	   to	   3%	   isofluorane.	   After	   2-­‐5	   minutes,	  
anaesthetised	  mice	  were	   individually	   transferred	   to	   a	  mat	   for	   administration	  of	   anaesthetic	   via	   a	  mask	  
apparatus.	  Both	  flanks	  of	  each	  mouse	  were	  shaved	  (using	  a	  Wella	  contour	  clipper) to	  allow	  clear	  access	  
and	  visibility	  in	  the	  region	  where	  the	  vaccine	  was	  to	  be	  administered.	  After	  spraying	  the	  shaved	  areas	  with	  
antiseptic	   (Chlorhexidine,	   Vetasept)	   and	   allowing	   to	   dry,	   intra-­‐dermal	   vaccinations	   were	   administered.	  
Vaccine	  was	  drawn	  up	   into	  a	  0.3	  ml	   insulin	  syringe	  with	  a	  30-­‐gauge	  needle	  (Beckton	  Dickinson,	  Franklin	  
Lakes,	  USA).	  Each	   flank	  was	  grasped	  between	  the	  thumb	  and	   index	   finger,	  at	   the	  same	  time	  pulling	  the	  
exposed	  skin	  taught.	  Fifty	  microlitres	  of	  vaccine	  were	  injected	  intra-­‐dermally	  per	  flank,	  with	  observation	  
of	  a	  skin	  bleb	  confirming	  successful	  intra-­‐dermal	  administration.	  Mice	  were	  then	  allowed	  to	  recover	  and	  
observed	  until	  mobile	  and	  resuming	  normal	  behaviour.	  For	  CFA,	  due	  to	  the	  high	  viscosity	  of	  the	  vaccine,	  
components	  were	   aspirated	   into	   a	   1ml	   syringe	   (Beckton	  Dickinson)	   and	   administered	  using	   a	   25	   gauge	  
(Beckton	  Dickinson)	  orange	  needle.	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2.2.2.5 Collection	  of	  blood	  and	  splenocytes	  
A	  No.	  10	  disposable	  blade	   (Swann	  Morton)	  was	  used	   to	  nick	   the	   tail	   tip	   to	  allow	  bleeding	   from	  the	   tail	  
vein.	  Blood	  was	  massaged	  from	  the	  tail	  vein	  into	  1ml	  tubes	  already	  aliquotted	  with	  40µl	  of	  sodium	  citrate	  
0.05M	   (12%)	   anticoagulant	   solution.	   A	   maximum	   of	   100µl	   of	   blood	   was	   collected	   at	   each	   bleed	   and	  
animals	  were	  bled	  no	  more	  than	  once	  in	  7	  days.	  To	  harvest	  splenocytes	  for	  the	  in	  vivo	  cytotoxicity	  assays,	  
up	  to	  5	  mice	  were	  culled	  at	  one	  time	  by	  exposure	  to	  a	  rising	  concentration	  of	  carbon	  dioxide	  (CO2)	   in	  a	  
CO2	  chamber.	  Following	  cessation	  of	  breathing,	  death	  was	  confirmed	  by	  dislocation	  of	  the	  neck.	  The	  left	  
upper	  abdomen	  was	  sterilized	  with	  antiseptic	  spray	  (Chlorhexidine,	  Vetasept)	  and	   incised	  to	  expose	  the	  
peritoneum.	  The	  spleen	  was	  dissected	  out	  using	  2	  pairs	  of	  sterile	  forceps.	  Spleens	  from	  splenocyte	  donors	  
were	  combined	  in	  a	  50ml	  Falcon	  tube	  (Beckton	  Dickinson)	  containing	  5-­‐10ml	  of	  PBS	  or	  single	  spleens	  were	  
transferred	  to	  individual	  Bijoux	  tubes	  (Beckton	  Dickinson)	  containing	  1-­‐2	  ml	  of	  PBS.	  
	  
2.2.2.6 Immunophenotyping	  of	  PBMCs	  and	  splenocytes	  in	  murine	  vaccination	  studies	  
Pentamer	  staining	  
Staining	  was	   performed	   as	   recommended	  by	   the	  manufacturers	   (Proimmune,	  Oxford,	  UK).	   Each	   vial	   of	  
pentamer	  was	  stored	  at	  4oC	  and	  protected	  from	  light	  exposure.	  Prior	  to	  use,	  the	  vial	  was	  centrifuged	  at	  
14,000×g	   (Rotanta	  460R	  centrifuge)	   for	  5-­‐10	  minutes	  and	  stored	  on	   ice	  until	  use.	  Aliquots	  of	  10µl	  R-­‐PE-­‐	  
RMFPNAPYL/Db	  pentamer	  were	  pipetted	  into	  test	  wells	  of	  a	  labeled	  96-­‐well	  U-­‐bottom	  plate	  (Greiner	  Bio	  
One,	  Frickenhousen,	  Germany).	  R-­‐PE-­‐	  SIINFEKL/Kb	  pentamer,	  in	  2μl	  aliquots,	  was	  added	  to	  40	  μl	  of	  whole	  
blood	   in	   wells	   of	   a	   96	   well	   plate.	   R-­‐PE-­‐	   SIINFEKL/Kb	   Pentamer	   was	   titrated	   with	   antigen	   specific	   OT-­‐1	  
splenocytes	  to	  saturation	  point	  to	  allow	  a	  reduction	  in	  the	  volume	  used	  per	  test	  (data	  not	  shown).	  10	  μl	  of	  
R-­‐PE-­‐FQPQNGQFI/Db	   pentamer	   (specific	   for	   the	   LCMV	   nucleoprotein	   396-­‐404)	   were	   used	   (per	   test)	   to	  
provide	  an	   irrelevant	   control	  pentamer;	  mice	   kept	   in	   the	  pathogen-­‐free	   facilities	   should	  not	  have	  been	  
exposed	   to	   this	   virus.	   In	   some	   experiments,	   irrelevant	   control	   pentamers	   were	   either	   R-­‐PE-­‐	  
RMFPNAPYL/Db	  or	  R-­‐PE-­‐	  SIINFEKL/Db	  in	  mice	  immunized	  with	  OVA-­‐SIINF	  or	  WT1-­‐RMF	  respectively.	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Following	  pipetting	  of	  pentamer	  into	  the	  relevant	  wells,	  40	  µl	  of	  blood	  from	  each	  mouse	  was	  transferred	  
into	  appropriate	  wells	  and	   left	  at	   room	  temperature,	   in	   the	  dark	   for	  20	  minutes.	  After	  20	  minutes,	   test	  
and	  control	  antibody	  stains	  were	  set	  up	  as	  per	  Table	  2-­‐6	  and	  left	  to	  stain	  for	  a	  further	  20	  minutes	  at	  room	  
temperature.	   After	   incubation,	   150µl	   of	   red	   blood	   cell	   (RBC)	   lysis	   solution	   was	   added	   to	   each	   well	  
followed	   by	   thorough	   re-­‐suspension.	   After	   10	   minutes,	   the	   plate	   was	   centrifuged	   at	   560-­‐620g	   for	   5	  
minutes.	  Supernatants	  were	  aspirated	  and	  a	   further	  200µl	  of	  RBC	   lysis	  solution	  was	  added	  to	  each	  well	  
and	  re-­‐suspended.	  Again,	  the	  samples	  were	  left	  for	  10	  minutes	  before	  centrifugation	  at	  the	  same	  settings	  
and	   aspiration	  of	   the	   supernatant.	   Following	   this,	   cells	  were	  washed	   twice	   as	   above	  with	   200µl	   of	   PBS	  
before	   re-­‐suspending	   in	  200µl	  of	  PBS	   to	   read	  on	   the	   flow	  cytometer	   (FACS	  Canto	   II,	  Beckton	  Dickinson,	  
Franklin	  Lakes,	  USA).	  
86	  
Table	  2-­‐6	  Antibody	  cocktails	  used	  for	  assessment	  of	  T-­‐cell	  responses	  to	  vaccination	  
Sample	  type	   Antibodies	   Volumes	  




Rat	  IgG2b	  Κ	  Isotype	  Control	  eFluor®	  450	  
Rat	  IgG2a	  Κ	  Isotype	  Control	  PerCP-­‐Cy5.5	  








αCD8α	  PerCP	  Cy5.5	  
αCD19	  PE-­‐Cy7	  
R-­‐PE-­‐	  FQPQNGQFI/Db)	  OR	  	  








Test	  pentamer	   αCD3	  e450	  










Intracellular	  staining	  for	  FoxP3	  expression:	  identification	  of	  Tregs.	  
In	  a	  new	  96-­‐well	  U-­‐bottom	  plate	  anti-­‐CD4	  and	  anti-­‐CD25	  antibodies	  (or	  isotype	  control	  antibodies)	  were	  
added	  as	  described	  in	  Table	  2-­‐7.	  Forty	  microlitres	  of	  whole	  blood	  from	  each	  mouse	  was	  transferred	  into	  
the	   relevant	   test	   and	   control	  wells.	   The	   plate	  was	   left	   to	   incubate	   in	   the	   dark	   for	   30	  minutes.	   Fix	   and	  
Permeabilization	   buffer	   was	   prepared	   as	   per	   the	  manufacturer’s	   instructions	   (eBiosciences,	   San	   Diego,	  
USA)	  and	  stored	  on	   ice.	  As	   for	   the	  surface	  staining	  described	  above,	  2	   rounds	  of	  RBC	   lysis	  and	  washing	  
were	   performed.	   After	   the	   second	   wash,	   the	   supernatant	   was	   removed	   and	   replaced	   with	   200µl	   of	  
fixation	  and	  Permeabilization	  buffer	  per	  well	  and	  resuspended	  thoroughly.	  The	  plate	  was	  then	  left	  for	  a	  
minimum	  of	  half	  an	  hour	  at	  4oC.	  After	  incubation,	  the	  plate	  was	  centrifuged	  at	  560g	  x	  5	  minutes	  and	  the	  
supernatant	  aspirated.	  The	  wells	  were	  then	  washed	  twice	  in	  200µl	  of	  1x	  Permeabilization	  buffer.	  After	  the	  
second	  wash,	  the	  wells	  were	  resuspended	  in	  200µl	  of	  1x	  Permeabilization	  buffer	  per	  well,	  to	  which	  was	  
added	  1.5µl	  of	  either	  the	  anti-­‐FoxP3	  PE	  antibody	  or	  the	  isotype	  control	  PE	  antibody	  (Table	  2-­‐8)	  followed	  
by	  thorough	  resuspension.	  The	  plate	  was	  left	  to	  incubate	  for	  30	  minutes	  at	  4oC	  before	  washing	  once	  in	  1x	  
Permeabilization	  buffer,	  once	   in	  PBS	  and	   then	  being	   resuspended	   in	  200µl	  PBS	   for	  analysis	  on	   the	   flow	  
cytometer.	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Table	  2-­‐7	  Antibody	  volumes	  per	  well	  for	  control	  and	  test	  samples	  (quantification	  of	  Treg	  frequencies)	  
Sample	  type	   Antibodies	   Volumes	  
Isotype	  control	  for	  APC	  
FITC	  
Rat	  IgG1 Κ	  Isotype	  Control	  APC	  
Rat	  IgG2b	  Κ	  Isotype	  Control	  FITC	  
1µl	  
1µl	  
Isotype	  control	  for	  
FoxP3	  














*Administered	  after	  fixation	  and	  permeabilisation
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Intracellular	  staining	  for	  IFNγ 	  
Following	  5-­‐hour	  incubation	  (see	  in	  vivo	  cytotoxicity	  assay,	  2.2.2.7),	  splenocytes	  were	  centrifuged	  at	  560g	  
for	  5	  minutes.	  After	  aspiration	  of	  the	  supernatant,	  200µl	  PBS	  was	  added	  to	  each	  well	  and	  washed	  again	  
(centrifuged	  at	  560g	  x	  5	  minutes).	  In	  a	  new	  96-­‐well	  U-­‐bottom	  plate	  anti-­‐CD3	  and	  anti-­‐CD8	  antibodies	  (or	  
isotype	  control	  antibodies)	  were	  added	  as	  described	  in	  Table	  2-­‐8.	  Following	  centrifugation,	  supernatants	  
were	  removed	  from	  the	  culture	  plate;	  each	  well	  was	  re-­‐suspended	  in	  100µl	  of	  PBS	  and	  then	  transferred	  to	  
the	  matching	  position	  in	  the	  staining	  plate.	  The	  staining	  plate	  was	  incubated	  for	  20	  minutes	  in	  the	  dark	  at	  
room	  temperature.	  After	  20	  minutes,	  each	  well	  was	  topped-­‐up	  with	  100µl	  PBS	  and	  the	  plate	  was	  spun	  at	  
560g	   x	  5	  minutes.	   Following	   centrifugation,	   supernatants	  were	  aspirated	  and	  each	  well	   resuspended	   in	  
200µl	  of	  PBS	  before	  a	   further	  wash	   (same	  settings).	  100µl	  of	  PBS	  was	  added	  to	  each	  well	  and	  then	  the	  
contents	   transferred	   to	   individual,	   appropriately	   labelled	   equivalent	   FACS	   tubes	   (Beckton	   Dickinson,	  
Franklin	   Lakes,	  USA).	   Cells	  were	   fixed	  by	   slowly	   adding	   100µl	   of	   cold	   intracellular	   fixation	  buffer	  whilst	  
vortexing	   each	   tube.	   The	   total	   volume	   per	   tube	   was	   maintained	   at	   approximately	   200µl,	   as	   per	  
manufacturer’s	   protocol.	   Tubes	  were	   incubated	   in	   the	  dark	   at	   room	   temperature	   for	   20	  minutes,	   after	  
which,	  without	  washing,	  2ml	  ice-­‐cold	  1xPermeabilization	  buffer	  (diluted	  in	  deionised	  water)	  was	  added	  to	  
each	  tube.	  Tubes	  were	  then	  centrifuged	  at	  300-­‐400g	  x	  5	  minutes.	  After	  discarding	  the	  supernatants,	  cell	  
pellets	  were	  re-­‐suspended	  in	  2	  ml	  of	  1X	  Permeabilization	  Buffer	  and	  centrifuged	  at	  300-­‐400g	  x	  5	  minutes.	  
Once	   supernatants	   had	   been	   discarded,	   each	   well	   was	   re-­‐suspended	   in	   100	   μl	   of	   1X	   Permeabilization	  
Buffer.	  A	  fresh	  staining	  plate	  was	  prepared	  and	  2.5	  µl	  of	  either	  the	  Rat	  IgG1Κ	  Isotype	  Control	  PE	  or	  αIFNγ-­‐
PE	  antibodies	  was	  added	  to	  the	  appropriate	  wells.	  The	  relevant	  100µl	  volume	  samples	  were	  transferred	  
to	  the	  respectively	  labeled	  wells	  in	  the	  staining	  plate	  containing	  PE	  antibodies.	  The	  plate	  was	  then	  left	  in	  
the	  dark	  for	  20	  minutes.	  After	  incubation,	  100µl	  of	  1X	  Permeabilization	  Buffer	  was	  added	  to	  each	  well	  and	  
again	   spun	  at	   300-­‐400g	   x	   5minutes.	   Cells	  were	  washed	  once	  more	   at	   the	   same	   settings	   in	   200µl	   of	   1X	  






Table	  2-­‐8	  Antibody	  volumes	  per	  well	  for	  control	  and	  test	  samples	  (intracellular	  IFNγ	  assay)	  
Sample	  type	   Antibodies	   Volumes	  
Isotype	  control	  for	  eFluor®	  450	  
PerCP	  Cy5.5	  
Rat	  IgG2b	  Κ	  Isotype	  Control	  eFluor®	  450	  
Rat	  IgG2a	  Κ	  Isotype	  Control	  PerCP-­‐Cy5.5	  
2µl	  
1µl	  
Isotype	  control	  for	  PE	   Rat	  IgG1	  Κ	  Isotype	  Control	  PE*	  
αCD3	  e450	  












*Only	  added	  after	  fixation	  and	  Permeabilization	  steps	  have	  been	  completed	  
T2	  stabilisation	  assay	  
TAP-­‐deficient	  T2	  cells	  were	  plated	  in	  a	  24-­‐well	  plate	  (Beckton	  Dickinson,	  Franklin	  Lakes,	  USA),	  1ml	  per	  well	  
at	  a	  concentration	  of	  5x105	  cells/ml	  in	  10%	  FCS/RPMI.	  Known	  HLA-­‐A2	  binding	  peptides	  (kind	  gifts	  from	  Dr	  
Linda	  Barber)	  were	  YLLPAIVHI148-­‐156	  (derived	  from	  ATP-­‐dependent	  RNA	  helicase)	  and	  NLVPMVATVQ495-­‐504	  
(CMV	  pp65	  peptide).	  These	  peptides	  had	  been	  reconstituted	  in	  10%DMSO/PBS	  at	  a	  stock	  concentration	  of	  
20mg/ml.	   Similarly,	   WT1-­‐RMF	   and	   OVA-­‐SIINF	   peptides	   were	   each	   reconstituted	   at	   20mg/ml	   in	  
10%DMSO/PBS.	   Five	  microlitres	   of	   control	   (known	   HLA-­‐A2	   binders)	   and	   test	   peptides	   (each	   at	   a	   stock	  
concentration	  of	  20mg/ml)	  were	  added	  to	  wells	  containing	  T2	  cells	  as	  follows:	  
T2	  cells	  alone	  
T2	  cells	  +	  10%DMSO/PBS	  (no	  peptide)	  
T2	  cells	  +	  WT1-­‐RMF	  (freshly	  prepared)	  
T2	  cells	  +	  WT1-­‐RMF	  (previously	  prepared,	  frozen	  and	  thawed)*	  
T2	  cells	  +	  OVA-­‐SIINF	  
T2	  cells	  +	  YLLPAIVHI	  
T2	  cells	  +	  NLVPMVATVQ	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*to	  compare	  whether	  frozen	  and	  then	  thawed	  WT1-­‐RMF	  had	  similar	  ability	  to	  stabilise	  HLA-­‐A2	  expression	  
on	  T2	  cells	  as	  freshly	  prepared	  WT1-­‐RMF.	  
The	   plate	   was	   incubated	   overnight	   at	   37oC	  with	   5%	   CO2.	   Contents	   of	   each	  well	   were	   transferred	   to	   7	  
individually	  labelled	  FACS	  tubes	  and	  washed	  twice	  at	  300-­‐400g	  x	  5	  minutes	  in	  PBS	  before	  resuspending	  in	  
0.1ml	  PBS.	  Twenty	  microlitres	  of	  mouse	  anti-­‐human	  HLA-­‐A2-­‐PE	  antibody	  (BD	  Biosciences,	  Franklin	  Lakes,	  
USA)	  was	  added	  to	  each	  well	  and	  left	  to	  incubate	  in	  the	  dark	  for	  30	  minutes	  at	  room	  temperature.	  After	  2	  
washes	   in	  PBS	  (same	  settings),	   the	  samples	  were	  resuspended	   in	  100	  µl	  of	  PBS	  and	  analysed	  on	  the	  BD	  
FACS	  Canto	  II	  machine.	  
	  
Compensation	  set-­‐up	  for	  Fluorescence-­‐activated	  cell	  sorting	  (FACS)	  
Compensations	   were	   set	   up	   at	   least	   monthly	   using	   Anti-­‐Rat	   Ig/Negative	   Control	   (FBS)	   Compensation	  
Particles	  Set	  (Beckton	  Dickinson).	  100µl	  aliquots	  of	  PBS	  were	  added	  to	  7	  individually	  labelled	  FACS	  tubes	  
(Beckton	  Dickinson).	   After	   vortexing,	   one	   drop	   of	   BD	  CompBeads	  Negative	   Control	   (FBS)	   followed	  by	   1	  
drop	  of	  the	  BDTM	  CompBeads	  Anti-­‐Rat	  Ig	  beads	  was	  added	  to	  each	  tube	  and	  vortexed.	  One	  tube	  was	  used	  
as	   the	   unstained	   control;	   appropriate	   volumes	   of	   rat	   antibodies	   fluorescently	   labeled	  with	   PE,	   PE-­‐Cy7,	  
FITC,	  e450,	  PerCP	  Cy5.5	  and	  APC	  were	  added	  to	  individual	  tubes	  (one	  fluorochrome-­‐labelled	  antibody	  per	  
tube).	   Tubes	  were	   left	   to	   stain	   at	   room	   temperature	   for	   20	  minutes;	   after	   this,	   compensation	   samples	  




A	  3-­‐laser	  FACS	  Canto	  II	  (Beckton	  Dickinson,	  Franklin	  Lakes,	  USA)	  was	  used	  for	  all	  flow	  cytometry	  studies.	  
The	  high-­‐throughput	  sampler	  (HTS)	  facility	  was	  used	  for	  plate-­‐based	  samples.	  All	  samples	  were	  acquired	  
using	  the	  FACS	  Diva	  programme	  (Beckton	  Dickinson,	  Franklin	  Lakes,	  USA).	  All	  samples	  were	  analysed	  using	  
FLOWJO	  software	  (Treestar	  Inc,	  Oregon,	  USA).	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2.2.2.7 In	  vivo	  Cytotoxicity	  Assay	  
Healthy	   spleens	   were	   harvested	   from	   female	   C57BL/6	   mice	   as	   described	   above.	   One	   spleen	   yielded	  
approximately	  4-­‐5x107	  splenocytes,	  therefore	  an	  appropriate	  number	  of	  mice	  were	  sacrificed	  as	  required	  
for	  a	  particular	  experiment.	  After	  harvesting,	  excess	  PBS	  was	  removed	  from	  the	  50	  ml	  Falcon	  tube	  and	  the	  
spleens	  transferred	  into	  a	  Petri	  dish	  containing	  sufficient	  PBS	  to	  cover	  its	  base.	  The	  spleens	  were	  mashed	  
using	   the	   base	   of	   a	   ridged	   plunger	   from	   a	   10ml	   syringe	   (Beckton	   Dickinson).	   The	   spleen	   pulp	  mix	  was	  
passed	   through	   a	   40µM	   cell	   strainer	   (Beckton	   Dickinson)	   into	   an	   empty	   50ml	   Falcon	   tube.	   Cells	   were	  
washed	  in	  PBS	  (620g	  x	  5minutes)	  and	  then	  resuspended	  in	  10-­‐15ml	  of	  sterile	  filtered	  RBC	  lysis	  buffer.	  Cells	  
were	  then	  washed	  twice	  in	  PBS	  at	  the	  same	  settings.	  The	  cell	  pellet	  was	  re-­‐suspended	  in	  10ml	  of	  X-­‐VIVO	  
15	  and	  a	  cell	  count	  performed	  using	  a	  1:10	  dilution	  in	  Trypan	  Blue	  (Sigma-­‐Aldrich)	  in	  a	  haemocytometer.	  
Cells	  were	  re-­‐suspended	  to	  a	  concentration	  of	  1-­‐2x107	  splenocytes/ml	  and	  then	  distributed	  equally	   into	  
2x	  50	  ml	  Falcon	  tubes.	  These	  2	  tubes	  were	  to	  hold	  the	  peptide	  loaded	  (target)	  cells	  and	  the	  non-­‐peptide	  
loaded	  (non-­‐target)	  cells	  respectively.	   In	  some	  experiments,	  different	  sets	  of	  peptide	   loaded	  target	  cells	  
were	  required	  (i.e.	  OVA-­‐SIINF-­‐loaded	  splenocytes	  and	  WT1-­‐RMF-­‐loaded	  splenocytes)	  –	  cell	  numbers	  were	  
adjusted	   accordingly	   per	   tube	   depending	   on	   the	   number	   of	   recipient	   mice.	   However,	   the	   cell	  
concentration	  was	  maintained	  the	  same	  between	  all	  tubes.	  	  
	  
10µg/ml	  of	  the	  relevant	  peptide	  was	  added	  to	  the	  peptide	  loaded	  (target)	  tube(s).	  All	  tubes	  were	  left	  in	  
the	  incubator	  at	  37oC	  for	  1	  hour	  with	  gentle	  shaking	  to	  redistribute	  the	  peptide	  every	  15	  minutes.	  After	  1	  
hour,	  X-­‐VIVO	  15	  was	  added	   to	  each	   tube,	  which	  was	   then	  centrifuged	  at	  620g	  x	  5minutes.	  Sterile	  Fetal	  
Bovine	   Serum	   (FBS,	   Life	   Technologies,	   Carlsbad,	  USA)	  was	   added	   to	   sterile	   PBS	   to	   create	   a	   5%	   v/v	   FBS	  
solution	   in	   PBS.	   Cells	   were	   re-­‐suspended	   in	   5%	   v/v	   FBS/PBS	   and	   washed	   once.	   They	   were	   then	   re-­‐
suspended	   in	   the	   same	   volumes	   used	   earlier	   to	   maintain	   a	   concentration	   between	   1-­‐2x107	  
splenocytes/ml.	  A	  solution	  of	  5mM	  CFSE	  was	  prepared	   in	  Dimethylsulfoxide	  (DMSO)	  and	  added	  to	  each	  
peptide-­‐loaded	   tube	   such	   that	   the	   final	   CFSE	   concentration	  was	   0.3mM	   and	   to	   the	   non-­‐target	   cells	   to	  
reach	  a	  final	  concentration	  of	  3mM	  CFSE.	  Cells	  were	   incubated	  for	  up	  to	  7	  minutes	  and	  then	  washed	   in	  
5%FBS/PBS	  twice,	  followed	  by	  a	  further	  wash	  in	  PBS.	  	  Following	  the	  final	  wash,	  cells	  were	  re-­‐suspended	  at	  
a	  concentration	  of	  1x108	  splenocytes/ml.	  100µl	  of	  cells	   from	  each	  tube	  were	  added	  to	  1900µl	  of	  PBS	   in	  
separate	  Bijou	  tubes.	  FACS	  tubes	  were	  prepared	  containing	  mixtures	  of	  known	  proportions	  of	  CFSE	  “low”	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and	  “high”-­‐labelled	  cells	  to	  evaluate	  the	  CFSE	  staining	  and	  allow	  any	  adjustment	  in	  final	  volumes	  injected	  
to	  enable	  approximately	  50:50	  of	  “low”	  and	  “high”	  cells	  in	  each	  injection.	  The	  target	  and	  non-­‐target	  cells	  
were	   analysed	   on	   the	   FACS	  machine	   to	   confirm	   that	   2	   separate	   CFSE-­‐labelled	   populations	   (“low”	   and	  
“high”)	  were	  discernible.	  The	  voltage	  threshold	  for	  FITC	  was	  adjusted	  to	  ensure	  that	  the	  peak	  of	  the	  CFSE	  
low	  population	  was	  located	  roughly	  between	  103-­‐104	  and	  that	  the	  peak	  of	  the	  CFSE	  high	  population	  was	  
between	   104	   and	   105.	   Prior	   to	   injection,	   peptide-­‐loaded	   and	   unloaded	   cells	  were	  mixed.	   A	   1ml	   syringe	  
(Beckton	  Dickinson)	  was	  used	  to	  draw	  up	  the	  splenocytes	  and	  100µl	   (1x107	  cells)	  were	  injected	  into	  the	  
tail	  vein	  of	  each	  mouse	  using	  a	  30G	  yellow	  needle	  (Beckton	  Dickinson),	  taking	  care	  to	  regularly	  re-­‐suspend	  
the	  cells.	  	  
	  
Eighteen	  hours	  later,	  mice	  were	  culled	  and	  splenocytes	  harvested.	  	  One	  ml	  of	  PBS	  was	  added	  to	  wells	  of	  a	  
24	  well	  plate	  labelled	  for	  each	  group	  and	  mouse.	  One	  spleen	  was	  transferred	  to	  the	  appropriate	  well	  and	  
then	  mashed	  using	  a	  1	  or	  2ml	  syringe	  (Beckton	  Dickinson).	  Each	  well	  was	  filled	  with	  PBS	  and	  up	  to	  2ml	  of	  
cells	  were	  transferred	  from	  each	  well	  to	  a	  respectively	  labelled	  15ml	  Falcon	  tube,	  avoiding	  any	  sediment.	  
Cells	  were	  washed	   in	  PBS	  at	  620g	   x	  5	  minutes.	  After	  discarding	   the	   supernatant,	   cells	  were	   lysed	  using	  
500µl	   of	   filtered	   RBC	   lysis	   buffer	   and	   then	  washed	   again	   in	   PBS	   (same	   settings).	   Splenocytes	  were	   re-­‐
suspended	  in	  10ml	  PBS	  per	  tube	  and	  750-­‐1000µl	  of	  cells	  were	  transferred	  into	  respectively	  labelled	  FACS	  
tubes	   and	   read	   on	   the	   FACS	  machine	   to	   determine	   the	   percentages	   of	   CFSE	   “low”	   and	   “high”	   cells.	   A	  
minimum	  of	  2000	  events	  in	  the	  CFSE-­‐labelled	  population	  was	  recorded.	  The	  percentage	  lysis	  of	  peptide-­‐
loaded	  cells	  was	  determined	  using	  the	  following	  equation:	  
	  
%	  lysis	  =	  1	  - [(no.	  of	  targets/no.	  of	  control	  cells	  in	  immunized	  animal)/(no.	  of	  targets/no.	  of	  control	  cells	  in	  
unimmunised	  animal)]	  X	  100.	  
	  
2.2.2.8 In	  vitro	  stimulation	  of	  splenocytes	  for	  the	  intracellular	  IFNγ 	  assay	  
Cell	  counts	  were	  performed	  on	  the	  splenocyte	  samples	  prepared	  as	  per	  2.2.2.7	  using	  Trypan	  Blue	  (Sigma)	  
in	  a	  haemocytometer	  to	  determine	  viable	  cells.	  Cells	  were	  then	  centrifuged	  at	  1900	  RPM	  x	  5	  minutes	  and	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re-­‐suspended	  in	  an	  appropriate	  volume	  of	  Roswell	  Park	  Memorial	  Institute	  (RPMI)-­‐1640	  medium	  (Sigma-­‐
Aldrich)	   to	  give	  a	   final	   concentration	  of	  5x106	  cells/ml.	  A	  96-­‐well	  U-­‐bottom	  culture	  plate	  was	  prepared,	  
with	   test	  wells	  containing	  splenocytes	   from	   individual	  mice	  and	  a	  peptide	  stimulus	  or	  control	   irrelevant	  
peptide,	  along	  with	  3-­‐5	  wells	  of	  each	  of	  the	  following	  types	  of	  control:	  
1.	  Unstimulated	  cells	  
2.	  Cells	  to	  be	  used	  for	  staining	  with	  PE	  isotype	  control	  
3.	  Cells	  to	  be	  used	  for	  staining	  with	  e450	  and	  PerCP	  Cy5.5	  isotype	  controls	  
4.	  Cells	  for	  in	  vitro	  stimulation	  with	  Phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  and	  Ionomycin	  (both	  Sigma)	  
	  
One	   million	   cells	   (200µl)	   were	   plated	   per	   well	   containing	   3mM	  Monensin	   (Sigma	   or	   BD	   GolgiStopTM),	  
1µg/ml	  αCD28	  antibody	  (Beckton	  Dickinson	  or	  eBiosciences)	  and	  1µg/ml	  of	  the	  stimulating	  peptide.	  Cells	  
used	  for	  positive	  controls	  were	  separately	  re-­‐suspended,	  in	  medium	  containing	  20ng/ml	  PMA	  and	  1µg/ml	  
Ionomycin,	  along	  with	  Monensin	  at	  a	  final	  concentration	  of	  3mM.	  After	  culturing	  for	  5	  hours	  at	  37oC,	  the	  
protocol	  for	  intracellular	  IFNγ	  staining	  was	  followed	  as	  outlined	  in	  2.2.2.6.	  
	  
2.2.2.9 Statistical	  analyses	  
All	   data	   were	   analysed	   using	   GraphPad	   Prism	   software	   version	   5	   (GraphPad	   software,	   San	   Diego,	  
California,	  USA).	  All	  analyses	  required	  evaluation	  of	  3	  or	  more	  groups	  of	  mice	  therefore	  One-­‐way	  Analysis	  
Of	   Variance	   between	   groups	   (ANOVA)	   was	   employed.	   Post	   hoc	   tests	   were	   performed	   using	   Tukey’s	  




2.2.3 Whole	  cell	  vaccination	  using	  CD80/IL-­‐2	  modified	  AML	  blasts	   in	  patients	  with	   relapsed	  AML	  post	  
allogeneic	  HSCT	  (Chapter	  5)	  
2.2.3.1 Patients	  and	  treatment	  assignment	  
Full	  details	  of	  patient	  eligibility,	  treatment	  and	  clinical	  monitoring	  are	  provided	  in	  the	  latest	  version	  of	  the	  
clinical	   trial	   protocol	   included	   in	  Appendix	  C.	  All	   patients	   screened	   for,	   or	   recruited	   to,	   the	   clinical	   trial	  
gave	   informed	   consent	   according	   to	   the	   declaration	   of	   Helsinki	   for	   trial	   related-­‐procedures,	   as	   per	   the	  
ethically	  approved,	  latest	  version	  (3.0)	  of	  the	  clinical	  trial	  protocol.	  
	  
In	  brief,	   all	   patients	  >	  18	  years	  of	   age	  with	  a	  diagnosis	  of	  AML	  according	   to	  WHO	  criteria	   (Appendix	  A)	  
were	  considered	  eligible	  for	  cryopreservation	  of	  AML	  blasts.	  Patients	  who	  had	  undergone	  allogeneic	  HSCT	  
and	  experienced	  morphological	  relapse	  of	  AML	  with	  >5%	  blasts	   in	  the	  bone	  marrow	  aspirate	  and	  ≥	  25%	  
donor	  CD3+	  T-­‐cell	  chimerism	  were	  also	  eligible	  for	  blast	  cryopreservation.	  AML	  patients	  undergoing	  any	  
type	   of	   allogeneic	   HSCT	   could	   be	   recruited;	   details	   of	   relevant	   conditioning	   regimens	   are	   listed	   in	  
Appendix	  B.	  All	  but	  4	  of	  the	  screened	  patients	  underwent	  transplantation	  at	  King’s	  College	  Hospital;	  those	  
patients	   transplanted	   at	   King’s	   College	   Hospital	   had	   undergone	   in	   vivo	   lymphodepletion	   with	   either	  
alemtuzumab	  or	  anti-­‐thymocyte	  globulin	  (ATG)	  according	  to	  the	  regimen.	  GvHD	  prophylaxis	  immediately	  
post-­‐HSCT	  consisted	  of	  cyclosporine	  1.5	  mg/kg	   i.v.	  twice	  daily	  (converted	  to	  oral	  route	  after	  recovery	  of	  
oral	   intake)	   starting	   on	   day	   -­‐1,	   titrated	   according	   to	   plasma	   trough	   levels	   (range,	   150-­‐	   200	   ng/L),	   and	  
tapered	  from	  day	  +56	  onward.	  	  
	  
Suspected	  AML	   relapse	   post-­‐HSCT	  was	   confirmed	   by	   bone	  marrow	   aspirate	   and	   trephine	   biopsy.	   Bone	  
marrow	   aspirate	   samples	   underwent	   morphologic,	   immunophenotypic,	   cytogenetic	   and	   chimerism	  
analyses.	  Up	   to	   fifty	  millilitres	   of	   bone	  marrow	  aspirate	   (where	  possible)	   and	  50ml	   of	   peripheral	   blood	  
were	   collected	   in	   EDTA-­‐containing	   vacutainer	   tubes	   (Beckton	   Dickinson)	   for	   isolation	   and	  
cryopreservation	   of	  mononuclear	   cells	   (cryopreservation	   procedures	   described	   in	   2.2.3.2)	   from	  eligible,	  
consenting	  patients.	  Blood	  samples	  collected	  contemporaneously	  with	  bone	  marrow	  and	  blood	  harvests	  
were	  sent	  to	  the	  South	  London	  Specialist	  Virology	  Centre	  laboratories	  at	  King’s	  College	  Hospital,	  London	  
for	  virology	  screening	  (tests	  described	  in	  2.2.3.4).	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Following	   confirmation	   of	   relapsed	   AML,	   patients	   underwent	   salvage	   chemotherapy	   according	   to	   the	  
treating	  physician’s	  discretion.	  Details	  of	   the	   chemotherapy	  protocols	  used	  are	   supplied	   in	  Appendix	  B.	  
Patients	  were	  reviewed	  at	  King’s	  College	  Hospital	  upon	  clinical	  and	  haematological	   recovery	  (neutrophil	  
count	   >1.0	   x109/L)	   and	   underwent	   repeat	   bone	   marrow	   evaluation	   as	   described	   above	   to	   confirm	  
morphological	   remission	   (<5%	   blasts	   in	   the	   bone	   marrow	   aspirate,	   confirmed	   by	   trephine	   histology).	  
Those	   patients	   who	   had	   achieved	   a	   morphological	   remission	   were	   offered	   entry	   into	   the	   clinical	   trial	  
following	   confirmation	   that	   inclusion	   and	   exclusion	   criteria	   for	   enrolment	   were	   satisfied	   (summarised	  
below	  and	  listed	  in	  full	  in	  the	  clinical	  trial	  protocol,	  Appendix	  C:	  
	  
Inclusion	  criteria	  
1. Patients	  must	  be	  able	  to	  give	  written	  informed	  consent	  and	  be	  willing	  to	  comply	  for	  the	  duration	  
of	  the	  study	  
2. Sufficient	   blasts	   must	   have	   been	   stored	   to	   enable	   a	   minimum	   of	   3	   doses	   of	   vaccine	   to	   be	  
produced	  
3. Patients	  need	  to	  have	  achieved	  morphological	  remission	  (as	  defined	  by	  <	  5%	  blasts	  in	  the	  bone	  
marrow)	  following	  cytoreductive	  chemotherapy	  for	  treatment	  of	  disease	  relapse	  
4. Patients	   must	   have	   recovering	   lymphocyte	   count	   of	   >	   0.5x109/L	   following	   cytoreductive	  
chemotherapy	  
5. Patients	  must	  be	  HIV-­‐negative	  at	  relapse	  
6. Patients	   must	   not	   have	   active	   viral	   infection	   including	   Human	   T-­‐lymphotropic	   Virus	   (HTLV-­‐1),	  
hepatitis	  B	  or	  C	  
7. Patients	   must	   have	   adequate	   renal	   and	   liver	   function	   confirmed	   by:	   creatinine	   clearance/	  
estimated	   glomerular	   filtration	   rate	   (eGFR)	   >30mls/min;	   bilirubin	   <3.0	   x	   upper	   limit	   of	   normal;	  
Aspartate	  aminotransferase	  (AST)	  <3.0	  x	  upper	  limit	  of	  normal	  
8. Patients	  must	   demonstrate	   a	   performance	   status	   of	   2	   or	   less	   by	   Easter	   Cooperative	  Oncology	  
Group	  (ECOG)	  criteria	  or	  >60%	  by	  the	  Karnofsky	  score	  (defined	  in	  the	  clinical	  trial	  protocol)	  
9. Women	  of	   childbearing	  potential	   (WCBP)	  must	  have	  a	  negative	   serum	  or	  urine	  pregnancy	   test	  




1. Life	  expectancy	  of	  <24	  weeks	  
2. Evidence	  of	  graft	  versus	  host	  disease	  
3. Concurrent	  use	  of	  other	  forms	  of	  anti-­‐leukaemic	  therapy	  for	  relapse	  
4. Other	  active	  malignancy	  with	  the	  exception	  of	  carcinoma	  in	  situ	  
5. Significant	   history	   of	   heart	   disease	   (unstable	   angina,	   myocardial	   infarction	   within	   the	   past	   six	  
months)	  
6. Positive	  pregnancy	  test	  
	  
Patients	   were	   allocated	   in	   a	   non-­‐random,	   alternating	   manner	   into	   either	   of	   the	   trial	   arms,	   arm	   A	  
(escalating	  doses	  of	  DLI)	  and	  arm	  B	  (escalating	  doses	  of	  DLI	  and	  AML	  Cell	  Vaccine,	  ACV),	  Table	  2-­‐9.	  Doses	  
of	   DLI	   with/without	   ACV	   were	   administered	   at	   strict	   6-­‐week	   intervals	   and	   without	   delay	   unless	   dose-­‐
limiting	   toxicity	   or	   other	   clinically	   significant	   event	   requiring	   investigation	   necessitated	   withholding	   of	  
treatment	   until	   investigated	   and	   re-­‐commencement	   of	   therapy	   on	   trial	   approved	   by	   the	   Principal	  
Investigator	  (PI).	  
Table	  2-­‐9	  Study	  treatments	  according	  to	  assignment	  arm	  
Dose	  number	   Arm	  A	  treatment:	  DLI	   Arm	  B	  treatment:	  DLI	  &	  ACV	  
Dose	  1	   5x105	  CD3+	  cells/kg	   5x105	  CD3+	  cells/kg	  
0.5-­‐1x105	  ACV	  cells	  in	  250µl	  carrier	  medium	  
Dose	  2	   5x106	  CD3+	  cells/kg	   5x106	  CD3+	  cells/kg	  
0.5-­‐1x106	  ACV	  cells	  in	  500µl	  carrier	  medium	  
Dose	  3	   1-­‐5x107	  CD3+	  cells/kg	   1-­‐5x107	  CD3+	  cells/kg	  
0.5-­‐1x107	  ACV	  cells	  in	  1ml	  carrier	  medium	  
Dose	  4*	   0.5-­‐1x108	  CD3+	  cells/kg	   0.5-­‐1x108	  CD3+	  cells/kg	  
0.5-­‐1x108	  ACV	  cells	  in	  1ml	  carrier	  medium	  
*	  where	  available,	  (applies	  to	  each	  arm)	  
	  
Unless	   stated	   otherwise,	   all	   manufacturing	   procedures	   were	   carried	   out	   under	   Good	   Manufacturing	  
Practice	  (GMP)	  conditions	  by	  Dr	  Lucas	  Chan	  PhD,	  King’s	  College	  London,	  in	  the	  Rayne	  Cell	  Therapy	  Suite	  
under	   provisions	   granted	   to	   the	   facility	   by	   the	  Medicines	   and	   Healthcare	   products	   Regulatory	   Agency	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(Manufacturer’s	   Authorisation	   for	   Investigational	  Medicinal	   Products	   (MAIMP),	   license	   14523)	   and	   the	  
Human	  Tissue	  Authority	  (license	  11023).	  	  
	  
2.2.3.2 Lentiviral	  vector	  and	  vaccine	  production	  
Lentiviral	  vector	  construct	  
Development	  of	  the	   lentiviral	  vector	  was	  previously	  described	   in	  Chan	  et	  al,	  2005258	  and	  finalised	   in	  the	  
Investigational	   Medicinal	   Product	   Dossier	   (IMPD)	   v4.0.	   Manufacture	   was	   carried	   out	   under	   GMP	  
conditions	  and	  in	  accordance	  with	  the	  Guideline	  on	  Development	  and	  Manufacture	  of	  Lentiviral	  Vectors	  
(CHMP/BWP/2458/03).	  Figure	  2-­‐1	  details	  a	  map	  of	  the	  lentiviral	  construct.	  
	  
Figure	  2-­‐1	  The	  self-­‐inactivating	  lentiviral	  vector	  –	  RRL’SINctwSVIL-­‐2/B7.1	  (RFUSIN2)	  
	  
Production	  of	  the	  RFUSIN2	  lentiviral	  vector	  
Large-­‐scale	  production	  of	  the	  4	  DNA	  plasmids	  that	  form	  the	  lentiviral	  packaging	  system	  was	  carried	  out	  by	  
the	   Bristol	   Institute	   for	   Transfusion	   Sciences	   under	   MAIMP	   license	   number	   13733.	   Design	   and	  
development	   of	   the	   4	   plasmids	   was	   previously	   described258,267.	   A	   Master	   Cell	   Bank	   (MCB),	   derived	   by	  
seeding	  and	  propagation	  of	  the	  293T/17	  cell	  line	  (American	  Type	  Culture	  Collection	  (ATCC)	  Number	  CRL-­‐
11268)	  in	  complete	  medium	  (10%	  FBS,	  90%	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM,	  Sigma-­‐Aldrich)	  
0.05%	  gentamicin	  sulphate	  (Beacon	  Pharmaceuticals	  Limited,	  East	  Sussex,	  UK),	  was	  generated	  to	  serve	  as	  
the	  host	  cell-­‐line	  to	  enable	  large-­‐scale	  vector	  production.	  These	  cells	  are	  referred	  to	  as	  293T/17	  MCB-­‐KCL	  
cells.	   The	   293T/17	   MCB-­‐KCL	   cells	   underwent	   sterility	   testing	   performed	   by	   the	   commercial	   company	  
BioReliance	  (Stirling,	  UK)	  and	  confirmed	  to	  be	  free	  of	  viral,	  fungal	  and	  bacterial	  contamination	  prior	  to	  use	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in	   lentiviral	  vector	  production.	  Furthermore,	  the	  company	  performed	  DNA	  fingerprinting	  to	  characterise	  
fully	  the	  identity	  of	  the	  cells	  with	  reference	  to	  the	  DNA	  profile	  of	  HEK	  293	  cells.	  BioReliance	  also	  excluded	  
the	   presence	   of	   retroviral	   reverse	   transcriptase	   (RT)	   activity	   in	   293T/17	   MCB-­‐KCL	   cells	   by	   fluorescent	  
product	  enhanced	  reverse	  transcriptase	  assay.	  	  
	  
A	  single	  batch	  of	   the	  RFUSIN2	  virus	  was	  prepared	   for	  use	   in	  all	  vaccine	  production	   for	   trial	   subjects.	  To	  
produce	   the	   RFUSIN2	   lentiviral	   vector	   supernatant,	   3x107	   293T/17	   MCB-­‐KCL	   cells	   were	   seeded	   and	  
propagated	  over	  7	  days	  in	  complete	  medium,	  10%	  FBS,	  90%	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (DMEM,	  
Sigma-­‐Aldrich),	  followed	  by	  transient	  transfection	  with	  the	  4-­‐plasmid	  lentiviral	  packaging	  system.	  After	  24	  
hours	   of	   incubation,	   a	   primary,	   lentiviral	   vector	   supernatant	   was	   harvested.	   The	   transfected	   293T/17	  
MCB-­‐KCL	  cells	  were	  replenished	  with	  medium	  to	  allow	  a	  second	  harvest	  of	  lentiviral	  vector	  supernatant	  to	  
be	   performed	   a	   further	   24	   hours	   later.	   The	   supernatants	  were	   concentrated	   and	   divided	   into	   aliquots	  
before	  cryopreservation	  at	   -­‐80oC,	  with	  an	  aliquot	   from	  each	  batch	  of	   concentrate	   reserved	   for	   titration	  
purposes.	   The	   RFUSIN2	   lentiviral	   vector	   also	   underwent	   sterility	   studies	   performed	   by	   BioReliance.	  
Another	  commercial	  company	  GenoSafe	  (Evry,	  France)	  performed	  characterisation	  of	  the	  lentiviral	  vector	  
and	   excluded	   the	   presence	   of	   HIV-­‐specific	   recombinants	   or	   replication	   competent	   lentivirus	   (RCL).	  
GenoSafe	  also	  excluded	  the	  presence	  of	  residual	  293T/17	  MCB-­‐KCL	  cell	  and	  plasmid	  DNA	  in	  the	  lentiviral	  
vector;	   these	   analyses	   were	   also	   corroborated	   by	   in-­‐house	   studies	   to	   exclude	   mobilisation	   and	  
transmission	  of	  the	  RFUSIN2	  vector	  from	  the	  AML	  cell	  vaccine,	  detailed	  in	  the	  IMPD.	  
	  
Titration	  of	  RFUSIN2	  lentiviral	  vector	  
The	   AML	   cell	   line	   U937	   (ATCC	   Number	   CRL-­‐1593.2)	   was	   used	   as	   the	   indicator	   cell	   line	   for	   RFUSIN2	  
titration.	  U937	  cells	  were	  inoculated	  at	  a	  cell	  density	  of	  5x105-­‐1x106/ml	  in	  Roswell	  Park	  memorial	  Institute	  
(RPMI)	  1640	  medium	  supplemented	  with	  10%	  FBS,	  1%	  penicillin	  and	  streptomycin	  (all	  Sigma,	  UK)	  in	  a	  12-­‐
well	  plate.	  Serial	  dilutions	  of	  the	  RFUSIN2	  vector	  supernatant	  were	  added	  to	  the	  U937	  target	  cells	  in	  the	  
presence	   of	   10	   µg/ml	   Diethylaminoethyl	   (DEAE)-­‐dextran	   viral	   complexing	   agent	   (GE	   Healthcare,	  
Amersham,	  UK).	  The	  percentage	  of	   cells	  expressing	  CD80	   in	  each	  sample	  was	  detected	  by	   fluorescence	  
activator	  cell	  sorting	  analysis	  and	  the	  titre	  of	  RFUSIN2	  determined	  by	  the	  proportion	  of	  CD80	  positive	  cells	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relative	   to	   the	   number	   of	   cells	   inoculated.	   Only	   cells	   showing	   CD80	   expression	   between	   5-­‐20%	   were	  
considered	  representative	  of	  single	  cell	  transduction	  by	  a	  single	  vector	  to	  allow	  titre	  calculation.	  The	  total	  
leukaemic	  cell	  infectious	  titre	  for	  RFUSIN2	  was	  calculated	  at	  3.5x1010	  i.u.	  .	  
	  
Vaccine	  production	  	  
Isolation	  of	  peripheral	  blood	  and	  bone	  marrow	  mononuclear	  cells	  at	  relapse	  or	  diagnosis	  
Peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  and	  bone	  marrow	  mononuclear	  cells	  (BMMCs)	  were	  isolated	  
by	   density	   gradient	   centrifugation	   (Ficoll-­‐Paque	   Premium,	   GE	   Healthcare	   Bio-­‐Sciences,	   Piscataway,	   NJ,	  
USA)	  and	  subsequently	  cryopreserved	  in	  vapour	  phase	  liquid	  nitrogen	  in	  a	  freezing	  mixture	  composed	  of:	  
Cryosure-­‐DMSO	  (Wak-­‐Chemie	  Medical	  GmbH,	  Steinbach	  T/s,	  Germany)	  (10%)	  
20%	  w/v	  human	  albumin	  (Bio	  Products	  Laboratory	  Limited,	  Herts,	  UK)	  (18%)	  and	  	  
X-­‐VIVO	  15	  (72%)	  	  
	  
Lentiviral	  transduction	  of	  primary	  AML	  blasts	  
Unselected	  bone	  marrow	  monoculear	  cells	  (BMMCs)	  cryopreserved	  under	  GMP	  conditions	  for	  the	  specific	  
trial	  subject	  were	  thawed	  from	  frozen	  and	  washed	  before	  re-­‐suspension	  in	  X-­‐VIVO	  15	  medium	  containing	  
20ng/ml	   recombinant	   human	   stem	   cell	   factor	   (rhuSCF,	   Amgen,	   Thousand	   Oaks,	   USA)	   and	   10ng/ml	  
interleukin	  3	  (rhuIL-­‐3,	  CellGenix,	  Freiburg,	  Germany).	  Cells	  were	  cultured	  under	  normal	  conditions	  (37oC	  
and	   5%	   carbon	   dioxide	   (CO2)	   concentration)	   for	   18	   hours	   -­‐	   3	   days.	   Transduction	   with	   RFUSIN2	   was	  
performed	  by	  inoculation	  with	  viral	  supernatant	  at	  an	  approximate	  multiplicity	  of	  infection	  (MOI)	  of	  5,	  in	  
the	  presence	  of	  5-­‐10mM	  DEAE-­‐dextran	  viral	  complexing	  agent	  under	  normal	  culture	  conditions	  over	  18-­‐
48	  hours,	  with	  allowance	   to	  extend	  culture	   (following	   replacement	  with	   fresh	  medium)	  up	   to	  3	   further	  
days.	  Transduced	  cells	  were	  divided	  for	  cryopreservation	   into	  up	  to	  4	  vaccine	  aliquots	  (according	  to	  the	  
ACV	  doses	  described	  in	  Table	  2-­‐9)	   in	  freezing	  medium	  as	  described	  earlier	  for	   initial	  cryopreservation	  at	  
blast	   harvest.	   Aliquots	   were	   stored	   at	   -­‐80oC	   overnight	   and	   then	   transferred	   to	   vapour	   phase	   liquid	  
nitrogen.	  During	  production,	  cells	  were	  kept	  aside	  for	  product	  validation	  and	  sterility	  analyses.	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Product	  validation	  and	  sterility	  analyses	  
Upon	  completion	  of	  vaccine	  production,	  samples	  of	  RFUSIN2-­‐transduced	  AML	  cells	  were	  sent	  immediately	  
to	   Wickham	   Laboratories	   (Hampshire,	   UK)	   to	   screen	   for	   bacterial	   contamination	   and	   Mycoplasma	  
Experience	   Limited	   (Reigate,	   UK)	   for	  Mycoplasma	   spp	   screening.	   Product	   validation	   was	   performed	   to	  
determine	   CD80	   staining	   and	   viability	   by	   FACS	   analysis	   using	   the	   FACSCANTO	   II.	   Between	   0.5-­‐1.5x106	  
RFUSIN2-­‐transduced	   AML	   cells	   were	   stained	   with	   anti-­‐human	   CD80-­‐PE	   and	   Annexin	   V	   APC	   (BD	  
Biosciences,	  CA,	  USA).	  Live	  cells	  were	  gated	  according	  to	  forwards	  and	  side	  scatter	  parameters	  to	  record	  a	  
minimum	  of	  1x104	  events.	   	  Percentage	  CD80	  expression	  and	  mean	  fluorescence	   intensity	   (MFI)	  of	  CD80	  
expression	  were	  measured	  along	  with	  the	  size	  of	   the	  Annexin	  V	  APC	  positive	  population.	  Only	  products	  
demonstrating	  a	  minimum	  of	  20%	  CD80	  positive	  events,	  with	  a	  MFI	   increased	  5-­‐fold	  above	  cells	  stained	  
with	  a	  PE	  isotype	  control	  and	  demonstrating	  viability	  of	  >50%	  by	  Annexin-­‐V	  APC	  stain	  could	  be	  released	  
for	  vaccination.	  For	  analysis	  of	  IL-­‐2	  production,	  a	  minimum	  of	  5x105	  RFUSIN2-­‐transduced	  AML	  cells	  were	  
cultured	  for	  24-­‐48	  hours,	  at	  a	  concentration	  of	  1x106	  cell/ml	   in	  X-­‐VIVO	  15	  supplemented	  with	  20	  ng/ml	  
rhuSCF	   and	   10ng/ml	   rhuIL-­‐3.	   Culture	   supernatant	   underwent	   serial	   5-­‐fold	   dilutions	   before	   plating	   in	  
triplicate	   in	  100µl	  volumes	   into	  a	  96-­‐well	  Enzyme-­‐linked	   Immunosorbent	  Assay	   (ELISA)	  plate	  pre-­‐coated	  
with	  IL-­‐2	  capture	  antibody	  (IL-­‐2	  Duo	  Set	  ELISA	  kit,	  R&D	  systems,	  MN,	  USA).	  ELISA	  was	  performed	  as	  per	  
the	  manufacturer’s	  instructions,	  with	  inclusion	  of	  the	  reference	  standards	  provided	  by	  the	  kit.	  Detection	  
of	   a	   minimum	   IL-­‐2	   secretion	   of	   0.1-­‐25ng/106cells	   per	   24	   hours	   was	   required	   to	   allow	   product	   release	  
(product	  specifications	  are	  detailed	  in	  the	  IMPD).	  
	  
2.2.3.3 Administration	  of	  vaccine	  and	  DLI	  and	  assessment	  for	  dose	  limiting	  toxicity	  
Cryopreserved	   aliquots	  of	   donor	   lymphocytes	  were	   thawed	  and	  administered	   according	   to	   institutional	  
protocol	   by	   infusion	   into	   a	   peripheral	   vein.	   No	   pre-­‐medication	   (such	   as	   hydrocortisone	   and	  
chlorpheniramine)	  were	  permitted	  prior	  to	  DLI	  unless	  agreed	  by	  the	  PI.	  	  
The	   appropriate	   aliquot	   of	  ACV	  was	   thawed	   and	   irradiated	   (50	  Gy	   gamma-­‐irradiation)	   before	   injection.	  
The	  entire	  contents	  of	  the	  vial	  were	  drawn	  into	  a	  1ml	  syringe	  and	  administered	  using	  a	  25G	  needle	  intra-­‐
dermally,	   into	   as	   many	   sites	   in	   the	   lower	   abdomen	   as	   possible,	   approximately	   equal	   to	   50-­‐100µl	   per	  
injection	   site,	   2-­‐3	   hours	   following	   DLI	   administration.	   Patients	   were	   monitored	   for	   adverse	   reactions,	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development	  of	   cytokine	   release	  or	   capillary	   leak	   syndromes	   for	   a	  minimum	  of	   24	  hours	  post-­‐injection	  
and	  then	  continued	  follow-­‐up	  and	  treatment	  as	  per	  the	  trial	  schedule	  on	  a	  3-­‐weekly	  basis.	  Patients	  were	  
observed	  for	  the	  development	  of	  erythema	  and	  induration	  at	  vaccination	  sites	  compatible	  with	  a	  delayed-­‐
type	   hypersensitivity	   (DTH)	   reaction252.	   Patients	   were	   assessed	   clinically	   for	   development	   of	   acute	   or	  
chronic	  GvHD	  following	  DLI	  according	  to	  recognised	  criteria268,269	  with	  histological	  confirmation	  by	  biopsy	  
wherever	   possible.	   Adverse	   events	   were	   graded	   according	   to	   the	   National	   Cancer	   Institute	   Common	  
Toxicity	   Criteria	   for	   Adverse	   Events,	   NCI	   CTCAE	   version	   3.0270.	   Dose-­‐limiting	   toxicity	   (DLT)	   was	   defined	  
according	  to	  the	  protocol,	  following	  the	  identification	  of	  either	  (1)	  a	  Grade	  3	  (based	  on	  NCI	  CTCAE270)	  or	  
higher	  non-­‐haematological	  toxicity	  that	  was	  considered	  to	  be	  vaccine	  and/or	  DLI	  related,	  (2)	  prolonged	  (≥	  
grade	  4	  haematological)	  myelosuppression	  persisting	  for	  more	  than	  4	  weeks	  and	  confirmed	  by	  evidence	  
of	  a	  hypocellular	  marrow	  (<5%	  cellularity)	  with	  no	  signs	  of	  disease	  progression	  (≥5%	  blasts	  bone	  marrow)	  
or	  (3)	  Grade	  3	  or	  more	  acute	  GvHD	  or	  moderate	  chronic	  GvHD	  requiring	  systemic	  immunosuppression.	  
Patients	  developing	  DLT	  or	  exhibiting	  morphological	  relapse	  of	  disease	  (≥5%	  blasts	  on	  the	  bone	  marrow	  
aspirate,	  confirmed	  by	  trephine	  histology)	  were	  removed	  from	  the	  study	  and	  transferred	  to	  the	  follow-­‐up	  
phase	  of	  monitoring	  as	  per	  the	  trial	  protocol	  (Appendix	  C).	  A	  cumulative	  assessment	  of	  DLT	  within	  each	  
arm	  was	  maintained	   to	   allow	  discontinuation	   of	   recruitment	   according	   to	   the	   stopping	   criteria	   for	  DLT	  
detailed	  in	  the	  protocol.	  
	  
2.2.3.4 Trial	  monitoring	  investigations	  (clinical	  laboratories)	  
Blood	   and/or	   bone	   marrow	   samples	   were	   sent	   to	   diagnostic	   laboratories	   at	   King’s	   College	   Hospital	  
according	  to	  the	  clinical	  trial	  protocol	  schedule	  for	  evaluation	  of	  full	  blood	  counts	  and	  biochemical	  status	  
as	  well	  as	  the	  following	  specific	  tests:	  
	  
Bone	   marrow	   morphology,	   cytogenetics	   and	   immunophenotyping,	   peripheral	   blood	   and	   marrow	  
chimerism	  
Bone	  marrow	  morphology,	  immunophenotyping	  and	  cytogenetic	  studies	  on	  bone	  marrow	  aspirates	  were	  
performed	  according	  to	  standardised	  protocols	  as	  outlined	  by	  the	  European	  Leukaemia	  Net	  guidelines2.	  
Standard	  multi-­‐parametric	   flow-­‐cytometric	   evaluation	   allowed	   quantification	   of	   CD34+	   precursors	   with	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phenotypic	  characteristics	  of	  myeloid	  blasts2.	  Following	  overnight	  cultures,	  a	  minimum	  of	  20	  metaphase	  
cells	  were	  analysed	  for	  karyotypic	  evaluation.	  Fluorescent	  in-­‐situ	  hybridization	  (FISH)	  analysis	  was	  used	  as	  
an	  adjunct	  to	  chimerism	  studies	  in	  sex-­‐mismatch	  donor	  pairs	  (X-­‐	  Y-­‐	  probes)	  and	  to	  detect	  new	  or	  recurrent	  
cytogenetic	  changes	  at	  AML	  relapse2.	  Chimerism	  studies	  were	  performed	  on	  bone	  marrow	  and/or	  blood	  
(unfractionated	   whole	   blood	   and	   CD3+	   and	   CD15+	   fractions)	   by	   PCR	   and	   fluorescent	   analysis	   of	   short	  
tandem	  repeat	  sequences	  using	  the	  Promega	  Plus	  PowerPlex	  16	  System	  (Promega,	  Madison,	  WI).	  
	  
Bone	  marrow,	  liver	  and	  skin	  histology	  
Bone	   marrow	   trephine	   samples	   were	   prepared	   according	   to	   standardised	   protocols	   at	   the	   diagnostic	  
histopathology	   lab,	   King’s	   College	   Hospital,	   London.	   Trephine	   samples	   were	   fixed	   in	   zinc	   formalin	  
decalcified	  using	  Shandon	  TBD-­‐1	  Reagents	  (Thermo	  Electron,	  Anatomic	  Pathology	  International,	  Cheshire,	  
United	  Kingdom).	  Paraffin	  sections	  (4mm)	  were	  prepared	  and	  stained	  with	  haematoxylin	  and	  eosin	  (H	  &	  
E),	  Giemsa	  and	  Gordon-­‐Sweet	  silver	  stain	  (reticulin	  analysis).	  Immunostains	  were	  performed	  to	  assess	  for	  
CD34+	  and	  CD117+	  populations	  (both	  from	  Dako,	  Ely,	  UK).	  Skin	  and	  liver	  samples	  were	  also	  fixed	  in	  zinc	  
formalin	  with	  subsequent	  preparation	  of	  paraffin	  sections	  as	  above	  and	  stained	  with	  H	  &	  E.	  Liver	  sections	  
were	  also	  stained	  for	  cytokeratin7	  expression	  (also	  from	  Dako,	  Ely,	  UK).	  .	  
Virology	  
All	  peripheral	  blood	  samples	  collected	  for	  virological	  studies	  were	  analysed	  in	  the	  South	  London	  Specialist	  
Virology	  Centre	  Laboratories	  at	  King’s	  College	  Hospital,	  London.	  EBV	  and	  CMV	  DNA	  loads	  were	  analysed	  
by	  real-­‐time	  quantitative	  PCR	  (RQ-­‐PCR)	  on	  whole	  blood	  according	  to	  standardised	  institutional	  protocols.	  
Enzyme-­‐Linked	   Immunoassay	   (ELISA)	   was	   performed	   on	   serum	   for	   exposure	   to	   HIV	   1&2,	   HIV-­‐1	   p24	  
antigen,	   HTLV	   1&2,	   Hepatitis	   B	   and	   C	   viruses,	   Treponema	   pallidum,	   Epstein-­‐Barr	   virus	   (EBV)	   and	  
Cytomegalovirus	  (CMV)	  according	  to	  routine	  diagnostic	  institutional	  protocols.	  	  
Immunology	  
Serum	  samples	  were	  sent	   to	   the	  diagnostic	   Immunology	  service	  at	  King’s	  College	  Hospital	   to	  screen	   for	  
autoantibodies	   (anti-­‐nuclear	   antibodies,	   anti-­‐double-­‐stranded	   DNA	   antibodies,	   anti-­‐neutrophil	  
cytoplasmic	   antibodies,	   anti-­‐smooth	  muscle	   antibodies,	   anti-­‐mitochondrial	   antibodies,	   anti-­‐liver	   kidney	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microsomal	  antibody	  and	  anti-­‐gastric	  parietal	   cell	  antibody),	  presence	  of	  a	  monoclonal	   immunoglobulin	  
by	  capillary	  serum	  electrophoresis	  and	  quantitation	  of	  complement	  components	  C3	  and	  C4,	  rheumatoid	  
factor	  and	  beta-­‐2	  microglobulin	  according	  to	  the	  trial	  monitoring	  schedule.	  
	  
2.2.3.5 Safety	  and	  immune	  reconstitution	  assays	  for	  monitoring	  of	  trial	  subjects	  
Drs	   Yuqian	  Ma,	   PhD	   and	   Sabine	   Domning,	   PhD,	   King’s	   College	   London,	   carried	   out	   all	   trial	   monitoring	  
safety	  and	  immune	  reconstitution	  assays	  according	  to	  the	  protocol	  schedule.	  Analysis	  of	  peripheral	  blood	  
immunophenotyping	  data	  was	  performed	  by	  myself.	  	  
	  
qPCR	  for	  detection	  of	  vector	  integration	  into	  genomic	  DNA	  of	  patient	  PBMCs	  and	  BMMCs	  
Genomic	  DNA	   (gDNA)	  was	   isolated	   from	  PBMCs	   and	   bone	  marrow	  mononuclear	   cells	   (BMMCs)	   at	   trial	  
monitoring	   sampling	   points	   using	   the	   QIAamp	   DNA	   Mini	   Kit	   (QIAGEN,	   Hilden,	   Germany).	   A	   set	   of	  
reference	  standards	  were	  produced	  in-­‐house	  by	  transducing	  U937	  cells	  with	  RFUSIN2	  lentiviral	  vector	  as	  
described	   in	   titration	  of	   the	   lentiviral	   vector,	   2.2.3.2.	   Serial	   dilutions	  of	   the	   lentiviral	   vector	  were	   again	  
used	  to	  allow	  selection	  of	  the	  population	  of	  U937	  cells	  showing	  approximately	  10%	  expression	  of	  CD80	  by	  
FACS	   analysis.	   gDNA	  was	   isolated	   from	   both	   wild	   type	   (WT),	   non-­‐transduced	   U937	   cells	   and	   from	   the	  
selected	  RFUSIN2-­‐transduced	  U937	  population.	  Undiluted	  gDNA	  from	  the	  RFUSIN2-­‐transduced	  population	  
showing	  10%	  expression	  of	  CD80	  was	  considered	  to	  have	  1	  copy	  of	  the	  lentiviral	  vector	  per	  10	  cells.	  Serial	  
dilutions	  of	  gDNA	  from	  RFUSIN2-­‐transduced	  U937	  cells	  in	  WT	  U937	  gDNA	  equating	  to	  reference	  standards	  
ranging	   from	  1	   lentiviral	   vector	   copy/10	  cells	   to	  1	   lentiviral	   vector	   copy/106	   cells	  were	  produced,	  along	  
with	  WT	  U937	  gDNA	  alone	  as	   a	  negative	   control	   (absence	  of	   the	   lentiviral	   vector	   gDNA).	   Primers	  were	  
designed	  that	  spanned	  the	  junction	  site	  encoding	  the	  CD80/IL-­‐2	  fusion	  protein	  and	  therefore	  are	  specific	  
to	  the	  lentiviral	  vector,	  since	  they	  could	  only	  be	  present	  in	  RFUSIN2-­‐transduced	  U937	  gDNA;	  serial	  dilution	  
of	  the	  standards	  proportionately	   increased	  the	  cycle	  threshold	  (Ct).	  Assay	  sensitivity	  was	  defined	  as	  the	  
lowest	   dilution	   segregating	   the	   Ct	   (determined	   at	   1	   copy	   in	   104	   cells).	   Primers	   recognising	   CD80	   alone	  
recognise	   gDNA	   sequences	   in	   RFUSIN2-­‐transduced	  U937,	  WT	  U937	   and	   patient	   cells	   (positive	   control).	  
Real-­‐time	  PCR	  was	  performed	   in	   a	   25µl	   reaction	   containing	  2µl	   of	   gDNA	   sample	  or	   standard,	   12.5µl	   of	  
2xPower	  SYBR	  Green	  Master	  Mix	  (Life	  Technologies)	  for	  detection,	  distilled	  water	  (dH20)	  9.5µl	  and	  1µl	  of	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primers.	  Primers	  were	  diluted	  1:10	  from	  stock	  to	  form	  a	  mixture	  before	  adding	  1µl	  to	  the	  reaction.	  qPCR	  	  
was	   performed	   on	   the	   StepOnePlus™	   Real-­‐Time	   PCR	   System	   (Applied	   Biosystems/Life	   Technologies,	  
Canada)	  and	  settings	  were	  fixed:	  Hold	  Stage	  (95oC,	  10	  minutes),	  PCR	  cycles	  (35	  in	  total)	  of	  Melt	  (95oC,	  15	  
seconds),	  Anneal	  (63oC,	  15	  seconds)	  and	  Extend	  (72oC	  for	  1	  minute).	  A	  standard	  curve	  for	  detection	  of	  the	  
CD80/IL-­‐2	   fusion	   sequence	   was	   generated	   and	   sensitivity	   determined	   based	   on	   the	   lowest	   dilution	   of	  
standard	  whereby	  sensitivity	  of	  qPCR	  detection	  of	  the	  CD80/IL-­‐2	  fusion	  sequence	  was	  lost	  due	  to	  failure	  
of	  the	  curves	  to	  segregate.	  All	  primer	  sequences	  are	  listed	  in	  Materials	  (2.1.3).	  
	  
qRT-­‐PCR	  for	  detection	  of	  replicated	  lentivirus	  in	  patient	  serum	  
Normal	  human	  serum	  was	  spiked	  with	  a	  known	  concentration	  of	  RFUSIN2	  lentiviral	  vector;	  serial	  dilutions	  
were	  performed	  prior	  to	  extraction	  of	  RNA	  using	  the	  QIAamp®	  MinElute®	  Virus	  Spin	  Kit	  (QIAGEN,	  Hilden,	  
Germany)	  according	  to	  manufacturer’s	  instructions.	  cDNA	  synthesis	  was	  performed	  using	  the	  QuantiTect®	  
Reverse	  Transcription	  Kit	   (QIAGEN,	  Hilden,	  Germany)	  according	   to	  manufacturer’s	   instructions.	  qRT-­‐PCR	  
was	  performed	  using	  the	  same	  conditions	  described	  for	  qPCR	  described	  above	  but	  using	  primers	  designed	  
to	  recognise	  the	  sequence	  encoding	  wild	  type	  (W/T)	  CD80	   in	  order	  to	  generate	  a	  standard	  curve.	  Assay	  
sensitivity	  was	  defined	  by	  the	  lowest	  dilution	  of	  viral	  vector	  that	  segregated	  Ct;	  for	  this	  set	  of	  primers	  and	  
conditions,	   this	  dilution	  was	  3x102	  copies/ml.	  Patient	   serum	  was	   treated	  similarly	   (isolation	  of	  RNA	  and	  
cDNA	   synthesis);	   in	   addition,	   400µl	   of	   patient	   serum	   was	   spiked	   with	   RFUSIN2	   at	   a	   concentration	   of	  
2.5x104	  viral	  copies/ml	   (i.e.	  above	   the	  sensitivity	   threshold	   for	   the	  assay)	  as	  a	  positive	  control.	  qRT-­‐PCR	  
was	  performed	  using	  the	  same	  conditions	  and	  primers.	  	  
	  
Screening	   for	   systemic	   IL-­‐2	   elevation	  by	   IL-­‐2	   ELISA	   and	   for	   replication	   competent	   lentivirus	   or	   partial	  
recombinants	  by	  p24	  ELISA	  	  
IL-­‐2	   and	   p24	   antigen	   levels	   were	   analysed	   by	   ELISA	   using	   kits	   from	   R&D	   system,	   MN,	   USA	   and	  
PerkinElmer,	  MA,	   USA	   respectively.	   ELISA	   was	   performed	   as	   per	   the	  manufacturers’	   instructions,	   with	  
inclusion	  of	   the	   reference	  standards	  and	  negative	  controls	  provided	  by	   the	  kit	  as	  well	  as	  healthy	  donor	  
serum	  as	  an	  additional	  reference.	  Supernatant	  collected	  from	  a	  previously	  RFUSIN2-­‐transduced	  U937	  cell-­‐
line	   known	   to	   produce	   IL-­‐2	   was	   used	   as	   a	   biological	   positive	   control	   in	   the	   IL-­‐2	   ELISA.	   Normal	   human	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serum	  spiked	  with	  RFUSIN2	  virus	  was	   included	   in	   the	  p24	  ELISA	  as	  a	  biological	  positive	  control.	  Quality	  
control	  indicators	  included	  ensuring	  that	  R2	  was	  >	  0.98	  for	  the	  standard	  curve,	  that	  the	  optical	  density	  at	  
450nm	   (IL-­‐2	   ELISA)	   and	   490nm	   (p24	   ELISA)	   was	   >1.0	   for	   wells	   at	   the	   highest	   concentration	   of	   the	  
standards	  and	  that	  consistency	  was	  observed	  between	  replicates.	  Assay	  sensitivity	  was	  20pg/ml	  for	   IL-­‐2	  
and	  15pg/ml	  for	  p24.	  
	  
Assessment	  of	  immune	  reconstitution	  in	  trial	  subjects	  
Immunophenotyping	  of	  PBMCs	  
PBMCs	  were	   isolated	   at	   the	   specified	   trial	   time	   points	   under	   non-­‐GMP	   conditions	   but	   using	   the	   same	  
method	  described	  in	  2.2.3.4.	  Cryopreserved	  PBMCs	  were	  thawed	  rapidly	  and	  washed	  in	  X-­‐VIVO	  15	  at	  300g	  
for	   5	   minutes.	   2.5-­‐5x105	   cells	   were	   stained	   with	   antibody	   cocktails	   as	   described	   in	   Table	   2-­‐10	   and	  
lymphocyte	  subsets	  characterised	  according	  to	  expression	  markers	  listed	  in	  Table	  2-­‐11.	  Examples	  of	  flow	  
cytometric	   analyses	   are	   given	   in	   Figures	   2-­‐2	   to	   2-­‐6.	   Compensation	   controls	   were	   prepared	   using	   anti-­‐
mouse	   immunoglobulin	   compensation	   beads	   (BD	   Biosciences)	   as	   per	   the	   manufacturer’s	   instructions.	  
Intracellular	   forkhead	   box	   P3	   (FoxP3)	   staining	   was	   performed	   using	   the	   fixation	   and	   permeabilization	  
protocol	   supplied	  by	   the	  manufacturer	   (eBiosciences,	  CA,	  USA).	  All	   samples	  were	  analysed	  on	   the	  FACS	  
CANTO	   II	   (BD)	  using	  FACS	  Diva	   software	   (BD).	  Results	  were	  analysed	  using	  FLOWJO	  software	   (Tree	  Star	  
Inc.,	  Oregon,	  USA).	  
The	  lymphocyte	  subset	  data	  derived	  from	  eleven	  healthy,	  age-­‐matched	  volunteers	  were	  kindly	  provided	  
by	  Dr	  Linda	  Barber.	  The	  median	  age	  of	  the	  11	  volunteers	  was	  50	  years	  (interquartile	  range	  44-­‐54	  years).	  
Drs	   Katie	   Matthews	   and	   Linda	   Barber	   had	   previously	   performed	   the	   immunophenotyping	   studies	   and	  
analyses	   and	   the	   results	   were	   presented	   as	   part	   of	   the	   study	   described	   in	   Matthews	   et	   al271.	   The	  
antibodies	   used	   for	   those	   immunophenotyping	   studies	   comprised:	   CD4	   (clone	   SK3),	   CD8	   (SK1),	   CD25	  
(2A3),	  CD27	   (M-­‐T271),	  CD45RO	   (UCHL1),	  CD56	   (B159),	   (BD	  Biosciences)	   and	  CD3	   (OKT3),	  CD19	   (HIB19),	  
FoxP3	   (PCH101),	   and	   rat	   IgG2a	   isotype	   control	   (eBR2a)	   (eBioscience).	   The	   definitions	   of	   the	   individual	  
lymphocyte	   subsets	  were	   as	   described	   in	   Table	   2-­‐11;	   however,	   Tregs	  were	   defined	   as	   CD4+	   CD25high,	  
Foxp3+	  (without	  the	  use	  of	  CD27).	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Table	  2-­‐10	  Antibody	  cocktails	  used	  for	  immunophenotyping	  of	  B-­‐,	  T-­‐	  and	  NK-­‐cell	  subsets	  during	  RFUSIN2-­‐
AML1	  trial	  follow-­‐up	  
Cell	  subset	  of	  
interest	  























































































































Table	  2-­‐11	  Immunophenotypic	  markers	  used	  to	  identify	  lymphocyte	  subsets	  in	  RFUSIN2-­‐AML1	  trial	  
subjects	  during	  follow-­‐up	  
Cell	  Subset	   Phenotype	  
CD4	  T-­‐cell	   CD3+	  CD4+	  
Activated	  CD4	  T-­‐cell	   CD3+	  CD4+	  CD69+	  or	  HLA-­‐DR+	  
CD4	  naïve	  	   CD3+	  CD4+	  CD45RO-­‐	  CD27+	  
CD4	  memory	   CD3+	  CD4+	  CD45RO+	  CD27+	  
CD4	  effector	   CD3+	  CD4+	  CD45RO+	  CD27-­‐	  
CD4	  terminal	  effector	   CD3+	  CD4+	  CD45RO-­‐	  CD27-­‐	  
CD4	  regulatory	  T-­‐cell	   CD3+	  CD4+	  CD25high	  CD27+	  Foxp3+	  	  
CD8	  T-­‐cell	   CD3+	  CD4-­‐	  
Activated	  CD8	  T-­‐cell	   CD3+	  CD4-­‐	  CD69+	  or	  HLA-­‐DR+	  
CD8	  naïve	  	   CD3+	  CD4-­‐	  CD45RO-­‐	  CD27+	  
CD8	  memory	   CD3+	  CD4-­‐	  CD45RO+	  CD27+	  
CD8	  effector	   CD3+	  CD4-­‐	  CD45RO+	  CD27-­‐	  
CD8	  terminal	  effector	   CD3+	  CD4-­‐	  CD45RO-­‐	  CD27-­‐	  
B-­‐cell	   CD19+	  CD3-­‐	  	  
NK-­‐cell	  
CD3-­‐	  CD56+	  CD16+/-­‐	  
CD56	  bright	  CD16	  +/-­‐	  
CD56	  dim	  CD16	  +/-­‐	  
NK	  activation	  markers	  
CD3-­‐	  CD56+	  NKG2D+	  
CD3-­‐	  CD56+	  DNAM-­‐1+	  
CD3-­‐	  CD56+	  NKp44+	  
CD3-­‐	  CD56	  bright/dim	  NKG2D+	  
CD3-­‐	  CD56	  bright/dim	  DNAM-­‐1+	  


















Representative	  plots	  demonstrating	  the	  identification	  of	  peripheral	  blood	  lymphocytes	  and	  subsets	  in	  trial	  
subjects	  or	  healthy	  volunteers.	  (a-­‐c)	  Following	  doublet	  discrimination,	  low	  forward	  and	  side	  scatter	  
properties	  are	  used	  to	  identify	  the	  lymphocyte	  population.	  (d)	  Staining	  with	  anti-­‐CD19	  and	  anti-­‐CD3	  
fluorescent	  antibodies	  allows	  identification	  of	  B-­‐	  and	  T-­‐cells.	  Figures	  given	  are	  percentages.	  
Figure	  2-­‐2	  Representative	  plots	  demonstrating	  the	  gating	  strategies	  used	  to	  identify	  B-­‐cells	  



























Following	  surface	  staining	  with	  anti-­‐CD4,	  anti-­‐CD25	  and	  anti-­‐CD27	  fluorescent	  antibodies,	  fixation	  and	  
permeabilisation	  of	  cells	  according	  to	  the	  manufacturer’s	  protocol	  was	  performed.	  Intracellular	  staining	  
for	  FoxP3	  expression	  with	  an	  anti-­‐FoxP3	  fluorochrome	  was	  performed.	  After	  gating	  on	  lymphocytes	  (as	  in	  
Figure	  2-­‐2a-­‐c),	  representative	  plots	  show	  identification	  of	  CD4+	  T-­‐cells	  (a),	  gating	  of	  CD4+	  CD25high	  T-­‐cells	  
(b)	  and	  CD27+	  FoxP3+	  T-­‐regulatory	  cells.	  Expression	  of	  CD27	  was	  used	  to	  distinguish	  T-­‐regulatory	  cells	  































After	  gating	  on	  lymphocytes	  (Figure	  2-­‐2	  a-­‐c),	  surface	  staining	  with	  CD3	  was	  used	  to	  identify	  T-­‐cells,	  which	  
were	  then	  divided	  by	  CD4	  expression	  into	  CD4+	  and	  CD8+	  T-­‐cells.	  CD27	  and	  CD45RO	  expression	  was	  used	  
to	  identify	  naïve,	  memory,	  effector	  and	  terminal	  effector	  CD4+	  and	  CD8+	  T-­‐cells	  respectively	  (see	  Table	  2-­‐



































After	  identification	  of	  CD4+	  and	  CD8+	  T-­‐cells	  (as	  shown	  in	  Figure	  2-­‐4),	  expression	  of	  the	  activation	  

















Following	  identification	  of	  lymphocytes	  and	  CD3-­‐	  CD19-­‐	  events	  (Figure	  2-­‐2),	  NK-­‐cells	  were	  identified	  by	  
absent	  CD3	  expression	  and	  expression	  of	  CD56	  (Figure	  2-­‐6a).	  High	  and	  low	  intensity	  expression	  of	  CD56	  by	  
these	  NK-­‐cells	  allowed	  distinction	  into	  the	  NK	  ”bright”	  and	  “dim”	  sub-­‐populations	  (Figure	  2-­‐6b)	  which	  
were	  shown	  to	  have	  differential	  expression	  of	  CD16	  (Figure	  2-­‐6c),	  as	  previously	  described274.	  Figures	  given	  
are	  percentages.	  
	  








































c.	  Measurement	  of	  
CD16	  expression	  by	  	  
CD56	  "dim"	  and	  
"bright"	  NK-­‐cells	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High	  throughput	  sequencing	  of	  T-­‐Cell	  receptor	  sequences	  
gDNA	   samples	   isolated	   from	   PBMCs	   were	   sent	   to	   Adaptive	   Biotechnologies	   (Seattle,	   USA)	   to	   undergo	  
high-­‐throughput	  sequencing	  using	  the	  ImmunoSEQ	  assay.	  This	  technology	  was	  used	  to	  permit	  sequencing	  
of	  TCR	  β-­‐chain	  CDR3	  regions	  using	  a	  multiplex	  PCR	  assay	  with	  established	  methodology275,276.	  The	  assay	  
uses	  52	  forward	  primers	  designed	  to	  recognise	  the	  range	  of	  Vβ	  genes	  and	  13	  reverse	  primers	  recognising	  
each	   Jβ	   gene	   in	   order	   to	   generate	   60	   base-­‐pair	   fragments	   encompassing	   the	   entire	   range	   of	   VDJ	  
combinations.	  These	  were	  then	  sequenced	  using	  the	  Illumina	  HiSeq	  platform	  and	  the	  sequences	  analysed	  
using	  ImmunoSeq	  software	  tools	  by	  Dr	  David	  Hamm,	  PhD	  at	  Adaptive	  Biotechnologies.	  The	  total	  number	  
of	   reads	   for	   each	   sample	  was	  measured	  and	   sub-­‐divided	   into	  productive,	  out	  of	   frame	  and	   stop-­‐codon	  
containing	   sequences.	   The	   number	   of	   unique	   sequences	   (productive,	   out	   of	   frame	   and	   stop	   codon-­‐
containing)	  was	  determined	  following	  error	  corrections	  as	  described	  in	  Robins	  et	  al,	  2009275.	  A	  measure	  of	  
Shannon’s	  entropy	  for	  each	  sample	  was	  performed	  by	  Adaptive	  Biotechnologies	  as	  a	  recognised	  means	  to	  
analyse	   clonality	   within	   the	   dataset277.	   Adaptive	   Biotechnologies	   used	   normalized	   entropy	   (entropy	  
divided	   by	   the	   log	   base	   2	   of	   the	   number	   of	   productive	   unique	   sequences)	   to	   determine	   clonality.	   The	  
international	   IMmunoGeneTics	   (IMGT)	   database	   was	   searched	   via	   the	   ImmunoSeq	   analysis	   tools	   to	  
identify	  the	  Vβ	  and	  Jβ	  genes	  used	  to	  produce	  individual	  CDR3β	  sequences278.	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Chapter	  3 Outcomes	   Following	   Donor	   Lymphocyte	   Infusions	   Post-­‐T-­‐cell	  
Depleted	   Allogeneic	   Haematopoietic	   Stem	   Cell	   Transplants	   for	   Acute	  
Myeloid	  Leukaemia	  and	  Myelodysplastic	  Syndromes	  
3.1 Introduction	  
Whilst	  donor	  lymphocyte	  infusions	  (DLI)	  have	  been	  used	  with	  considerable	  success	  to	  treat	  recurrence	  of	  
chronic	  myeloid	   leukaemia	   post-­‐allogeneic	   transplantation,	   their	   efficacy	   in	   the	   context	   of	   other	  more	  
rapidly	   progressive	  myeloid	  malignancies,	   such	   as	   AML	   or	  MDS,	   is	   uncertain.	   The	  majority	   of	   available	  
data	   regarding	  outcomes	   following	   therapeutic	  DLI	   (tDLI)	   are	  derived	  predominantly	   from	  retrospective	  
studies	  of	  small	  heterogeneous	  patient	  cohorts	  or	  combined	  from	  transplant	  registry	  records.	  A	  number	  
of	   these	  reports	  are	  summarised	   in	  Table	  1-­‐2.	  Thus	   far,	  outcomes	   following	   tDLI	   for	   recurrent	  AML	  and	  
MDS	   mainly	   following	   myeloablative	   and/or	   T-­‐replete	   HSCT	   have	   been	   unsatisfactory,	   with	   survival	  
frequently	  estimated	  at	   less	   than	  25%	  by	  2	  years	   following	   tDLI	  and	   rates	  of	  GvHD	  reaching	  more	   than	  
50%11,21,130-­‐136.	  There	  have	  been	  few	  reports	  specifically	  of	  outcomes	  following	  tDLI	   for	  AML	  and	  MDS	  in	  
the	  context	  of	  reduced	  intensity	  conditioning	  (RIC)	  regimens	  incorporating	  T-­‐cell	  depletion	  (TCD)13,139,140.	  
In	  one	  study,	  while	  more	   than	  half	  of	  patients	   showed	  complete	  or	  partial	  disease	   regression	   following	  
tDLI,	   rates	  of	  GvHD	  were	  higher	   than	  50%139.	  Our	  own	  preliminary	  data	   in	  AML	  and	  MDS	  patients	  with	  
recurrent	  disease	  following	  alemtuzumab-­‐containing	  RIC	  HSCT	  suggested	  response	  rates	  to	  tDLI	  of	  greater	  
than	   50%	   confined	   to	   those	   patients	  with	   low	   disease	   burden,	   but	   long-­‐term	   follow-­‐up	   data	   has	   been	  
lacking140.	  These	  data	  are	  particularly	  relevant	   in	  the	  context	  of	  this	  thesis,	  since	  the	  use	  of	  an	  AML	  cell	  
vaccine	  (ACV)	  to	  combine	  with	  administration	  of	  tDLI	  to	  treat	  recurrent	  AML	  post-­‐HSCT	  aims	  to	  boost	  the	  
induction	   of	   GvL	   activity.	   However,	   there	   remains	   a	   risk	   of	   triggering	   harmful	   GvHD.	   A	   clearer	  
understanding	   of	   the	   efficacy	   and	   toxicity	   of	   tDLI	   in	   the	   absence	   of	   co-­‐administration	   of	   the	   ACV	   is	  
informative	  with	  respect	  to	  providing	  benchmarks	  against	  which	  the	  combination	  of	  ACV	  with	  tDLI	  can	  be	  
evaluated	  in	  the	  future.	  
	  
Our	   own	   data	   and	   that	   from	   other	   groups	   have	   raised	   the	   possibility	   that	   DLI	   may	   be	   particularly	  
efficacious	  where	  disease	  burden	   is	   low	  e.g.	   in	  the	  setting	  of	  cytogenetic	  but	  not	  morphological	  disease	  
recurrence13,140.	  This	  may	  be	  further	  extended	  to	  the	  setting	  of	  impending	  relapse,	  although	  identification	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of	  at	  risk	  patients	   is	  an	  area	  of	  debate.	  Mixed	  donor	  chimerism,	  particularly	   in	  the	  T-­‐cell	  depleted	  HSCT	  
setting,	   where	   it	   is	   more	   commonly	   observed,	   has	   been	   variably	   linked	   to	   increased	   risk	   of	   disease	  
recurrence139,147,150.	   Declining	   donor	   T-­‐cell	   percentages	   and	   persistent,	   predominant	   recipient	   T-­‐cell	  
chimerism	  have	  been	  considered	   indicators	   to	   initiate	  pre-­‐emptive	  DLI	   (pDLI)	   to	  drive	  conversion	  to	   full	  
donor	   chimerism	  and	  prevent	   relapse143,151.	  However,	   there	   is	   a	   lack	   of	   consensus	   regarding	   the	  donor	  
CD3	   percentage	   threshold	   that	   should	   trigger	   therapy,	   as	   well	   as	   the	   dosing	   and	   scheduling	   of	   pDLI.	  
Timing	   of	   initiation	   of	   pDLI	   has	   been	   a	   specific	   area	   of	   debate,	   following	   a	   report	   of	   greater	   than	   50%	  
GvHD	  incidence	  in	  patients	  who	  received	  DLI	  at	  less	  than	  6	  months	  following	  TCD	  RIC	  HSCT137.	  However,	  in	  
the	  context	  of	  diseases	  such	  as	  AML	  that	  may	  show	  a	  rapid	   tempo	  of	   recurrence	   (often	  within	   the	   first	  
year	  post-­‐HSCT),	  early	  administration	  of	  pDLI	  for	  low	  or	  falling	  chimerism	  may	  be	  warranted155.	  We	  have	  
treated	  a	  uniform	  cohort	  of	  patients	  at	  our	  institution	  with	  pDLI	  according	  to	  an	  escalating	  dose	  protocol,	  
which	   is	   sometimes	  administered	  before	  6	  months	  post-­‐TCD	  RIC	  HSCT	   for	  AML	  and	  MDS.	   I	  present	   the	  
efficacy	  and	  toxicity	  of	  our	  approach	  in	  this	  thesis.	  	  
	  
I	  analysed	  the	  outcomes	  following	  pre-­‐emptive	  or	  therapeutic	  DLI	  in	  113	  patients	  following	  T-­‐cell	  depleted	  
RIC	  HSCT	  for	  AML	  or	  MDS	  treated	  at	  King’s	  College	  Hospital	  between	  1999	  and	  2010.	  The	  results	  of	  this	  
retrospective	   study	  were	   published	   in	   Biology	   of	   Blood	   and	  Marrow	   Transplantation,	   2013,	   19(4):	   562-­‐
568,	   and,	   in	   accordance	   with	   the	   regulations	   governing	   PhD	   Theses	   at	   King’s	   College,	   London,	   I	   have	  
chosen	  to	  present	  this	  work	  as	  published.	  
	  
3.2 Results	  
I	  collected	  the	  clinical	  data	   for	   this	  study	  using	  electronic	  and	  paper	  records.	   I	  analysed	  the	  data	  that	   is	  
presented	   in	   the	   publication	   below	   using	   SPSS	   software.	   Dr	   Victoria	   T.	   Potter	   also	   contributed	   to	   data	  
collection	   and	   analysis.	   My	   statistical	   analyses	   were	   verified	   independently	   by	   Dr	   Rachel	   Pearce,	   who	  
performed	  the	  competing	  risk	  analyses.	  I	  wrote	  the	  manuscript,	  which	  was	  critically	  reviewed	  and	  edited	  


























3.2.1 Supplementary	  data	  
Table	  S1.	  Details	  of	  conditioning	  regimens	  
FBC	  (n=99)	   Fludarabine	  30	  mg/m2	  iv	  D-­‐8	  to	  D-­‐4	  
CAMPATH	  (Alemtuzumab)	  20mg	  iv	  D-­‐8	  to	  D-­‐4	  
Busulphan	  3.2	  mg/kg	  iv	  or	  4mg/kg	  po	  D-­‐3	  to	  D-­‐2*	  
FBATG	  (n=12)	   Fludarabine	  30mg/m2	  iv	  D-­‐9	  to	  D-­‐5	  
Busulphan	  3.2	  mg/kg	  iv	  D-­‐4	  to	  D-­‐3	  
ATG	  6mg/kg	  (total	  dose)	  iv	  D-­‐4	  to	  D-­‐1	  
FLAMSA	  (n=2)	   Fludarabine	  30mg/m2	  iv	  D-­‐12	  to	  D-­‐9	  
Cytarabine	  2g/m2	  iv	  D-­‐12	  to	  D-­‐9	  
Amsacrine	  100mg/m2	  iv	  D-­‐12	  to	  D-­‐9	  
Busulphan	  3.2mg/kg	  iv	  D-­‐5	  to	  D-­‐4	  
ATG	  2.5mg/kg	  iv	  D-­‐4	  to	  D-­‐2	  
*	  19	  patients	  received	  total	  of	  4	  doses	  of	  busulphan	  D-­‐5	  to	  D-­‐2	  
ATG,	  Anti-­‐thymocyte	  globulin	  
	  
Table	  S2.	  DLI	  dose	  escalation	  schedule.	  
	  	  	  DLI	  dose:	  total	  CD3+	  cell	  dose/kg	   5x105,	  1x106,	  5x106,	  1x107,	  5x107,	  1x108	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Table	  S3.	  tDLI	  cohort:	  relapse	  and	  treatment	  characteristics	  
Characteristic	   No	  of	  patients	  (total=51)	  
Cytogenetics	  at	  relapse	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Normal	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Recurrence	  of	  original	  abnormality	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Recurrence	  of	  original	  +	  new	  clonal	  abnormality	  






Blast	  percentage	  pre	  tDLI	  
	  	  	  	  	  	  	  	  	  	  	  	  <5%	  
	  	  	  	  	  	  	  	  	  	  	  	  >5%	  
	  	  	  	  	  	  	  	  	  	  	  	  5-­‐10%	  
	  	  	  	  	  	  	  	  	  	  	  	  	  >10%	  







Intensive	  chemotherapy	  (total)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  FLAG/FLAG-­‐Ida	  
	  	  	  	  	  	  	  	  	  	  	  	  	  High	  Dose	  Cytarabine	  
	  	  	  	  	  	  	  	  	  	  	  	  	  DA	  
	  	  	  	  	  	  	  	  	  	  	  	  	  ADE	  
	  	  	  	  	  	  	  	  	  	  	  	  	  Melphalan	  








Non-­‐intensive	  chemotherapy	  (total)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  Low	  dose	  cytarabine	  







This	  article	  was	  published	  at	  the	  same	  time	  as	  a	  report	  by	  Liga	  et	  al.	  presenting	  data	  from	  15	  patients	  after	  
myeloablative	   HSCT	   incorporating	   alemtuzumab	   who	   were	   given	   DLI	   pre-­‐emptively	   for	   mixed	   donor	  
chimerism,	  or	  prophylactically	  due	  to	  perceived	  high	  risk	  of	  recurrent	  acute	  leukaemia279.	  Using	  low	  doses	  
of	  DLI	  (median	  cumulative	  cell	  dose	  2x106	  CD3+	  cells/kg)	  delivered	  at	  a	  median	  of	  162	  days	  post-­‐HSCT,	  a	  
high	   relapse-­‐free	   survival	   (72%	   +/-­‐12%	   at	   2	   years)	   in	   8	   recipients	   of	   pDLI	   for	   mixed	   chimerism	   was	  
observed279.	   Six	   (75%)of	   the	  mixed	  chimeric	  patients	   converted	   to	  complete	  donor	  chimerism	   following	  
DLI.	   However,	   incidence	   of	   GvHD	   was	   50%	   in	   these	   patients	   and	   overall,	   a	   DLI-­‐related	   mortality	  
(principally	  due	  to	  GvHD)	  of	  27%	  was	  described279.	  Whilst	  the	  favourable	  response	  rates	  are	  encouraging,	  
it	  should	  be	  noted	  that	  the	  threshold	  for	  commencement	  of	  pDLI	  for	  mixed	  chimerism	  was	  as	  low	  as	  5%	  
recipient	   cells	   i.e.	   95%	   donor	   cells,	   the	   median	   being	   a	   recipient	   unfractionated	   chimerism	   in	   the	  
peripheral	  blood	  cells	  of	  7.5%	  (range	  5-­‐15%)279.	  Also	  of	  note,	  doses	  of	  alemtuzumab	  used	  in	  these	  patients	  
following	   a	  myeloablative	   protocol	   ranged	   from	  10-­‐20mg,	  which	   is	   substantially	   lower	   than	   the	   100mg	  
used	  in	  our	  patients.	  In	  combination,	  it	  is	  likely	  that	  such	  differences	  account	  for	  the	  higher	  incidence	  and	  
severity	  of	  post-­‐DLI	  GvHD	  reported	  in	  this	  study.	  
	  
These	   issues	  were	   highlighted	   in	   an	   accompanying	   editorial	   published	   in	   Biology	   of	   Blood	   and	  Marrow	  
Transplantation,	  2013,	  19(4):	  507-­‐508,	  280	  which	  commented	  on	  our	  findings	  and	  those	  of	  Liga	  et	  al.	  The	  
encouraging	  disease-­‐free	  survival	  reported	  by	  both	  studies	  in	  patients	  experiencing	  improved	  chimerism	  
following	  pDLI,	  supporting	  provision	  of	  effective	  GvL	  activity	  by	  pDLI	   in	  responders	  was	  highlighted.	  The	  
multitude	  of	  variables	  that	  impact	  upon	  the	  risk	  of	  GvHD	  following	  DLI	  was	  discussed,	  with	  emphasis	  on	  
use	   (and	   type)	   of	   TCD	   in	   the	   initial	   conditioning	   regimen,	   CD3+	   T-­‐cell	   dose	   administered	   in	   DLI,	   timing	  
post-­‐HSCT	   and	  degree	   of	  HLA-­‐matching	   between	  donor	   and	   recipients280.	   It	   is	   evident	   that	   prospective	  
studies,	   in	  the	  context	  of	  uniform	  patient	  cohorts	  with	  clearly	  identified	  indications	  and	  dose	  scheduling	  
of	  pDLI,	  incorporating	  patients	  not	  requiring	  pDLI	  as	  a	  control	  arm,	  are	  required	  to	  increase	  knowledge	  of	  
the	  risks	  and	  benefits	  of	  this	  therapy.	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Our	   data	   support	   the	   potential	   for	  DLI	   to	   promote	  GvL	   activity	  without	   inducing	   unacceptable	   rates	   of	  
severe	  GvHD.	   In	   the	   context	   of	   relapsed	   disease,	   tDLI	  was	  most	   effective	   in	   the	   setting	   of	   low	   disease	  
burden	   (complete	  morphological	   remission	   or	   recurrent	   cytogenetic	   disease	   only)	   in	   patients	   relapsing	  
later	   than	   6	   months	   post-­‐HSCT.	   The	   5-­‐year	   relapse/progression	   rate	   of	   69%	   (95%	   CI,	   54%-­‐81%)	   in	  
recipients	  of	  tDLI	  highlights	  the	  need	  to	  boost	  the	  induction	  of	  sustained	  GvL	  responses	  in	  these	  patients.	  
One	  means	  to	  achieve	  this	  may	  be	  by	  combining	  tDLI	  with	  active	  immunotherapeutic	  strategies,	  such	  as	  






Chapter	  4 Combined	  Adjuvants	  for	  Synergistic	  Activation	  of	  Cell-­‐Mediated	  
Immunity	  (CASAC)	  combine	  with	  WT1	  peptide	  vaccination	  to	  induce	  WT1-­‐
specific	  T-­‐cell	  responses	  
4.1 Introduction	  
The	   data	   presented	   in	   Chapter	   1	   outlined	   the	   rationale	   for	   immunotherapeutic	   targeting	   of	   the	   WT1	  
protein	  in	  tumours	  that	  frequently	  over-­‐express	  this	  transcription	  factor,	  such	  as	  AML.	  Whilst	  early	  phase	  
clinical	  studies	  have	  shown	  that	  it	  is	  possible	  to	  induce	  WT1-­‐specific	  immune	  responses	  in	  AML	  and	  MDS	  
patients,	   the	   short-­‐lived	   T-­‐cell	   expansions	   of	   low	   magnitude	   resulting	   from	   vaccination	   suggest	   a	  
requirement	  for	  additional	  factors	  to	  promote	  durable	  and	  potent	  cytotoxic	  T-­‐cell	  activity198-­‐201.	  A	  major	  
limitation	   in	  cancer	  vaccination	  trials	  has	  been	  the	  absence	  of	  clinically	  safe,	  effective	  adjuvants	   for	   the	  
promotion	  of	  cell-­‐mediated	  immunity.	  Advances	  in	  our	  understanding	  of	  the	  importance	  of	  TLR	  agonists	  
in	   licensing	   DCs	   to	   provide	   essential	   signals	   for	   activation	   of	   cognate	   naive	   T-­‐cells	   has	   offered	   the	  
possibility	  of	   introducing	  more	  powerful	  adjuvants	   into	  the	  clinical	  setting227,234.	  Previous	  work	  from	  our	  
group	   highlighted	   the	   ability	   of	   selected	   adjuvants	   to	   synergise	   to	   induce	   large	   expansions	   of	   antigen-­‐
specific	   T-­‐cells	   following	   repeated	   vaccination	   in	   a	  murine	  model.	   This	  was	   effective	   in	   the	   context	   not	  
only	  of	  a	   xenoantigen	  but	  also	  a	   self-­‐antigen,	  TRP-­‐2,	  which	   is	  overexpressed	  by	   the	  B16	  melanoma	  cell	  
line.	   	  Specifically,	  CASAC/TRP-­‐2	  vaccinations	  were	  able	  to	  prolong	  the	  survival	  of	  B16	  melanoma-­‐bearing	  
C57BL/6	  mice238.	  
	  
Given	  these	  observations	  and	  the	  immunotherapeutic	  potential	  of	  targeting	  WT1,	  the	  ability	  of	  CASAC	  to	  
enhance	  WT1-­‐specific	   immunity	   was	   assessed	   in	   the	   following	   studies.	   C57BL/6	  mice	  were	   immunised	  
with	  WT1-­‐RMF,	  a	  well-­‐defined	  WT1	  epitope	  in	  the	  context	  of	  both	  HLA-­‐A*02:01	  in	  humans	  and	  H-­‐2Db	  in	  
mice159,173,179	   and	   induction	   of	   WT1-­‐specific	   T-­‐cell	   responses	   was	   examined.	   Other	   factors	   that	   may	  
combine	  with	  CASAC	  to	  increase	  the	  potency	  of	  WT1-­‐specific	  T-­‐cell	  responses	  or	  extend	  the	  applicability	  
of	  WT1	  peptide	  vaccination	   to	  all	  patients,	   irrespective	  of	  HLA-­‐type,	  were	  also	  evaluated.	  A	  heteroclitic	  
modification	   of	   the	  WT1-­‐RMF	   epitope	   (WT1-­‐YMF),	   reported	   to	   be	  more	   effective	   at	   inducing	   immune	  
responses	   in	   CTLs	   that	   cross-­‐react	   with	   native	   WT1-­‐RMF	   in	   the	   context	   of	   human	   HLA	   A*02:01	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presentation190,201,203,	   was	   compared	   with	   wild-­‐type	   WT1-­‐RMF	   in	   CASAC	   vaccination	   studies	   in	   H-­‐2b-­‐
expressing	  C57BL/6	  mice.	  	  
Additionally,	  a	  promising	  approach	  to	  vaccination	  studies,	  namely	  use	  of	  an	  overlapping	  peptide	  pool	  for	  
immunisations,	   was	   studied.	   Such	   a	   strategy	   has	   shown	   efficacy	   in	   the	   therapy	   of	   cervical	   cancer	   and	  
human	  papilloma	  virus	  (HPV)	  positive	  vulval	  intraepithelial	  neoplasia	  in	  Phase	  II	  clinical	  trials	  but	  has	  not	  
been	  previously	  explored	   in	   the	  context	  of	  vaccinations	  targeting	  WT1216,217.	  A	  pool	  of	  overlapping	  WT1	  
peptides	  is	  available	  from	  Miltenyi	  Biotec	  Ltd	  (WT1	  PepTivator®).	  This	  comprises	  a	  cocktail	  of	  lyophilized	  
peptides,	  mainly	  15-­‐mer	  sequences	  with	  11	  amino	  acid	  overlap,	  covering	  the	  complete	  sequence	  of	  the	  
human	  WT1	  protein.	   It	  has	  been	  created	  principally	   for	   the	  purpose	  of	  generating	  WT1-­‐specific	  CTLs	   in	  
vitro	   for	   subsequent	   adoptive	   immunotherapy	   against	   WT1-­‐expressing	   malignancies.	   A	   Good	  
Manufacturing	  Practice	  (GMP)	  Grade	  version	  of	  the	  WT1	  PepTivator® is	  also	  available	  and	  therefore	  this	  
product	  could	  be	  translated	  to	  the	  clinical	  setting	  with	  ease.	  
	  
The	   following	   studies	   demonstrate	   the	   feasibility	   of	   CASAC	   vaccinations	   targeting	  WT1	   to	   induce	  WT1-­‐
specific	  T-­‐cell	  expansions	  demonstrating	   functional	  efficacy	   in	   the	   in	  vivo	   setting.	  Strategies	   to	  optimise	  
and	  extend	  this	  approach	  that	  could	  translate	  WT1	  peptide	  vaccination	  to	  the	  broader	  patient	  population	  
are	  also	  explored.	  
	  
4.2 Results	  
4.2.1 Feasibility	  and	  specificity	  of	  WT1	  peptide	  and	  CASAC	  vaccination	  	  
Previous	  studies	  by	  Wells	  et	  al	  had	  demonstrated	  that	  immunising	  C57BL/6	  mice	  against	  the	  ovalbumin-­‐
derived	  Class	  I	  peptide	  OVA-­‐SIINF	  in	  combination	  with	  either	  a	  Class	  II	  peptide	  or	  an	  agonistic	  anti-­‐CD40	  
antibody,	   IFNγ and	  the	  TLR	  agonists	  CpG	  and	  poly	  I:C,	  all	  admixed	  with	  an	  emulsion	  containing	  0.4%	  v/v	  
Tween	   80,	   4.4%	   v/v	   squalene	   in	   PBS,	   induced	   OVA-­‐SIINF	   specific	   CD8+	   T-­‐cell	   expansion.	   Vaccinations	  
administered	   on	   days	   1	   and	   10	   using	   these	   components	   resulted	   in	   detection	   of	   a	   population	   of	  OVA-­‐
SIINF-­‐specific	  CD8+	  T-­‐cells	  using	  pentamer-­‐based	  quantification	  of	  antigen-­‐specific	  T-­‐cells	  on	  day	  20.	  This	  
population	  accounted	  for	  approximately	  25-­‐30%	  of	  all	  circulating	  CD8+	  T-­‐cells238.	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A	  similar	  schedule	  was	  therefore	  adopted	  to	  determine	  whether	  vaccinations	  against	  WT1-­‐RMF	  combined	  
with	   CASAC	   could	   result	   in	   the	   induction	   of	   a	   WT1-­‐RMF	   specific	   immune	   response.	   The	   heteroclitic	  
modification	   of	  WT1-­‐RMF,	  WT1-­‐YMF,	  was	   predicted	   to	   show	   superior	   binding	   to	  H-­‐2Db	   than	  WT1-­‐RMF	  
using	   the	   SYFPEITHI	   prediction	   tool	   and	   the	   IEDB	   database	   (Table	   4-­‐1).	   Groups	   of	   mice	   undergoing	  
vaccinations	  incorporating	  the	  OVA-­‐SIINF	  peptide	  and	  CASAC	  (as	  described	  above)	  were	  used	  as	  positive	  
controls	  in	  these	  studies	  to	  confirm	  biologic	  activity	  of	  the	  CASAC	  components.	  	  
	  
Table	  4-­‐1	  Binding	  affinity	  of	  WT1-­‐RMF	  and	  WT1-­‐YMF	  to	  H-­‐2Db	  
Epitope	   SYFPEITHI	  score§	   IC50	  (nM,	  ANN	  method)¶	  
WT1-­‐RMF	   24	   81	  
WT1-­‐YMF	   25	   24	  
§SYFPEITH	  scores	  performed	  using	  the	  SYFPEITHI	  database180	  
¶	  	  Artificial	  Neural	  Network	  method	  used	  by	  IEDB	  	  (www.iedb.org)	  to	  report	  pMHC	  binding	  affinities281,282	  
The	  lower	  the	  IC50	  value,	  the	  higher	  the	  binding	  	  affinity	  of	  the	  peptide	  for	  the	  class	  I	  molecule.	  
	  
4.2.1.1 Vaccinations	  combining	  CASAC	  and	  WT1-­‐RMF	  induce	  expansion	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  and	  
WT1-­‐RMF	  specific	  target	  cell	  lysis	  in	  vivo	  
Groups	  of	  mice	  (5	  per	  group)	  were	  immunised	  with	  OVA-­‐SIINF,	  WT1-­‐RMF	  or	  its	  heteroclitic	  modification,	  
WT1-­‐YMF.	  Either	  no	  Class	   II	  peptide,	   the	  Class	   II	  ovalbumin	  derived	  peptide	   ISQAVHAAHAEINEAGR323-­‐339	  
(OVA-­‐ISQ)	   or	   the	   PAn-­‐HLA-­‐DR-­‐Epitope	   (PADRE)	   were	   combined	   with	   Class	   I	   peptide	   and	   CASAC	  
components	   (CpG,	   poly	   I:C	   and	   IFNγ,	   mixed	   50:50	   with	   emulsion	   as	   above).	   One	   hundred	   µg	   of	   each	  
peptide	  were	  administered	  per	  mouse,	  per	   injection,	   as	  described	  previously	  by	  Wells	   et	   al	   and	  CASAC	  
components	  were	  also	  used	  in	  quantities	  established	  to	  be	  effective	  in	  the	  original	  publication238.	  OVA-­‐ISQ	  
had	  been	  used	  in	  the	  context	  of	  CASAC	  vaccinations	  whereas	  PADRE	  had	  not	  been	  assessed	  previously	  in	  
CASAC	   studies.	   The	   PADRE	   965.10	   peptide	   (KSSAKXVAAWTLKAAA)	   is	   a	   synthetic	   Class	   II	   helper	   peptide	  
designed	  to	  bind	  to	  a	  range	  of	  Class	  II	  molecules	  to	  activate	  CD4+	  T-­‐helper	  responses.	  Studies	  carried	  out	  
during	   its	   initial	  development	  demonstrated	  this	  peptide’s	  ability	   to	  effectively	  promote	   in	  vivo	  CD4+	  T-­‐
cell	   responses	   in	   C57BL/6	  mice	   and	   to	   bind	   to	   HLA	   Class	   II	   and	   stimulate	   human	   T-­‐cell	   proliferation	   in	  
vitro266.	  One	  rationale	  for	  investigating	  PADRE	  within	  CASAC	  was	  to	  determine	  whether	  it	  might	  be	  useful	  
as	   a	   universal	   helper	   peptide	   that	   could	   allow	   comparisons	   between	   vaccinations	   with	   varying	   Class	   I	  
peptides	  or	  CASAC	  components.	  Furthermore,	  if	  demonstrated	  to	  be	  effective	  as	  a	  helper	  peptide	  in	  pre-­‐
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clinical	  models,	   PADRE	   could	   easily	   be	   used	   as	   a	   helper	   peptide	   in	   studies	   of	   peptide	   vaccination	  with	  
CASAC	  in	  humans,	  since	  it	  has	  been	  shown	  to	  be	  safe	  in	  clinical	  trials	  thus	  far283,284.	  
After	   2	   rounds	   of	   vaccination,	   on	   day	   20,	   mice	   were	   bled	   to	   assess	   for	   antigen-­‐specific	   CD8+	   T-­‐cell	  
responses	   using	   fluorescent	   pentamers	   containing	   the	   peptide	   against	   which	   the	   mouse	   had	   been	  
immunized.	  Two	  types	  of	  negative	  controls	  were	  used:	  1)	  unimmunized	  mice	  stained	  with	  the	  pentamers	  
containing	  the	  immunizing	  peptide	  and	  2)	  an	  irrelevant	  pentamer	  containing	  a	  peptide	  derived	  from	  the	  
lymphochoriomeningitis	   virus	   (LCMV),	   to	  which	  mice	   housed	   in	   the	   pathogen-­‐free	   environment	   should	  
not	   have	   been	   exposed	   and	   therefore	   only	   low	   (background)	   frequency	   of	   LCMV-­‐specific	   CD8+	   T-­‐cells	  
would	   be	   expected.	   Figure	   4-­‐1	   (a-­‐d)	   illustrates	   the	   gating	   strategy	   used	   to	   determine	   the	   frequency	   of	  
antigen-­‐specific	  T-­‐cells	  in	  a	  representative	  OVA-­‐SIINF/ISQ	  immunized	  mouse	  by	  staining	  of	  murine	  PBMCs.	  
This	  gating	  strategy	  was	  applied	  to	  PBMCs	  collected	  from	  all	  immunized	  and	  unimmunized	  mouse	  groups.	  	  
The	  frequencies	  of	  antigen	  specific	  CD8+	  T-­‐cells	  detected	  in	  mice	  immunized	  against	  either	  OVA-­‐SIINF	  or	  
WT1-­‐RMF	  after	  2	  rounds	  of	  vaccination	  are	  illustrated	  in	  Figures	  4-­‐2	  and	  4-­‐3.	  
	  
Mean	   frequencies	  of	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	   following	  2	   rounds	  of	  vaccination	   ranged	   from	  18-­‐
24%	   amongst	   the	   3	   groups	   with	   no	   significant	   differences	   between	   groups	   observed.	   These	   mean	  
percentages	  are	  comparable	  with	  the	  results	  achieved	  in	  the	  original	  paper	  by	  Wells	  et	  al,	  suggesting	  that	  
the	  experimental	  procedure	   recapitulated	   the	  published	  protocol238.	  Within	  each	  OVA-­‐SIINF	   immunized	  
group,	  there	  was	  variability	  in	  terms	  of	  the	  magnitude	  of	  OVA-­‐SIINF	  specific	  T-­‐cell	  expansion	  that	  was	  not	  
specifically	   commented	  upon	   in	   the	   original	   publication	   but	   has	   been	  observed	  by	   others	   in	   our	   group	  
(Gee	  Jun	  Tye,	  unpublished	  observations).	  The	  basis	  for	  this	  variability	  between	  individuals	  within	  a	  cohort	  






Figure	  4-­‐1	  Gating	  strategy	  for	  pentamer	  studies.	  	  
Fluorescently	  labelled	  PBMCs	  from	  a	  representative	  OVA-­‐SIINF/ISQ-­‐immunised	  mouse	  following	  2	  
vaccinations	  are	  shown.	  (a)	  Lymphocytes	  (Ly)	  were	  identified	  based	  on	  forward	  (FSC)	  and	  side	  (SSC)	  
scatter	  properties.	  (b)	  A	  plot	  of	  FSC	  versus	  CD19	  expression	  identified	  CD19+	  B-­‐cells	  and	  CD19-­‐	  
populations:	  a	  gate	  including	  all	  CD19-­‐	  events	  was	  created.	  (c)	  The	  CD19-­‐	  population	  was	  then	  
analysed	  for	  expression	  of	  CD3	  and	  CD8	  to	  allow	  identification	  of	  CD3+	  and	  CD8+	  T-­‐cells.	  (d)	  The	  CD3+	  
CD8+	  population	  was	  then	  assessed	  for	  binding	  of	  the	  Kb/SIINF	  pentamer	  by	  plotting	  CD8	  against	  
Kb/SIINF.	  	  
	  




















































































	   	  
Groups	  of	  up	  to	  5	  mice	  were	  immunised	  with	  CASAC	  and	  using	  100	  µg	  OVA-­‐SIINF	  alone	  or	  in	  
combination	  with	  100	  µg	  OVA-­‐ISQ	  or	  PADRE	  per	  mouse.	  Unimmunised	  mice	  served	  as	  controls.	  CASAC	  
consisted	  of	  the	  following	  components	  per	  vaccination:	  CpG	  1826	  25µg,	  Poly	  I:C	  50µg,	  IFNγ	  1ng	  admixed	  
in	  a	  4.4%	  squalene	  emulsion	  (see	  Chapter	  2	  for	  further	  details).	  Pentamer	  staining	  was	  used	  to	  detect	  
the	  frequency	  of	  CD8+	  T-­‐cells	  recognizing	  OVA-­‐SIINF/Kb	  in	  the	  peripheral	  blood.	  All	  groups*:	  a	  sample	  
from	  each	  immunised	  group	  was	  stained	  with	  an	  irrelevant	  pentamer	  containing	  the	  LCMV-­‐derived	  
peptide	  FQPQ,	  serving	  as	  a	  negative	  control.	  Mean	  and	  standard	  deviation	  (SD)	  for	  each	  group	  of	  mice	  is	  
shown.	  No	  significant	  differences	  in	  the	  frequency	  of	  antigen-­‐specific	  T-­‐cells	  between	  any	  of	  the	  groups	  
were	  detected.	  OVA,	  ovalbumin;	  SIINF,	  SIINFEKL;	  ISQ,	  ISQAVHAAHAEINEAGR;	  PADRE,	  Pan-­‐HLA-­‐DR	  
















































































Figure	  4-­‐2	  Expansion	  of	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	  following	  2	  rounds	  of	  vaccination	  with	  OVA-­‐SIINF	  and	  
CASAC	  in	  the	  presence	  or	  absence	  of	  a	  helper	  peptide.	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In	  the	  same	  experiment,	  mice	  immunised	  with	  CASAC	  in	  combination	  with	  WT1-­‐RMF	  (+/-­‐	  PADRE)	  or	  YMF	  
+	  PADRE	  were	  also	  assessed	  after	  2	  rounds	  of	  vaccination	  for	  the	  development	  of	  WT1-­‐RMF	  specific	  CD8+	  
T-­‐cell	  expansion	  (Figure	  4-­‐3).	  Only	  one	  mouse	  of	  five	  in	  the	  WT1-­‐RMF	  vaccinated	  group	  had	  pentamer	  
staining	  4.4%	  above	  the	  background	  for	  unimmunised	  mice.	  	  No	  pentamer	  staining	  above	  background	  was	  
seen	  in	  any	  mouse	  following	  immunization	  with	  WT1-­‐RMF	  &	  PADRE	  or	  WT1-­‐YMF	  &	  PADRE.	  Given	  the	  
requirement	  to	  break	  tolerance	  against	  a	  self-­‐antigen	  in	  the	  vaccinations	  targeting	  WT1,	  contrasting	  with	  
the	  immunogenicity	  of	  peptides	  deriving	  from	  the	  xenoantigen	  OVA,	  the	  absence	  of	  detectable	  WT1-­‐RMF	  
specific	  CD8+	  T-­‐cells	  following	  only	  2	  rounds	  of	  vaccination	  in	  all	  except	  one	  mouse	  was	  not	  entirely	  
surprising.	  	  
	  
To	  determine	  whether	  repeated	  exposure	  to	  WT1	  peptides	  and	  CASAC	  could	  promote	  expansion	  of	  WT1-­‐
RMF	  specific	  CD8+	  T-­‐cells,	  vaccinations	  were	  continued	  in	  these	  mice	  for	  a	  further	  2	  rounds,	  given	  on	  days	  
24	  and	  36.	  The	  frequencies	  of	  antigen-­‐specific	  T-­‐cells	  were	  analysed	  by	  pentamer	  analyses	  on	  days	  35	  and	  
45.	   As	   a	   comparator,	   vaccinations	   were	   similarly	   continued	   in	   the	   OVA-­‐SIINF	   exposed	   groups;	   results	  
following	  4	  rounds	  of	  vaccination	  are	  presented	  in	  Figure	  4-­‐4a	  and	  b.	  High	  levels	  of	  background	  staining	  
were	   observed	   for	   the	   LCMV	   peptide-­‐containing	   pentamer	   FQPQ/Db-­‐R-­‐PE	   in	   this	   experiment	   but	   were	  
reduced	   in	   subsequent	   studies	   by	   centrifugation	   of	   pentamers	   for	   10	   minutes	   prior	   to	   use	   to	   avoid	  
pipetting	  of	  aggregates	  into	  the	  wells.	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Figure	  4-­‐3	  Low	  frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  following	  2	  rounds	  of	  vaccination	  with	  
WT1-­‐RMF	  or	  the	  heteroclitic	  peptide	  WT1-­‐YMF	  with	  CASAC,	  in	  the	  presence	  of	  absence	  of	  the	  helper	  
peptide	  PADRE	  
	  
In	  the	  same	  experiment	  described	  in	  Figure	  4-­‐2,	  groups	  of	  up	  to	  5	  mice	  were	  immunised	  using	  WT1-­‐
RMF	  alone	  or	  in	  combination	  with	  PADRE	  or	  WT1-­‐YMF	  and	  PADRE.	  Unimmunised	  mice	  served	  as	  
controls.	  Pentamer	  staining	  was	  used	  to	  detect	  the	  frequency	  of	  CD8+	  T-­‐cells	  recognizing	  WT1-­‐RMF/Kb	  
in	  the	  peripheral	  blood.	  A	  sample	  from	  each	  immunised	  group	  was	  stained	  with	  an	  irrelevant	  
pentamer	  containing	  the	  LCMV-­‐derived	  peptide	  FQPQ,	  serving	  as	  a	  negative	  control.	  Mean	  and	  SD	  for	  
each	  group	  of	  mice	  is	  shown.	  No	  significant	  differences	  in	  the	  frequency	  of	  antigen-­‐specific	  T-­‐cells	  
between	  any	  of	  the	  groups	  were	  detected.	  Please	  note	  the	  differences	  in	  y-­‐axis	  scale	  between	  Figures	  
4-­‐2	  and	  4-­‐3.	  WT1,	  Wilms’	  Tumour	  protein;	  RMF,	  RMFPNAPYL;	  YMF,	  YMFPNAPYL	  (Y	  denotes	  
substitution	  of	  tyrosine	  for	  arginine	  at	  position	  1);	  PADRE,	  Pan-­‐HLA-­‐DR	  Epitope;	  FQPQ,	  FQPQNGQFI;	  


















































































Following	  4	  rounds	  of	  vaccination,	  an	  increase	  in	  the	  mean	  frequencies	  of	  OVA-­‐SIINF-­‐specific	  CD8+	  T-­‐cells	  
was	   detected	   for	   both	   the	   OVA-­‐SIINF	   and	   OVA-­‐SIINF	   &	   ISQ	   immunized	   groups	   (30.4%	   and	   37%	  
respectively,	   Figures	   4-­‐4a	   and	   b).	   The	  mean	   frequencies	   of	  OVA-­‐SIINF-­‐specific	   T-­‐cells	   in	   these	   2	   groups	  
were	   significantly	   higher	   than	   those	   observed	   in	   the	   unimmunized	   group	   (p≤0.01	   for	  OVA-­‐SIINF	   versus	  
unimmunized	  and	  p≤0.001	  for	  OVA-­‐SIINF	  &	  ISQ),	  consistent	  with	  the	  findings	  of	  Wells	  et	  al	  that	  expansion	  
of	   CD8+	   T-­‐cells	  may	   be	   enhanced	  where	   vaccinations	   include	   a	   Class	   II	   peptide238.	   However,	   the	  mean	  
frequency	  of	  OVA-­‐SIINF-­‐specific	  CD8+	  T-­‐cells	  was	  significantly	  higher	   in	   the	  OVA-­‐SIINF	  &	   ISQ-­‐immunised	  
mice	  than	  the	  OVA-­‐SIINF&PADRE	  group	  (where	  the	  mean	  frequency	  was	  13%),	  Figures	  4-­‐4a	  and	  b.	  These	  
findings	  suggested	  that	  PADRE	  might	  not	  be	  as	  effective	  as	   the	  OVA-­‐derived	  helper	  peptide	  OVA-­‐ISQ	   in	  
the	  context	  of	  vaccinating	  C57BL/6	  mice.	  	  
	  
After	  4	  rounds	  of	  vaccination,	  a	  rise	  in	  the	  frequency	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  was	  observed	  in	  2	  mice	  
within	   the	   group	   receiving	  WT1-­‐RMF	   Class	   I	   peptide	   alone	  with	   CASAC,	   suggesting	   the	   induction	   of	   an	  
antigen-­‐specific	   immune	  response	  (Figure	  4-­‐4c).	  The	  remaining	  3	  mice	  did	  not	  show	  such	  an	  expansion,	  
implying	   that	   while	   CASAC	   can	   combine	   with	   WT1-­‐RMF	   to	   induce	   WT1-­‐RMF	   specific	   T-­‐cell	   expansion	  
following	  4	  vaccinations,	  this	  response	  is	  not	  consistently	  observed	  in	  all	  subjects	  within	  one	  group.	  There	  
is	  a	  suggestion	  that	  the	  2	  mice	  showing	  the	  highest	  responses	  after	  3	  vaccinations	  exhibited	  a	  reduction	  in	  
the	   frequencies	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  after	   the	   fourth	  vaccination	   (Figure	  4-­‐4d).	   In	   this	  particular	  
experiment	  the	  mice	  were	  not	  tagged	  to	  allow	  identification	  of	  individual	  responses.	  This	  observation	  may	  
represent	  a	  true	  waning	  in	  the	  frequency	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  in	  the	  peripheral	  blood	  following	  4	  
vaccinations.	  However,	  it	  could	  also	  reflect	  the	  difference	  in	  timings	  of	  phlebotomy	  following	  vaccinations	  
(at	  11	  days	  post	  the	  third	  and	  9	  days	  post	  the	  fourth	  vaccination).	  	  
Similarly,	  two	  of	  the	  five	  mice	  in	  the	  WT1-­‐RMF	  &	  PADRE	  and	  the	  WT1-­‐YMF	  &	  PADRE	  immunized	  groups	  
respectively	   showed	   increased	   WT1-­‐RMF	   pentamer	   staining	   above	   background	   following	   4	   rounds	   of	  
vaccination	   (Figure	   4-­‐4c).	   However,	   in	   both	   groups,	   the	   frequencies	   of	   WT1-­‐RMF	   specific	   T-­‐cells	   were	  
lower	   than	   the	   2	   highest	   responses	   in	   the	  WT1-­‐RMF	   immunized	   group.	   This	   suggests	   that	   addition	   of	  
PADRE	  to	  WT1-­‐RMF	  or	  use	  of	  WT1-­‐YMF	  for	  induction	  of	  WT1-­‐RMF	  specific	  responses	  is	  not	  beneficial	  and	  
may	  even	  be	  detrimental.	  Due	  to	  variability	  of	  the	  response	  rates	  between	  groups,	  these	  differences	  were	  
not	  shown	  to	  be	  statistically	  significant.	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Figure	  4-­‐4	  Induction	  of	  antigen-­‐specific	  T-­‐cells	  following	  4	  rounds	  of	  vaccination	  against	  OVA-­‐
SIINF	  or	  WT1-­‐RMF	  with	  CASAC	  	  
Figure	  4-­‐4(a)	  Following	  4	  rounds	  of	  vaccination,	  in	  the	  same	  groups	  of	  mice	  depicted	  in	  Figure	  4-­‐2,	  
OVA-­‐SIINF	  specific	  CD8+	  T-­‐cell	  frequencies	  (including	  group	  means	  and	  SD)	  were	  determined	  by	  
pentamer	  analysis.	  Results	  of	  staining	  with	  the	  irrelevant	  LCMV-­‐specific	  FQPQ/Db	  pentamer	  in	  a	  
representative	  sample	  from	  each	  group	  are	  also	  shown	  (All	  groups*).	  (b)	  Longitudinal	  representation	  
of	  individual	  frequencies	  of	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	  in	  each	  group	  after	  2,	  3	  and	  4	  rounds	  of	  
vaccination.	  No	  significant	  differences	  (by	  2-­‐way	  analysis	  of	  variance,	  ANOVA)	  were	  observed	  in	  the	  

























































































Figure	  4-­‐4	  continued.	  	  
4-­‐4	  (c)	  Following	  4	  rounds	  of	  vaccination,	  in	  the	  same	  groups	  of	  mice	  depicted	  in	  Figure	  4-­‐3,	  WT1-­‐RMF	  
specific	  CD8+	  T-­‐cell	  frequencies	  (including	  group	  means	  and	  SD)	  were	  determined	  by	  pentamer	  
analysis.	  Results	  of	  staining	  with	  the	  irrelevant	  LCMV-­‐specific	  FQPQ/Db	  pentamer	  in	  a	  representative	  
sample	  from	  each	  group	  are	  also	  shown	  (All	  groups*).	  (d)	  Longitudinal	  representation	  of	  individual	  
frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  in	  each	  group	  after	  2,	  3	  and	  4	  rounds	  of	  vaccination.	  No	  
significant	  differences	  (by	  2-­‐way	  analysis	  of	  variance,	  ANOVA)	  were	  observed	  in	  the	  frequencies	  of	  























































































In	  vivo	  cytolysis	  assay	  
An	   in	   vivo	   cytotoxicity	   assay	  was	   carried	   out	   as	   a	   functional	   assessment	   of	  WT1-­‐RMF-­‐specific	   immune	  
responses.	   The	   relative	   in	   vivo	   lysis	   of	  OVA-­‐SIINF	  or	  WT1-­‐RMF	  peptide-­‐loaded	   syngeneic	   splenocytes	   in	  
comparison	   to	   non-­‐loaded	   splenocytes	   was	   assessed	   in	   OVA-­‐SIINF	   or	   WT1-­‐RMF/YMF	   immunized	   mice	  
respectively.	   The	   fluorescent	   label,	   carboxyfluorescein	   diacetate,	   succinimidyl	   ester	   (CFSE)	  was	   used	   to	  
differentially	   label	   target	   and	   non-­‐target	   populations	   to	   give	   low	   or	   high	   intensities	   of	   fluorescence	  
staining	  (Figure	  4-­‐5c).	  Unimmunized	  mice	  served	  as	  controls.	  The	  assay	  was	  carried	  out	  on	  day	  48,	  12	  days	  
following	  the	  fourth	  vaccination.	  Relative	  lysis	  of	  the	  2	  CFSE	  labeled	  populations	  in	  control	  and	  immunized	  
mice	   allowed	   a	   measure	   of	   peptide-­‐specific	   target	   cell	   lysis	   to	   be	   made	   for	   each	   mouse.	   The	   gating	  
strategy	   is	   depicted	   in	   Figure	   4-­‐5.	   The	   results	   of	   the	   in	   vivo	   cytolysis	   assay	   in	   OVA-­‐SIINF	   and	   WT1-­‐
RMF/YMF	  immunized	  mice	  are	  shown	  in	  Figure	  4-­‐6.	  
	  
CFSE-­‐labelled	   splenocytes	   (1x107),	   comprising	   a	   50:50	   mixture	   of	   CFSE	   “high”	   intensity	   staining,	   non-­‐
peptide	   loaded	   targets	   and	  CFSE	   “low”	   intensity	   staining,	   peptide-­‐loaded	   targets	  were	   injected	   i.v.	   into	  
each	  of	  the	  immunised	  and	  unimmunised	  mice.	  Eighteen	  hours	  later,	  spleens	  were	  harvested	  from	  each	  
mouse	  and	  assessment	  of	  the	  relative	  proportions	  of	  the	  2	  CFSE-­‐labelled	  populations	  used	  to	  determine	  
the	  degree	  of	  antigen-­‐specific	   lysis	  of	  target	  peptide-­‐loaded	  cells.	  Mice	  immunised	  with	  OVA-­‐SIINF	  were	  
challenged	  with	  a	  mixture	  containing	  OVA-­‐SIINF-­‐loaded	  splenocytes;	  mice	   immunised	  with	  WT1-­‐RMF	  or	  
YMF	  were	  challenged	  with	  a	  mixture	  containing	  WT1-­‐RMF-­‐loaded	  splenocytes.	  Of	   the	  5	  control	  mice,	  1	  
received	  a	  mixture	  of	  splenocytes	  containing	  OVA-­‐SIINF-­‐loaded	  targets	  whilst	  the	  remaining	  4	  received	  a	  
mixture	   containing	  WT1-­‐RMF-­‐loaded	   targets.	   As	   an	   example,	   the	   calculation	   to	   determine	   percentage	  
lysis	  of	  peptide-­‐loaded	  target	  cells,	  based	  on	  the	  results	  shown	  in	  Figures	  4-­‐5	  and	  4-­‐6,	  is	  outlined	  below:	  
	  
Calculation	  of	  antigen-­‐specific	  lysis	  of	  target	  cells	  in	  the	  in	  vivo	  cytolysis	  assay	  
Unimmunised	  control	  mouse	  challenged	  with	  WT1-­‐RMF	  targets:	  	   	  
Number	  of	  events	  in	  the	  CFSE	  “low”	  target	  population	  	   =	   3716	   =	  1.24	  
Number	  of	  events	  in	  the	  CFSE	  “high”	  non-­‐target	  population	   	   2986	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Averaged	  ratios	  from	  4	  unimmunised	  mice	  =	  [1.24+1.28+1.29+1.29]/4	  =	  1.28	  
	  	  	  
WT1-­‐RMF	  immunised	  mouse:	  
Number	  of	  events	  in	  the	  CFSE	  “low”	  target	  population	  	   =	   1407	   =	  0.23	  
Number	  of	  events	  in	  the	  CFSE	  “high”	  non-­‐target	  population	   	   6043	  
	  
%	  Target	  cell	  lysis	  =	  1-­‐	  [0.23/1.28]	  x	  100%	  	  =	  	  82%	  lysis	  of	  WT1-­‐RMF+	  targets	  
	  
When	  possible,	  at	  least	  2,000	  events	  in	  the	  CFSE+	  gate	  were	  collected,	  to	  obtain	  a	  reliable	  reading.	  	  Ratios	  
determined	   in	   individual	  unimmunised	  mice	  were	  normalised	  to	  the	  average	  ratio	   from	  4	  unimmunised	  



















Figure	  4-­‐5	  Gating	  strategy	  for	  assessment	  of	  peptide-­‐loaded	  target	  cell	  lysis	  in	  the	  in	  vivo	  cytotoxicity	  
assay.	  	  
	  
Eighteen	  hours	  post	  injection	  of	  1x107	  CFSE-­‐labelled	  splenocytes,	  FACS	  analysis	  of	  CFSE	  ”low”	  (target,	  
peptide-­‐loaded)	  and	  CFSE	  “high”	  (non-­‐target,	  non-­‐loaded)	  was	  performed	  on	  splenocytes	  harvested	  
from	  immunised	  and	  unimmunised	  mice.	  Gating	  of	  splenocytes	  and	  the	  CFSE	  labelled	  populations	  are	  
shown	  in	  (a)	  and	  (b).	  Unimmunised	  mice	  served	  as	  the	  control	  population,	  demonstrating	  the	  
presence	  of	  both	  populations	  of	  CFSE	  low	  and	  high	  signal	  cells,	  (c).	  Following	  4	  rounds	  of	  OVA-­‐SIINF	  




	  All	   immunized	   mice	   showed	   significantly	   higher	   lysis	   of	   peptide-­‐loaded	   target	   splenocytes	   than	  
unimmunized	  mice	  (Figure	  4-­‐6).	  Within	  the	  3	  groups	  of	  mice	  immunized	  against	  WT1,	  greatest	   lysis	  was	  
seen	   for	   the	  WT1-­‐RMF	   immunized	  mice	   (mean	  percentage	   lysis,	   74%	   (56-­‐92%),	   confidence	   interval	   (CI)	  	  
95%)	   compared	  with	  mean	  percentage	   lysis	  of	   1%	   (-­‐0.77-­‐2.9%,	  CI	   95%)	   in	  unimmunized	  mice,	  p≤0.001.	  
Lysis	  was	  seen	  in	  each	  of	  the	  WT1-­‐RMF&PADRE	  (mean	  lysis	  46%,	  17-­‐76%,	  CI	  95%)	  and	  WT1-­‐YMF&PADRE	  
(mean	   lysis	   49%,	   14%-­‐85%	   CI	   95%)	   immunised	   groups	   but	   at	   lower	   mean	   frequencies	   than	   for	   mice	  
receiving	  WT1-­‐RMF	  alone.	  The	  lower	  mean	  percentage	  lysis	  in	  the	  groups	  exposed	  to	  PADRE	  did	  not	  reach	  
statistical	  significance.	  
	  
The	   data	   from	   the	   in	   vivo	   cytolysis	   assay	   contrasts	   with	   the	   findings	   from	   pentamer	   studies	   in	   WT1	  
immunised	  mice,	  since	  only	  2/5	  mice	  demonstrated	  increased	  frequencies	  of	  WT1-­‐RMF	  pentamer	  staining	  
T-­‐cells	   after	   3-­‐4	   vaccinations,	   but	   all	   5	  mice	   within	   that	   group	   showed	   at	   least	   50%	   lysis	   of	  WT1-­‐RMF	  
loaded	  target	  cells.	  Similarly	  in	  the	  WT1-­‐RMF/YMF	  and	  PADRE	  immunised	  mice,	  despite	  the	  detection	  of	  
low	  frequencies	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  in	  4	  of	  10	  mice	  by	  pentamer	  studies,	  lysis	  of	  WT1-­‐RMF	  loaded	  
splenocytes	  was	  observed	  in	  all	  mice	  in	  these	  2	  groups.	  One	  explanation	  for	  this	  apparent	  discrepancy	  is	  
that	  low	  affinity	  of	  the	  WT1-­‐specific	  TCR	  for	  the	  WT1-­‐RMF	  pentamer	  limits	  the	  sensitivity	  of	  this	  assay	  to	  
detect	   the	   expansions	   of	   WT1-­‐specific	   T-­‐cells	   and	   therefore	   underestimates	   the	   magnitude	   of	   the	  
responses	   induced.	  The	   in	  vivo	   lysis	  assay	  appears	   to	  show	  specificity	   in	   that	  unimmunised	  mice	  do	  not	  
lyse	  OVA-­‐SIINF	  or	  WT1-­‐RMF	  loaded	  splenocytes	  and	  may	  be	  a	  more	  sensitive	  assay	  for	  the	  detection	  of	  
WT1-­‐RMF	   specific	   responses.	   Furthermore,	   functionality	   of	  WT1-­‐specific	   cytotoxic	   T-­‐cell	   responses	  may	  
be	  distinct	  from	  the	  numeric	  frequency	  of	  WT1-­‐specific	  T-­‐cells.	  
	  
The	   possibility	   that	   PADRE	   was	   impeding	   the	   induction	   of	   antigen-­‐specific	   responses	   was	   noted.	   To	  
investigate	  whether	  this	  could	  have	  resulted	  from	  induction	  of	  regulatory	  CD4+	  T-­‐cell	  expansion	  triggered	  
through	  repeated	  vaccination	  with	  a	  helper	  epitope,	  the	  frequencies	  of	  this	  population	  in	  PBMCs	  isolated	  
from	  the	  control	  and	  immunised	  mice	  were	  assessed.	  The	  gating	  strategy	  and	  results	  of	  Treg	  analyses	  are	  
shown	   in	  Figure	  4-­‐7	   (a-­‐g).	  After	   four	   rounds	  of	  vaccination,	  no	   increase	   in	   the	   frequencies	  of	  Tregs	  was	  
detected	  in	  mice	  that	  received	  PADRE	  (Figure	  4-­‐7g).	  In	  fact,	  frequencies	  of	  Tregs	  were	  significantly	  lower	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in	   PADRE-­‐immunised	   mice	   than	   in	   all	   other	   groups,	   therefore	   this	   was	   not	   the	   explanation	   for	   the	  
apparent	   detrimental	   effect	   of	   PADRE	   inclusion	   in	   vaccinations	   on	   immune	   response	   induction.	   To	  
determine	   if	   this	   was	   a	   persistent	   phenomenon,	   PADRE	   was	   evaluated	   again	   in	   a	   subsequent	   study,	  
described	   in	   4.2.2.1.	   Importantly,	   peripheral	   blood	   Treg	   frequencies	   were	   not	   elevated	   in	   any	   CASAC	  
immunised	  mice	  above	  the	  observed	  frequencies	  in	  unimmunised	  mice	  (Figure	  4-­‐7g).	  This	  is	  of	  relevance,	  
since	  Treg	  expansion	  could	  suppress	  the	  induction	  of	  immune	  responses	  to	  a	  LAA	  such	  as	  WT1,	  preventing	  
vaccination	  from	  having	  therapeutic	  efficacy.	  
	  	  
Vaccinations	  that	  included	  WT1-­‐YMF	  generated	  antigen-­‐specific	  T-­‐cell	  responses	  that	  cross-­‐reacted	  against	  
the	  native	  WT1-­‐RMF	  peptide,	  as	  shown	  in	  the	  in	  vivo	  lysis	  assay.	  Such	  cross-­‐reactivity	  is	  vital	  following	  
immunisation	  using	  the	  heteroclitic	  peptide,	  since	  target	  tumour	  cells	  will	  present	  only	  the	  native	  peptide.	  
However,	  from	  the	  results	  presented	  so	  far,	  the	  heteroclitic	  peptide	  had	  not	  been	  as	  effective	  as	  the	  native	  
peptide	  for	  induction	  of	  WT1-­‐RMF-­‐specific	  immune	  responses	  and	  this	  became	  the	  subject	  of	  further	  
investigation	  (section	  4.2.1.2).	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Figure	  4-­‐6	  Potent	  in	  vivo	  cytolytic	  activity	  following	  4	  rounds	  of	  vaccinations	  with	  CASAC	  and	  OVA-­‐SIINF	  
or	  WT1-­‐RMF.	  	  
	  
Mean	   and	   SD	   of	   percentage	   lysis	   of	   peptide-­‐loaded	   splenocytes	   following	   in	   vivo	   challenge	   in	   each	  
group	   (n=	   5	   mice,	   except	   for	   the	   OVA-­‐SIINF	   group	   (positive	   control)	   where	   only	   1	   mouse	   was	  
challenged).	   The	   assay	   was	   performed	   in	   the	   same	   groups	   of	   mice	   whose	   antigen-­‐specific	   T-­‐cell	  
responses	  were	  demonstrated	  in	  Figures	  4-­‐2	  to	  4-­‐4.	  Peptides	  loaded	  on	  CFSE	  ”low”	  target	  splenocytes	  
were	  WT1-­‐RMF	   (for	   the	  3	   groups	  of	  mice	   immunised	   against	  WT1-­‐RMF/YMF)	  or	  OVA-­‐SIINF	   (for	   the	  
mouse	   immunised	   against	   OVA-­‐SIINF).	   One	   unimmunised	   mouse	   was	   challenged	   with	   OVA-­‐SIINF-­‐
loaded	   targets;	   the	   remaining	   4	  were	   challenged	  with	  WT1-­‐RMF-­‐loaded	   targets.	   Percentage	   lysis	   of	  
target	   cells	   by	   unimmunised	   mice	   was	   used	   as	   a	   negative	   control	   and	   to	   allow	   calculation	   of	  
















































































































































































































































































































































































































































































































































































































Figure	  4-­‐7	  No	  increase	  in	  peripheral	  blood	  Treg	  frequencies	  is	  observed	  following	  repeated	  
CASAC	  vaccinations	  	  
Analysis	  of	  Treg	  frequencies	  was	  performed	  using	  surface	  and	  intracellular	  fluorescent	  staining	  of	  
Treg	  markers	  on	  PBMCs	   isolated	   from	  mice	   in	  parallel	  with	  monitoring	  of	  antigen-­‐specific	  T-­‐cell	  
frequencies	   by	   pentamer	   studies.	   Figures	   4-­‐6	   (a-­‐f)	   outline	   the	   gating	   strategy.	   After	   doublet	  
discrimination	  (a),	  the	  mononuclear	  population	  was	  identified	  by	  FSC	  and	  SSC	  properties	  (b).	  The	  
CD4+	  population	  was	  identified	  (c)	  and	  the	  CD4+	  CD25+	  sub-­‐population	  selected	  (d).	  A	  rat	  IgGκ-­‐PE	  
isotype	  control	  antibody	  was	  used	  to	  determine	  the	  gating	  threshold	  for	  expression	  of	  FoxP3	  (e)	  
prior	  to	  analysis	  of	  test	  samples	  –	  a	  representative	  control	  from	  a	  WT1-­‐RMF	  &	  PADRE	  immunised	  
mouse	  is	  shown.	  Frequencies	  of	  CD4+	  CD25+	  FoxP3+	  T-­‐cells	  as	  a	  percentage	  of	  CD4+	  T-­‐cells	  were	  






















Figure	  4-­‐7	  continued.	  
(g)	   Following	   4	   rounds	   of	   vaccination,	   Treg	   frequencies	   were	   analysed	   in	   each	  
immunisation	   group;	   mean	   and	   SD	   are	   shown	   for	   each	   group	   in	   the	   plot.	   Lower	  
frequencies	  of	  Tregs	  were	  observed	  in	  the	  peripheral	  blood	  of	  mice	  that	  received	  PADRE	  
or	   ISQ	   in	   the	   immunisation	   in	   comparison	   with	   the	   corresponding	   group	   that	   did	   not	  
receive	  a	  helper	  epitope.	  These	  differences	  were	  statistically	  significant.	  Treg,	  regulatory	  
T-­‐cell;	   MNC,	   mononuclear	   cell;	   FoxP3,	   forkhead	   box	   P3;	   PBMCs,	   peripheral	   blood	  




































4.2.1.2 Specificity	  of	  the	  immune	  responses	  induced	  following	  CASAC	  and	  WT1	  peptide	  vaccination	  is	  
demonstrated	  by	  peptide	  specific	  IFNγ 	  secretion	  upon	  stimulation	  of	  murine	  splenocytes	  
Whilst	   potent	   immune	   responses	   to	   peptide	   vaccinations	   can	   arise	   using	   CASAC,	   there	   is	   potential	   for	  
non-­‐specific	  stimulation	  of	  immune	  cells	  to	  occur,	  leading	  to	  off-­‐target	  activity.	  To	  assess	  this,	  splenocytes	  
from	  immunised	  mice	  were	  re-­‐stimulated	  in	  vitro	  with	  either	  the	  immunising	  or	  an	  irrelevant	  peptide	  and	  
IFNγ	  production	  was	  assessed.	  Given	  that	  the	  previous	  study	  had	  suggested	  that	  addition	  of	  PADRE	  might	  
have	   limited	   the	  magnitude	  of	   the	   immune	   responses	   generated	  with	   either	  WT1-­‐RMF	  or	  WT1-­‐YMF,	   a	  
comparison	   of	   the	   effects	   of	   using	   either	   WT1-­‐YMF	   or	   WT1-­‐RMF	   without	   PADRE	   for	   vaccination	   was	  
performed	   in	  a	  separate	  experiment.	  The	  specificity	  of	   the	  observed	  responses	  was	  assessed	  by	   in	  vitro	  
quantification	   of	   peptide-­‐specific	   IFNγ	   production	   by	   in	   vivo	   primed	   T-­‐cells.	   Groups	   of	   mice	   were	  
immunised	  four	  times	  (days	  1,	  9,	  20	  and	  27)	  with	  CASAC	  as	  in	  the	  previous	  experiment	  (but	  without	  any	  
Class	  II	  peptides)	  and	  either	  the	  WT1-­‐RMF	  or	  WT1-­‐YMF	  Class	  I	  peptides.	  In	  vivo	  cytolysis	  and	  intracellular	  
IFNγ	  assays	  were	  performed	  on	  days	  37	  and	  38.	  	  
	  
Following	  4	  rounds	  of	  vaccination	  mean	  frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  were	  14%	  in	  both	  
the	  WT1-­‐RMF	  and	  WT1-­‐YMF	  immunised	  groups,	  demonstrating	  large	  expansions	  of	  T-­‐cells	  recognising	  the	  
native	  WT1-­‐RMF	  peptide	  (Figure	  4-­‐8a).	  However,	  as	  seen	  in	  the	  previous	  study	  in	  4.2.1,	  some,	  but	  not	  all	  
of	   the	   immunised	   mice	   from	   each	   group	   showed	   increased	   WT1-­‐RMF	   pentamer	   staining	   above	  
background.	  Despite	  this,	  all	  immunised	  mice	  showed	  lysis	  of	  WT-­‐RMF-­‐loaded	  target	  cells	  (Figure	  4-­‐8	  b,	  c),	  
although	  the	  rate	  of	  lysis	  was	  variable	  within	  groups.	  As	  mice	  were	  not	  ear-­‐tagged,	  it	  was	  not	  possible	  to	  
link	  absence	  of	  WT1-­‐RMF	  pentamer	   staining	  with	   reduced	   lysis	  of	  WT1-­‐RMF	   loaded	   targets.	  WT1-­‐RMF-­‐
loaded	  target	  cell	  lysis	  was	  significantly	  higher	  in	  the	  WT1-­‐RMF-­‐immunised	  mice	  relative	  to	  that	  observed	  
not	   only	   in	   the	   unimmunised	   controls	   but	   also	   the	   WT1-­‐YMF-­‐immunised	   mice,	   reflecting	   the	   pattern	  
observed	   in	   the	   previous	   study.	   Splenocytes	   harvested	   at	   the	   time	   of	   the	   in	   vivo	   cytolysis	   assay	   were	  
stimulated	  with	  relevant	  or	   irrelevant	  peptides	   in	  vitro	  and	   IFNγ	  production	  was	  assessed	  after	  5	  hours.	  
The	   gating	   strategy	   for	   this	   assay	   is	   shown	   in	   Figure	   4-­‐9	   and	   results	   of	   the	   re-­‐stimulation	   of	   WT1-­‐
RMF/YMF	   immunised	  mice	   are	   provided	   in	   Figure	   4-­‐10.	   Secretion	   of	   IFNγ	   by	   splenocytes	   stimulated	   in	  
vitro	  was	  specific	  to	  challenge	  with	  the	  immunising/wild	  type	  peptide	  because	  there	  was	  no	  response	  to	  
irrelevant	  peptide.	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Figure	  4-­‐8	  Greater	  lysis	  of	  native	  WT1-­‐RMF	  peptide	  loaded	  targets	  by	  WT1-­‐RMF	  immunised	  mice	  
compared	  with	  WT1-­‐YMF	  immunised	  mice	  
	  
(a)	  Frequency	  of	  WT1-­‐RMF-­‐specific	  CD8+	  T-­‐cells	  detected	  following	  the	  fourth	  immunisation	  for	  mice	  
immunised	  with	  CASAC	  (no	  Class	  II	  peptide)	  and	  either	  WT1-­‐RMF	  or	  WT1-­‐YMF	  or	  unimmunised	  (U)	  mice	  
(n=3-­‐5	  per	  group).	  All	  groups*:	  staining	  of	  a	  representative	  sample	  from	  each	  group	  with	  irrelevant	  
LCMV-­‐specific	  FQPQ/Db	  pentamer.	  No	  significant	  differences	  in	  frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐
cells	  were	  observed	  between	  the	  immunised	  and	  unimmunised	  groups.	  Representative	  WT1-­‐RMF	  
pentamer	  staining	  plots	  are	  shown	  in	  the	  right	  panel	  for	  a	  WT1-­‐RMF-­‐immunised	  mouse	  (top)	  and	  an	  
unimmunised	  mouse	  (bottom).	  
(b)	  Lysis	  of	  WT1-­‐RMF-­‐loaded	  target	  splenocytes	  by	  the	  3	  groups	  following	  the	  fourth	  vaccination.	  	  
(c)	  Representative	  histograms	  of	  CFSE-­‐labelled	  events	  obtained	  in	  the	  in	  vivo	  cytolysis	  assay	  in	  an	  





















































































As	  demonstrated	  in	  Figure	  4-­‐10,	  the	  proportions	  of	  CD8+	  cells	  isolated	  from	  the	  spleens	  of	  WT1-­‐RMF	  and	  
WT1-­‐YMF	  immunised	  mice	  secreting	  IFNγ	  following	  re-­‐stimulation	  with	  the	  native	  WT1-­‐RMF	  peptide	  were	  
significantly	  higher	  than	  background	  secretion	  by	  unimmunised	  mouse	  splenocytes.	  Importantly,	  cytokine	  
production	  was	  not	  observed	  when	   the	   same	   cells	  were	   challenged	  with	   the	   irrelevant	  Class	   I	   peptide,	  
OVA-­‐SIINF,	  suggesting	  specificity	  of	  the	  induced	  CD8+	  T-­‐cell	  responses.	  	  
	  
The	  mean	  frequencies	  of	  IFNγ+	  CD8+	  T-­‐cells	  were	  10.5%	  (1.6-­‐19.4%,	  95%	  CI)	  and	  5.7%	  (2.2-­‐9.3%,	  95%	  CI)	  
upon	  re-­‐stimulation	  with	  WT1-­‐RMF	  in	  the	  WT1-­‐RMF	  and	  WT1-­‐YMF	  immunised	  groups	  respectively.	  Whilst	  
the	   difference	   in	   these	   means	   was	   not	   statistically	   significant,	   the	   pattern	   of	   response	   replicated	   the	  
results	  of	   the	   in	  vivo	  cytolysis	  assay	   in	  Figure	  4-­‐8b.	  Taken	  together,	   these	  observations	  suggest	   that	   the	  
heteroclitic	  WT1-­‐YMF	  peptide	  may	  not	  be	  superior	  to	  the	  WT1-­‐RMF	  peptide	  when	  combined	  with	  CASAC	  
to	   immunise	   C57BL/6	  mice	   for	   the	   induction	   of	   cytotoxic	   T-­‐cell	   responses	   against	   the	   native	  WT1-­‐RMF	  
peptide.	  	  
150	  
Figure	  4-­‐9	  Gating	  strategy	  for	  intracellular	  IFNγ	  assay.	  	  
	  
Following	   the	   in	   vivo	   cytolysis	   assay,	   splenocytes	   were	   harvested	   and	   challenged	   with	   relevant	   or	  
irrelevant	  peptides	  in	  vitro	  during	  a	  5-­‐hour	  intracellular	  IFNγ	  assay.	  (a)	  Live	  splenocytes	  were	  identified	  
based	   on	   FSC	   and	   SSC	   properties.	   (b)	   The	   larger	   CFSE-­‐negative	   population	   is	   chosen	   from	   the	   live	  
splenocyte	  population	  for	  analysis,	  to	  avoid	  overflow	  of	  CFSE-­‐signal	  into	  the	  PE	  detection	  channel.	  (c)	  
CFSE-­‐negative	   splenocytes	   were	   assessed	   for	   CD8	   expression,	   by	   gating	   on	   CD8+	   cells.	   (d)	   PE-­‐
conjugated	   isotype	  control	  used	  to	  define	   IFNγ	  negative	  population.	   (e)	  Example	  plot	  demonstrating	  
the	   presence	   of	   a	   large	   population	   (17.8%	  of	   CD8+	   splenocytes)	   of	   IFNγ-­‐producing	   splenocytes	   in	   a	  
WT1-­‐RMF-­‐immunised	  mouse	  re-­‐stimulated	  with	  WT1-­‐RMF	  peptide	  in	  vitro	  
	  














































































From	  these	  studies,	  the	  following	  conclusions	  were	  drawn:	  
1. 	  Following	  2	  rounds	  of	  vaccination,	  only	  a	  single	  WT1-­‐RMF	  and	  CASAC	   immunised	  mouse	  showed	  
increased	  WT1-­‐RMF	  pentamer	   staining	   above	   the	   background	   staining	   in	   unimmunised	  mice.	  No	  
increase	  in	  WT1-­‐RMF-­‐specific	  T-­‐cells	  was	  detected	  in	  groups	  that	  received	  WT1-­‐RMF	  plus	  PADRE	  or	  
WT1-­‐YMF	  plus	  PADRE	  as	  the	  immunising	  peptides	  (Figure	  4-­‐3).	  This	  was	  in	  contrast	  to	  mice	  that	  had	  
been	   immunised	  with	  OVA-­‐SIINF,	  OVA-­‐SIINF	  plus	  OVA-­‐ISQ	  or	  OVA-­‐SIINF	  plus	  PADRE,	  although	  the	  
mean	  frequencies	  of	  OVA-­‐SIINF-­‐specific	  T-­‐cells	   in	  each	  of	  the	  3	  OVA-­‐SIINF-­‐containing	  groups	  were	  
not	  significantly	  higher	  than	  the	  background	  percentage	  detected	  in	  the	  unimmunised	  mice,	  due	  to	  
the	  within-­‐group	  wide	  variation	  in	  response	  magnitudes	  (Figure	  4-­‐2).	  
Figure	  4-­‐10	  WT1-­‐RMF-­‐specific	  immune	  responses	  can	  be	  generated	  following	  CASAC	  and	  WT1-­‐RMF	  
/YMF	  vaccination.	  
Splenocytes	  were	  harvested	  from	  each	  group	  of	  mice	  after	  4	  rounds	  of	  vaccination,	  at	  the	  time	  of	  the	  
in	  vivo	  cytotoxicity	  assay	  and	  challenged	  with	  either	  the	  native	  WT1-­‐RMF	  peptide,	  or	  the	  heteroclitic	  
YMF	   peptide	   or	   an	   irrelevant	   peptide	   (OVA-­‐SIINF)	   in	   a	   5-­‐hour	   intracellular	   IFNγ	   assay.	   Results	   for	  
individual	   mice	   are	   shown	   (along	   with	   mean	   and	   SD)	   for	   each	   group	   and	   peptide	   stimulus.	   U,	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2. Following	  4	  rounds	  of	  vaccination,	  it	  was	  possible	  to	  detect	  expansions	  of	  WT1-­‐RMF-­‐specific	  T-­‐cells	  
using	  pentamer	   studies	   in	  2	  of	  5	  WT1-­‐RMF-­‐immunised	  mice	   (Figure	  4-­‐4c,d).	  This	   finding	   suggests	  
that	  4	  rather	  than	  2	  vaccinations	  are	  required	  to	  induce	  expansions	  of	  WT1-­‐RMF	  specific	  T-­‐cells.	  	  
3. Within	  groups	  of	  WT1-­‐RMF	  immunised	  mice,	  the	  rate	  of	  response	  induction	  was	  low,	  with	  typically	  
2	   responding	   mice	   per	   group.	   Furthermore,	   marked	   variability	   in	   the	   magnitude	   of	   immune	  
responses	   induced	   (evidenced	   by	   pentamer	   and	   functional	   analyses)	   was	   repeatedly	   observed;	  
suggesting	  that	  further	  optimisation	  of	  CASAC	  vaccinations	  was	  required.	  
4. 	  The	  magnitude	   of	   the	  WT1-­‐RMF	   specific	   CD8+	   T-­‐cell	   population	   detected	   by	   pentamer	   analyses	  
was	   typically	   smaller	   than	   the	   OVA-­‐SIINF	   specific	   populations	   observed.	   This	   likely	   reflects	   the	  
comparative	   ease	   of	   generating	   immune	   responses	   against	   a	   xenoantigen	   in	   comparison	   to	  
targeting	  a	  self-­‐antigen	  such	  as	  WT1-­‐RMF.	  
5. Despite	  detection	  of	  low	  frequencies	  of	  WT1-­‐RMF-­‐specific	  CD8+	  T-­‐cells	  by	  pentamer	  analyses	  after	  
4	   rounds	   of	   vaccination	   in	   the	   first	   experiment,	   potent	   lytic	   capability	  was	   observed	   in	   all	   three	  
groups	  of	  mice	  exposed	  to	  WT1	  peptides	  and	  CASAC	  (Figure	  4-­‐6).	  Underestimation	  of	  the	  size	  of	  the	  
WT1-­‐RMF	   specific	   T-­‐cell	   population	   by	   pentamer	   analyses	   could	   be	   due	   to	   the	   lower	   affinity	  
interaction	  between	  the	  WT1-­‐RMF/Db	  complexes	  and	  the	  cognate	  TCR	  in	  comparison	  with	  the	  high	  
affinity	  interaction	  existing	  between	  OVA-­‐SIINF/Kb	  and	  the	  OVA-­‐SIINF	  specific	  TCR,	  allowing	  greater	  
ease	   of	   detection.	   Furthermore,	   even	   though	   the	   frequency	   of	  WT1-­‐RMF	   specific	   T-­‐cells	  may	   be	  
low,	  the	  functional	  potency	  of	  this	  population	  could	  be	  higher.	  	  
6. In	  both	  OVA-­‐SIINF	  and	  WT1-­‐RMF-­‐immunised	  mice,	  use	  of	  PADRE	  as	  the	  Class	  II	  peptide	  resulted	  in	  
lower	  frequencies	  of	  antigen-­‐specific	  responses	  detected	  by	  pentamer	  studies	  (significantly	  lower	  in	  
the	   context	   of	   OVA-­‐SIINF	   immunisations).	   Although	   differences	   were	   not	   significant,	   the	   mean	  
antigen-­‐specific	   lytic	   activity	   also	   appeared	   lower	   for	   the	   groups	   that	   received	   PADRE	   compared	  
with	  the	  groups	  that	  did	  not	  receive	  this	  epitope.	  This	  response	  reduction	  was	  not	  due	  to	  induction	  
of	  Tregs,	  as	   the	  use	  of	  a	  helper	  epitope	   in	  vaccinations	  was	  associated	  with	   lower	   frequencies	  of	  
peripheral	  blood	  Tregs	  (Figure	  4-­‐7g).	  
7. The	  heteroclitic	  WT1-­‐YMF	  peptide	  was	  not	  superior	  in	  the	  context	  of	  CASAC	  vaccinations	  in	  H-­‐2Db-­‐
bearing	  mice	  to	  the	  native	  WT1-­‐RMF	  peptide	  for	  induction	  of	  WT1-­‐RMF-­‐specific	  cytolytic	  activity	  or	  
IFNγ	  production	  following	  4	  rounds	  of	  vaccination.	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4.2.2 Strategies	  aiming	  to	  optimise	  immune	  response	  stimulation	  following	  CASAC	  and	  WT1	  peptide	  
vaccination	  
The	  data	  presented	   in	  4.2.1	   suggested	   that	   it	  was	  possible	   to	  break	   tolerance	   to	   the	   self-­‐antigen	  WT1	  by	  
peptide	   vaccinations	   targeting	   WT1,	   in	   combination	   with	   CASAC.	   Within	   groups,	   a	   proportion	   of	   mice	  
showed	  antigen-­‐specific	   responses	   to	  WT1	  peptide	   vaccination	  whilst	   responses	  were	   less	  pronounced	  or	  
absent	   in	  others,	   suggesting	   that	   the	   vaccinations	  were	  not	   yet	   fully	  optimised.	   Therefore	   the	  next	   set	  of	  
studies	   aimed	   to	  enhance	   the	  efficacy	  of	   immune	   response	   induction.	   The	  Class	   I	   peptide	  dose,	   emulsion	  
composition	  and	  type	  of	  Class	  II	  peptide	  used	  for	  immunisations	  were	  assessed	  in	  subsequent	  experiments	  
for	  their	  effects	  on	  WT1-­‐RMF	  specific	  immune	  response	  stimulation.	  
	  
4.2.2.1 Vaccinations	  containing	  100µg	  of	  WT1-­‐RMF	  peptide	  are	  as	  effective	  as	  vaccinations	  containing	  
400µg	  of	  WT1-­‐RMF	  peptide	  for	  immune	  response	  stimulation	  
In	   the	  original	  data	   reported	  by	  Wells	   et	   al.,	   a	  peptide	  derived	   from	   the	   self-­‐antigen	   tyrosinase-­‐related	  
protein	  2,	  TRP-­‐2180-­‐188,	  was	  analysed	  in	  the	  context	  of	  CASAC	  immunisations.	  Tolerance	  to	  this	  melanoma-­‐
associated	   antigen	   could	   be	   broken,	   with	   induction	   of	   TRP-­‐2180-­‐188	   specific	   T-­‐cells	   following	   repeated	  
immunisations.	   Importantly,	   it	  was	   observed	   that	   antigen-­‐specific	   cytokine	   production	   in	   vitro	   by	   CD8+	  
cells	  and	   in	  vivo	  cytolytic	  activity	  correlated	  with	  the	  use	  of	  higher	  doses	  (up	  to	  400µg)	  of	  TRP-­‐2180-­‐188	   in	  
each	  vaccination,	  Figure	  4-­‐11.	  Based	  on	  these	  findings,	  Wells	  et	  al.	  had	  pursued	  therapeutic	  vaccination	  
against	  B16	  melanoma	  using	  400	  µg	  of	  TRP-­‐2180-­‐188	  peptide	  per	  mouse
238.	  
	  
Therefore,	   it	   was	   hypothesised	   that	   one	   means	   to	   increase	   the	   magnitude	   and	   reliability	   of	   immune	  
response	   stimulation	   following	  WT1-­‐RMF	   peptide/CASAC	   vaccination	  might	   be	   to	   increase	   the	   dose	   of	  
WT1-­‐RMF	  peptide	  per	  vaccination.	  This	  was	  investigated	  by	  immunising	  groups	  of	  mice	  on	  days	  1,	  10,	  20	  
and	  33	  with	  either	  100,	  200	  or	  400	  µg	  of	  WT1-­‐RMF	  peptide.	  Frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  
on	   days	   19,	   29	   and	   42	  were	   determined	   along	  with	   in	   vivo	   cytolytic	   activity	   after	   the	   fourth	   round	   of	  
vaccination	  (day	  45).	  In	  parallel,	  an	  identical	  dose	  escalation	  study	  was	  performed	  in	  3	  further	  groups	  of	  
mice,	   but	   also	   including	   the	   helper	   PADRE	   to	   further	   investigate	   the	   effects	   of	   including	   this	   helper	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peptide	  on	  WT1-­‐RMF	  specific	   immune	  response	   induction.	  The	   results	  of	   this	  dose	  escalation	  study	  are	  




























Figure	  4-­‐11	  Greater	  immune	  responses	  to	  vaccination	  using	  TRP-­‐2180-­‐188	  and	  CASAC	  with	  higher	  
immunising	  doses	  of	  TRP-­‐2180-­‐188	  
Groups	  of	  mice	  were	  immunised	  on	  days	  0,	  11	  and	  19	  with	  either	  100,	  200	  or	  400µg	  of	  TRP-­‐
2180-­‐188	  and	  CASAC.	  (a)	  IFNγ	  production	  by	  splenocytes	  isolated	  from	  immunised	  mice	  after	  3	  
rounds	  of	  vaccination	  and	  restimulated	  with	  TRP-­‐2180-­‐188	  peptide	   in	  vitro	  showed	  a	  positive	  
correlation	  with	  increasing	  immunising	  dose	  of	  TRP-­‐2180-­‐188.	  	  
(b)	  When	  in	  vivo	  CTL	  activity	  was	  assessed,	  the	  greatest	  lysis	  was	  discernible	  at	  the	  highest	  





















Figure	  4-­‐12	  Four	  rounds	  of	  CASAC	  vaccinations	  using	  400µg	  of	  WT1-­‐RMF	  peptide	  per	  dose	  do	  not	  induce	  
larger	  or	  more	  potent	  antigen-­‐specific	  immune	  responses	  in	  mice	  than	  doses	  containing	  100	  or	  200	  µg	  of	  
WT1-­‐RMF	  	  
Groups	  of	  5	  mice	  were	   immunised	  4	   times	   (days	  0,	  9,	  20	  and	  33)	  with	  CASAC	  and	  either	  100µg,	  200µg	  or	  
400µg	  of	  WT1-­‐RMF	  peptide	  alone	  or	   in	  combination	  with	  100µg	  per	  vaccination	  of	  PADRE	   (schematic).	   (a)	  
Frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  by	  pentamer	  studies	  in	  WT1-­‐RMF	  (upper	  panel)	  and	  WT1-­‐RMF	  
&	  PADRE	  (lower	  panel)	   immunised	  mice,	  after	  2,	  3	  &	  4	  doses	  of	  vaccination.	  The	  only	  significant	  difference	  
observed	  was	  between	  the	  mean	  frequencies	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  at	  days	  19	  and	  42	  in	  mice	  receiving	  
400µg	  of	  WT1-­‐RMF	  peptide	  alone	  (p=0.01).	  *All	  groups:	  a	  sample	  from	  each	  group	  was	  stained	  with	  the	  with	  
irrelevant	  LCMV-­‐specific	  FQPQ/Db	  pentamer.	  V(X),	  vaccination	  (number);	  D,	  day.	  	  Figures	  (4-­‐12a,	  this	  page,	  4-­‐




































































































































Figure	  4-­‐12	  continued	  (b,c)	  
(b)	  Individual	  frequencies,	  group	  means	  and	  SD	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  after	  4	  rounds	  of	  vaccination.	  
No	  significant	  differences	  between	  groups	  were	  detected.	  (c)	  Percentage	  lysis	  of	  WT1-­‐RMF	  loaded	  target	  
cells	  following	  4	  rounds	  of	  vaccination	  in	  CASAC	  and	  WT1-­‐RMF	  or	  WT1-­‐RMF	  &	  PADRE	  immunised	  mice.	  










































































































Figure	  4-­‐13	  Reduction	  in	  frequencies	  of	  peripheral	  blood	  regulatory	  T-­‐cells	  following	  4	  vaccinations	  
combining	  WT1-­‐RMF	  and	  PADRE	  	  	  
Frequencies	  of	  Tregs	  following	  4	  rounds	  of	  vaccination	  were	  determined	   in	  parallel	  with	  the	  pentamer	  
analyses	   in	   the	   same	  mice	  described	   in	   Figure	  4-­‐12.	   Frequencies	  of	  peripheral	   blood	  Tregs	   along	  with	  

































In	   contrast	   to	   the	   studies	   of	   TRP-­‐2180-­‐188	   vaccinations
238,	   no	   significant	   differences	   with	   respect	   to	  
frequencies	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  were	  observed	  using	  higher	  doses	  of	  WT1-­‐RMF	  peptide	  for	  
immunisation	   (Figure	   4-­‐12).	   A	   significant	   increase	   in	   lysis	   of	   WT1-­‐RMF	   loaded	   target	   cells	   above	   the	  
background	  observed	   in	  unimmunised	  mice	  was	  observed	   in	  all	   groups	  except	   the	  mice	   receiving	  WT1-­‐
RMF	   100µg	   and	   PADRE,	   a	   pattern	   of	   response	  which	   was	   similar	   to	   the	   findings	   comparing	  WT1-­‐RMF	  
(100µg)	  with	  WT1-­‐RMF	  (100µg)	  and	  PADRE,	  demonstrated	  in	  Figure	  4-­‐6.	  There	  was	  no	  significantly	  higher	  
percentage	   lysis	   of	  WT1-­‐RMF-­‐loaded	   targets	   in	   the	   assay	   in	  mice	   vaccinated	  with	   400	  µg	  of	  WT1-­‐RMF,	  
despite	  the	  suggestion	  of	  more	  uniform	  response	  induction	  within	  this	  group.	  	  
	  
While	  no	  statistically	  significant	  differences	  in	  the	  magnitude	  of	  the	  immune	  responses	  observed	  between	  
the	  three	  groups	  of	  mice	  receiving	  WT1-­‐RMF	  and	  PADRE	  were	  observed,	   the	  higher	  mean	  frequency	  of	  
WT1-­‐RMF	  specific	  T-­‐cells	  in	  the	  group	  of	  mice	  receiving	  200-­‐400µg	  of	  WT1-­‐RMF	  suggests	  that	  this	  higher	  
dose	  may	  have	  been	  able	  to	  overcome	  any	  negative	  impact	  of	  the	  inclusion	  of	  PADRE	  (Figure	  4-­‐12b).	  This	  
may	   be	   due	   to	   competition	   for	   uptake	   by	   APCs	   between	  WT1-­‐RMF	   and	   PADRE.	   A	   “family”	   of	   PADRE	  
epitopes	  was	   initially	   designed	   to	   bind	   universally	   to	  MHC	  Class	   II	  molecules	   	   (PADRE760,	   PADRE906	   and	  
PADRE965	   peptides).	   PADRE965	   was	   reported	   to	   have	   good	   binding	   affinity	   for	   IA
b,	   the	   C57BL/6	   Class	   II	  
molecule	  and	  therefore	  was	  used	  in	  the	  vaccination	  studies	  presented	  here.	  PADRE760	  and	  PADRE906	  were	  
described	  as	  being	  unable	  to	  bind	  to	  human	  HLA	  Class	  I	  molecules	  in	  the	  original	  publication	  by	  Alexander	  
et	   al,	   although	   binding	   affinity	   of	   PADRE965	   to	   HLA-­‐Class	   I/H-­‐2D
b	   was	   not	   discussed266.	   Therefore	  
competitive	  binding	  of	  Class	  I	  epitopes	  processed	  from	  PADRE965	  to	  H-­‐2D
b	  may	  provide	  an	  explanation	  for	  
the	   results	   presented	   herein.	   Analysis	   of	   regulatory	   T-­‐cell	   frequencies	   in	   mice	   receiving	   vaccinations	  
containing	   PADRE	   again	   demonstrated	   a	   significant	   reduction	   in	   peripheral	   blood	   Tregs	   relative	   to	   the	  
corresponding	  groups	  not	  exposed	   to	  PADRE	   (Figure	  4-­‐13),	   similarly	   to	   the	  earlier	   findings	  described	   in	  
4.2.1,	  Figure	  4-­‐7.	  	  Together	  these	  observations	  suggest	  that	  Treg-­‐mediated	  suppression	  is	  not	  responsible	  
for	  the	  lower	  magnitude	  of	  immune	  response	  induction	  following	  PADRE	  and	  CASAC	  vaccinations.	  	  
	  
Both	   this	   study	   and	   that	   reported	   in	   4.2.1	   (Figure	   4-­‐4)	   demonstrated	   no	   significant	   differences	   in	   the	  
mean	  frequencies	  of	  antigen-­‐specific	  T-­‐cells	  after	  3	  or	  4	  rounds	  of	  vaccination.	  However,	  in	  one	  condition	  
160	  
in	   this	   set	   of	   vaccinations	   (CASAC	   vaccination	   using	  WT1-­‐RMF	   400µg	   alone,	   Figure	   4-­‐12a)	   there	  was	   a	  
significant	  difference	  between	   frequencies	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  between	   the	  day	  42	  assessment	  
(mean	   3.38%	  WT1-­‐RMF	   specific	   T-­‐cells,	   0.82-­‐5.95%,	   CI	   95%)	   and	   the	   day	   19	   assessment	   (mean	   0.53%	  
WT1-­‐RMF	  specific	  T-­‐cells,	  0.36-­‐0.7%,	  CI	  95%,	  p=0.01).	  Given	  that	  frequencies	  of	  antigen-­‐specific	  T-­‐cells	  did	  
not	  increase	  after	  dose	  3	  or	  4,	  it	  was	  decided	  to	  analyse	  antigen	  specific	  T-­‐cell	  frequencies	  in	  subsequent	  
experiments	   after	   the	   second	   and	   third	   vaccinations	  with	   functional	   assessment	   alone	  performed	   after	  
the	  fourth	  vaccination.	  This	  reduced	  the	  number	  of	  procedures	  performed	  in	  the	  mice.	  	  
	  
4.2.2.2 Emulsion	  composition	  may	  affect	  efficacy	  of	  CASAC/WT1-­‐RMF	  vaccinations:	  effects	  of	  varying	  
squalene	  concentration	  	  
CASAC	   vaccinations	   targeting	   OVA-­‐SIINF	   result	   in	   induction	   of	   potent	   immune	   responses	   with	   a	   high	  
frequency	   of	   responding	  mice.	   Conversely,	  whilst	   antigen-­‐specific	   immune	   responses	   can	   be	   generated	  
following	  CASAC	  and	  WT1-­‐RMF	  vaccinations,	  variability	  of	  the	  induced	  responses	  suggests	  that	  fine-­‐tuning	  
of	   vaccine	   components	   might	   improve	   immune	   response	   generation.	   Wells	   et	   al.	   suggested	   that	   the	  
presence	  and	  quantity	  of	  squalene	  in	  the	  emulsion	  did	  not	  impact	  upon	  the	  efficacy	  of	  CASAC	  vaccinations	  
targeting	  OVA-­‐SIINF;	  only	  the	  requirement	  of	  2	  TLR	  agonists	  and	  Tween	  80	  for	  effective	  immune	  response	  
generation	  was	   essential238.	   Squalene	   is	   included	   in	   the	   emulsion	   as	   the	   oily	   phase	   of	   this	   oil-­‐in-­‐water	  
(o/w)	  emulsion238,285.	  The	  CASAC	  emulsion	  itself	  is	  similar	  in	  composition	  to	  MF59®,	  which	  forms	  a	  stable	  
emulsion	   in	   clinical	   grade	   vaccine,	   increases	   bioavailability	   of	   vaccine	   components	   and	   appears	   to	  
promote	  induction	  of	  an	  immunocompetent	  milieu	  at	  the	  vaccination	  site285.	  It	  is	  possible	  therefore,	  that	  
squalene	   composition	   of	   the	   emulsion	   could	   still	   be	   relevant	   for	   immunisations	   targeting	   less	  
immunogenic	   epitopes	   than	   OVA-­‐SIINF.	   Therefore,	   whether	   squalene	   composition	   might	   affect	  
vaccination	  efficacy	  targeting	  WT1-­‐RMF	  was	  evaluated	  by	  testing	  3	  different	  squalene	  concentrations	   in	  
separate	  emulsions:	  2.2%	  v/v,	  4.4%	  v/v	  (used	  in	  the	  Wells	  paper)	  and	  8%	  v/v.	  	  
	  
Consistent	  with	  the	  data	  reported	  by	  Wells	  et	  al.,	  there	  was	  no	  effect	  of	  altering	  the	  squalene	  composition	  
of	   the	   emulsions	   on	   generation	   of	   OVA-­‐SIINF-­‐specific	   CD8+	   T-­‐cell	   responses	   (Figure	   4-­‐14a).	   In	   vivo	  
cytolysis	   was	   not	   assessed	   for	   these	   OVA-­‐SIINF	   immunised	   mice	   as	   experience	   using	   this	   vaccination	  
161	  
suggested	   that	   with	   the	   observed	   percentages	   of	   OVA-­‐SIINF-­‐specific	   T-­‐cells,	   lysis	   of	   OVA-­‐SIINF-­‐loaded	  














Groups	  of	  mice	  were	  immunised	  with	  OVA-­‐SIINF	  and	  CASAC	  (Figure	  4-­‐14a,	  this	  page)	  or	  WT1-­‐RMF	  and	  
CASAC	  (Figure	  4-­‐14b,c,	  following	  page)	  vaccines	  containing	  2.2%,	  4.4%	  or	  8%	  v/v	  emulsions.	  (a)	  Following	  
2	  vaccinations,	  no	  significant	  difference	  in	  the	  frequencies	  of	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	  were	  
observed	  following	  OVA-­‐SIINF	  vaccinations	  using	  either	  4.4%	  or	  8%	  squalene	  v/v	  emulsions.	  Mean	  and	  SD	  
are	  shown	  for	  each	  group.	  
Figure	  4-­‐14	  Reduced	  magnitude	  of	  WT1-­‐RMF	  specific,	  but	  not	  OVA-­‐SIINF	  specific,	  immune	  response	  










































Figure	  4-­‐14	  continued	  (b,c)	  	  
Results	  of	  WT1-­‐RMF	  pentamer	  analyses	  following	  3	  rounds	  of	  vaccination	  are	  combined	  from	  2	  similar	  
experiments	  with	   in	  vivo	   lysis	  assay	  performed	   in	  a	  subset	  of	  these	  mice.	   (b)	  Frequencies	  of	  WT1-­‐RMF	  
specific	  CD8+	  T-­‐cells	  following	  the	  third	  vaccination	  targeting	  WT1-­‐RMF	  using	  CASAC	  with	  each	  emulsion	  
type	  are	  shown.	  *All	  groups:	  staining	  of	  representative	  samples	  from	  each	  group	  with	  irrelevant	  control	  
LCMV	   pentamer.	   (c)	   Percentage	   lysis	   of	   target	   WT1-­‐RMF-­‐loaded	   splenocytes	   following	   the	   fourth	  
vaccination	  in	  a	  subset	  of	  mice	  (2.2%	  squalene,	  n=4,	  4.4%	  squalene,	  n=7,	  8%	  squalene,	  n=8).	  Mean	  and	  
SD	  are	   shown	   for	  each	  group;	  no	  statistically	   significant	  differences	   in	   lysis	  of	  WT1-­‐RMF	   loaded	   target	  











































































However,	   in	  WT1-­‐RMF/CASAC	   immunised	  mice,	   using	   2.2%,	   4.4%	   and	   8%	   emulsions	   in	   2	   separate	   but	  
similar	   experiments	   (Figure	   4-­‐14b,c)	   altering	   the	   squalene	   composition	   affected	   the	   magnitude	   of	   the	  
immune	  response	  generated	  (as	  demonstrated	  by	  pentamer	  studies	  and	  in	  vivo	  cytolysis).	  	  
A	   significantly	   higher	  mean	   frequency	   of	  WT1-­‐RMF	   specific	   CD8+	   T-­‐cells	  was	   observed	   in	   the	   4.4%	   v/v	  
squalene	  emulsion	  group	  above	  the	  background	  staining	  observed	  with	  the	  irrelevant	  control	  pentamer,	  
although	   statistically	   significant	   differences	   between	   groups	   receiving	   emulsions	  with	   varying	   squalene	  
concentration	  were	  not	  detected	  (Figure	  4-­‐14b).	  These	  findings	  suggest	  that	  composition	  of	  the	  vaccine	  
emulsion	  may	  differ	  according	  to	  the	  target	  peptide,	  highlighting	  the	  importance	  of	  detailed	  evaluations	  
of	  individual	  peptides	  used	  within	  the	  context	  of	  CASAC.	  	  
	  
4.2.2.3 A	  WT1-­‐derived	  Class	  II	  peptide,	  an	  unrelated	  Class	  II	  peptide	  or	  agonist	  anti-­‐CD40	  antibody	  may	  
combine	  with	  WT1-­‐RMF/CASAC	  to	  induce	  WT1-­‐specific	  CD8+	  T	  cell	  responses	  	  
	  
The	  data	  presented	  by	  Wells	  et	  al	  stated	  that	  inclusion	  of	  either	  a	  Class	  II	  peptide,	  related	  or	  unrelated	  to	  
the	  target	  Class	  I	  peptide,	  or	  an	  agonist	  anti-­‐CD40	  antibody	  within	  CASAC	  could	  effectively	  promote	  OVA-­‐
SIINF	   specific	   CD8+	   T-­‐cell	   expansion	   following	   repeated	   vaccination238.	   However,	   studies	   presented	  
earlier,	  using	  PADRE	  as	  a	  helper	  peptide,	  had	  not	  demonstrated	  superior	  induction	  of	  immune	  responses	  
in	   groups	   receiving	   this	   peptide	   in	   the	   context	   of	   CASAC	   vaccinations.	   The	  OVA-­‐derived	   Class	   II	   helper	  
peptide	  OVA-­‐ISQ	  was	  shown	  to	  combine	  with	  OVA-­‐SIINF	  to	  enhance	  expansion	  of	  OVA-­‐SIINF	  specific	  CD8+	  
T-­‐cells	  in	  the	  data	  presented	  by	  Wells	  et	  al,	  although	  a	  direct	  comparison	  of	  vaccinations	  targeting	  OVA-­‐
SIINF	   using	   CpG,	   poly	   I:C,	   IFNγ with	   or	  without	  OVA-­‐ISQ	  was	   not	   described238.	   Inclusion	   of	   an	   effective	  
Class	  II	  helper	  peptide	  in	  vaccinations	  could	  aid	  the	  generation	  of	  a	  long-­‐term	  memory	  response210,211,286,	  
as	  demonstrated	  by	  the	  strong	  recall	   responses	  observed	   in	  mice	  previously	   immunised	  with	  OVA-­‐SIINF	  
and	  CASAC	  more	  than	  100	  days	  earlier238.	  	  
	  
Whilst	   OVA-­‐ISQ	  may	   be	   an	   effective	   Class	   II	   helper	   peptide	   in	   the	   context	   of	   the	   experimental	  mouse	  
model,	  more	  clinically	  relevant	  Class	   II	  peptides	  for	  use	   in	  CASAC	  vaccinations	  targeting	  WT1	   in	  humans	  
are	  ultimately	  desirable.	  A	  long	  Class	  II	  helper	  peptide	  PGCNKRYFKLSHLQMHSRKHTG	  (WT1-­‐PGC)	  used	  in	  a	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clinical	  trial	  of	  WT1	  peptide	  vaccination201,	  homologous	  in	  humans	  and	  mice	  and	  predicted	  to	  bind	  to	  I-­‐Ab	  
using	   the	   immune	   epitope	   database	   (IEDB)181	   (see	   Table	   2-­‐3),	   was	   therefore	   evaluated	   in	   CASAC	  
vaccinations	  targeting	  WT1-­‐RMF.	  OVA-­‐ISQ	  was	  used	  as	  a	  comparator	  for	  provision	  of	  Class	  II	  help	  due	  to	  
its	  demonstrable	  compatibility	  with	  CASAC.	  Vaccinations	  using	  WT1-­‐RMF	  without	  a	  class	  II	  peptide,	  shown	  
earlier	   to	   induce	   detectable	   WT1-­‐RMF-­‐specific	   T-­‐cells	   and	   promote	   significant	   lytic	   activity,	   were	   also	  
included	  as	  positive	  controls.	  	  
	  
Vaccinations	  were	  delivered	  on	  days	  1,	  11,	  21	  and	  29	  with	  analysis	  of	  WT1-­‐RMF	  CD8+	  T-­‐cell	  frequencies	  
on	   days	   15,	   26	   and	   in	   vivo	   cytolytic	   analysis	   on	   day	   35.	   The	   results	   are	   shown	   in	   Figure	   4-­‐15.	   No	  
statistically	   significant	   enhancement	   of	   WT1-­‐RMF	   specific	   CD8+	   T-­‐cell	   expansion	   or	   lysis	   of	   WT1-­‐RMF	  
loaded	  targets	  was	  observed	  with	  the	  inclusion	  of	  either	  OVA-­‐ISQ	  or	  WT1-­‐PGC	  in	  vaccinations	  (Figure	  4-­‐
15a-­‐b).	   However,	   as	   seen	   previously,	   1-­‐2	   mice	   within	   each	   of	   the	   groups	   receiving	   a	   helper	   epitope	  
exhibited	  robust	  responses	  but	  there	  was	  considerable	  variability	  in	  immune	  response	  stimulation	  against	  
WT1-­‐RMF	   using	   CASAC.	   Although	   this	   particular	   study	   suggests	   there	  may	   be	   an	   advantage	   to	   include	  
helper	   epitopes	   in	   vaccinations,	   this	   is	   only	   supported	   by	   small	   numbers	   of	   responding	   mice	   in	   these	  
groups	  and	  uniformity	  of	  responses	  was	  not	  demonstrable.	   	   In	  vitro	  re-­‐stimulation	  was	  performed	  using	  
either	  the	  same	  Class	  I	  or	  II	  peptides	  used	  for	  immunisations	  or	  peptides	  which	  had	  not	  been	  included	  in	  
the	   vaccines	   and	   to	   which	   CD4+	   and	   CD8+	   T-­‐cells	   would	   be	   naïve	   (negative	   controls).	   These	   results	  
demonstrated	  the	  specificity	  of	  the	  responses	  generated,	  with	  higher	  frequencies	  of	  IFNγ-­‐producing	  CD8+	  
and	  CD4+	  T-­‐cells	  respectively	  upon	  re-­‐stimulation	  with	  the	  same	  peptides	  used	  at	  immunisation	  (Figure	  4-­‐
15	  c-­‐d).	  Of	  note,	  the	  in	  vitro	  CD4+	  IFNγ	  responses	  following	  re-­‐stimulation	  with	  OVA-­‐ISQ	  are	  robust	  whilst	  
responses	  to	  WT1-­‐PGC	  are	  much	  lower	  (Figure	  4-­‐15d).	  This	  suggests	  that	  WT1-­‐PGC	  has	  low	  helper	  activity	  
in	  the	  context	  of	  WT1-­‐RMF	  and	  CASAC	  vaccinations	  in	  C57BL/6	  mice.	  
	  
Overall,	   lower	   WT1-­‐RMF	   CD8+	   T-­‐cell	   expansion	   and	   functional	   activity	   were	   observed	   in	   these	  
experiments	   compared	   with	   earlier	   studies	   presented	   in	   4.2.1.	   No	   change	   in	   suppliers	   of	   peptides	   or	  
CASAC	   constituents,	   or	  methods	  of	   reconstitution	  or	   storage,	   took	  place	   to	   account	   for	   the	  diminished	  
responses.	   Freeze-­‐thaw	   cycles	   were	   also	   kept	   to	   the	   absolute	   minimum	   in	   order	   not	   to	   compromise	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peptide	  stability.	  The	  WT1-­‐RMF	  peptide	  was	  able	  to	  bind	  stably	  to	  HLA-­‐A2-­‐expressing	  T2	  cells,	  suggesting	  
that	  it	  was	  intact	  (even	  after	  freezing	  and	  thawing,	  Figure	  4-­‐16).	  To	  ensure	  that	  CASAC	  components	  were	  
functional,	   in	   all	   subsequent	   experiments,	   OVA-­‐SIINF	   and	   CASAC	   immunised	   mice	   were	   included	   as	  
positive	   controls	   since	   an	   expected	   and	   predictable	   response	   with	   CASAC	   immunisations	   using	   this	  
































































Figure	  4-­‐15	  (a-­‐d)	  A	  relevant	  or	  irrelevant	  helper	  peptide	  may	  be	  used	  to	  promote	  WT1-­‐specific	  
immune	  responses	  following	  CASAC	  vaccination	  
Groups	  of	  up	  to	  4	  mice	  were	  immunised	  4	  times	  with	  WT1-­‐RMF	  and	  CASAC	  alone	  or	  in	  combination	  
with	  WT1-­‐PGC	   or	   OVA-­‐ISQ.	   (a)	   Results	   of	   pentamer	   analyses	   following	   the	   third	   vaccination	   are	  
shown.	   *All	   groups:	   a	   representative	   sample,	   from	   each	   group,	   was	   stained	   with	   the	   irrelevant	  
LCMV	  pentamer.	  (b)	  After	  the	  fourth	  vaccination,	  in	  vivo	  lysis	  of	  WT1-­‐RMF-­‐loaded	  splenocytes	  was	  
assessed.	  One	  mouse	   in	   the	  WT1-­‐RMF&ISQ	  group	  died	  during	  the	   in	  vivo	  CTL	  assay	  and	  therefore	  
was	   lost	   to	   analysis.	  Mean	   +/-­‐	   SD	   for	   each	   group	   is	   shown.	  No	   statistically	   significant	   differences	  
were	  observed	  between	  any	  of	  these	  groups	  in	  either	  experiment.	  Figure	  4-­‐15	  continues	  overleaf.	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Figure	  4-­‐15	  continued.	  
Splenocytes	  harvested	  from	  the	  same	  mice	  described	  in	  Figures	  4-­‐15	  a	  and	  b	  were	  re-­‐stimulated	  in	  a	  
5	  hour	  intracellular	  IFNγ	  assay	  with	  WT1-­‐RMF	  (or	  OVA-­‐SIINF	  as	  an	  irrelevant	  peptide)	  to	  assess	  IFNγ	  
production	  by	  CD8+	  T-­‐cells	  (c)	  or	  with	  OVA-­‐ISQ	  or	  WT1-­‐PGC	  to	  assess	  IFNγ	  production	  by	  CD4+	  T-­‐
cells	  (d).	  Mean	  +/-­‐	  SD	  for	  each	  group	  is	  shown.	  No	  significant	  differences	  between	  groups	  were	  

















































































Figure	  4-­‐16	  Binding	  of	  WT1-­‐RMF	  peptide	  even	  following	  previous	  freeze-­‐thaw	  cycles	  allows	  stabilisation	  
of	  HLA-­‐A2	  expression	  by	  TAP-­‐defective	  T2	  cells	  
The	   ability	   of	   either	   freshly	   prepared	   or	   previously	   frozen	   and	   thawed	  WT1-­‐RMF	   peptide	   to	   stabilise	  
HLA-­‐A2	  expression	  by	  T2	  cells	  was	  used	  as	  a	  surrogate	  of	  persisting	  peptide	  stability.	  5x105	  T2	  cells	  were	  
cultured	   overnight	   in	   the	   presence	   of	   known	  HLA-­‐A2	   binding	   peptides	   (YLL,	   NLV	   or	  WT1-­‐RMF)	   or	   the	  
non-­‐A2	  binding	  OVA-­‐SIINFEKL	  peptide,	  or	  no	  peptide.	  The	  next	  day,	  cells	  were	  single-­‐stained	  with	  anti-­‐
HLA-­‐A2-­‐PE	  and	   the	  MFI	  of	   the	  bound	  antibody	  determined	  by	   FACS.	   (a)	  Histogram	  demonstrating	   the	  
relative	  HLA-­‐A2	  expression	  profiles	  for	  the	  different	  peptides	  or	  T2	  cells	  in	  the	  absence	  of	  antibody;	  the	  
MFI	   is	   also	   depicted	   per	   cell	   type	   in	   the	   accompanying	   bar	   chart.	   (b)	   Histogram	   demonstrating	   the	  
relative	  expression	  of	  HLA-­‐A2	  by	  T2	  cells	  cultured	  in	  the	  absence	  of	  peptide	  or	  presence	  of	  DMSO	  alone	  
as	   negative	   controls.	   T2,	   Transporter	   for	   Antigen	   Processing	   (TAP)-­‐defective	   cells;	   MFI,	   median	  
fluorescence	   intensity;	   YLL,	   YLLPAIVHI,	   RNA-­‐dependent	   helicase148–156	   peptide;	   NLV,	   NLVPMVATVQ	  
derived	  from	  cytomegalovirus	  structural	  protein	  pp65,	  DMSO,	  dimethyl	  sulfoxide	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In	   the	  absence	  of	  a	  Class	   II	  helper	  peptide,	  direct	   ligation	  of	  CD40	  on	  DCs	  may	  be	  achieved	  by	  using	  an	  
agonist	   anti-­‐CD40	   antibody	   (rather	   than	   relying	   on	   ligation	   of	   CD40	   on	   DCs	   by	   CD40L	   expressed	   by	  
activated	  CD4+	  T-­‐cells).	  Ligation	  of	  CD40	  activates	  DCs,	  which	  then	  secrete	  cytokines	  such	  as	  IL-­‐12,	  a	  vital	  
third	   signal	   in	   priming	   of	   T-­‐cell	   responses234,287,288.	   The	   original	   data	   regarding	   CASAC	   suggested	   that	  
inclusion	   of	   either	   a	   Class	   II	   peptide	   or	   an	   agonistic	   anti-­‐CD40	   antibody	   in	   CASAC	   could	   effectively	  
stimulate	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cell	  expansion238.	  One	  benefit	  of	  this	  approach,	  should	  it	  be	  equally	  
efficacious	   to	   vaccinations	   including	   a	   Class	   II	   peptide,	   would	   be	   to	   avoid	   the	   requirement	   to	   identify	  
individual	   immunogenic	   Class	   II	   peptides	   within	   the	   target	   antigen	   binding	   to	   selected	   HLA	   Class	   II	  
molecules.	  	  
	  
To	  address	  whether	  anti-­‐CD40	  antibody	  could	  substitute	   for,	  or	  even	  promote	  more	  sizable	  and	  potent	  
WT1-­‐specific	   immune	  responses,	  anti-­‐CD40	  antibody	  was	  compared	  with	  OVA-­‐ISQ	  or	  WT1-­‐PGC	   in	  WT1-­‐
RMF	  and	  CASAC	  vaccinations	  (see	  Figure	  4-­‐17).	  This	  comparison	  demonstrated	  no	  significant	  differences	  
with	  respect	  to	  short-­‐term	  immune	  response	  generation	  where	  a	  related	  or	  unrelated	  Class	  II	  peptide	  or	  
anti-­‐CD40	  antibody	  was	  used	  as	  part	  of	  CASAC.	  Overall,	  the	  magnitude	  of	  the	  observed	  immune	  responses	  
in	   the	   WT1-­‐RMF	   immunised	   mice	   was	   lower	   than	   that	   observed	   in	   earlier	   experiments.	   The	   vigorous	  
responses	  seen	  in	  the	  OVA-­‐SIINF	  immunised	  mice	  indicates	  that	  all	  CASAC	  components	  were	  functioning	  
effectively,	  suggesting	  that	  the	  variability	  of	  observed	  responses	  against	  WT1	  epitopes	  may	  be	  related	  to	  
properties	   of	   this	   particular	   peptide	   and/or	   the	   difficulty	   of	   breaking	   tolerance	   to	   induce	   an	   effective	  




















Figures	  4-­‐17a,	  b	  this	  page,	  4-­‐17c,	  following	  page.	  Mice	  (n=3-­‐4)	  were	  immunised	  4	  times	  with	  CASAC	  and	  
OVA-­‐SIINF	  (plus	  either	  OVA-­‐ISQ	  or	  anti-­‐CD40	  antibody)	  or	  CASAC	  and	  WT1-­‐RMF	  (plus	  OVA-­‐ISQ,	  anti-­‐CD40	  
antibody	  or	  WT1-­‐derived	  Class	  II	  peptide	  WT1-­‐PGC).	  Figure	  4-­‐17a	  (this	  page):	  Frequencies	  of	  antigen-­‐
specific	  CD8+	  T-­‐cells	  following	  3	  rounds	  of	  vaccination	  were	  detected	  using	  OVA-­‐SIINF/Kb	  or	  WT1-­‐RMF/Db	  
pentamers	  in	  OVA-­‐SIINF	  or	  WT1-­‐RMF-­‐immunised	  mice	  respectively.	  LCMV	  (FQPQ/Db)	  irrelevant	  pentamer	  
staining	  of	  representative	  PBMC	  samples	  from	  each	  group	  of	  immunised	  mice	  served	  as	  negative	  controls.	  
Fb	  In	  vivo	  lysis	  of	  splenocytes	  loaded	  with	  the	  immunising	  peptide	  (OVA-­‐SIINF	  or	  WT1-­‐RMF)	  in	  OVA-­‐SIINF	  
and	  WT1-­‐RMF	  immunised	  mice	  respectively,	  was	  measured	  following	  4	  rounds	  of	  vaccination.	  
Unimmunised	  mice	  were	  challenged	  with	  OVA-­‐SIINF	  loaded	  splenocytes	  (n=2),	  or	  WT1-­‐RMF-­‐loaded	  
splenocytes	  (n=2).	  No	  statistically	  significant	  differences	  were	  detected	  between	  groups.	  Mean	  and	  SD	  per	  
group	  are	  shown	  in	  each	  graph.	  Figures	  4-­‐17a,	  b	  this	  page,	  4-­‐17c,	  following	  page.	  
Figure	  4-­‐17	  Related	  or	  unrelated	  Class	  II	  peptides,	  or	  an	  agonist	  anti-­‐CD40	  antibody	  may	  be	  used	  in	  CASAC	  






























































































Figure	  4-­‐17	  continued	  
	  
4.2.2.4 Summary	  
The	  results	  from	  these	  studies	  demonstrated	  the	  following:	  
1. The	  observation	   that	   increasing	  doses	  of	  WT1-­‐RMF	  peptide	  did	  not	   increase	   the	  magnitude	  of	  
WT1-­‐RMF	   specific	   CD8+	   T-­‐cell	   frequencies	   or	   in	   vivo	   lysis	   contrasts	   with	   the	   published	  
observations	   regarding	  TRP-­‐2180-­‐188
238.	  Although	   the	   cause	   for	   this	   is	   unknown,	   it	   suggests	   that	  
increasing	  exposure	   to	  WT1-­‐RMF	  dose	  during	  vaccination	   is	   insufficient	   to	  overcome	   tolerance	  
mechanisms	  controlling	  responses	  against	  this	  particular	  self-­‐antigen.	  
2. Another	   example	   of	   the	   differential	   behaviour	   of	   immunising	   peptides	   within	   the	   context	   of	  
CASAC	  was	   the	   demonstration	   that	   alterations	   in	   the	   squalene	   composition	   of	   emulsion	   could	  
affect	  the	  magnitude	  of	  WT1-­‐RMF	  specific	  responses	  but	  not	  OVA-­‐SIINF	  specific	  responses.	  This	  
(c)	  Antigen-­‐specific	  production	  of	  IFNγ	  was	  assessed	  by	  stimulation	  of	  splenocytes	  harvested	  following	  4	  
rounds	  of	  vaccination	  with	  relevant	  (immunising)	  or	  irrelevant,	  non-­‐immunising	  peptides.	  No	  statistically	  
significant	   differences	   were	   detected	   between	   groups.	   Mean	   and	   SD	   per	   group	   are	   shown.	  



















































observation	  highlights	  the	  need	  to	  assess	  each	  candidate	  peptide	  rigorously	  within	  the	  context	  of	  
CASAC,	   as	   separate	   components	   of	   vaccination	   may	   need	   to	   be	   optimised	   to	   reach	   maximal	  
efficacy	  for	  a	  given	  peptide.	  
3. Within	  the	  studies	  presented	  here,	  inclusion	  of	  a	  Class	  II	  peptide	  that	  is	  related,	  or	  unrelated,	  to	  
the	  target	  Class	  I	  peptide,	  or	  agonist	  anti-­‐CD40	  antibody,	  increases	  the	  frequency	  of	  responders	  
to	   WT1-­‐RMF	   vaccinations	   using	   CASAC.	   However,	   no	   clear	   advantage	   for	   inclusion	   of	   helper	  
epitope	  or	  agonist	  anti-­‐CD40	  antibody	  for	  short-­‐term	  induction	  of	  WT1-­‐specific	   immunity	  could	  
be	  demonstrated	  due	  to	  within	  group	  variation.	  The	  utility	  of	  relevant/irrelevant	  helper	  epitopes	  
or	   agonist	   anti-­‐CD40	   antibody	   in	   CASAC	   vaccinations	   is	   in	   keeping	   with	   the	   published	   data	  
regarding	  CASAC	  vaccinations238.	  
	  
4.2.3 Extension	  of	  CASAC	  vaccinations	  targeting	  WT1	  to	  the	  clinical	  context:	  immunisations	  using	  a	  WT1	  
peptide	  pool	  and	  comparison	  of	  CASAC	  vaccinations	  with	  complete	  Freund’s	  adjuvant	  
The	  ultimate	  goal	  of	  these	  preclinical	  studies	  of	  CASAC	  and	  WT1	  peptide	  vaccination	  is	  to	  identify	  a	  broad	  
strategy,	   applicable	   to	   all	   potential	   patients	   irrespective	   of	   HLA	   type,	   which	   effectively	   induces	   WT1-­‐
specific	  cytotoxic	  T-­‐cell	  responses.	  Such	  a	  vaccination	  must	  be	  at	   least	  as	  efficacious	  as	  the	  current	  best	  
available	  strategies,	  described	  in	  the	  Introduction	  (section	  1.6.2).	  Not	  only	  the	  choice	  of	  WT1	  peptides	  but	  
also	  the	  adjuvant	  components	  used	  for	  vaccinations	  are	  under	  investigation	  in	  this	  context.	  CASAC	  needs	  
to	   show	   equivalence	   or	   superiority	   over	   currently	   used	   adjuvants	   (whilst	   maintaining	   safety	   and	  
preferably	   increased	   tolerability)	   before	   it	   can	  be	   translated	   into	   the	   clinical	   trial	   setting.	   The	   following	  
studies	  describe	  means	   to	   increase	  applicability	  of	  WT1	  peptide	  vaccination	   to	  all	   patients	   (rather	   than	  
those	  with	  selected	  HLA	   types)	  and	   to	  compare	   the	  efficacy	  of	  CASAC	   for	  vaccinations	  over	   the	  current	  
standard	  vaccine	  adjuvant	  (Freund’s	  adjuvant).	  
	  
4.2.3.1 Use	  of	  a	  pool	  of	  overlapping	  WT1	  peptides	  combined	  with	  CASAC	  to	   induce	  WT1-­‐RMF	  specific	  
immune	  responses	  	  
Whilst	  different	  Class	  II	  peptides	  have	  been	  shown	  in	  4.2.3	  to	  combine	  with	  CASAC	  vaccinations	  targeting	  
WT1-­‐RMF	   to	   induce	  WT1-­‐RMF	   specific	   immune	   responses,	   no	   single	   Class	   II	   peptide	  was	   shown	   to	   be	  
superior	  over	  the	  other	  with	  respect	  to	  ability	  to	  induce	  antigen	  specific	  immune	  responses	  in	  vaccinated	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mice.	  The	  optimal	  WT1-­‐derived	  helper	  peptide	  for	  use	  in	  vaccinations	  is	  unclear.	  Indeed	  it	  is	  possible	  that	  
several	  potentially	  effective	  Class	  II	  helper	  peptides	  exist	  within	  WT1.	  	  This	  has	  been	  suggested	  by	  recent	  
findings	  from	  Doubrovina	  et	  al215.	  	  
	  
The	  overlapping	  peptide	  pool	  WT1	  PepTivator®	  is	  therefore	  attractive	  as	  a	  means	  to	  potentially	  induce	  a	  
range	  of	  responses	  against	  WT1	  epitopes	  without	  requirement	  for	  matching	  to	  the	  individual	  HLA-­‐types.	  	  
The	  cocktail	  consists	  of	  113	  peptides,	  mainly	  15-­‐mer	  sequences,	  with	  11	  amino	  acid	  overlap,	  covering	  the	  
entire	  sequence	  of	  the	  human	  WT1	  protein.	  It	  was	  administered	  in	  CASAC	  vaccinations	  and	  given	  that	  the	  
WT1-­‐RMF	  epitope	  (one	  of	  the	  higher	  scoring	  peptides	  for	  binding	  to	  HLA-­‐A*02:01/H-­‐2Db)	  can	  be	  detected	  
using	  the	  WT1-­‐RMF-­‐specific	  pentamer,	  WT1-­‐RMF	  specific	  immune	  response	  induction	  was	  used	  as	  a	  read-­‐
out.	  A	  dose	  approximating	  to	  200µg	  of	  the	  WT1	  peptide	  pool	  per	  immunization	  was	  compared	  with	  WT1-­‐
RMF	   along	  with	  WT1-­‐PGC	   (amounting	   to	   a	   total	   dose	   of	   200µg	   of	   peptide).	   Figure	   4-­‐18	   demonstrates	  
results	  following	  immunisations	  on	  days	  1,	  10,	  21	  and	  28.	  There	  was	  no	  evidence	  (by	  pentamer	  staining)	  
of	   an	   increase	   in	   WT1-­‐RMF	   specific	   CD8+	   T-­‐cells	   in	   either	   of	   the	   immunized	   groups	   relative	   to	  
unimmunized	  mice	  after	  3	   rounds	  of	  vaccination	   (Fig	  4-­‐18a).	  However,	   in	  vivo	   lysis	  of	  WT1-­‐RMF	   loaded	  
splenocytes	   after	   4	   vaccinations	   was	   observed	   in	   both	   immunized	   groups	   above	   that	   seen	   in	   the	  
unimmunized	   controls.	   Within	   each	   group	   there	   was	   variability	   in	   the	   magnitude	   of	   the	   response.	   As	  
observed	   in	   some	   of	   the	   earlier	   studies	   described	   in	   4.2.1	   and	   4.2.2,	   there	   was	   a	   lack	   of	   correlation	  
between	  detection	  of	  WT1-­‐RMF	  specific	  T-­‐cells	  by	  pentamer	  studies	  and	  functional	  activity	  as	  assessed	  by	  
the	  in	  vivo	  lysis	  assay.	  
	  
It	   is	   relevant	   that	   the	   quantity	   of	   the	   WT1-­‐RMF	   epitope	   within	   the	   dose	   of	   WT1	   PepTivator®	  
administered	   in	   each	   vaccination	   is	   substantially	   smaller	   than	   that	   administered	  when	   the	   single	  WT1-­‐
RMF	  peptide	  was	  combined	  with	  WT1-­‐PGC.	  The	   full	  RMFPNAPYL	  epitope	   is	   represented	   twice	  amongst	  
the	  113	  overlapping	  WT1	  sequences	  and	   therefore	   the	  quantity	  of	  WT1-­‐RMF	  per	  vaccination	  with	  WT1	  
PepTivator®	  is	  approximately	  4	  µg,	  contrasting	  with	  the	  100µg	  of	  WT1-­‐RMF	  in	  each	  WT1-­‐RMF	  and	  WT1-­‐
PGC	  vaccine.	  	  Despite	  this,	  equivalent	  in	  vivo	  lysis	  of	  WT1-­‐RMF	  peptide	  loaded	  splenocytes	  was	  observed	  
in	  both	  the	  WT1	  peptide	  pool	  immunized	  mice	  and	  those	  mice	  immunized	  with	  the	  Class	  I	  and	  II	  peptides.	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As	  such,	  it	  may	  be	  inferred	  that	  processing	  and	  cross-­‐presentation	  of	  the	  WT1-­‐RMF	  epitope	  derived	  from	  
the	  peptide	  pool	  by	  DC’s	  resulted	  in	  activation	  of	  responding	  CD8+	  T-­‐cells.	  In	  this	  study,	  this	  approach	  was	  
at	  least	  as	  effective	  as	  immunizing	  with	  the	  individual	  Class	  I	  and	  II	  peptides	  at	  a	  higher	  concentration.	  The	  
degree	  of	   in	   vivo	   lysis	  observed	  when	  using	  WT1-­‐RMF	  and	  WT1-­‐PGC	  was	   comparable	   to	   that	  observed	  
previously	   (Figure	  4-­‐17)	  but	  overall	  appears	   lower	  than	  that	  seen	  using	  WT1-­‐RMF	  alone	  for	  vaccination.	  
On	  this	  occasion,	  WT1-­‐RMF	  alone	  was	  not	  included	  as	  a	  condition	  but	  should	  be	  considered	  for	  inclusion	  
in	   all	   future	   studies	   as	   a	   comparator	   since	   this	   has	   so	   far	   been	   the	   most	   successful	   for	   short-­‐term	  
induction	  of	  WT1-­‐RMF	  specific	  immune	  responses.	  Induction	  of	  WT1-­‐specific	  immune	  responses	  using	  the	  
WT1	  PepTivator® remains	  a	  tantalising	  area	  for	  future	  investigation	  and	  following	  optimisation	  would	  be	  




















Figure	  4-­‐18	  An	  overlapping	  peptide	  pool	  spanning	  the	  whole	  WT1	  protein	  can	  combine	  with	  CASAC	  to	  
induce	  WT1-­‐RMF	  specific	  immune	  responses	  
The	  efficacy	  of	  CASAC	  vaccination	  using	  the	  WT1	  peptide	  pool	  versus	  2	  individual	  WT1-­‐derived	  peptides	  
(WT1-­‐RMF	  &	  WT1-­‐PGC)	  was	  assessed.	   (a)	  The	  frequency	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	   following	  3	  
rounds	   of	   vaccination	   are	   shown;	   representative	   samples	   from	   each	   group	   were	   stained	   with	   the	  
irrelevant	   LCMV-­‐specific	   FQPQ/Db	   pentamer	   (*All	   groups).	   (b)	   In	   vivo	   lysis	   of	   WT1-­‐RMF-­‐loaded	  
splenocytes	  following	  four	  rounds	  of	  vaccination.	  Mean	  and	  SD	  are	  shown	  for	  each	  group;	  no	  statistically	  
significant	  differences	  were	  observed	  between	  groups	   for	  either	  of	   the	  2	  analyses.	  WT1	  PepTivator®,	  






















































4.2.3.2 Efficacy	  of	  CASAC	  vaccinations	  in	  comparison	  with	  current	  adjuvant	  systems:	  CASAC	  is	  as	  
effective	  as	  complete	  Freund’s	  adjuvant	  for	  induction	  of	  WT1-­‐specific	  immune	  responses	  	  
A	  key	   issue	   in	  cancer	  vaccination	   is	   to	   identify	  potent	  mediators	  of	  cellular	   immunity	  that	  have	  minimal	  
toxicity.	  Complete	  Freund’s	  adjuvant	  (CFA)	  remains	  the	  standard	  adjuvant	  component	  used	  in	  pre-­‐clinical	  
vaccination	   studies.	   It	   consists	   of	   the	  mineral	   oil	  mannide	  monooleate	   containing	   killed	  M.tuberculosis	  
organisms	   that	   trigger	   the	   immune	   response	   following	   uptake	   by	   macrophages	   or	   monocytes	   and	  
therefore	   is	  an	  effective	  activator	  of	  cell-­‐mediated	   immunity.	  However,	  CFA	  inclusion	   in	  vaccines	  causes	  
granuloma	  formation	  and	  local	  irritation/inflammation	  at	  vaccination	  sites,	  such	  that	  it	  is	  not	  considered	  
suitable	   for	  use	   in	  humans289.	  The	  mineral	  oil	   alone,	   lacking	   the	  mycobacterial	   component,	   is	   known	  as	  
Incomplete	  Freund’s	  Adjuvant	   (IFA)	   and	   is	  used	   for	   vaccinations	  after	   initial	  priming	  using	  CFA	   to	  avoid	  
granulomatous	   lesion	  formation	   in	  experimental	  animals289.	  A	  clinically	  approved	  adjuvant	  based	  on	  the	  
composition	   of	   IFA	   is	   Montanide290,	   which	   has	   been	   used	   as	   a	   vaccine	   adjuvant	   in	   clinical	   trials	   of	  
vaccinations,	  including	  WT1	  peptide	  vaccination199,201.	  	  
	  
Wells	  used	  CFA/IFA	  as	  a	  comparator	  for	  studies	  of	  CASAC	  efficacy	  in	  the	  original	  publication	  and	  reported	  
CASAC	   to	   be	   associated	   with	   a	   20-­‐30-­‐fold	   higher	   expansion	   of	   OVA-­‐SIINF-­‐specific	   CD8+	   T-­‐cells	   in	  






Taken	  from	  Wells	  et	  al238.	  
Activation of DC subsets and IL-12 secretion in vivo
We studied draining inguinal LN of mice 24 h following i.d.
injection of individual CASAC constituents by flow cytometry
(Fig. 4). The presence of peptide Ag had no effect on DC num-
ber, activation marker expression, or IL-12 secretion and is
therefore omitted. Myeloid DCs (mDCs), defined by CD11c and
MHC class II coexpression, were subclassified based on CD8
and CD205 expression as described (12). Plasmacytoid DCs
(pDCs) were identified as CD11c!mPDCA1!B220!. Numbers
of LN-resident CD8!CD205" mDCs and skin-derived
CD8"CD205! mDCs were unchanged by any adjuvant combi-
nation (Fig. 4a), whereas the numbers of LN-resident
CD8"CD205" mDC were significantly increased by IFN-! in-
jection but not by TLR agonists. By contrast, expression of the
DC activation markers CD86 and CD40 was up-regulated by
TLR agonists, especially in combination (Fig. 4b). This in-
creased expression of costimulatory molecules was most dra-
matic on CD8"CD205" mDCs. pDCs were also activated by
TLR agonists, although the levels of CD86 and CD40 on this
subset were much lower than those on mDCs. IFN-! (Fig 4b)
and anti-CD40 Ab (not shown) had little effect on DC activation
markers. MHC class II expression levels were not consistently
changed on any of the subsets. The data suggest that CASAC
induces DC migration from the skin to the draining LNs and
activates multiple LN-resident DC subsets.
Because DC secretion of IL-12 is crucial for cell-mediated im-
munity, we measured the bioactive IL-12 p70 heterodimer in the
serum of mice injected as above (Fig. 4c). In contrast to the CD86/
CD40 data, IL-12 p70 was induced by anti-CD40 alone and this
was further enhanced by TLR agonists. CpG was more effective
than polyI:C at the induction of IL-12, and IFN-! injection had no
effect. The individual constituents of CASAC therefore appear to
FIGURE 3. CASAC is more potent than alum and CFA in both CD8 T cell induction and Th1 polarization. a, Representative plots of intracellular
IL-4 and IFN-! production by LN-derived CD4 T cells from mice immunized with indicated Ag plus CASAC. Similar data were obtained in two
independent experiments (n # 4). b, CD4 Th1 polarization (measured as in a) induced by 1 mg of OVA in PBS plus individual CASAC components
as shown. Representative LN and spleen data from groups of three mice are shown; similar data were obtained in two independent experiments. c,
Comparison of SIINFEKL-specific PBL CD8 T cell levels following one (day 11) or two (day 20) immunizations with OVA in combination with
CASAC (n # 3), showing control staining with a H-2Kb/SVYDFFVWL pentamer in the lower panels. Similar data were obtained in two independent
experiments. d, SIINFEKL-specific CD8 T cells in the blood induced by immunization with OVA in combination with alum, CFA/IFA, or CASAC.
Samples were taken on day 21 (n # 5); similar data were obtained in two independent experiments. e and f, Analysis of serum OVA-specific IgG1
and IgG2a in C57BL/6 (e) or BALB/c (f) mice immunized with OVA and the indicated adjuvants (n # 5) on days 0 and 10. Similar data were
obtained in two independent experiments.
FIGURE 4. Induction of in vivo DC activation/accumulation in draining LNs and secretion of IL-12 in response to constituents of CASAC. a, DC subset
numbers in pooled inguinal LNs following primary i.d. injection of individual adjuvants in PBS/Tween 80 after 24 h. b, Mean fluorescent intensities of
CD86 and CD40 staining in gated DC populations from the draining LNs of mice as in a. All events were gated on CD11c!I-Ab! events (DCs). c, Serum
levels of IL-12 p70 at 24 h as in a and b. Data shown are means $ SEM from groups of four mice pooled from two independent experiments. Statistical
comparisons are against the control (Tween only) group.
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Figure	  4-­‐19	  CASAC	  vaccination	  induces	  significantly	  higher	  frequencies	  of	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	  
in	  comparison	  with	  Complete	  Freund’s	  Adjuvant	  
Percentage	   of	   OVA-­‐SIINF	   specific	   CD8+	   T-­‐cells	   assessed	   by	   pentamer	   studies	   after	   2	   rounds	   of	  
immunisation	   using	   alum,	   CFA/IFA	   or	   CASAC	   as	   adjuvant	   (naïve	   unimmunised	   mice	   shown	   as	  
controls).	  CFA,	  Complete	  Freund’s	  Adjuvant;	  IFA,	  Incomplete	  Freund’s	  Adjuvant.	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Furthermore,	   use	   of	   CASAC	   in	   immunisations	   containing	   the	   whole	   ovalbumin	   protein	   (OVA)	   enabled	  
induction	  of	  an	  antibody	  response	  associated	  with	  a	  Th1-­‐type	  of	  immune	  response.	  Rapid	  and	  sustained	  
production	   of	   Th1-­‐associated	   IgG2a	   antibodies	   at	   higher	   levels	   than	   IgG1	   (an	   immunoglobulin	   subclass	  
typically	  associated	  with	  Th2-­‐type	  responses)	  was	  observed.	  This	  pattern	  of	  antibody	  responses	  was	  not	  
seen	  with	  CFA/IFA	  or	  alum-­‐based	  vaccinations238.	  	  
	  
Vaccinations	   targeting	   the	   WT1-­‐RMF	   epitope	   using	   either	   CASAC	   or	   the	   CFA	   adjuvant	   system	   were	  
therefore	   undertaken	   in	   order	   to	   allow	   a	   clinically	   relevant	   assessment	   of	  WT1	   vaccinations	   using	   the	  
novel	  adjuvant	  combination	  in	  direct	  comparison	  with	  the	  most	  well	  established	  experimental	  adjuvant.	  
Four	  rounds	  of	  vaccination	  were	  used	  for	  this	  experiment,	  in	  contrast	  to	  that	  described	  by	  Wells	  et	  al238.	  	  
In	   this	  experiment,	  CFA	  was	  used	  as	   the	  adjuvant	   for	   the	   first	  vaccination	   in	   the	  CFA-­‐immunised	  group;	  
4.4%	   v/v	   squalene	   emulsion	   (with	   no	   TLR	   agonists	   or	   IFNγ)	  was	   used	   for	   the	   3	   booster	   vaccinations	   to	  
allow	  a	  closer	  comparison	  with	  the	  emulsion	  used	  in	  the	  CASAC-­‐immunised	  groups.	  	  
	  
A	   significantly	   higher	   frequency	   of	   OVA-­‐SIINF-­‐specific	   CD8+	   T-­‐cells	  was	   observed	   following	   3	   rounds	   of	  
vaccination	  using	  CASAC	   rather	   than	  CFA	  as	   the	  adjuvant,	  with	  no	   increase	   in	  pentamer	   staining	  above	  
background	  in	  the	  CFA/OVA-­‐SIINF	  immunised	  mice	  (p<0.05,	  Figure	  4-­‐20).	  This	  result	  is	  in	  keeping	  with	  the	  
findings	  presented	  by	  Wells	  et	  al	  (shown	  in	  Figure	  4-­‐19)238.	  The	  in	  vivo	  lysis	  study	  however	  demonstrated	  
that	  in	  the	  context	  of	  OVA-­‐SIINF	  vaccinations,	  similarly	  potent	  in	  vivo	  cytolytic	  activity	  could	  be	  observed	  
using	  CFA	  or	  CASAC	  as	  adjuvants	  (no	  statistically	  significant	  difference	  between	  the	  2	  conditions,	  Figure	  4-­‐
20a).	  This	  is	  despite	  the	  lack	  of	  detection	  of	  OVA-­‐SIINF-­‐specific	  CD8+	  T-­‐cells	  induced	  using	  CFA/OVA-­‐SIINF.	  
This	  suggests	  that	  although	  the	  magnitude	  of	  the	  antigen-­‐specific	  population	  induced	  by	  CFA/OVA-­‐SIINF	  
vaccination	  was	  small,	  those	  T-­‐cells	  that	  had	  been	  primed	  were	  functionally	  effective.	  Also,	   it	   is	  possible	  
that	   the	   use	   of	   the	   4.4%	   v/v	   squalene	   emulsion	   rather	   than	   incomplete	   Freund’s	   Adjuvant	   (IFA)	   for	  
vaccinations	   2,	   3	   and	   4	  may	   have	   produced	  more	   potent	   responses	   than	  would	   be	   seen	   using	   IFA	   (as	  
described	  in	  Wells’	  data)238.	  An	  additional	  explanation	  for	  these	  findings	  is	  that	  in	  this	  study,	  4	  rounds	  of	  
vaccination	   (rather	   than	   the	   2	   rounds	   described	   in	   the	   original	   publication)	  were	   used	   and	   could	   have	  
sufficiently	  boosted	  even	  weaker	  immune	  responses	  induced	  by	  CFA	  and	  emulsion.	  This	  particular	  study	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should	   be	   repeated	   in	   future	   using	   CFA	   for	   the	   first	   vaccination	   followed	   by	   IFA	   for	   subsequent	  
immunisations	  2,	  3	  and	  4	  versus	  CASAC.	  
In	  the	  case	  of	  WT1-­‐RMF	  immunisations,	  no	  increase	  in	  the	  frequencies	  of	  WT1-­‐RMF-­‐specific	  T-­‐cells	  above	  
background	  was	  demonstrated	  following	  3	  rounds	  of	  vaccination	  using	  CASAC	  or	  CFA	  as	  adjuvants	  (Figure	  
4-­‐20a).	  As	  observed	  in	  the	  studies	  presented	  earlier,	  despite	  the	  absence	  of	  detectable	  WT1-­‐RMF	  specific	  
T-­‐cells	  in	  these	  groups,	  large	  lytic	  responses	  were	  observed	  (Figure	  4-­‐20b).	  No	  significant	  differences	  were	  
observed	  with	  respect	  to	   in	  vivo	   lysis	  of	  WT1-­‐RMF	  loaded	  targets	  following	  WT1-­‐RMF	  and	  CASAC	  or	  CFA	  
immunisations.	  Wells	  et	  al	  did	  not	  describe	  a	  comparison	  of	  in	  vivo	  cytolysis	  following	  vaccinations	  against	  
OVA-­‐SIINF	  using	  CASAC	  or	  CFA	  as	  adjuvants	   in	   the	  original	  work238.	  The	  apparent	  equivalence	  of	  CASAC	  
with	   CFA	   for	   induction	   of	   functional,	   WT1-­‐RMF	   specific	   immune	   responses	   is	   encouraging,	   given	   that	  

















































































































Figure	  4-­‐20	  CASAC	  is	  as	  effective	  as	  Complete	  Freund’s	  Adjuvant	  for	  promotion	  of	  WT1-­‐RMF	  specific	  
immune	  responses	  
Results	  of	  immunisations	  using	  CFA	  or	  CASAC	  and	  WT1-­‐RMF	  or	  OVA-­‐SIINF	  with	  OVA-­‐ISQ	  are	  shown.	  (a)	  
Following	  3	   rounds	  of	   vaccination,	  OVA-­‐SIINF/Kb	  and	  WT1-­‐RMF/Db	  pentamers	  were	  used	   to	   identify	  
antigen-­‐specific	   T-­‐cell	   frequencies	   in	   OVA-­‐SIINF	   or	   WT1-­‐RMF-­‐immunised	   mice	   respectively.	   *All	  
groups:	   the	   pentamer	   containing	   the	   non-­‐immunising	   peptide	   was	   used	   as	   a	   negative	   control	   in	   a	  
sample	   from	   each	   immunised	   group.	   CD8+	   T-­‐cells	   from	   unimmunised	  mice	   were	   also	   stained	   with	  
pentamers	   as	   controls.	   (b)	   In	   vivo	   lytic	   activity	   following	   immunisations	   was	   assessed	   using	   target	  
splenocytes	  loaded	  with	  either	  OVA-­‐SIINF	  or	  WT1-­‐RMF	  peptide	  for	  OVA-­‐SIINF	  or	  WT1-­‐RMF-­‐immunised	  




The	  results	  described	  in	  section	  4.2.3	  demonstrate	  the	  following:	  
1. That	   CASAC	   vaccination	   may	   combine	   with	   an	   overlapping	   peptide	   pool	   to	   induce	   WT1-­‐RMF	  
specific	   immune	   responses.	  Specifically,	   cross	  presentation	  of	  a	  Class	   I	  epitope	  within	   the	  WT1	  
peptide	  pool	  has	  taken	  place.	  It	  is	  conceivable	  that	  cross-­‐presentation	  of	  other	  epitopes,	  binding	  
to	   a	   range	   of	   Class	   I	   HLA	  molecules	  may	   also	   result	   from	   vaccination	   using	   these	   overlapping	  
peptides.	  This	  could	  extend	  utility	  of	  WT1	  peptide	  vaccination	  to	  patients	  with	  HLA	  types	  other	  
than	  the	  most	  commonly	  studied	  alleles	  (such	  as	  HLA-­‐A*02:01).	  
2. Repeated	  CASAC	  vaccination	  targeting	  WT1	  is	  at	  least	  as	  effective	  as	  repeated	  vaccinations	  using	  
CFA	  as	  the	  primary	  adjuvant.	  Further	  exploration	  of	  CASAC	  to	  combine	  with	  WT1	  peptide	  
vaccination	  should	  therefore	  be	  pursued,	  aiming	  to	  improve	  immune	  responses	  over	  and	  above	  
those	  achieved	  with	  this	  “classical”	  adjuvant.	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4.3 Discussion	  
The	   WT1	   protein	   shows	   frequent	   over-­‐expression	   by	   AML	   blasts	   and	   a	   range	   of	   solid	   tumours291.	  
Accordingly,	   experts	   in	   immunotherapy	   have	   prioritized	   this	   protein	   for	   detailed	   evaluation	   as	   a	  
therapeutic	   target	  using	  adoptive	   transfer	  of	  WT1-­‐specific	  T-­‐cells	   and	   immunization	  approaches157.	  Pre-­‐
clinical	  and	  clinical	  studies	  of	  WT1	  peptide	  vaccination	  in	  the	  context	  of	  myeloid	  malignancies	  (described	  
in	  chapter	  1)	  have	  demonstrated	  evidence	  of	  vaccination-­‐induced	  WT1-­‐specific	  T-­‐cell	  responses.	  In	  a	  few	  
cases,	  such	  responses	  have	  coincided	  with	  disease	  stabilisation.	  Predominantly,	   immune	  responses	  have	  
been	  of	   low	  magnitude	   and	  not	   sustained	  beyond	   treatment	   termination.	   Furthermore	   the	  majority	   of	  
vaccination	   studies	   have	   focused	   on	   vaccinations	   using	   a	   handful	   of	   single	   epitopes	   (usually	   Class	   I)	  
directed	  at	  specific	  HLA	  types,	  such	  as	  HLA-­‐A*02:01198-­‐201.	  There	  is	  therefore	  a	  clear	  need	  to	  improve	  the	  
potency	  of	  WT1	  vaccination	  as	  well	  as	  its	  applicability	  to	  all	  HLA	  types.	  
	  
This	  chapter	  has	  described	  a	  novel	  approach,	  using	  a	  synergistic	  combination	  of	  adjuvants,	  to	  induce	  cell-­‐
mediated	   immune	   responses	   against	  WT1	   epitopes.	   Repeated	   vaccinations	   using	   CASAC	   and	  WT1-­‐RMF	  
can	   result	   in	   large	   expansions	   of	  WT1-­‐RMF	   specific	   CD8+	   T-­‐cells.	   The	   frequencies	   of	  WT1-­‐RMF	   specific	  
CD8+	  T-­‐cells	  induced	  after	  3	  or	  4	  vaccinations	  using	  CASAC	  were	  at	  least	  as	  large,	  and	  occasionally	  much	  
greater,	   than	   those	   described	   by	   Kohrt	   et	   al.	   in	   the	   most	   comparable	   study	   of	   WT1-­‐RMF	   peptide	  
vaccination	   in	  healthy	  C57BL/6	  mice182.	  Following	  4	  WT1-­‐RMF	  peptide	  vaccinations	  administered	   in	   IFA,	  
this	  group	  observed	  ~1%	  WT1-­‐RMF	  specific	  cells	  amongst	  CD8+	  T-­‐cells	  using	  WT1-­‐RMF	  tetramer	  analyses,	  
shown	  in	  Figure	  1-­‐5.	  This	  group	  did	  not	  specifically	  assess	  lysis	  of	  WT1-­‐RMF	  loaded	  targets.	  However,	  after	  
short	   term	   cultures	   of	   lymphocytes	   isolated	   from	  mice	   following	   4	   vaccinations	  with	   a	  WT1-­‐expressing	  
tumour	  cell	  line,	  IFNγ	  production	  reached	  10-­‐13%	  by	  CD8+	  T-­‐cells.	  The	  frequency	  of	  WT1-­‐RMF	  specific	  T-­‐
cells	   amongst	   the	   CD8+	   T-­‐cell	   population	   induced	   using	   CASAC	   reached	   up	   to	   10-­‐30%	   in	   some	   of	   our	  
presented	   studies.	   These	  WT1-­‐specific	   T-­‐cells	   were	   also	   functional,	   effectively	   lysing	  WT1-­‐RMF	   loaded	  
target	  cells	  in	  vivo	  and	  secreting	  IFNγ	  (at	  best,	  up	  to	  15-­‐20%	  of	  CD8+	  T-­‐cells	  in	  responding	  mice)	  following	  
re-­‐stimulation	  with	  WT1-­‐RMF	  peptide	  in	  vitro.	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Similarly	  to	  Man,	  the	  WT1	  protein	  shows	  a	  tissue-­‐restricted	  pattern	  of	  expression	  throughout	  embryonic	  
development	  and	  into	  adulthood	  in	  mice74.	  Therefore	  the	  ability	  to	  induce	  WT1-­‐specific	  T-­‐cell	  responses	  
following	  repeated	  vaccination	  suggests	  that	  tolerance	  mechanisms	  have	  been	  subverted.	  Despite	  this,	  no	  
mice	   immunized	   with	  WT1	   peptide(s)	   died	   or	   showed	   loss	   of	   condition	   during	   the	   course	   of	   therapy,	  
suggesting	  no	  autoimmune	  toxicity.	  CASAC	  was	  at	  least	  as	  effective	  at	  inducing	  WT1-­‐RMF	  specific	  immune	  
responses	  as	  the	  most	  commonly	  used	  pre-­‐clinical	  adjuvant,	  Complete	  Freund’s	  Adjuvant	  (CFA).	  Given	  the	  
limited	   range	   of	   clinically	   acceptable	   adjuvants	   for	   cell-­‐mediated	   immunity,	   the	   presented	   findings	  
provide	  a	  strong	  basis	  for	  future	  investigation	  of	  CASAC	  and	  WT1	  peptide	  vaccinations	  for	  AML	  therapy.	  	  
	  
Wells	   et	   al	   had	   documented	   the	   ability	   of	   CASAC	   to	   combine	   with	   whole	   protein	   (ovalbumin)	  
immunisations	   and	   result	   in	   cross-­‐presentation	   of	   the	   OVA-­‐SIINF	   epitope	   to	   cognate	   CD8+	   T-­‐cells238.	  
Indeed,	  ligation	  of	  TLR3292	  and	  TLR9293,294	  has	  been	  shown	  to	  promote	  cross-­‐presentation	  of	  endocytosed	  
antigens	   by	  DCs.	   These	  observations	   provided	   a	   rationale	   for	   exploring	  CASAC	   in	   combination	  with	   the	  
WT1	  PepTivator®	  for	  immunisations,	  since	  the	  long	  peptides	  (15mers)	  would	  need	  to	  be	  cross-­‐presented	  
in	   order	   to	   elicit	   cytotoxic	   T-­‐cell	   responses.	   Such	   an	   approach,	   if	   shown	   to	   be	   efficacious,	   would	   be	  
attractive,	  due	  to	  the	  potential	  to	  broaden	  the	  applicability	  of	  WT1	  peptide	  vaccination	  to	  a	  range	  of	  HLA	  
types.	  	  
	  
The	  demonstration	  of	  CD8+	  T-­‐cells	  recognising	  the	  WT1-­‐RMF	  epitope	  following	  4	  rounds	  of	  immunisations	  
using	  the	  overlapping	  WT1	  peptide	  pool,	  despite	  the	  considerably	   lower	  concentration	  of	  the	  WT1-­‐RMF	  
epitope	   within	   the	   dose	   of	   WT1	   PepTivator®	   administered	   per	   mouse,	   is	   encouraging.	   No	   significant	  
differences	   in	   the	   frequencies	  of	  WT1-­‐RMF	   specific	  CD8+	  T-­‐cells	   or	  magnitude	  of	  WT1+	   target	   cell	   lysis	  
were	   detected	   between	   the	   group	   receiving	   WT1	   PepTivator® or	   WT1-­‐RMF	   and	   WT1-­‐PGC	   in	  
immunisations.	  These	  observations	  suggest	  that	  long	  peptides	  within	  WT1	  PepTivator®	  can	  be	  processed	  
effectively	   to	   allow	   cross-­‐presentation	   of	   WT1-­‐RMF	   by	   professional	   APCs	   in	   the	   context	   of	   H-­‐2Db	   to	  
cognate	   CD8+	   T-­‐cells.	   This	   parallels	   observations	   made	   in	   vitro	   by	   Doubrovina	   et	   al,	   whereby	   healthy	  
donor	  PBMCs	  were	  cultured	  with	  an	  overlapping	  peptide	  pool	  encompassing	  the	  whole	  of	  WT1,	  eliciting	  
CD4+	  and	  CD8+	  T-­‐cell	  responses215.	  The	  WT1-­‐RMF	  epitope	  nested	  within	  the	  pool	  was	  cross-­‐presented	  to	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CD8+	   CTLs,	   resulting	   in	   IFNγ	   production	   and	   lysis	   of	   primary	  WT1+	   leukaemic	   targets215.	   	   Significantly,	  
WT1-­‐RMF	  was	   found	  to	  be	   just	  one	  of	  42	   immunogenic	  epitopes	  within	  the	  WT1	  peptide	  pool,	  most	  of	  
which	  were	   previously	   unknown.	   In	   fact	  WT1-­‐RMF	   elicited	   T-­‐cell	   responses	   of	   smaller	  magnitude	   than	  
some	  of	  the	  other	  newly	  identified	  epitopes.	  Furthermore,	  10	  of	  the	  novel	  epitopes	  could	  activate	  T-­‐cells	  
from	  donors	   of	   up	   to	   4	   different	  HLA-­‐types215.	  Our	   studies	   concentrated	  on	   the	   ability	   to	  use	   the	  WT1	  
PepTivator® to	  immunise	  mice,	  using	  the	  identification	  of	  WT1-­‐RMF	  specific	  T-­‐cell	  responses	  as	  a	  read-­‐
out,	   due	   to	   well-­‐established	   immunogenicity	   of	   this	   epitope	   and	   availability	   of	   WT1-­‐RMF	   pentamers.	  
However,	   the	   complementary	   findings	   of	   Doubrovina	   et	   al	   highlight	   the	   potential	   for	   the	   WT1	  
PepTivator® to	  generate	   immune	  responses	  within	  donors	  (and	  patients),	  some	  of	  which	  may	  be	  more	  
potent	   than	   those	   induced	   by	   the	   most	   well-­‐studied	   WT1	   epitope	   to	   date,	   WT1-­‐RMF215.	   Given	   the	  
observation	   by	   Rezvani	   et	   al	   that	   repeated	   vaccination	   targeting	   the	  WT1-­‐RMF	   epitope	   alone	   induced	  
predominantly	   low	  avidity	  CTL	   responses200,	  our	   findings	   in	  combination	  with	   those	  of	  Doubrovina	  et	  al	  
support	  exploration	  of	  the	  role	  of	  WT1	  PepTivator®/CASAC	  immunisations	  in	  future	  studies.	  	  
	  
I	   also	   demonstrated	   that	   certain	   peptides	   predicted	   to	   combine	  with	   CASAC	   to	   enhance	   promotion	   of	  
WT1-­‐RMF	  specific	  immune	  responses	  did	  not	  achieve	  the	  expected	  results.	  Firstly,	  the	  heteroclitic	  peptide	  
WT1-­‐YMF	  was	  not	   superior	   to	  WT1-­‐RMF	   for	   induction	  of	  WT1-­‐RMF	  specific	  cytotoxic	  or	   IFNγ	   responses	  
using	  CASAC	   in	   C57BL/6	  mice.	   This	   contrasted	  with	   findings	   in	   humans,	  where	   in	   vitro	   studies	   (such	   as	  
measurement	   of	   IFNγ	   production	   upon	   challenge	   with	   WT1+	   targets	   by	   T-­‐cell	   lines	   derived	   from	  
prolonged	   cultures	   with	   WT1-­‐RMF	   or	   WT1-­‐YMF)	   suggested	   that	   the	   heteroclitic	   rather	   than	   native	  
peptide	   might	   more	   efficaciously	   induce	   T-­‐cell	   responses	   against	   the	   native	   peptide.	   This	   had	   been	  
predicted	   based	  on	   higher	   binding	   affinity	   of	  WT1-­‐YMF	   for	  HLA	  A*02:01	   in	   comparison	  with	  WT1-­‐RMF	  
(SYFPEITHI	   scores	  24	  and	  22	   respectively).	  As	   shown	   in	  Table	  4-­‐1,	  higher	  binding	  affinity	  and	   lower	   IC50	  
concentrations	  for	  WT1-­‐YMF	  over	  WT1-­‐RMF	  in	  the	  context	  of	  H-­‐2Db	  suggested	  this	  might	  also	  be	  the	  case	  
in	  mice.	  	  However	  significantly	  higher	  in	  vivo	  lysis	  of	  the	  WT1-­‐RMF	  loaded	  targets	  in	  mice	  immunised	  with	  
the	  native	  rather	  than	  the	  heteroclitic	  peptide	  was	  found	  (Figure	  4-­‐8).	  Secretion	  of	   IFNγ	  was	  also	  higher	  
upon	   in	   vitro	   re-­‐challenge	   with	   WT1-­‐RMF	   for	   mice	   immunised	   with	   WT1-­‐RMF	   rather	   than	   WT1-­‐YMF.	  
Results	   therefore	   show	   that	  WT1-­‐YMF	   is	   not	   effective	   as	   a	   heteroclitic	   modification	   in	   the	   context	   of	  
murine	   H-­‐2Db.	   It	   is	   also	   possible	   that	   the	   interaction	   between	   Db/YMF	   and	   the	   murine	   TCR	   is	   less	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favourable	  than	  that	  with	  Db/RMF.	  This	  has	  been	  questioned	  in	  the	  context	  of	  human	  TCR/HLA	  A*02:01	  
interactions,	   following	  a	  recent	  study	  of	  the	  crystallographic	  structure	  of	  the	  human	  HLA-­‐A*02:01/WT1-­‐
YMF	  complex	  interacting	  with	  the	  human	  WT1-­‐TCR.	  Borbulevych	  et	  al.	  demonstrated	  that	  the	  WT1-­‐YMF	  
peptide	   bound	   to	   the	  HLA-­‐A*02:01	   binding	   groove	   in	   similar	   configuration	   to	  WT1-­‐RMF.	   However,	   the	  
WT1-­‐YMF	  peptide	  altered	  the	  position	  of	  charged	  side	  chains	  and	  the	  electrostatic	  surface	  potential	  of	  the	  
HLA-­‐A*02:01/peptide	   complex	   when	   compared	   to	   the	   WT1-­‐RMF	   peptide/HLA	   complex.	   The	   authors	  
concluded	  that	  such	  alterations	  may	  negatively	  impact	  on	  the	  WT1-­‐TCR	  recognition	  of	  the	  WT1-­‐YMF/HLA	  
A*02:01	   complex,	   given	   the	   recognised	   role	   of	   side	   chain	   interactions	   within	   the	   TCR-­‐MHC/peptide	  
complex	   in	   determining	   binding	   affinity295.	   	   My	   findings	   highlight	   caveats	   in	   extrapolating	   immune	  
response	   induction	   in	   mice	   and	   humans	   and	   the	   need	   to	   verify	   in	   silico	   predictions	   experimentally.	  
Furthermore,	  given	  reports	  suggesting	  that	  heteroclitic	  peptides	  do	  not	  always	  induce	  immune	  responses	  
that	   recognise	   the	   native	   peptides	   and	   can	   show	   different	   results	   when	   evaluated	   in	   vivo	   versus	   in	  
vitro206,296,	  heteroclitic	  epitopes	  should	  be	  thoroughly	  evaluated	  before	  clinical	  translation.	  
	  
Secondly,	   vaccinations	   combining	   CASAC	   with	   the	   universal	   Class	   II	   helper	   epitope	   PADRE	   were	   less	  
efficacious	  for	  expansion	  of	  functional	  WT1-­‐RMF	  or	  OVA-­‐SIINF	  specific	  CD8+	  T-­‐cells	  than	  using	  the	  Class	  I	  
peptide	  alone.	  The	  reasons	  for	  these	  observations	  are	  not	  known.	  PADRE	  itself	  had	  not	  been	  previously	  
assessed	  as	  a	  helper	  peptide	   in	   the	  context	  of	  CASAC.	  Whilst	   there	  are	  different	  sequences	  of	  “PADRE”	  
peptide	  with	  differential	   “helper”	  potencies,	   the	  particular	  PADRE	   sequence	  used	   in	  our	   immunisations	  
had	  been	  shown	  to	  be	  efficacious	  as	  a	  helper	  epitope	  when	  administered	  in	  saline	  to	  C57BL/6	  mice266.	  In	  
that	   study	   however,	   a	   single	   vaccination	   was	   administered	   with	   the	   assessments	   of	   helper	   activity	  
determined	  following	  subsequent	   in	  vitro	  culture266.	  PADRE	  was	  administered	  with	  WT1-­‐RMF	  in	  IFA	  as	  a	  
comparator	  group	  in	  a	  study	  of	  WT1	  DNA	  vaccination:	  IFNγ	  production	  using	  ELISpot	  analysis	  showed	  no	  
advantage	   for	   combining	   PADRE	  with	  WT1-­‐RMF	   to	   induce	   functional	   CTL	   responses297.	   However,	   other	  
studies,	  using	  PADRE	  fused	  to	  the	  target	  Class	  I	  epitope	  either	  in	  peptide	  or	  DNA	  vaccinations	  against	  viral	  
or	  tumour	  antigens	  have	  suggested	  efficacy	  of	  this	  universal	  helper	  epitope284,298.	  One	  recent	  pilot	  study	  
of	  a	  multi-­‐epitope	  vaccine	  in	  humans	  (including	  WT1-­‐RMF	  as	  one	  of	  the	  peptides	  and	  using	  Montanide	  as	  
the	   oil-­‐based	   adjuvant)	   demonstrated	   an	   increase	   in	   PADRE	   specific	   T-­‐helper	   cells	   after	   vaccination.	  
However,	   these	   CD4+	   T-­‐cells	   produced	   limited	   IL-­‐2	   and	   overall	   an	   increase	   in	   T-­‐regulatory	   cells	   was	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observed299.	   Although	   T-­‐regulatory	   cells	   were	   not	   observed	   in	   our	   studies	   to	   have	   increased	   in	   the	  
peripheral	   blood	   and	   in	   fact	   appeared	   to	   be	   lower	   in	   mice	   that	   received	   PADRE	   immunisations,	   the	  
possibility	   that	   T-­‐regulatory	   cells	   expanded	   at	   the	   draining	   lymph	   node	   sites	   cannot	   be	   excluded.	  
Ultimately,	  the	  decision	  to	  evaluate	  the	  potential	  for	  PADRE	  to	  assist	  in	  WT1-­‐RMF	  vaccination	  was	  based	  
on	  having	  a	  universal	  helper	  epitope	   to	  broaden	   the	  applicability	  of	  WT1-­‐RMF	  and	  CASAC	  vaccinations:	  
given	  the	  potential	  immunogenicity	  of	  WT1	  PepTivator®, the	  role	  of	  PADRE	  is	  somewhat	  redundant.	  	  	  
	  
The	  findings	  above	  highlight	  the	  importance	  of	  thoroughly	  evaluating	  individual	  peptides	  in	  the	  context	  of	  
CASAC	  vaccinations.	  Wells	  et	  al	  had	  demonstrated	  previously	  that	  CASAC	  combines	  with	  variable	  efficacy	  
with	   individual	   peptides	   to	   induce	   antigen-­‐specific	   immune	   responses	   during	   their	   examination	   of	   a	  
selection	   of	   self	   and	   foreign	   Class	   I	   peptides	   for	   induction	   of	   antigen-­‐specific	   CD8+	   T-­‐cell	   expansion238.	  
Clearly	  induction	  of	  responses	  against	  a	  self-­‐antigen	  requires	  subversion	  of	  tolerance	  mechanisms	  that	  do	  
not	  govern	  the	  development	  of	  responses	  against	  a	  xenoantigen,	  such	  as	  OVA-­‐SIINF.	  However,	  of	  4	  self-­‐
peptides	   evaluated	   by	   Wells	   et	   al	   in	   CASAC	   vaccinations,	   only	   3	   led	   to	   CD8+	   T-­‐cell	   expansion.	   One	  
explanation	   for	   the	   difference	   in	   immunogenicity	   of	   these	   peptides	   was	   the	   lower	   SYFPEITHI	   binding	  
scores	  of	   the	  poorly	   immunogenic	   self-­‐peptides238.	  My	   findings	   also	   suggest	   that	   other	   factors,	   such	   as	  
emulsion	  composition,	  may	  need	  to	  be	  optimised	  and	  tailored	  to	  the	  individual	  immunising	  peptide,	  since	  
alteration	   of	   the	   squalene	   percentage	  within	   the	   emulsion	   influenced	   the	  magnitude	   of	   the	  WT1-­‐RMF	  
specific	   immune	  responses	  generated.	   In	  concordance	  with	  the	  previous	  studies	  of	  CASAC,	  alteration	  of	  
the	   squalene	  quantity	  within	   the	  emulsion	  when	   targeting	   the	   immunogenic	   foreign	  epitope	  OVA-­‐SIINF	  
did	   not	   affect	   immune	   response	   induction.	   The	   observation	   that	   4.4%	   v/v	   squalene	   emulsion,	   but	   not	  
2.2%	  or	   8%	   squalene	   v/v	   emulsion	   could	   induce	  WT1-­‐RMF	   specific	   CD8+	  T-­‐cell	   responses	   suggests	   that	  
induction	   of	   T-­‐cell	   responses	   against	   this	   self	   antigen	   are	   finely	   balanced	   and	   small	   differences	   in	   the	  
vaccine	  composition	  can	  affect	  outcomes.	  The	  greater	  ease	  of	  generating	  an	  immune	  response	  against	  a	  
foreign	   epitope	   may	   explain	   why	   such	   apparently	   minor	   variations	   have	   a	   lesser	   impact	   on	   immune	  
response	  induction.	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The	  difficulty	  of	  stimulating	  immune	  responses	  against	  WT1-­‐RMF	  was	  also	  highlighted	  by	  the	  variability	  of	  
results,	   both	   within	   groups	   of	   mice	   and	   between	   experiments.	   This	   variability	   was	   present	   in	   all	  
experiments	  and	  consistency	  was	  not	  improved	  by	  modulation	  of	  CASAC	  components	  or	  escalation	  of	  the	  
immunising	  peptide	  dose	  in	  our	  studies.	  Despite	  using	  the	  same	  mouse	  strain	  and	  fresh	  stocks	  of	  reagents	  
from	  consistent	  suppliers,	  the	  frequency	  of	  WT1-­‐RMF	  specific	  CD8+	  T-­‐cells	  could	  range	  from	  below	  1%	  to	  
almost	  30%	  and	  the	  degree	  of	  lysis	  of	  WT1-­‐RMF	  loaded	  targets	  ranged	  from	  <10%	  to	  approximately	  80%.	  
Indeed	   in	   some	   vaccination	   experiments,	   no	   WT1-­‐RMF	   specific	   immune	   responses	   (evaluated	   by	  
pentamer	  or	  in	  vivo	  lysis	  studies)	  could	  be	  observed	  after	  4	  rounds	  of	  vaccination	  (data	  not	  shown).	  In	  2	  of	  
these	   studies,	   no	   WT1-­‐RMF-­‐specific	   T-­‐cell	   expansion	   or	   lysis	   of	   WT1-­‐RMF	   loaded	   targets	   immune	  
responses	  could	  be	  induced	  using	  either	  WT1-­‐RMF	  or	  the	  WT1	  PepTivator®.	  In	  these	  same	  experiments,	  
CASAC	  would	  consistently	  promote	  OVA-­‐SIINF	  specific	  responses	  of	  the	  expected	  magnitude	  based	  on	  the	  
work	  of	  Wells	  and	  our	  own	  observations238.	  CASAC	  and	  OVA-­‐SIINF	   immunised	  mice	  were	  considered	  as	  
positive	  controls	  for	  vaccination	  since	  the	  observed	  large	  magnitude,	  functionally	  highly	  potent	   immune	  
responses	  induced	  suggested	  integrity	  of	  the	  CASAC	  components	  themselves.	  No	  changes	  were	  made	  to	  
the	  handling	  and	  storage	  of	  the	  WT1-­‐RMF	  peptide	  and	  the	  same	  supplier	  of	  synthetic	  peptides	  was	  used	  
throughout	  the	  study.	  The	  ability	  of	  thawed	  WT1-­‐RMF	  to	  stabilise	  HLA-­‐A*02:01	  molecules	  on	  the	  surface	  
of	  T2	  cells	  was	  used	  as	  a	  surrogate	   to	  suggest	   integrity	  of	   the	  WT1-­‐RMF	  peptide	   following	   freezing	  and	  
thawing.	   	  Despite	   this,	  no	  clear	  cause	   for	   the	  variability	  of	   immune	  responses	  between	  mice	  was	   found	  
during	  the	  time-­‐period	  available	  for	  these	  studies.	  It	  is	  most	  likely	  that	  this	  observation	  reflects	  the	  need	  
to	  consider	  other	  factors	  that	  may	  combine	  with	  CASAC	  to	   influence	   immune	  response	  generation.	  This	  
could	   include	   the	   addition	   of	   even	   more	   stimulatory	   signals,	   such	   as	   IFNα,	   anti-­‐CD40	   ligation	   in	  
combination	  with	  Class	  II	  peptide	  provision	  or	  a	  third	  TLR	  agonist.	  	  Removal	  of	  inhibitory	  factors,	  such	  as	  
regulatory	  T-­‐cells	  or	  signals	  e.g.,	  via	  CTLA-­‐4,	  PD1/PDL1	  could	  help	  to	  tip	  the	  balance	  in	  favour	  of	  WT1-­‐RMF	  
specific	  T-­‐cell	  activation	  and	  reduce	  variability	  in	  the	  observed	  immune	  responses.	  These	  suggestions	  will	  
be	  explored	  further	  in	  Chapter	  6.	  
	  
In	  conclusion,	  the	  use	  of	  CASAC,	  particularly	  in	  combination	  with	  the	  WT1	  overlapping	  peptide	  pool,	  has	  
shown	  potential	   for	  effective	   induction	  of	  WT1-­‐specific	   immune	  responses	   that	  could	  be	  applied	  across	  
the	   HLA	   spectrum.	   Future	   work	   should	   aim	   to	   optimise	   these	   immune	   responses	   further,	   to	   reduce	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variability	   in	   their	   magnitude	   and	   potency,	   prior	   to	   assessment	   of	   therapeutic	   benefit	   in	   a	   murine	  
leukaemia	  model.	   Should	   anti-­‐leukaemic	   responses	  be	  observed	  pre-­‐clinically,	   an	   attractive	   therapeutic	  
approach	  would	   be	   to	   use	   CASAC/WT1	   peptide	   vaccination	   in	   AML	   patients	  with	  WT1-­‐over	   expressing	  
blasts	  for	  remission	  maintenance	  following	  debulking	  chemotherapy,	  with	  the	  ultimate	  aim	  of	  eradicating	  






Chapter	  5 Whole	  cell	  vaccination	  using	  CD80/IL-­‐2	  modified	  AML	  blasts	  for	  
remission	  maintenance	  in	  patients	  with	  relapsed	  AML	  post	  allogeneic	  
HSCT.	  
5.1 Introduction	  
Chapter	  3	  described	  that	  patients	  with	  relapsed	  AML	  and	  MDS	  post	  allogeneic	  HSCT	  show	  an	  estimated	  5-­‐
year	   overall	   survival	   of	   40%	   following	   treatment	   with	   therapeutic	   DLI	   (tDLI).	   However,	   the	   5-­‐year	  
relapse/progression	   rate	   was	   69%	   (54%-­‐81%,	   CI	   95%),	   with	   only	   a	   minority	   of	   patients	   experiencing	  
durable	  remissions	  following	  tDLI.	   In	  the	  majority	  of	  patients	  analysed,	   there	  was	  either	  no	  response	  to	  
tDLI	  or	  leukaemia	  ultimately	  recurred,	  highlighting	  that	  induction	  of	  GvL	  activity	  was	  neither	  universal	  nor	  
sustained	  in	  this	  setting.	  Incidence	  of	  GvHD	  was	  still	  moderate,	  occurring	  in	  41%	  of	  patients	  post-­‐tDLI	  and	  
was	  more	  commonly	  observed	  in	  those	  who	  experienced	  a	  disease	  response	  to	  tDLI.	  Whilst	  these	  findings	  
support	  the	  therapeutic	  potential	  of	  DLI,	  there	  is	  a	  clear	  need	  to	  enhance	  the	  efficacy	  of	  this	  treatment	  to	  
increase	  response	  rates	  overall	  and	  confer	  sustained	  GvL	  activity.	  Strategies	  that	  can	  favour	  induction	  of	  
effective	  GvL	  provision	  by	  DLI	  whilst	  limiting	  GvHD	  induction	  are	  highly	  desirable.	  	  
	  
Accumulating	   evidence	   supports	   the	   crucial	   role	   of	   activation	   of	   naïve	   alloreactive	   donor	   T-­‐cells	   in	  
providing	  GvL	  activity	  post-­‐HSCT42,300,301.	   It	   is	   likely	  that	  minor	  histocompatibility	  antigen	  (mHag)-­‐derived	  
peptides,	  in	  the	  context	  of	  a	  fully	  HLA-­‐matched	  allo-­‐HSCT,	  will	  provide	  the	  most	  potent	  stimuli	  to	  activate	  
these	   naïve	   T-­‐cells	   because	   these	   epitopes	   will	   be	   entirely	   novel	   to	   the	   donor	   immune	   system42,301.	  
Indeed,	  T	  cells	  that	  recognize	  haematopoietic	  cell-­‐restricted,	  mHag-­‐derived	  epitopes	  from	  DLI-­‐responsive	  
patients	   have	   been	   isolated300,302-­‐304.	   Tissue	   restricted	   expression	   of	   these	   mHags	   to	   cells	   of	   the	  
haematopoietic	   system	   suggests	   that	   induction	   of	   responses	   against	   these	   targets	   may	   result	   in	   GvL	  
without	   damage	   to	   other	   organs	   (GvHD).	   Furthermore,	   correlation	   of	   the	   emergence	   of	   leukaemia	  
antigen-­‐specific	  T-­‐cells	   in	  recipients	  following	  DLI	  with	  disease	  control	  suggests	  that	  these	  epitopes	  may	  
also	  be	  able	  to	  induce	  GvL	  activity305,306.	  In	  one	  study,	  low	  frequencies	  of	  WT1-­‐specific	  donor	  T-­‐cells	  were	  
detectable	   in	   the	   pre-­‐infusion	   DLI	   products;	   following	   infusion	   and	   isolation	   of	   T-­‐cells	   from	   PB	   of	   the	  
recipients,	   expansion	   of	   the	   same	   clones	   and	   additional,	   newly	   arising,	   WT1-­‐specific	   clones	   were	  
identified	  in	  vitro305.	  Graft-­‐versus-­‐leukaemia	  responses	  may	  include	  not	  only	  CD8+	  T-­‐cell	  but	  also	  CD4+	  T-­‐
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cell	   responses:	   Rutten	   et	   al	   have	   recently	   isolated	   alloreactive	   CD4+	   T-­‐cells	   detectable	   after	   DLI	   in	  
responding	  patients	  and	  specific	  for	  patient,	  but	  not	  donor,	  HLA-­‐DP	  molecules307.	  Since	  the	  expression	  of	  
HLA	  Class	   II	  molecules	   is	   largely	   confined	   to	  haematopoietic	   cells,	   this	  provides	  an	  additional	   target	   for	  
leukaemia-­‐specific	   responses.	   It	   is	   therefore	   plausible	   that	   active	   approaches	   to	   ensure	   effective	  
stimulation	   of	   infused	   naïve	   donor	   CD4+	   and	   CD8+	   T-­‐cells	   against	   a	   range	   of	   leukaemia-­‐associated	   or	  
specific	   antigens	   will	   increase	   the	   efficacy	   of	   this	   treatment.	   Targeting	   several	   antigens,	   rather	   than	   a	  
single	   antigen,	   may	   avoid	   immunoselection	   pressures	   favouring	   the	   generation	   of	   tumour	   escape	  
mutants.	  	  
	  
The	   variable	   response	   rates	   observed	   in	   studies	   of	   therapeutic	   DLI	   suggest	   that,	   despite	   provision	   of	  
immune	  competent	  cells	  in	  the	  infused	  product	  capable	  of	  GvL	  activity,	  the	  patients’	  leukaemic	  cells	  may	  
fail	   to	   encounter	  or	   effectively	   stimulate	   these	   cells.	   	   As	  outlined	   in	  Chapter	   1,	   not	  only	  do	  AML	  blasts	  
express	  a	  range	  of	  target	  leukaemia-­‐associated	  antigens	  (see	  Table	  1-­‐1)46	  and	  potentially	  donor-­‐recipient	  
discordant	  mHags59,300,304,	  but	  they	  also	  express	  MHC	  Class	  I	  and	  II	  antigens	  and	  often	  adhesion	  molecules	  
including	  ICAM199,308,309.	  These	  features	  should	  enable	  them	  to	  act	  effectively	  as	  APCs.	  However,	  they	  also	  
show	   low	   expression	   of	   the	   vital	   co-­‐stimulatory	   molecule	   CD80	   and	   may	   secrete	   immunosuppressive	  
factors99,308,309.	   AML	   blasts	   are	   therefore	   likely	   to	   be	   sub-­‐optimal	   stimulators	   of	   immune	   responses.	  
Importantly,	  ineffective	  co-­‐stimulation	  of	  responding	  naïve	  T-­‐cells	  results	  in	  induction	  of	  an	  anergic	  state	  
and	  failure	  to	  respond	  to	  their	  target310.	  	  
	  
Gene	  therapy	  affords	  an	  opportunity	  to	  overcome	  these	  deficiencies	  and	  boost	  immune	  cell	  activation	  by	  
AML	   blasts.	   Expression	   of	   CD80	   by	   genetically	   engineered	   AML	   blasts	  may	   increase	   their	   ability	   to	   co-­‐
stimulate	   naïve	   T-­‐cells.	   Induction	   of	   IL-­‐2	   secretion	   by	   gene	   transfer	   provides	   a	   proliferative	   stimulus	   to	  
lymphocytes	  and	  may	  reverse	  an	  anergic	  state310.	  As	  described	  in	  Chapter	  1,	  in	  vitro	  and	  in	  vivo	  data	  have	  
demonstrated	   the	   superior	   induction	   of	   leukaemia-­‐specific	   cytolytic	   activity	   in	   responder	   T-­‐cells	   by	  
CD80/IL-­‐2	  modified	  AML	  blasts	  compared	  with	  activation	  by	  unmodified	  AML	  blasts	  or	  blasts	  modified	  to	  
express	  CD80	  or	   IL-­‐2	  alone120,258.	  Allogeneic	  T-­‐cells	  previously	   co-­‐cultured	  with	  CD80/IL-­‐2	  modified	  AML	  
blasts	   demonstrated	   significant	   IFNγ production	   and	   lysis	   of	   primary	   unmodified	   AML	   blasts	   on	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subsequent	   challenge,	   despite	   the	   presence	   of	   immune	   suppressive	   Tregs	   in	   some	   cultures261.	  
Furthermore,	   the	   enhanced	   ability	   of	   CD80/IL-­‐2	   modified	   AML	   blasts	   to	   activate	   NK-­‐cell	   mediated	  
cytotoxicity	   provides	   an	   additional	  means	   to	   stimulate	   leukaemic	   cell	   lysis121.	   Prophylactic,	   single	   gene-­‐
modified	  AML	  cell	  vaccination	  within	   the	   first	  100	  days	  post	  allo-­‐HSCT	   for	  high	  risk	  AML/MDS	  has	  been	  
reported246.	  However,	  the	  novel	  approach	  described	  here	  combines	  vaccinations	  comprising	  tumour	  cells	  
modified	   to	   express	   two	   complementary	   immunostimulatory	   genes,	   with	   provision	   of	   an	   immune	  
competent	   donor	   repertoire	   in	   the	   form	   of	   donor	   lymphocyte	   infusions,	   in	   order	   to	   generate	   a	   more	  
effective	  GvL	  response.	  
	  
Herein,	  a	  phase	   I	  study	  to	  assess	  safety	  and	  toxicity	  of	  CD80/IL-­‐2	  gene-­‐modified	  AML	  cell	  vaccination	   in	  
patients	   with	   relapsed	   AML	   post-­‐allogeneic	   HSCT	   currently	   recruiting	   at	   King’s	   College	   Hospital	   is	  
reported.	  Following	  morphological	  remission	  re-­‐induction	  using	  salvage	  chemotherapy,	  four	  patients	  have	  
been	  treated	  to	  date.	  Two	  subjects	  have	  been	  allocated	  to	  each	  arm	  (Arm	  A:	  standard	  care	  with	  escalating	  
dose	  DLI	  vs.	  Arm	  B:	   treatment	  with	  escalating	  dose	  DLI	  co-­‐administered	  with	  the	  patient-­‐specific,	  gene-­‐
modified,	  CD80/IL-­‐2	  expressing	  AML	  Cell	  Vaccine,	  termed	  ACV	  for	  ease	  of	  reference).	  The	  data	  presented	  
in	  this	  chapter	  demonstrate	  that	  vaccination	  of	  two	  patients	  has	  been	  clinically	  safe.	  There	  has	  been	  no	  
evidence	  of	  replication	  competent	  lentivirus	  formation	  as	  a	  result	  of	  gene	  therapy,	  or	  systemic	  elevation	  
of	   IL-­‐2	  due	  to	  vaccination.	  Ability	  to	  respond	  to	  vaccination	  will	  be	  dependent	  on	   immune	  competence.	  	  
Therefore,	   the	  numbers	   and	   relative	   frequencies	  of	   lymphocyte	   subsets	   in	  peripheral	   blood	  of	   subjects	  
during	  treatment	  and	  follow	  up	  were	  assessed	  and	  compared	  to	  healthy	  age-­‐matched	  volunteers.	  	  	  
	  
5.2 Results	  
5.2.1 Characteristics	  of	  patients	  screened	  for	  potential	  trial	  entry	  
Between	   1st	   July	   2009	   and	   28th	   February	   2013	   inclusive,	   a	   total	   of	   41	   patients	   underwent	   AML	   blast	  
collection	  either	  at	  the	  time	  of	  AML	  diagnosis	  or	  at	  relapse	  post-­‐HSCT	  (Table	  5-­‐1).	  In	  2009,	  collection	  was	  
performed	  for	  one	  patient	  and	  12,	  16,	  10,	  and	  2	  were	  screened	  in	  2010,	  2011,	  2012	  and	  until	  March	  2013	  
respectively.	  Peripheral	  blood	  and	  bone	  marrow	  mononuclear	  cells	  (PBMC	  and	  BMMC	  respectively)	  were	  
cryopreserved	   under	   GMP	   conditions	   for	   all	   eligible	   patients.	   Blood	   and	   bone	  marrow	   harvest	   yielded	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sufficient	  viable	  cells	  to	  permit	  production	  of	  a	  minimum	  of	  3	  doses	  of	  the	  AML	  Cell	  Vaccine	  (ACV)	  in	  36	  of	  
the	  screened	  patients.	  Four	  of	  these	  patients	  were	  eventually	  enrolled	  onto	  the	  study.	  	  
Reasons	  for	  non-­‐enrolment	  included:	  	  
(1)	  patient	  did	  not	  undergo	  HSCT	  (n=6),	  	  
(2)	   persistent	   disease	   following	   chemotherapy	   for	   relapse	   post-­‐HSCT	   and/or	   following	   chemotherapy	  
(n=11),	  	  	  
(3)	  presence	  of	  exclusion	  criteria	   (active	  GvHD,	  n=4;	  presence	  of	  comorbidity,	  n=1;	  primary	  diagnosis	  of	  
myelodysplastic	  syndrome	  with	  excess	  of	  blasts	  rather	  than	  AML,	  n=1;	  patients	  whose	  cells	  were	  stored	  at	  
diagnosis	  did	  not	  relapse	  post-­‐HSCT,	  n=3)	  or	  	  
(4)	  inability	  to	  locate	  donor	  to	  obtain	  donor	  lymphocytes	  (n=1).	  	  
Four	  patients	  were	  continuing	  treatment	  for	  relapse	  as	  of	  March	  2013.	  	  
	  
Two	  eligible	  patients	  (UPN	  31	  and	  UPN	  38)	  could	  not	  be	  enrolled	  onto	  the	  study	  as	  the	  ACV	  failed	  to	  meet	  
specifications	  permitting	  product	  release	  on	  trial.	  	  The	  specifications	  are:	  
1. CD80	  expression:	  	  ≥20%	  of	  cells	  in	  the	  vaccine	  product	  must	  express	  CD80	  with	  at	  least	  a	  5-­‐fold	  
increase	  in	  MFI	  above	  cells	  stained	  with	  an	  isotype	  control	  in	  place	  of	  anti-­‐CD80	  
2. IL-­‐2	  secretion:	  	  ≥	 0.1ng/106	  cells	  and	  ≤	  25	  ng/106	  cells	  per	  24	  hours	  
3. Viability	  ≥	  50%	  based	  on	  Annexin-­‐V	  staining,	  prior	  to	  freezing	  
4. Sufficient	  cell	  numbers	  to	  achieve	  the	  minimum	  3	  doses	  of	  ACV	  (Dose	  1:	  0.5-­‐1x105	  cells,	  Dose	  2:	  
0.5-­‐1x106	  cells,	  Dose	  3:	  0.5-­‐1x107	  cells,	  Dose	  4:	  0.5-­‐1x108	  cells).	  
	  
CD80	   was	   expressed	   by	   only	   8.5%	   of	   cells	   with	   just	   a	   2.05-­‐fold	   increase	   in	   MFI	   above	   the	   control	  
population	   in	   the	   product	  manufactured	   for	   UPN	   31.	   Furthermore	   no	   IL-­‐2	   secretion	  was	   detected.	   For	  
UPN	  38,	  22%	  of	  cells	  expressed	  CD80	  (associated	  with	  a	  4.19-­‐fold	  increase	  in	  MFI).	  IL-­‐2	  secretion	  was	  low,	  
at	  0.035	  ng/106	  cells	  per	  24	  hours.	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Variability	   in	   the	   transduction	   efficacy	   of	   primary	  AML	   blasts	   has	   been	   observed	   in	   prior	   pre-­‐clinical	   in	  
vitro	  studies258	  suggesting	  that	  AML	  cells	  may	  possess	  inherently	  different	  susceptibility	  to	  infection	  with	  
the	  lentiviral	  vector.	   	  No	  specific	  causes	  for	  the	  UPN31	  and	  UPN38	  transduction	  failures	  were	  identified.	  
Transduction	   of	   U937	   targets	   performed	   in	   parallel	   was	   successful	   in	   both	   cases	   indicating	   that	   a	  
procedural	   fault	  was	  unlikely.	  Myeloid	  blasts	  comprised	  56%	  and	  23%	  of	  the	  total	  nucleated	  cells	   in	  the	  
bone	  marrow	  of	  UPN	  31	  and	  UPN	  38	  respectively,	  and	  showed	  typical	  myeloid	  phenotype	  (CD34+,	  CD13+,	  
CD117+	  with	  myeloperoxidase	  expression)	  and	  karyotypes	  (normal	  in	  UPN	  31	  and	  inversion	  16	  in	  UPN	  38).	  
Therefore	  adequate	  numbers	  of	  AML	  blasts	  with	   typical	   surface	  marker	  expression	  were	  present	   in	   the	  
BMMCs	   used	   in	   lentiviral	   transduction	   cultures.	   However,	   cell	   viability	   was	   <50%	   for	   the	   product	  
produced	   for	   UPN	   31	   and	   58%	   (just	   over	   the	   specification	   threshold)	   for	   UPN	   38.	   Therefore	   low	   cell	  
viability	  may	  have	  contributed	  to	  transduction	  failures.	  Ongoing	  investigations	  to	  refine	  the	  transduction	  
procedure	  seek	  to	  increase	  the	  efficacy	  of	  this	  process.	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Table	  5-­‐1	  continued	  	  






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table	  5-­‐1	  continued.	  	  
Full	   details	   of	   transplant	   regimens	   are	   given	   in	   Appendix	   B.	   MR,	   morphological	   remission	   (<5%	   bone	  
















































































































































































































































































































































































































































































































































































































































































































































































































































































































The	  slow	  initial	  recruitment	  of	  patients	  to	  the	  study	  was	  due	  to	  the	  study	  design,	  which	  focussed	  solely	  on	  
patients	  with	   sibling	  donors,	  demonstrating	  persistent	  morphological	  evidence	  of	  disease	  prior	   to	  HSCT	  
and	  undergoing	  FBC-­‐conditioned	  HSCT.	  As	  a	  result,	  recruitment	  was	  challenging	  due	  to	  the	  low	  frequency	  
of	  matched	   sibling	   transplants.	   Furthermore,	   clinical	   practice	  within	   the	   department	   changed	   after	   the	  
initial	   protocol	   was	   developed,	   such	   that	   patients	   with	   matched	   sibling	   donors	   now	   undergo	   FBATG-­‐
conditioned	  HSCT.	  This	  change	  was	  adopted	  following	  internal	  review	  of	  findings	  suggesting	  a	  higher	  risk	  
of	   relapse	   for	   patients	   following	   FBC-­‐conditioned	   HSCT	   using	  matched	   sibling	   as	   opposed	   to	   volunteer	  
unrelated	  donors	  (VUD)	  (data	  not	  shown).	   In	  addition,	   following	  the	  publication	  of	  data	  from	  Schmid	  et	  
al311,	  those	  patients	  with	  persistent	  morphological	  disease	  prior	  to	  HSCT	  underwent	  FLAMSA-­‐conditioned	  
HSCT	   from	   2008	   onwards.	   	   Accordingly,	   I	   wrote	   and	   submitted	   protocol	   modifications	   that	   were	  
subsequently	   approved	   by	   the	   Gene	   Therapy	   Advisory	   Committee,	  Medicines	   and	   Healthcare	   products	  
Regulatory	   Agency	   and	   the	   local	   ethical	   review	  board	   that	   enabled	   recruitment	   to	   progress	   from	  2010	  
onwards.	  These	  modifications	  included	  changes	  that	  substantially	  altered	  the	  protocol	  such	  that	  patients	  
could	   be	   recruited	   irrespective	   of	   donor	   type	   (related	   or	   unrelated)	   or	   conditioning	   regimen	   received.	  
Despite	  these	  efforts,	  as	  demonstrated	  by	  Table	  5-­‐1,	  recruitment	  to	  this	  study	  has	  remained	  challenging,	  
primarily	   due	   to	   the	   frequent	   incidence	   of	   chemotherapy	   refractory	   disease	   at	   relapse	   post-­‐allogeneic	  
HSCT.	  
	  
5.2.2 Characteristics,	  dosing	  and	  clinical	  course	  of	  study	  patients	  
Between	  January	  2010	  and	  December	  2012,	  4	  patients	  were	  enrolled	  onto	  the	  study.	  The	  clinical	  course	  
of	  each	  patient	  is	  outlined	  in	  Figure	  5-­‐1	  and	  a	  summary	  of	  adverse	  events	  is	  provided	  in	  Table	  5-­‐2.	  	  
	  
ACV	  and	  DLI	  as	  consolidation	  following	  remission	  re-­‐induction	  	  
Two	  patients	  were	  allocated	  to	  the	  vaccine	  and	  DLI	  treatment	  arm:	  UPN	  13	  and	  UPN	  22.	  UPN13	  was	  a	  36-­‐
year	  old	  male	  with	  a	  history	  of	  AML	  transformed	  from	  MDS	  (refractory	  anaemia	  with	  ringed	  sideroblasts,	  
as	   per	   the	   World	   Health	   Organisation	   2008	   classification1)	   and	   poor	   risk	   karyotype	   (trisomies	   of	  
chromosomes	  8,	  12	  and	  21)	  at	  diagnosis312.	  This	  patient	   relapsed	  by	  6	  months	  post-­‐FBC	  RIC	  MUD	  HSCT	  
and	   entered	   a	   complete	  morphological,	   but	   not	   cytogenetic,	   remission	  prior	   to	   study	   entry.	   The	  donor	  
197	  
CD3	   chimerism	   analysis	   showed	   minimal	   improvement	   post	   remission	   re-­‐induction	   therapy	   (donor-­‐
derived	   T-­‐cells	   comprised	   56%	  of	   CD3+	   T-­‐cells	   prior	   and	   63%	   following	   FLAG	   chemotherapy),	   details	   of	  
chemotherapy	  regimens	  are	  provided	  in	  Appendix	  B.	  This	  patient	  was	  assigned	  to	  the	  DLI	  and	  vaccine	  arm	  
of	  the	  study	  and	  received	  a	  single	  dose	  of	  DLI	  (5x105	  CD3+/kg)	  and	  the	  patient-­‐specific	  vaccine	  (0.5-­‐1x105	  
cells	  in	  250µl).	  This	  vaccine	  met	  specifications,	  with	  CD80	  expression	  at	  47%	  (MFI	  increased	  11-­‐fold	  over	  
background	  non-­‐transduced	  cells),	  viability	  83%	  by	  Annexin-­‐V	  staining	  and	  secretion	  of	  0.23-­‐0.36	  ng	  of	  IL-­‐
2	  per	  106	  cells,	  per	  24	  hours.	  A	   total	  of	  7	   injections	  were	  administered	   intradermally	  over	   the	  patient’s	  
lower	  abdomen	  without	  any	  immediate	  or	  late	  adverse	  reactions.	  Unfortunately,	  at	  week	  3	  of	  the	  study,	  
peripheral	  blood	  cytopenias	  were	  noted	  and	  a	  bone	  marrow	  biopsy	  confirmed	  relapse	  of	  AML	  with	  24%	  
blasts	   by	   morphology	   showing	   characteristic	   immunophenotypic	   profile.	   In	   accordance	   with	   the	   trial	  
protocol,	  the	  patient	  was	  withdrawn	  from	  treatment	  on	  the	  study	  but	  completed	  follow-­‐up	  assessments.	  
The	  patient	  commenced	  a	  series	  of	  investigational	  agents	  to	  attempt	  to	  treat	  their	  refractory	  AML	  before	  































































































































UPN	  22	  was	  a	  52-­‐year	  old	   female	  who	  had	  AML	  relapse	  at	  34	  months	  post-­‐FBATG	  HSCT	   from	  her	  male	  
sibling	   donor	   for	   normal	   karyotype	   AML	   with	   myelodysplasia-­‐related	   changes1.	   At	   the	   end	   of	   vaccine	  
production,	  sufficient	  cell	  numbers	  for	  3	  doses	  of	  ACV	  were	  available.	  Fifty	  percent	  of	  the	  cells	  in	  the	  ACV	  
product	  expressed	  CD80	  (MFI	  increased	  7-­‐fold	  over	  control	  cells).	  The	  cells	  secreted	  0.15	  ng	  IL-­‐2	  per	  106	  
cells	  per	  24	  hours	  and	  74%	  of	  cells	  were	  viable	  prior	   to	  cryopreservation.	  Escalating	  doses	  of	  ACV	  were	  
administered	  at	  6-­‐weekly	   intervals	   [0.5-­‐1x105	   cells	   (dose	  1),	   0.5-­‐1x106	   cells	   (dose	  2)	   and	  0.5-­‐1x107	   cells	  
(dose	  3)].	  Each	  ACV	  administration	  followed	  same	  day	  infusion	  of	  DLI:	  5x105	  CD3+	  cells/kg	  	  (dose	  1),	  5x106	  
CD3+	   cells/kg	   (dose	   2)	   and	   5x107	   CD3+	   cells/kg	   (dose	   3).	   The	   three	   doses	   of	   ACV	   were	   administered	  
intradermally	  in	  the	  lower	  abdomen	  divided	  in	  as	  many	  sites	  as	  possible	  (dose	  1,	  14	  sites;	  dose	  2,	  13	  sites	  
and	   dose	   3,	   18	   sites).	   No	   treatment-­‐related	   Grade	   3	   adverse	   events	   were	   recorded	   following	  
administration	  of	  any	  of	  the	  doses	  of	  vaccine	  and	  DLI,	  including	  no	  fevers,	  chills	  or	  rigors	  suggestive	  of	  any	  
systemic	  inflammatory	  response,	  Table	  5-­‐2.	  Mild	  induration	  and	  erythema	  were	  observed	  at	  vaccination	  
sites	  24	  hours	  following	  the	  first	  and	  second	  doses	  of	  ACV,	  Figure	  5-­‐2	  (a).	  Following	  the	  third	  dose	  of	  ACV,	  
more	   pronounced	   local	   reactions	   were	   observed,	   which	   persisted	   approximately	   96	   hours	   post	  
vaccination	   (Figure	  5-­‐2b).	   Similar	   changes	  were	  not	  observed	   in	  a	   control	   vaccination	   site	   injected	  with	  
0.9%	  normal	  saline,	  Figure	  5-­‐2	  (c).	  	  
Diagnostic	  skin	  punch	  biopsies	  were	  collected	  from	  an	  un-­‐injected	  site	  and	  from	  a	  vaccination	  site	  at	  96	  
hours	  post	  dose	  3.	  At	  this	  point,	  induration	  and	  erythema	  at	  vaccination	  sites	  had	  waned	  and	  was	  only	  
just	  discernible.	  Despite	  this,	  haematoxylin	  and	  eosin	  stain	  of	  the	  punch	  biopsy	  specimen	  from	  the	  
vaccination	  site	  demonstrated	  a	  normal	  epidermis	  and	  a	  predominantly	  perivascular	  infiltrate	  around	  
both	  upper	  and	  lower	  dermal	  blood	  vessels,	  composed	  of	  lymphocytes	  with	  small	  numbers	  of	  eosinophils,	  
mast	  cells	  and	  neutrophils.	  Immunohistochemical	  staining	  demonstrated	  the	  lymphocytic	  infiltrate	  to	  
consist	  of	  T-­‐cells,	  staining	  positively	  with	  CD2,	  CD3,	  CD5	  and	  CD7	  with	  absence	  of	  staining	  for	  B-­‐cell	  (CD20,	  
CD79a)	  or	  NK-­‐cell	  (CD56)	  markers	  (data	  not	  shown).	  CD4+	  and	  CD8+	  T-­‐cells	  were	  present	  in	  a	  2:1	  ratio.	  
The	  clinical	  and	  histological	  findings	  were	  compatible	  with	  the	  development	  of	  a	  delayed-­‐type	  
hypersensitivity	  (DTH)	  reaction	  in	  UPN	  22	  occurring	  upon	  re-­‐challenge	  with	  the	  ACV	  at	  week	  12,	  following	  
2	  prior	  vaccinations.
201	  
Figure	  5-­‐2	  Suspected	  delayed-­‐type	  hypersensitivity	  reaction	  in	  UPN	  22	  at	  24-­‐96	  hours	  post	  third	  dose	  of	  
ACV	  and	  DLI.	  	  
	  
Figure	  5-­‐2	  (a)	  UPN	  22,	  week	  6	  
	  
Figure	  5-­‐2	  (b)	  UPN	  22,	  week	  12	  
	  
Figure	  5-­‐2	  (c)	  UPN	  22,	  week	  12,	  close-­‐up	  of	  control	  and	  ACV	  sites	  
Control	   injection	   site	  
(infiltrated	   with	   0.1ml	  
0.9%	  normal	  saline	  only)	  
ACV	  injection	  sites	  
Figure	  5-­‐2	  (d)	  Histology	  of	  skin	  biopsies	  from	  vaccination	  site,	  UPN	  22,	  week	  12	  
	  
(a)	  Photograph	  of	  injection	  sites	  at	  24	  hours	  following	  ACV	  dose	  2.	  (b)	  Photograph	  of	  injection	  sites	  at	  24	  
hours	  following	  ACV	  dose	  3.	  (c).	  Detail	  of	  vaccine	  sites,	  to	  left	  of	  umbilicus,	  visible	  in	  Figure	  5-­‐2	  (b),	  
demonstrating	  quiescent	  appearance	  of	  control	  vaccination	  site	  and	  erythema	  at	  ACV	  administration	  sites	  (d)	  
Haematoxylin	  and	  eosin	  (H&E)	  stain	  of	  skin	  punch	  biopsy	  at	  low	  (left)	  and	  20x	  	  (right)	  magnifications	  
demonstrating	  egress	  of	  lymphocytes	  from	  a	  superficial	  vessel.	  H&E	  staining	  and	  immunostains	  were	  
performed	  by	  the	  Department	  of	  Histopathology	  at	  King’s	  College	  Hospital	  with	  morphological	  interpretation	  




Subsequently,	  UPN	  22	  completed	  all	  trial	  follow-­‐up	  visits	  and	  converted	  to	  full	  donor	  chimerism	  (FDC)	  in	  
myeloid	  and	  lymphoid	  lineages	  by	  week	  22,	  which	  was	  maintained	  throughout	  the	  remaining	  follow-­‐up	  
period	  (Figure	  5-­‐1).	  Interestingly,	  Grade	  2	  hepatic	  dysfunction	  (by	  NCI	  CTCAE	  version	  3	  criteria,	  
http://ctep.info.nih.gov)	  was	  temporarily	  observed	  at	  week	  22	  in	  UPN	  22	  (Table	  5-­‐2).	  This	  coincided	  with	  
conversion	  to	  FDC.	  No	  definitive	  causes,	  such	  as	  viral	  hepatitis,	  drug	  reaction	  or	  anomaly	  on	  liver	  ultra-­‐
sound	  scan,	  were	  identified	  and	  no	  evidence	  of	  GvHD	  was	  observed.	  This	  abnormality	  spontaneously	  
resolved	  within	  3	  weeks.	  The	  only	  other	  abnormality	  was	  a	  low-­‐level	  anti-­‐smooth	  muscle	  antibody	  titre	  
(1:40)	  that	  was	  intermittently	  detected	  at	  weeks	  3	  and	  15	  that	  resolved	  by	  week	  18	  and	  remained	  
undetectable	  thereafter.	  There	  was	  no	  clinical	  evidence	  of	  autoimmune	  toxicity.	  Grade	  1	  neutropenia	  was	  
detected	  between	  weeks	  6	  and	  22,	  resolving	  by	  week	  30.	  Bone	  marrow	  cellularity	  was	  maintained	  at	  40-­‐
50%	  at	  all	  time	  points	  with	  no	  evidence	  of	  bone	  marrow	  failure.	  The	  patient	  was	  free	  from	  GvHD	  and	  in	  
morphological	  remission	  with	  full	  donor	  chimerism	  at	  the	  time	  of	  writing,	  18	  months	  following	  AML	  
relapse.	  	  
	  
DLI	  without	  vaccine	  as	  consolidation	  following	  remission	  re-­‐induction	  
UPN	   14	  was	   a	   44-­‐year	   old	   female	  with	   a	   history	   of	   de	   novo,	   intermediate	   cytogenetic	   risk2,	   AML	  with	  
maturation1,	  transplanted	  in	  CR2	  using	  a	  sibling	  donor.	  Following	  the	  documentation	  of	  mixed	  chimerism,	  
this	  patient	  received	  2	  doses	  of	  pre-­‐emptive	  DLI	  at	  7	  and	  10	  months	  post-­‐HSCT.	  Despite	  an	  improvement	  
in	   donor	   CD3%	   from	   48%	   to	   83%	   at	   3	   months	   following	   the	   second	   DLI	   dose,	   UPN14	   relapsed	  
morphologically	   at	   18	  months	  post-­‐HSCT.	   Following	   assignment	   to	   the	  DLI	   arm	  of	   the	   vaccine	   trial,	   the	  
patient	   received	  a	   total	  of	  4	  escalating	  doses	  of	  DLI.	  Due	   to	   lack	  of	  availability	  of	  a	  dose	  at	  1x108	  CD3+	  
cells/kg,	  the	  patient	  received	  5.4x107	  CD3+	  cells/kg	  as	  the	  fourth	  dose	  at	  week	  18.	  At	  3	  weeks	  following	  
the	   final	  dose	  of	  DLI,	  UPN	  14	  developed	  hepatic	  dysfunction	   (maximum	  severity	  Grade	  3	  by	  NCI	  CTCAE	  
version	   3	   criteria).	   This	   progressed	   and	   the	   patient	   additionally	   experienced	   other	   features	   compatible	  
with	   a	   diagnosis	   of	   chronic	   GvHD,	   including	   mild	   sicca	   syndrome	   and	   oral	   ulceration.	   A	   liver	   biopsy	  
demonstrated	  peri-­‐portal	  inflammation,	  most	  consistent	  with	  GvHD.	  This	  development	  was	  classed	  as	  the	  
first	   dose	   limiting	   toxicity	   (DLT)	   of	   the	   study,	   in	   accordance	   with	   the	   trial	   protocol.	   Additionally,	   anti-­‐
nuclear	  antibodies	  (nucleolar	  pattern,	  titre	  1/160)	  were	  observed	  in	  this	  patient	  at	  week	  36	  but	  were	  not	  
detected	  at	  week	  44.	  The	  patient	  was	  treated	  with	  single-­‐agent	   immunosuppressive	  therapy,	  with	  good	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response,	  but	  unfortunately	  experienced	  extramedullary	  (gingival)	  relapse	  of	  AML,	  2	  years	  after	  the	  initial	  
relapse,	  and	  remains	  on	  active	  treatment	  at	  this	  time.	  	  
	  
The	  fourth	  patient,	  UPN	  32,	  a	  55-­‐year	  old	  male,	  experienced	  early	  recurrence	  of	  AML	  with	  myelodysplasia	  
related	   changes1	   6	   months	   following	   FB4ATG-­‐conditioned	   HSCT	   from	   their	   male	   sibling	   donor.	   Three	  
doses	   of	   DLI	   alone	   were	   well	   tolerated	   by	   this	   patient.	   Due	   to	   absence	   of	   availability	   of	   5x107	   CD3+	  
cells/kg,	   the	   final	   dose	  of	  DLI	   in	  UPN	  32	  was	  4.5x107	  CD3+	   cells/kg.	  UPN	  32	  experienced	  no	   treatment-­‐
related	  Grade	   3	   adverse	   events	   although	   asymptomatic	   Grade	   1-­‐2	   neutropenia	  was	   detected	   between	  
weeks	  6-­‐25	  of	  treatment	  and	  was	  most	  likely	  reflective	  of	  persistent	  dysplasia	  within	  the	  bone	  marrow.	  A	  
bone	   marrow	   biopsy	   at	   week	   25	   suggested	   a	   morphological	   excess	   of	   blasts	   (7%)	   that	   was	   not	  
corroborated	   by	   other	   diagnostic	  modalities	   (cytogenetic,	   immunophenotyping	   and	   chimerism	   studies)	  
and	  on	  subsequent	  repeat	  bone	  marrow	  studies,	  no	  excess	  of	  blasts	  was	  confirmed.	  Incidental	  detection	  
of	  anti-­‐nuclear	  antibodies	  (nucleolar	  staining	  pattern,	  titre	  ranging	  from	  1/80	  to	  1/1280)	  was	  observed	  in	  
UPN	  32	  from	  week	  9	  onwards	  and	  persisted	  until	  end	  of	  follow-­‐up.	  By	  March	  2013,	  the	  patient	  completed	  







Table	  5-­‐2	  Adverse	  events	  recorded	  for	  patients	  treated	  on	  the	  RFUSIN2-­‐AML1	  trial	  according	  to	  NCRI	  
CTCAE	  version	  3	  	  
Adverse	  event	  and	  maximum	  grade	  experienced	  
(where	  applicable)	  
DLI	  only	  (n=2)	  arm	  
Total	  number	  of	  events	  
DLI	  and	  vaccine	  (n=2)	  arm	  











Colitis	  with	  Grade	  1-­‐2	  neutrophils	  
URTI	  (presumed	  viral),	  Grade	  2	  
Cellulitis,	  Grade	  2	  











Asymptomatic	  autoimmune	  reaction:	  Grade	  1	  
Nature	  of	  the	  antibodies:	  
Anti-­‐smooth	  muscle	  antibody	  	  


















Acute	  graft-­‐versus-­‐host	  disease:	  
Chronic	  graft-­‐versus-­‐host	  disease:	  





Dyspnoea	  (during	  DLI):	  
Grade	  1-­‐2	  




















































CTCAE,	  Common	  Terminology	  Criteria	   for	  Adverse	  Events;	  DLI,	  Donor	  Lymphocyte	   Infusion;	  URTI,	  Upper	  
Respiratory	  Infection	  
¶ Adverse	  events	  were	  recorded	  during	  the	  follow-­‐up	  phase	  for	  UPN13,	  during	  which	  period	  the	  patient	  
had	   active	   disease	   and	  was	   undergoing	   a	   range	  of	   drug	   treatments	   responsible	   for	   the	  majority	   of	   the	  
documented	   adverse	   events.	   Apart	   from	   Grade	   1	   thrombocytopenia,	   all	   haematological	   toxicity	   was	  
experienced	  following	  withdrawal	  from	  treatment	  on	  trial	  
§ UPN22	  had	  developed	  a	  basal	   cell	   carcinoma	  during	   remission	   re-­‐induction	   therapy	   that	  was	  excised	  
during	  the	  course	  of	  the	  trial	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¥	   UPN32	   had	   microbiologically	   confirmed	   colitis	   (due	   to	   Salmonella	   ridge)	   that	   was	   treated	   with	  
appropriate	  antibiotics	  
*	  Anti-­‐smooth	  muscle	  antibody	  in	  UPN22,	  highest	  titre	  1/40	  
**Anti-­‐nuclear	   antibody	   (ANA)	   in	   UPN14,	   highest	   titre	   1/160	   with	   nucleolar	   pattern;	   ANA	   in	   UPN32,	  
highest	  titre	  1/1280	  with	  nucleolar	  pattern.	  
	  	  
5.2.3 Absence	  of	  replication	  competent	  lentivirus	  generation	  or	  systemic	  elevation	  of	  serum	  IL-­‐2	  in	  
vaccine-­‐treated	  patients	  suggests	  safety	  of	  the	  AML	  Cell	  Vaccine	  
In	   addition	   to	   clinical	   safety	  monitoring,	   samples	  were	   collected	   at	   defined	   time-­‐points	   to	   exclude	   the	  
generation	  of	   replication	  competent	   lentivirus	   (RCL)	  or	  systemic	  elevation	  of	  serum	  IL-­‐2	   levels	   following	  
administration	  of	  ACV.	  No	  patients	  in	  either	  arm	  demonstrated	  evidence	  of	  RCL,	  as	  demonstrated	  by	  (1)	  
absence	  of	  viral	  integration	  into	  peripheral	  blood	  or	  bone	  marrow	  mononuclear	  cells	  (using	  virus-­‐specific	  
qPCR	  analysis	  of	  genomic	  DNA	  from	  these	  compartments);	  (2)	  absence	  of	  viral	  RNA	  in	  patients’	  sera	  (using	  
virus-­‐specific	  RT-­‐qPCR	  studies)	  and	   (3)	  absence	  of	  detectable	  HIV	  p24	  antigen	   in	  patients’	   sera	  by	  ELISA	  
studies	  (see	  Appendix	  D	  for	  data).	  Drs	  YuQian	  Ma	  and	  Sabine	  Domning	  performed	  and	  analysed	  the	  safety	  
studies	   described	   above.	  UPN	  32	   (who	  was	   not	   allocated	   to	   the	   vaccine	   treatment	   arm)	   demonstrated	  
marginally	  elevated	  levels	  of	  HIV	  p24	  antigen	  at	  weeks	  6	  and	  33	  that	  was	  not	  corroborated	  by	  analyses	  of	  
HIV	   1&2	   p24	   antigen	   performed	   at	   the	   South	   London	   Specialist	   Virology	   Centre	   laboratories	   at	   King’s	  
College	  Hospital,	   London.	  The	  result	  was	   therefore	   likely	  due	   to	  high	  background	  signal	  associated	  with	  
this	  particular	  assay.	  
	  
Serum	   IL-­‐2	   levels	  were	  assessed	  by	  ELISA	   to	  exclude	   the	  possibility	  of	   systemic	  elevation	  of	   IL-­‐2	  due	   to	  
secretion	  by	  ACV.	  UPNs	  13,	  14	  and	  22	  demonstrated	  no	  elevation	  of	  serum	  IL-­‐2	  above	  the	  threshold	  for	  
detection	  by	   ELISA	   at	   each	   consecutive	   time	  point.	  UPN	  32	  had	   consistently	   elevated	   serum	   IL-­‐2	   levels	  
during	  the	  course	  of	  the	  trial	  (Figure	  5-­‐3).	  Since	  the	  patient	  did	  not	  receive	  ACV,	  the	  IL-­‐2	  must	  be	  derived	  
from	  immune	  cells,	  such	  as	  T-­‐	  and	  NK-­‐cells,	  possibly	  in	  response	  to	  infection.	  Indeed,	  Figure	  5-­‐3	  shows	  a	  
parallel	   rise	   in	   lymphocyte	   numbers	   and	   serum	   IL-­‐2	   levels,	   which	   supports	   the	   possibility	   of	   rising	   IL-­‐2	  
levels	  due	   to	   increased	  circulating	   immune	  cells.	   	  Results	   to	  be	  presented	   later	   showed	   that	   the	   rise	   in	  
lymphocyte	  numbers	  was	  due	  to	  increased	  numbers	  of	  terminal	  effector	  CD8+	  T-­‐cells	  (Figure	  5-­‐8,	  section	  
5.2.4).	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Infectious	   organisms	   identified	   in	   this	   patient	   included	   salmonella	   ridge,	   isolated	   from	   diarrhoeal	   stool	  
cultures	   from	   the	   patient	   prior	   to	   study	   entry.	   Since	   the	   enteric	   symptoms	   responded	   completely	   to	  
antibiotic	   therapy	   within	   the	   first	   15	   weeks	   of	   the	   trial	   period,	   they	   are	   unlikely	   to	   account	   for	   the	  
subsequent	  rise	  in	  lymphocyte	  numbers	  and	  IL-­‐2	  levels.	  This	  patient	  also	  experienced	  fluctuating	  low-­‐level	  
reactivation	   of	   viruses	   including	   EBV	   and	   CMV	   (determined	   by	   PCR	   performed	   at	   the	   South	   London	  
Specialist	  Virology	  Centre	  laboratories	  at	  King’s	  College	  Hospital,	  London)	  during	  the	  course	  of	  follow-­‐up.	  
Both	  UPN	  32	  and	  their	  sibling	  donor	  had	  previously	  been	  exposed	  to	  EBV	  and	  CMV,	  demonstrable	  by	  the	  
detection	   of	   EBV	   and	   CMV	   specific	   IgG	   antibodies	   in	   their	   sera.	   	   UPN	   32	  was	   therefore	   at	   high	   risk	   of	  
experiencing	   reactivation	   of	   these	   viruses,	   due	   to	   transplant-­‐related	   immunosuppression	   and	  
lymphodepletion,	  and	  had	  already	  experienced	  CMV	  reactivation	  requiring	  antiviral	  drugs	  prior	  to	  study	  
entry.	  During	   trial	   follow-­‐up,	   CMV	  was	  detectable	   only	   at	  week	   33	   (1425	   copies/ml)	   and	   low-­‐level	   EBV	  
viraemia	  was	  observed	  predominantly	  from	  week	  18	  onwards	  (Figure	  5-­‐3).	  The	  substantial	  population	  of	  
terminal	  effector	  CD8+	  T-­‐cells	  present	  within	  UPN	  32	  at	  study	  entry	  (Figure	  5-­‐8)	  and	  the	  controlled,	  low-­‐
level	  viraemia	  observed	  during	  follow-­‐up	  suggest	  that	  effective	  anti-­‐viral	  T-­‐cell	  immunity	  may	  have	  been	  


















Figure	  5-­‐3	  Fold	  increase	  in	  serum	  IL-­‐2	  detected	  in	  UPN	  32	  at	  trial	  monitoring	  time	  points	  and	  parallel	  rise	  
in	  lymphocyte	  numbers.	  	  
































































Serum	  IL-­‐2	  concentration	  (pg/ml)	  was	  measured	  using	  ELISA.	  Results	  are	  normalised	  to	  the	  threshold	  of	  
detection,	  which	  showed	  inter-­‐assay	  variation	  (ranging	  from	  4.87	  pg/ml	  to	  36.5	  pg/ml,	  see	  Appendix	  D).	  
The	  grey	  panel	  outlines	  the	  time	  course	  of	  salmonella	  ridge	  infection.	  Time	  points	  where	  EBV	  and	  CMV	  
reactivation	  were	  detected	  by	  PCR	  studies	  during	  monitoring	  are	  also	  indicated	  (blue	  and	  green	  stars	  
respectively)	  along	  with	  the	  copy	  numbers	  of	  each	  virus	  detected	  per	  ml	  in	  the	  peripheral	  blood	  (PB).	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5.2.4 Analysis	  of	  lymphocyte	  subset	  composition	  in	  trial	  subjects	  following	  ACV	  and/or	  DLI	  treatment	  
Prolonged	   deficiencies	   in	   immune	   subset	   composition	   even	   late	   post-­‐HSCT	   have	   been	   reported313,314,	  
including	   in	   the	   naïve	   T-­‐cell	   compartment	  which	   is	   particularly	   important	   for	   promotion	   of	  GvL42,300,301.	  
One	  approach,	  considered	  during	  the	  design	  of	  this	  trial,	  to	  potentially	  overcome	  this	  issue,	  has	  been	  to	  
infuse	   donor	   lymphocytes	   alongside	   vaccine	   administration.	   However,	   to	   specifically	   address	   whether	  
lymphocyte	   subset	   deficiencies	  were	   present	   in	   subjects	   during	   therapy,	   their	   lymphocyte	   composition	  
prior	  to	  and	  during	  the	  course	  of	  treatment	  were	  assessed.	  	  Comparison	  was	  made	  with	  results	  from	  11	  
healthy,	  age-­‐matched	  volunteers.	  Measurement	  of	  frequencies	  and	  numbers	  of	   lymphocyte	  subsets	  and	  
expression	  of	  activation	  markers	  was	  undertaken	  (Tables	  2-­‐10	  and	  2-­‐11,	  Chapter	  2).	  Study	  of	  T-­‐	  and	  NK-­‐
cell	   populations	   was	   of	   particular	   interest	   given	   the	   prior	   in	   vitro	   data	   demonstrating	   the	   ability	   of	  
CD80/IL-­‐2	   modified	   AML	   blasts	   to	   activate	   leukaemia-­‐specific	   cytotoxicity	   by	   these	   cell	   types120,121.	  
Lymphocyte	  subset	  analysis	  for	  UPN	  13	  is	  not	  discussed	  here.	  This	  is	  because	  the	  rapid	  relapse	  following	  
just	  one	  dose	  of	  DLI	   and	   vaccine	  would	   confound	  evaluation	  of	   the	   impact	  of	  ACV	  and	  DLI,	   due	   to	   the	  
immunosuppressive	  nature	  of	  salvage	  chemotherapy	  and	  active	  leukaemia.	  
	  
5.2.4.1 A	  rise	  in	  lymphocyte	  numbers	  following	  trial	  therapy	  is	  observed	  in	  UPNs	  22	  and	  32	  
Sequential	  peripheral	  blood	  lymphocyte	  numbers	  post-­‐HSCT	  were	  available	  for	  UPNs	  14,	  22	  and	  32	  during	  
routine	  follow-­‐up	  after	  stem	  cell	  infusion,	  at	  relapse	  and	  over	  the	  trial	  monitoring	  period	  (Figure	  5-­‐4	  a	  and	  
b).	   Lymphocyte	  numbers	   in	  UPN	  22	   recovered	   to	  within	   the	  normal	   range	  observed	   in	   the	  11,	  healthy,	  
age-­‐matched	  volunteers,	  from	  around	  1	  year	  post-­‐HSCT	  (Figure	  5-­‐4a).	  The	  decline	  in	  absolute	  lymphocyte	  
count	   after	   relapse	   was	   likely	   due	   to	   the	   lymphodepleting	   effects	   of	   salvage	   chemotherapy.	   UPN	   22’s	  
lymphocyte	  count	  rose	  during	  the	  course	  of	  ACV	  and	  DLI	  administration	  but	  remained	  below	  the	  range	  for	  
healthy	  controls	  at	  the	  end	  of	  the	  trial	  monitoring	  period.	  	  
	  
The	  lymphocyte	  numbers	  in	  UPN	  14	  showed	  a	  gradual	  recovery	  following	  HSCT	  almost	  attaining	  the	  range	  
seen	  in	  the	  healthy	  controls.	  Following	  2	  doses	  of	  DLI	  for	  mixed	  chimerism,	  a	  small	  rise	  in	  the	  lymphocyte	  
numbers	  was	  noted.	  These	  numbers	  remained	  unchanged	  after	  relapse	  and	  receipt	  of	  DLI	  on	  trial,	  despite	  
onset	   of	   cGvHD	   and	   commencement	   of	   immunosuppressive	   therapy.	   Lymphocyte	   numbers	   below	   the	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range	   for	  healthy	  age-­‐matched	  volunteers	  were	  observed	   in	  UPN	  32	  during	   the	  early	  post-­‐HSCT	  period	  
(Figure	   5-­‐4b).	   Following	   salvage	   chemotherapy	   and	   during	   the	   course	   of	   the	   trial,	   a	   marked	   rise	   in	  
lymphocyte	  numbers	  was	  observed.	  This	  may	  have	  been	  due	  to	  ongoing	  lymphocyte	  reconstitution	  post-­‐
HSCT,	  increase	  in	  lymphocyte	  numbers	  following	  infusion	  of	  new	  donor	  lymphocytes	  or	  expansion	  of	  CD8	  
T	  cells	  due	  to	  antigenic	  stimulation,	  for	  example	  by	  the	  herpes	  viruses	  present	  in	  this	  patient	  (described	  in	  
5.2.3).	  
	  
The	  lowest	  pre-­‐study	  baseline	  lymphocyte	  count	  was	  observed	  in	  UPN	  22	  (absolute	  lymphocyte	  count	  470	  
lymphocytes/µl)	  whilst	  baseline	  lymphocyte	  counts	  were	  1520	  lymphocytes/µl	  and	  2800	  lymphocytes/µl	  
in	  UPNs	  14	  and	  32	  respectively.	  Lymphocyte	  numbers	  in	  UPN	  14	  remained	  unchanged	  from	  the	  pre-­‐study	  
levels	  for	  the	  duration	  of	  follow-­‐up.	  Two	  of	  the	  3	  patients,	  UPN	  22	  and	  UPN	  32	  demonstrated	  a	  doubling	  
in	   their	   absolute	   lymphocyte	  numbers	  by	   the	  end	  of	   the	   follow-­‐up	  period	   relative	   to	   the	   start	  of	   study	  
(1100	   lymphocytes/µl	   in	  UPN	  22	  and	  5590	   lymphocytes/µl	   in	  UPN	  32).	  However,	  the	  rise	   in	   lymphocyte	  
numbers	  seen	   in	  UPN	  22	  only	  partially	  corrected	  the	  deficiency	   in	  the	  count	  observed	  following	  salvage	  
chemotherapy	  for	  relapse.	  	  
	  
To	  summarise,	  all	  3	  patients	  demonstrated	  lymphopenia	  early	  post-­‐HSCT.	  A	  rise	   in	   lymphocyte	  numbers	  
during	  the	  course	  of	  therapy	  on	  trial	  was	  observed	  for	  2	  of	  the	  3	  patients,	  of	  whom	  one	  experienced	  a	  rise	  









Figure	  5-­‐4	  (a	  &	  b).	  Absolute	  lymphocyte	  counts	  in	  subjects	  during	  post-­‐transplant	  recovery,	  at	  relapse	  
and	  in	  the	  course	  of	  trial	  monitoring.	  	  






















Horizontal	  dotted	  lines	  encompassing	  light	  grey	  shaded	  areas	  mark	  median	  and	  interquartile	  range	  of	  
lymphocyte	  counts	  in	  eleven	  age-­‐matched	  healthy	  volunteers.	  The	  cross-­‐hatched	  area	  highlights	  the	  
period	  of	  treatment	  and	  follow-­‐up	  on	  the	  RFUSIN2-­‐AML1	  vaccine	  trial.	  Upwards	  arrows	  denote	  
administration	  of	  DLI	  with/without	  ACV	  according	  to	  the	  protocol	  and	  treatment	  assignment.	  Results	  for	  
UPN	  22	  (recipient	  of	  DLI	  and	  ACV,	  5-­‐4a)	  are	  shown	  on	  this	  page	  and	  overleaf	  for	  UPNs	  14	  and	  32	  (who	  
received	  DLI	  only,	  5-­‐4b).	  
	  
DTH,	  delayed	  type	  hypersensitivity	  reaction;	  DLI,	  donor	  lymphocyte	  infusion;	  ACV,	  AML	  Cell	  Vaccine;	  MMF,	  
mycophenolate	  mofetil;	  cGvHD,	  chronic	  Graft-­‐versus-­‐Host	  Disease.	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(b)	  Sequential	  lymphocyte	  counts	  in	  UPNs	  14	  and	  32	  (recipients	  of	  DLI	  only)	  post-­‐HSCT,	  upon	  relapse	  and	  
during	  trial	  monitoring	  
	  
	  














































5.2.4.2 Lymphocyte	  subset	  composition	  in	  trial	  subjects	  differs	  from	  healthy	  volunteers	  and	  remains	  
abnormal	  during	  therapy	  
More	   detailed	   analyses	   of	   the	   frequencies	   and	   numbers	   of	   individual	   lymphocyte	   subsets	   were	  
performed,	  and	  are	  shown	  for	  each	  subject	  in	  Figures	  5-­‐5	  and	  5-­‐6.	  Lymphocyte	  subset	  composition	  in	  the	  
trial	   subjects	   differed	   from	   that	   in	   healthy	   volunteers,	   with	   the	   greatest	   divergence	   observed	   in	   the	  
numbers	  and	  frequencies	  of	  the	  CD4+	  T-­‐cell	  population.	  CD4+	  T-­‐cells	  accounted	  for	  the	  major	  lymphocyte	  
subset	   in	  healthy	  volunteers	   (mean	  48%	  of	  all	   lymphocytes,	  Figure	  5-­‐5).	   In	  UPNs	  14,	  22	  and	  32	  the	  CD4	  
frequencies	  were	  11%,	  24%	  and	  12%	  respectively	  prior	  to	  trial	  therapy.	  At	  the	  end	  of	  the	  trial	  monitoring	  
period,	  the	  CD4+	  T-­‐cell	  percentages	  had	  increased	  in	  UPNs	  14	  and	  22	  but	  remained	  lower	  than	  the	  mean	  
observed	  in	  healthy	  volunteers,	  accounting	  for	  21%	  of	  all	  lymphocytes	  in	  UPN	  14,	  35%	  in	  UPN	  22	  and	  3%	  
in	  UPN	  32.	  This	  deficiency	  in	  the	  CD4+	  T-­‐cell	  populations	  reversed	  the	  normal	  CD4:CD8	  ratios.	  The	  mean	  
ratios	  during	  follow-­‐up	  were	  0.64	  (range	  0.28-­‐1.0)	  for	  UPN	  14,	  0.83	  (range	  0.38-­‐1.56)	  for	  UPN	  22	  and	  0.1	  
(range	  0.05-­‐0.18)	   for	  UPN	  32,	   contrasting	  with	   the	  mean	  CD4:CD8	   ratio	  of	   the	  11	  healthy	  age-­‐matched	  
volunteers	   of	   2.83	   (range	   0.83-­‐5.70).	   A	   lag	   in	   recovery	   of	   CD4+	   T-­‐cell	   numbers	   behind	   that	   of	   other	  
lymphocyte	   subsets	   following	   allogeneic	   transplantation315-­‐317,	   resulting	   in	   an	   inverted	   CD4:CD8	  
ratio313,318,319,	  has	  been	  previously	  reported	  by	  other	  groups.	  
	  
The	  numbers	  of	  B-­‐	  and	  NK-­‐	  cells	  and	  CD8+	  T-­‐cells	   in	  UPN	  14	  were	  similar	  to	  those	  in	  healthy	  volunteers	  
throughout	   the	   trial	   monitoring	   period	   (Figure	   5-­‐6).	   Therefore,	   the	   low	   lymphocyte	   numbers	   in	   this	  
patient	  prior	  to	  and	  during	  receipt	  of	  DLI	  are	  attributable	  to	  the	  deficiency	  in	  the	  CD4+	  T-­‐cell	  population.	  
Numbers	  of	  B-­‐	  and	  NK-­‐	  cells	   in	  UPN	  22	  were	  below	  that	  observed	   in	  healthy	  volunteers	  throughout	  the	  
trial	  follow-­‐up	  period,	  whilst	  numbers	  of	  CD8+	  T-­‐cells	  were	  near	  the	  range	  seen	  in	  the	  healthy	  volunteers.	  
The	  high	  lymphocyte	  count	  observed	  throughout	  therapy	  with	  DLI	  in	  UPN	  32	  was	  due	  to	  a	  large	  expansion	  
of	   CD8+	   T-­‐cells	   that	   was	   evident	   prior	   to	   DLI	   administration	   and	   persisted	   throughout	   follow-­‐up.	   The	  
mean	  CD8+	  T-­‐cell	  percentage	  amongst	  lymphocytes	  in	  the	  healthy	  volunteers	  was	  19.8%.	  At	  the	  time	  of	  
trial	  entry,	  the	  proportion	  of	  CD8+	  T-­‐cells	  amongst	  the	  lymphocyte	  population	  in	  UPN	  32	  was	  73.5%	  and	  
consistently	  comprised	  70-­‐80%	  of	  all	  lymphocytes	  before	  falling	  somewhat	  to	  60%	  by	  the	  end	  of	  follow-­‐up	  
(Figure	  5-­‐5).	  This	  patient	  also	  showed	  a	  rise	  in	  B-­‐cell	  numbers	  and	  frequency	  to	  just	  above	  the	  range	  seen	  
in	   the	  healthy	  volunteers	  during	   the	   follow-­‐up	  period	  after	   completion	  of	  DLI.	   In	   summary,	   lymphocyte	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subset	  composition	  was	  abnormal	  in	  all	  subjects	  during	  the	  course	  of	  therapy	  and	  follow-­‐up	  and	  was	  not	  
altered	  substantially	  following	  administration	  of	  ACV	  and/or	  DLI	  (with	  the	  exception	  of	  the	  increase	  in	  B-­‐
















Lymphocyte	   subset	   frequencies	   were	   sequentially	   analysed	   in	   trial	   subjects	   during	   the	   course	   of	  
treatment	  and	  follow-­‐up.	  Results	  are	  shown	  for	  the	  single	  recipient	  of	  DLI	  and	  ACV	  (UPN	  22)	  and	  the	  two	  
recipients	   of	   DLI	   only	   (UPNs	   14	   &32)	   on	   this	   and	   the	   following	   page	   respectively.	  Mean	   and	   standard	  
deviation	  are	  shown	  in	  each	  plot	  for	  11,	  healthy,	  age-­‐matched	  controls.	  
	  
























































Figure	  5-­‐5	  Lymphocyte	  subset	  composition	  in	  UPNs	  14	  &	  22	  is	  similar	  to	  that	  in	  healthy	  volunteers	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Absolute	  numbers	  of	  lymphocyte	  subsets	  were	  monitored	  sequentially	  in	  trial	  subjects	  during	  the	  course	  
of	  treatment	  and	  follow-­‐up.	  Results	  for	  the	  recipient	  of	  DLI	  and	  ACV	  (UPN22)	  and	  the	  two	  recipients	  of	  DLI	  
only	  (UPNs	  14	  and	  32)	  are	  shown	  on	  this	  page,	  and	  the	  following	  page,	  respectively.	  Mean	  and	  standard	  
deviation	  are	  shown	  in	  each	  plot	  for	  11,	  healthy,	  age-­‐matched	  volunteers	  (HV).	  
Figure	  5-­‐6	  Sequential	  analysis	  of	  lymphocyte	  subset	  numbers	  reveals	  reduced	  CD4+	  T-­‐cell	  numbers	  in	  all	  trial	  
subjects	  relative	  to	  healthy	  volunteers.	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5.2.4.3 CD4+	  and	  CD8+	  T-­‐cell	  subset	  composition	  is	  unchanged	  in	  subject	  during	  trial	  therapy	  
CD4+	  and	  CD8+	  T-­‐cell	  subset	  compositions	  were	  also	  assessed	  (Figures	  5-­‐7	  and	  5-­‐8	  respectively).	  Overall,	  
individual	   subsets	   showed	   stable	   frequencies	   over	   the	   course	   of	   follow-­‐up	   in	   all	   3	   patients.	   CD4+	   and	  
CD8+	  naïve,	  memory	  and	  effector	  T-­‐cell	  subset	  frequencies	  were	  most	  similar	  to	  the	  healthy	  volunteers	  in	  
UPNs	  14	  and	  22.	  Both	  of	  these	  patients	  were	  at	  least	  1	  year	  post	  allogeneic	  HSCT,	  possibly	  explaining	  the	  
near	  normal	  frequencies	  in	  these	  patients.	  By	  contrast,	  UPN	  32	  (who	  had	  undergone	  allogeneic	  HSCT	  less	  
than	  1	  year	  prior)	  differed	  most	  profoundly	  from	  healthy	  volunteers,	  with	  very	  high	  frequencies	  of	  CD4+	  
effector	  and	  CD8+	  terminal	  effector	  T-­‐cells	  and	  low	  frequencies	  of	  CD4+	  or	  CD8+	  naïve	  T-­‐cells.	  Analysis	  of	  
HLA-­‐DR	   expression	   on	   CD4+	   and	   CD8+	   T-­‐cells	   in	   UPN	   32	  was	   used	   to	   assess	   activation	   status	   of	   these	  
subsets320.	   High	   expression	   of	   HLA-­‐DR	   on	   over	   80%	   of	   CD4+	   and	   CD8+	   T-­‐cells	   was	   observed	   at	   study	  
baseline	   in	   this	   patient	   and	  waned	   during	   the	   course	   of	   follow-­‐up	   (Figure	   5-­‐9).	   By	   contrast,	   the	  mean	  
percentages	  of	  DR+	  T-­‐cells	  during	  follow-­‐up	  on	  trial	  were	  24%	  (CD4+)	  and	  38%	  (CD8+)	  in	  UPN	  14	  and	  30%	  
(CD4+)	  and	  57%	  (CD8+)	  in	  UPN	  22,	  with	  little	  change	  during	  the	  course	  of	  therapy	  (data	  not	  shown).	  The	  
activated	  profile	  and	  skewing	  of	  the	  T-­‐cell	  subsets	  again	  identifies	  activation	  and	  expansion	  of	  effector	  T-­‐
cells	   in	   UPN	   32.	   This	   could	   reflect	   ongoing	   activation	   of	   effector	   cells	   as	   a	   result	   of	   recent	   transplant	  
conditioning	  and	  chemotherapy	  or	  potentially	   responses	  against	  antigenic,	  microbial	   stimuli	  e.g.	  herpes	  
















CD4+	   T-­‐cell	   subset	   composition	  was	   determined	   for	   each	   trial	   subject	   during	   treatment	   and	   follow-­‐up.	  
Results	  for	  the	  recipient	  of	  DLI	  and	  ACV,	  UPN	  22,	  are	  shown	  on	  this	  page	  and	  for	  the	  two	  recipients	  of	  DLI	  
alone	  (UPNs	  14	  and	  32)	  on	  the	  next	  page.	  Mean	  and	  standard	  deviation	  of	  CD4+	  T-­‐cell	  subset	  frequencies	  
in	  11	  age-­‐matched	  volunteers	  is	  shown	  in	  each	  plot.	  
Legend
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Figure	  5-­‐7	  Despite	  a	  numerical	  reduction	  in	  CD4+	  T-­‐cells,	  CD4+	  T-­‐cell	  subset	  composition	  is	  similar	  to	  
controls	  in	  UPNs	  14	  &	  22.	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Figure	  5-­‐7	  continued





























































































CD8+	   T-­‐cell	   subset	   composition	  was	   determined	   for	   each	   trial	   subject	   during	   treatment	   and	   follow-­‐up.	  
Results	  for	  the	  recipient	  of	  DLI	  and	  ACV,	  UPN	  22,	  are	  shown	  on	  this	  page,	  and	  those	  for	  the	  two	  recipients	  
of	  DLI	   alone	   (UPNs	  14	   and	  32)	   are	   on	   the	   following	  page.	  Mean	   and	   standard	  deviation	  of	   CD8+	   T-­‐cell	  


















































































































































The	   frequencies	   of	   CD4+	   and	   CD8+	   T-­‐cells	   that	   were	   HLA-­‐DR	   positive	   at	   sequential	   time	   points	   were	  




















































Figure	  5-­‐9	  CD4+	  and	  CD8+	  T-­‐cells	  in	  UPN	  32	  showed	  an	  activated	  phenotype	  at	  baseline	  that	  waned	  during	  follow-­‐up	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5.2.4.4 No	  expansion	  of	  peripheral	  blood	  regulatory	  	  CD4+	  T-­‐cells	  is	  observed	  following	  administration	  
of	  DLI	  and	  ACV.	  
An	  important	  CD4+	  T-­‐cell	  population	  in	  the	  context	  of	  the	  ACV	  is	  the	  regulatory	  T-­‐cell	  (Treg)	  subset.	  The	  
secretion	  of	  interleukin-­‐2	  by	  the	  CD80/IL-­‐2	  modified	  AML	  vaccine	  could	  theoretically	  promote	  expansion	  
of	   Tregs	   with	   the	   capacity	   to	   suppress	   anti-­‐leukaemic	   effector	   functions.	   However,	   our	   previously	  
published	   in	   vitro	   data	   suggested	   that	   whilst	   the	   absolute	   numbers	   of	   Tregs	   rose	   in	   some	   co-­‐cultures	  
containing	   CD80/IL-­‐2	   modified	   blasts	   and	   PBMCs,	   lysis	   of	   AML	   blasts	   was	   not	   inhibited261.	   Sequential	  
analysis	   of	   Tregs,	   defined	   as	   CD27+	   FoxP3+	   CD25+	   CD4+	   T-­‐cells,	   in	   the	   peripheral	   blood	   of	   UPN	   22	  
revealed	  no	  change	  in	  numbers	  because	  of	  treatment	  (Figure	  5-­‐10).	  Expression	  of	  CD27	  on	  CD4+	  CD25+	  
FoxP3+	  cells	  was	  used	  to	  distinguish	  Tregs	  from	  activated	  CD4+	  effectors	  that	  transiently	  express	  FoxP3+	  
but	  are	  CD27	  negative321,322.	  
	  
The	  Treg	  population	  was	  markedly	  reduced	  in	  size	  relative	  to	  age-­‐matched	  controls	  in	  all	  3	  patients	  during	  
follow-­‐up,	   likely	   reflecting	   the	   low	   numbers	   of	   CD4+	   T-­‐cells	   after	   lymphodepleted	   HSCT.	   However,	   the	  
mean	  frequencies	  of	  Tregs	  amongst	  the	  CD4+	  T-­‐cell	  population	  in	  UPNs	  14,	  22	  and	  32	  were	  5.5%,	  8%	  and	  
2.6%	  respectively,	  which	  were	  similar	  values	  to	  the	  mean	  frequency	  observed	   in	   the	  healthy	  volunteers	  
(5.3%,	  ranging	  from	  3-­‐8.2%).	  There	  was	  no	  evidence	  of	  expansion	  of	  CD25	  (IL-­‐2Rα)-­‐bearing	  T-­‐regulatory	  
cells	  despite	  high	  levels	  of	  IL-­‐2	  in	  the	  serum	  of	  UPN	  32.	  Of	  note,	  a	  sustained	  rise	  in	  absolute	  Treg	  numbers	  
was	  seen	  in	  UPN	  14	  from	  approximately	  week	  28	  onwards,	  temporally	  associated	  with	  the	  onset	  of	  liver	  
cGvHD	  in	  this	  patient.	  A	  rise	  in	  Treg	  numbers	  in	  peripheral	  blood	  following	  the	  onset	  of	  cGvHD	  has	  been	  
previously	  observed	  in	  patients	  developing	  cGvHD	  following	  a	  similar	  RIC	  regimen	  that	  used	  alemtuzumab	  






















Absolute	  numbers	  of	  CD4+	  CD25+	  FoxP3+	  CD27+	  regulatory	  T-­‐cells	  in	  the	  recipient	  of	  DLI	  and	  ACV,	  UPN	  
22,	  are	  shown	  on	  this	  page	  and	  in	  the	  two	  recipients	  of	  DLI	  only	  (UPNs	  14	  and	  32)	  on	  the	  following	  page.	  



































Figure	  5-­‐10	  No	  expansion	  of	  peripheral	  blood	  regulatory	  T-­‐cell	  numbers	  in	  UPN	  22	  following	  DLI	  and	  ACV	  
administration	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5.2.4.5 Higher	  than	  normal	  proportions	  of	  CD56	  “bright”	  NK-­‐cells	  observed	  in	  UPNs	  22	  and	  32	  
Previously	  published	  in	  vitro	  data	  demonstrated	  that	  not	  only	  T-­‐cells	  but	  also	  NK-­‐cells	  could	  be	  activated	  
more	  effectively	  by	  CD80/IL-­‐2	  modified	  AML	  blasts	  compared	  with	  unmodified	  blasts,	  resulting	  in	  superior	  
lysis	  of	  primary	  unmodified	  AML	  targets121.	  Furthermore,	  IL-­‐2	  is	  capable	  of	  inducing	  NK-­‐cell	  proliferation.	  
Indeed,	   up-­‐regulation	   of	   a	   selection	   of	   NK-­‐cell	   activation	   receptors	   (DNAM1,	   NKp44	   and	   NKG2D)	   was	  
described	   following	   exposure	   of	   NK-­‐cells	   to	   CD80/IL-­‐2	   modified	   blasts	   in	   the	   in	   vitro	   experiments121.	  
Therefore,	  the	  number	  and	  activation	  status	  of	  peripheral	  blood	  NK-­‐cells	  was	  assessed	  during	  the	  course	  
of	  vaccine	  therapy	  and/or	  DLI	  by	  a	  sequential	  analysis	  of	  the	  major	  NK-­‐cell	  populations	  in	  the	  PB	  of	  trial	  
subjects	  during	  follow-­‐up.	  	  
	  
Figures	  5-­‐5	  and	  5-­‐6	  show	  the	  analyses	  of	  NK-­‐cell	  frequencies	  and	  numbers	  within	  UPNs	  14,	  22	  and	  32	  at	  
trial	   monitoring	   time	   points.	   Absolute	   CD56+	   NK-­‐cell	   number	   and	   frequency	   were	   highest	   throughout	  
follow-­‐up	  in	  UPN	  14,	  remaining	  within	  the	  range	  exhibited	  by	  the	  healthy	  volunteers,	  but	  were	  below	  the	  
normal	  range	  in	  UPNs	  22	  and	  32.	  The	  numbers	  of	  CD56+	  NK-­‐cells	  in	  the	  peripheral	  blood	  in	  each	  of	  the	  3	  
patients	  showed	  no	  sustained	  changes	  during	  the	  course	  of	  DLI	  treatments.	  Figure	  5-­‐11	  shows	  the	  NK-­‐cell	  
subset	   analyses,	   separated	   into	   CD56	   “bright”	   and	   CD56	   “dim”	   populations,	   for	   the	   trial	   subjects	   and	  
healthy	   volunteers.	   A	   high	   proportion	   of	   CD56	   “bright”	   NK-­‐cells	   relative	   to	   healthy	   volunteers	   was	  
observed	  in	  UPNs	  22	  and	  32,	  whereas	  the	  NK-­‐cell	  subset	  composition	  in	  UPN	  14	  closely	  resembled	  that	  of	  
the	   healthy	   volunteers.	   These	   differences	   remained	   unchanged	   during	   and	   after	   ACV	   and/or	   DLI	  
administration.	  The	   increased	   frequency	  of	  CD56	  “bright”	  NK-­‐cells	   in	  UPNs	  22	  and	  32	   is	  consistent	  with	  
previous	   reports	   of	  NK-­‐cell	   subset	   composition	   post-­‐HSCT324,325	   and	  was	   unaltered	   by	  DLI	  with/without	  
ACV.	  No	  changes	  to	  expression	  of	  the	  activation	  markers	  DNAM1,	  NKG2D	  and	  NKp44	  on	  peripheral	  blood	  













Results	  of	  sequential	  analysis	  of	  NK-­‐cell	  subsets	  (CD56bright	  and	  CD56dim	  populations)	  during	  treatment	  and	  
follow-­‐up	  time	  points	  are	  shown	  for	  UPN	  22	  on	  this	  page	  and	  for	  the	  two	  recipients	  of	  DLI	  only,	  UPNs	  14	  
and	  32,	  on	  the	  following	  page.	  Mean	  and	  standard	  deviation	  of	  the	  subset	  frequencies	  are	  shown	  in	  each	  
plot	  for	  11	  healthy	  age-­‐matched	  volunteers.	  




















































Figure	  5-­‐11	  Increased	  frequency	  of	  CD56	  “bright”	  NK-­‐cells	  in	  trial	  subjects	  in	  comparison	  to	  healthy	  
volunteers.	  
228	  


























































































5.2.5 TCRβ 	  repertoire	  analysis	  in	  trial	  subjects	  	  
An	   important	   factor	   likely	   to	   affect	   the	   efficacy	   of	   the	   AML	   cell	   vaccination	   is	   the	   diversity	   of	   the	   TCR	  
repertoire	  in	  these	  patients.	  A	  narrowed	  TCR	  repertoire	  might	  possess	  few	  leukaemia-­‐reactive	  T-­‐cells	  and	  
therefore	  represent	  a	  poor	  responder	  population	  for	  activation	  by	  the	  ACV.	  	  DLI	  is	  administered	  as	  part	  of	  
the	  trial	  protocol	  with	  the	  aim	  of	  increasing	  T	  cell	  numbers	  and	  repertoire	  diversity.	  	  	  
	  
Adaptive	  Biotechnologies,	  Seattle,	  provide	  a	  commercial	  high	  throughput	  sequencing	  (HTS)	  assay	  service	  
for	  analysis	  of	  the	  TCRβ	  CDR3	  region	  using	  genomic	  or	  cDNA	  as	  a	  sensitive	  means	  to	  evaluate	  diversity	  of	  
the	   repertoire.	   The	   technique	   also	   has	   utility	   for	   tracking	   changes	   in	   specific	   clone	   frequencies	   at	  
sequential	  time	  points275,326.	  Genomic	  DNA	  samples	  were	  sent	  to	  Adaptive	  Biotechnologies	  for	  analysis	  of	  
TCRβ	   repertoire	   diversity	   in	   UPNs	   14	   and	   22.	   These	   2	   patients	   were	   chosen	   for	   initial	   study	   as	  
representatives	  of	  each	   trial	   arm.	   Furthermore,	   they	  were	  both	   treated	  and	   studied	  at	   similar	  duration	  
after	   HSCT.	   	   Samples	   from	   selected	   trial	   monitoring	   time	   points	   were	   sent	   for	   these	   preliminary	  
investigations.	  Sampling	  time	  points	  were	  chosen	  to	  broadly	  cover	  the	  period	  prior	  to	  and	  following	  DLI	  
treatment	  to	  investigate	  whether	  any	  changes	  to	  TCR	  repertoire	  diversity	  were	  observed	  after	  infusion	  of	  
donor	   T-­‐cells.	   The	   number	   and	   frequencies	   of	   productive	   (in-­‐frame)	   unique	   CDR3	   sequences	   were	  
determined	   and	   used	   to	   derive	   a	   measurement	   of	   T-­‐cell	   clonality	   at	   each	   time	   point	   (Figure	   5-­‐12).	  
Individual	  unique	  productive	  CDR3	  sequences	  were	  tracked	  to	  assess	  any	  changes	  in	  frequency	  during	  and	  
after	  treatment	  (Figure	  5-­‐13).	  
	  
The	  number	  of	  sequence	  reads	  per	  patient	  ranged	  between	  0.95x106-­‐1.8x106	  for	  the	  4	  samples	  analysed	  
for	  UPN	  14	  and	  between	  0.36x106-­‐1.1x106	  for	  the	  7	  analysed	  from	  UPN	  22	  (Table	  5-­‐3).	  Such	  sequencing	  
depths	  were	  sufficient	   to	  allow	  an	  estimation	  of	   repertoire	  diversity.	  Productive	   (in-­‐frame	  and	   lacking	  a	  
stop	   codon)	   uniquely	   rearranged	   TCRβ	   CDR3	   regions	   sequences	   were	   identified	   using	   ImmunoSEQ	  
analysis	   software	   (Adaptive	   Biotechnologies)	   for	   each	   sample	   based	   on	   the	   accepted	   IMGT	   consensus	  
definitions327.	   The	   number	   of	   productive	   unique	   sequences	   ranged	   from	   5,837-­‐13,436	   for	   UPN	   14	   and	  
7,741-­‐15,091	  for	  UPN	  22	  (Table	  5-­‐3	  and	  Figure	  5-­‐12).	  Recent	  published	  data	  using	  the	  same	  technology	  
230	  
detected	  a	  median	  of	  629,606	  productive	  unique	  TCRβ	  CDR3	  sequences	   (range:	  58,009	  to	  1,161,823)	   in	  
healthy	  stem	  cell	  donors328.	  	  
Therefore,	  the	  2	  trial	  subjects	  demonstrated	  a	  lower	  number	  of	  unique	  productive	  CDR3	  sequences	  than	  
younger,	   healthy	   donors	   both	   before	   and	   after	   treatment,	   likely	   due	   to	   the	   T-­‐cell	   depleted	   transplant	  




Table	  5-­‐3	  Summary	  of	  TCRβ	  sequencing	  data	  derived	  from	  analyses	  using	  the	  ImmunoSEQ	  analysis	  tool	  
























































































































































































































































































































































































































































































































































































































































































































*OOF,	  Out	  of	  frame.	  See	  methods	  for	  description	  of	  entropy	  calculations.	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An	  assessment	  of	   repertoire	  diversity	  was	  made	  using	  a	  modification	  of	   Shannon’s	  entropy	   (Table	  5-­‐3).	  
Entropy	  is	  a	  commonly	  used	  metric	  of	  diversity	  that	  increases	  with	  both	  the	  number	  of	  elements	  (unique	  
sequences)	  and	  as	   the	  evenness	   (in	   frequency)	   increases.	  For	  a	  given	  number	  of	   sequences,	  diversity	   is	  
maximized	  when	  all	  sequences	  are	  equally	  abundant.	  As	  entropy	  is	  sensitive	  to	  the	  number	  of	  sequences	  
considered,	   to	   account	   for	   variation	   in	   sequencing	   depth,	   entropy	   was	   normalized	   by	   the	   log2	   of	   the	  
number	  of	  productive	  unique	  sequences.	  Clonality	  was	  then	  defined	  as	  the	  inverse	  of	  normalized	  entropy	  
to	  provide	  a	  metric	  varying	  between	  0	  and	  1.	  For	  the	  purpose	  of	  characterizing	  the	  immune	  repertoire,	  a	  0	  
value	  is	  returned	  when	  all	  sequences	  are	  equally	  abundant	  and	  1	  when	  a	  single	  sequence	  makes	  up	  the	  
entire	  sample	  (see	  methods).	  	  
	  
Figure	  5-­‐12	  depicts	  the	  results	  of	  serial	  analyses	  of	  the	  number	  of	  unique	  productive	  TCRβ	  sequences	  and	  
clonality	   for	   UPNs	   14	   and	   22	   listed	   in	   Table	   5-­‐3.	   The	   increasing	   number	   of	   unique	   productive	   CDR3	  
sequences	  observed	  during	  the	  course	  of	  DLI	  administration	  in	  UPN	  14,	  was	  associated	  with	  a	  reduction	  in	  
clonality,	  suggesting	  an	  increase	  in	  TCR	  repertoire	  diversity	  after	  DLI.	  No	  samples	  beyond	  the	  last	  dose	  of	  
DLI	   have	   thus	   far	   been	  analysed	   for	  UPN	  14	  and	   therefore	   changes	   to	   the	   repertoire	   size	   and	   clonality	  
during	   the	   onset	   and	   therapy	   of	   cGvHD	   are	   unknown.	   A	   small	   increase	   in	   the	   numbers	   of	   unique	  
productive	  sequences	  was	  observed	   in	  UPN	  22	  after	  the	  second	  and	  third	  doses	  of	  DLI	  and	  ACV,	  before	  
falling	   at	   the	   end	  of	   follow-­‐up	   to	   levels	   seen	   at	   the	   start	   of	   treatment.	   In	   contrast	   to	  UPN	  14,	  UPN	  22	  





















The	  number	  of	  unique	  productive	  (in-­‐frame,	  stop	  codon	   lacking)	  TCRβ CDR3	  sequences	  was	  determined	  
for	  each	  patient	  at	  each	  sampling	  time	  point	  (green	  line).	  Clonality	  (derived	  using	  a	  measure	  of	  Shannon’s	  
entropy)	  at	  each	  sampling	  time	  point	  is	  shown	  in	  blue.	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Figure	  5-­‐12	  TCRβ	  repertoire	  diversity	  increased	  during	  treatment	  in	  both	  UPNs	  14	  and	  22	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To	   investigate	   the	   increase	   in	  clonality	  observed	   in	  UPN	  22	  by	  week	  30,	   the	  most	  abundant	  TCRβ CDR3	  
sequences	   representing	   the	  dominant	  T-­‐cell	   clones	  at	   the	   last	   follow	  up	   time	  points	  were	   tracked	  back	  
through	   earlier	   time	   points.	   	   Tracking	   of	   the	   most	   abundant	   clones	   detected	   at	   week	   18	   was	   also	  
performed	  for	  UPN	  14.	  The	  tracked	  frequencies	  of	  the	  top	  25	  clones	  at	  the	  last	  follow	  up	  point	  for	  both	  
patients	  are	  shown	  in	  Figure	  5-­‐13.	  	  
	  
The	  top	  25	  clones	   in	  UPN	  14	  at	  week	  18	  were	  present	  at	  consistently	  high	  frequencies	  during	  and	  after	  
treatment,	   indicating	   stability	   of	   the	   repertoire.	   	   Only	   3	   of	   the	   25	   top	   clones	   at	   week	   18	   were	   not	  
previously	   detected	   at	   week	   0	   in	   this	   subject.	   Of	   note,	   UPN	   14	   also	   showed	   stable,	   full	   donor	   T-­‐cell	  
chimerism	  prior	  to	  receipt	  of	  DLI,	  which	  persisted	  during	  the	  course	  of	  therapy	  and	  follow-­‐up.	  	  
	  
By	   contrast,	   there	  was	   a	   complete	   change	   in	   the	   repertoire	   of	   the	   dominant	   clones	   in	   UPN	   22	   during	  
treatment.	  	  None	  of	  the	  10	  most	  abundant	  clones	  in	  UPN	  22	  at	  week	  30	  were	  detected	  at	  week	  0	  prior	  to	  
DLI.	   	   Most	   of	   these	   clones	   began	   to	   emerge	   from	   week	   15	   and	   rapidly	   increased	   to	   supersede	   the	  
dominant	  clones	  present	  before	  treatment.	  The	  time-­‐course	  of	   the	  emergence	  of	   these	  clones	  suggests	  
that	   they	  were	   introduced	  with	   the	  DLI	   and	  underwent	   extensive	  proliferation,	   perhaps	   in	   response	   to	  
antigen	  stimulation.	  This	  timing	  also	  coincides	  with	  conversion	  to	  full	  donor	  T-­‐cell	  chimerism	  in	  UPN	  22,	  
which	  was	   detected	   from	  week	   22	  onwards.	   In	   fact,	   the	   last	   donor	   T-­‐cell	   chimerism	  assessment	  was	   7	  
weeks	   prior	   to	   that,	   at	  week	   15,	   therefore	   conversion	   to	   full	   donor	   T-­‐cell	   chimerism	   could	   have	   taken	  
place	  at	  any	  time	  between	  weeks	  15	  and	  22,	  indicating	  that	  dominant	  T-­‐cell	  clones	  arising	  from	  this	  time	  






















Frequencies	  of	  individual	  clonotypes	  identified	  by	  unique	  productive	  CDR3	  sequences	  as	  a	  proportion	  
of	  the	  total	  reads	  at	  weeks	  18	  and	  30	  in	  UPNs	  14	  and	  22	  respectively	  were	  determined.	  Each	  
clonotype	  was	  then	  sorted	  in	  order	  of	  frequency	  and	  their	  prior	  frequencies	  tracked	  to	  investigate	  any	  
changes	  in	  frequencies	  during	  follow-­‐up.	  Clones	  that	  were	  present	  at	  week	  0	  are	  coloured	  in	  grey.	  
Clones	  that	  became	  detectable	  at	  later	  time	  points	  are	  coloured	  blue.	  The	  public	  EBV	  antigen-­‐specific	  
clonotypes	  CSVGTGGTNEKLFF	  and	  CSVGSGGTNEKLFF	  that	  are	  among	  the	  top	  25	  clones	  at	  the	  last	  time	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Figure	  5-­‐13	  Tracking	  the	  frequencies	  of	  the	  top	  25	  TCRβ 	  CDR3	  clones	  
present	  at	  either	  week	  18	  in	  UPN	  14	  or	  week	  30	  in	  UPN	  22.	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The	   CDR3	   amino	   acid	   sequences	   of	   the	   top	   10	   clones	   at	  week	   30	   in	   UPN	   22	  were	   predicted	   from	   the	  
nucleotide	   templates	   (Table	   5-­‐4).	   No	   obvious	   shared	   pattern	   or	   motif	   is	   observed	   among	   the	   CDR3	  
sequences,	  furthermore	  it	  is	  neither	  possible	  to	  imply	  or	  exclude	  from	  these	  sequences	  that	  recognition	  of	  
similar	   targets	   by	   these	   clones	   has	   occurred.	   Interestingly,	   two	   of	   the	   sequences	   are	   known	   public	  
clonotypes	   previously	   identified	   in	   T-­‐cells	   specific	   for	   HLA-­‐A*02:01	   binding	   the	   immunodominant	   EBV-­‐
derived	  peptide	  GL9	  (a	  nonamer	  sequence,	  GLCTLVAML259-­‐267,	  from	  within	  the	  early	  lytic	  protein	  BamHI-­‐M	  
leftward	   reading	   frame	   1,	   BMLF1)329,330.	   Such	   public	   TCR	   clonotypes	   comprise	   residue-­‐identical	   CDR3	  
sequences	  with	  the	  same	  Vβ	  and	  Jβ	  gene	  usage.	  	  They	  occur	  repeatedly	  within	  multiple	  individuals	  sharing	  
a	  specific	  MHC-­‐type.	  Public	  TCR	  clonotypes	  have	  most	  frequently	  been	  reported	  in	  the	  context	  of	  certain	  
infectious	   diseases	   (such	   as	   EBV,	   CMV)	   but	   are	   now	   increasingly	   being	   identified	   in	   other	   pathological	  
states	  such	  as	  malignancy	  and	  autoimmune	  disease331.	  
	  
Table	  5-­‐4	  Amino	  acid	  sequences	  and	  V	  and	   J	  gene	  usage	  of	   the	  CDR3	  regions	  of	   the	  10	  most	  abundant	  
clones	  at	  week	  30	  in	  UPN	  22	  (unique	  productive	  sequences	  only)	  
Amino	  acid	  sequence	   Variable	  (V)	  	  
beta-­‐chain	  gene	  
Junctional	  (J)	  	  
beta-­‐chain	  gene	  
Frequency	   of	   all	  
reads	  (%)	  
CSVGSGGTNEKLFF*	   TRB	  V29-­‐1	   TRB	  J1-­‐4	   6.75%	  
CASYLGRGIGDEQYF	   TRB	  V11-­‐2	   TRB	  J2-­‐7	   3.40%	  
CSVGTGGTNEKLFF*	   TRB	  V29-­‐1	   TRB	  J1-­‐4	   2.92%	  
CASGTEAFF	   TRB	  V12-­‐5	   TRB	  J1-­‐1	  	   2.60%	  
CASSKAGQGGDTEAFF	   TRB	  V9-­‐1	   TRB	  J1-­‐5	   1.19%	  
CASSLASRVGTDTQYF	   TRB	  V5-­‐1	   TRB	  J2-­‐3	   1.18%	  
CASSLGVSQPQHF	   TRB	  V12-­‐3/12-­‐4	   TRB	  J1-­‐1	   0.85%	  
CASSMGGNYGYTF	   TRB	  V9-­‐1	   TRB	  J1-­‐2	   0.72%	  
CASGRWNNEQFF	   TRB	  V12-­‐5	   TRB	  J2-­‐1	   0.64%	  
CASSPILGDTEAFF	   TRB	  V3-­‐1	   TRB	  J1-­‐1	   0.62%	  
*public	  clonotypes	  that	  recognise	  GL9/A2*01	  
CDR3	   sequences,	   Vβ	   and	   Jβ	   identities	   matched	   using	   the	   international	   IMmunoGeneTics	   (IMGT)	  
database278,332;	  TRB,	  T-­‐cell	  receptor	  β-­‐chain	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To	   put	   our	   observed	   clonotype	   frequencies	   into	   context,	   a	   recently	   published	   study	   of	   TCR	   repertoire	  
recovery	   after	   HSCT,	   using	   5’	   rapid	   amplification	   of	   cDNA	   ends	   PCR,	   found	   that	   19	   clonotypes	   at	  
frequencies	  >1%,	  were	  observed	  in	  a	  patient	  at	  138	  days	  post-­‐HSCT,	  with	  the	  highest	  clonotype	  frequency	  
reaching	  11%333.	  By	  contrast,	  individual	  clonotypes	  rarely	  accounted	  for	  more	  than	  1%	  of	  clones	  in	  healthy	  
volunteers.	   One	   of	   the	   dominant	   clonotypes	   identified	   by	   this	   group	   was	   the	   same	   public	   clonotype	  
CSVGSGGTNEKLFF	  observed	  in	  our	  study,	  which	  became	  prominent	  during	  an	  episode	  of	  EBV	  reactivation	  
in	  that	  patient333.	  	  
	  
UPN22	  is	  EBV	  antigen	  positive	  and	  therefore	  harboured	  latent	  virus	  within	  tissues.	  	  The	  two	  HLA-­‐A*02:01	  
restricted	   EBV	   specific	   public	   TCR	   clonotypes	  were	  not	   detected	   in	  UPN	  22	  prior	   to	   receipt	   of	  DLI.	   The	  
donor	   of	   UPN22	   was	   seronegative	   for	   EBV	   IgG	   indicating	   that	   the	   EBV	   specific	   T-­‐cells	   that	   expanded	  
rapidly	   after	   DLI	   likely	   emerged	   from	   the	   naïve	   T-­‐cell	   population	  within	   the	  DLI	   upon	   exposure	   to	   EBV	  
antigen	   in	   the	   patient.	   Emergence	   of	   new	   clonotypes	   after	   DLI	   suggests	   that	   delayed	   add	   back	   can	  
replenish	  the	  T-­‐cell	  repertoire.	  Screening	  for	  EBV	  reactivation	  by	  EBV	  PCR	  analysis	  on	  peripheral	  blood	  in	  
UPN	  22	  was	  negative	  at	  all	  trial	  time	  points	  prior	  to	  week	  22,	  at	  which	  point	  a	   low	  copy	  number	  of	  446	  
copies/ml	   was	   detected.	   EBV	   remained	   detectable	   (between	   92-­‐771	   copies	   per	   ml)	   until	   the	   last	  
monitoring	  time	  point	  in	  this	  patient.	  Prior	  to	  study	  entry,	  UPN22	  had	  experienced	  intermittent	  low-­‐level	  
fluctuations	   in	   EBV	   copy	   number	   of	   similar	   magnitude	   in	   their	   peripheral	   blood	   (data	   not	   shown).	  
Expansion	  of	  EBV	  specific	  clonotypes	  preceded	  the	  detection	  of	  EBV	  by	  PCR	  in	  the	  peripheral	  blood	  of	  the	  
recipient	  during	  the	  trial	  monitoring	  period.	  Given	  that	  EBV	  antigen	  would	  be	  present	  within	  the	  tissues	  of	  
the	  recipient,	  it	  is	  conceivable	  that	  expansion	  of	  EBV-­‐specific	  clones	  could	  occur	  without	  detectable	  EBV	  in	  
peripheral	  blood.	  
	  
By	  comparison,	  the	  EBV	  specific	  clonotype	  CSVGTGGTNEKLFF	  was	  observed	  in	  UPN	  14,	  who	  is	  also	  HLA-­‐
A*02:01+,	  at	  a	  frequency	  of	  1.8%	  at	  week	  18	  and	  this	  clone	  was	  detected	  before	  administration	  of	  DLI,	  at	  
week	  0	  (Figure	  5-­‐13).	  UPN	  14	  and	  their	  donor	  were	  both	  known	  to	  be	  EBV	  antigen	  positive.	  Furthermore	  
UPN	  14	  had	   full	   donor	  T-­‐cell	   chimerism	  at	   the	   time	  of	   receiving	   the	   first	  DLI.	   EBV	  was	   first	  detected	  at	  
week	  3	   in	  the	  peripheral	  blood	  of	  UPN	  14,	  at	  which	  point	  a	  very	   low	  copy	  number	  of	  92	  copies/ml	  was	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found.	  EBV	   then	  became	   transiently	  detectable	  at	  week	  24	  when	  918	  copies/ml	  were	  detected,	  before	  
becoming	   undetectable	   over	   the	   remainder	   of	   follow-­‐up	   on	   trial.	   This	   subject	   therefore	   showed	   no	  
dramatic	   clonal	   turnover	   following	  DLI	   or	   change	   in	   donor	   T-­‐cell	   chimerism	   and	   showed	   stability	   of	   an	  
EBV-­‐specific	  clonotype	  through	  treatment.	  Since	  UPN	  14’s	  donor	  had	  previously	  been	  exposed	  to	  EBV,	  by	  
contrast	  to	  UPN	  22’s	  donor,	  stimulation	  and	  expansion	  of	  naïve	  donor	  T-­‐cells	  would	  not	  be	  expected	  to	  
occur.	  
	  
These	  preliminary	  data	  show	  that	  although	  TCR	  repertoire	  diversity	  is	  reduced	  in	  trial	  subjects	  compared	  
with	   healthy	   donors,	   responses	   to	   antigens	   such	   as	   EBV	   emerge	   after	  DLI	   administration.	   A	   number	   of	  
other	   clonotypes	  were	  also	  only	  detected	   in	  UPN	  22	   following	  DLI	   administration	  and	  underwent	   rapid	  
expansion.	  At	  present,	   their	   antigen	   specificity	   remains	  unknown.	  However,	   these	   findings	   suggest	   that	  
DLI	  may	  also	  enable	  responses	  to	  other	  antigens,	  such	  as	  epitopes	  within	  the	  AML	  cell	  vaccine.	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5.3 Discussion	  
These	   data	   describe	   a	   novel	   approach	   to	   improve	   the	   unsatisfactory	   long-­‐term	   responses	   observed	   in	  
patients	   treated	   with	   therapeutic	   DLI	   for	   relapsed	   acute	   myeloid	   leukaemia.	   This	   is	   the	   first	   study	   to	  
combine	  a	  patient-­‐specific,	  gene-­‐modified	  whole	  AML	  cell	  vaccine	  with	  an	   immunotherapeutic	  platform	  
of	   DLI	   following	   salvage	   chemotherapy	   for	   relapsed	   AML,	   with	   the	   goal	   of	   generating	   a	   durable	   and	  
effective	  GvL	  response.	  The	  use	  of	  a	  whole	  cell	  vaccine	  enables	  presentation	  of	  a	  range	  of	  both	  defined	  
and	   undefined	   leukaemia-­‐associated	   antigens	   to	   the	   donor	   immune	   system.	   These	   include	  
haematopoietic-­‐cell	   restricted	  mHags	  capable	  of	  stimulating	  alloreactive	  GvL	  responses	   in	  donor	  T-­‐cells.	  
Exposure	  to	  a	  range	  of	  LAAs	  within	  the	  ACV	  has	  the	  potential	  advantage	  of	  avoiding	  induction	  of	  escape	  
mutants.	  A	  self-­‐inactivating,	  fourth	  generation	  lentiviral	  vector	  which	  was	  deleted	  of	  all	  viral	  genes	  (3’	  LTR	  
deletion)	  has	  been	  successfully	  employed	  to	  prioritise	  safety	  of	  this	  approach	  by	  virtually	  eliminating	  the	  
risk	  of	  generating	  replication	  competent	  lentivirus.	  	  
	  
The	   single	   patient,	   UPN	   22,	   who	   received	   3	   doses	   of	   ACV,	   demonstrated	   no	   vaccine-­‐related	   adverse	  
events.	  No	  evidence	  of	  replication	  competent	  lentivirus	  was	  observed	  in	  either	  of	  the	  2	  patients	  treated	  in	  
the	   vaccine	   and	  DLI	   arm.	   The	   primary	   endpoint	   of	   this	   Phase	   I	   study	   is	   safety	   and	   although	   the	   trial	   is	  
ongoing,	   absence	   of	   RCL	   generation	   post-­‐injection,	   using	   a	   combination	   of	   ELISA	   and	   PCR	   analyses	   for	  
detection,	  is	  highly	  encouraging	  and	  consistent	  with	  reports	  in	  the	  literature	  suggesting	  the	  safety	  of	  this	  
approach334,335.	   A	   single	   dose-­‐limiting	   toxicity,	   due	   to	   an	   expected	   complication	   of	   DLI	   administration,	  
namely	  cGvHD,	  was	  observed	  in	  UPN	  14	  (who	  received	  DLI	  alone).	  No	  clinical	  evidence	  of	  vaccine-­‐induced	  
autoimmune	   toxicity	   was	   observed	   in	   UPN	   22	   although	   a	   transient	   detection	   of	   anti-­‐smooth	   muscle	  
antibodies	  was	   detected	   during	   their	   treatment	   phase.	   Anti-­‐nuclear	   antibodies	  were	   also	   found	   in	   the	  
sera	  of	  UPNs	  14	  and	  32	  in	  the	  DLI	  only	  arm.	  De	  novo	  detection	  of	  naturally	  occurring	  autoantibodies	  has	  
been	  reported	  in	  recipients	  of	  allogeneic	  HSCT336.	  Autoantibodies	  have	  also	  been	  reported	  in	  patients	  with	  
cGvHD,	   including	   specifically	   anti-­‐nuclear	   antibodies,	   similarly	   to	  UPN	  14337.	  Whether	   this	   phenomenon	  
was	  present	  in	  these	  patients	  at	  earlier	  time-­‐points	  pre-­‐	  or	  post-­‐HSCT	  is	  unknown,	  given	  that	  these	  tests	  
are	  not	  part	  of	  routine	  follow-­‐up.	  The	  time-­‐course	  of	  autoantibody	  detection	  (and	  restricted	  detection	  in	  
UPNs	  14,	  22	  and	  32	  but	  not	  UPN	  13,	  who	  received	  only	  a	  single	  dose	  of	  DLI	  and	  ACV)	  raises	  the	  possibility	  
that	   infusion	  of	  DLI	  may	  have	   triggered	  autoantibody	  generation.	  This	   in	   turn	   could	   suggest	   infusion	  of	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CD4+	  T-­‐cells	   in	  DLI	   to	   recipients	  may	  provide	  helper	   function	   to	  activate	  B-­‐cells338;	  alternatively	  epitope	  
spreading	  as	  a	  consequence	  of	  tumour	  cell	  lysis	  by	  donor	  lymphocytes	  might	  be	  a	  further	  means	  to	  induce	  
such	  antibodies.	  Importantly	  these	  observations	  also	  highlight	  that	  screening	  for	  autoantibodies	  may	  not	  
reliably	  discriminate	  vaccine-­‐specific	  autoimmune	  complications	  from	  DLI-­‐related	  sequelae.	  	  
	  
The	  most	  compelling	  observation	  so	  far	  suggestive	  of	  an	  immune	  response	  to	  vaccination	  in	  UPN	  22	  has	  
been	   the	   development	   of	   a	   DTH	   response	   following	   dose	   3	   of	   ACV	   and	   DLI.	   Formal	   DTH	   response	  
evaluation	   measures	   antigen-­‐specific	   immune	   recall	   in	   cancer	   immunotherapy	   trials	   by	   re-­‐challenging	  
immune	  cells	  to	  an	   immunogen	  administered	  at	  a	  prior	  vaccination252.	  DTH	  is	  defined	  by	  observation	  of	  
induration	  and	  erythema	  at	   vaccination	   sites	  persisting	  at	  48-­‐72	  hours	   following	   re-­‐exposure;	  biopsy	  of	  
these	   sites	   typically	   reveals	   lymphocytic	   and	   granulocytic	   infiltration	   with	   accompanying	   evidence	   of	  
increased	  vascular	  permeability252.	  This	  has	  been	  shown	  in	  an	  animal	  model	  to	  typically	  comprise	  a	  CD4+,	  
Th1-­‐mediated	   recognition	   of	   peptides	   presented	   in	   the	   context	   of	   MHC	   Class	   II	   molecules339.	   The	  
vaccination	  site	  biopsy	  in	  UPN	  22	  did	  indeed	  contain	  a	  predominantly	  T-­‐lymphocytic	  infiltrate.	  Unlike	  the	  
peripheral	  blood,	  a	  more	  normal	  CD4:CD8	  T-­‐cell	  ratio	  of	  2:1	  was	  observed	  by	  immunohistochemistry	  (data	  
not	   shown),	   suggesting	   this	   represented	   a	   true	   DTH	   reaction.	   Development	   of	   DTH	   reactions	   at	  
vaccination	   sites	  was	   observed	   in	   long-­‐term	   responders	   following	   the	  most	   comparable	   gene-­‐modified	  
whole	  cell	  vaccination	  strategy	  to	  ours	  reported	  to	  date,	  by	  Ho	  and	  colleagues.	  In	  this	  study,	  15	  patients	  
with	   AML/MDS	   were	   vaccinated	   up	   to	   6	   times	   between	   day	   30	   and	   100	   post	   T-­‐replete	   HSCT	   with	   an	  
autologous	   vaccine	   genetically	  modified	  using	   an	   adenoviral	   vector	   to	   express	   granulocyte-­‐macrophage	  
colony	  stimulating	   factor	   (GM-­‐CSF)	  as	  an	   immune	  adjuvant246.	  All	  patients	  had	  persistent	  morphological	  
excess	   of	   blasts	   at	   transplant	   and	   therefore	   were	   at	   high	   risk	   of	   relapse.	   Seven	   of	   8	   patients	   who	  
underwent	   formal	   histological	   assessment	   for	   a	   DTH	   response	   following	   receipt	   of	   the	   fifth	   dose	   of	  
vaccine	   demonstrated	   histological	   changes	   compatible	   with	   development	   of	   a	   DTH	   reaction.	   These	  




Some340-­‐342,	   but	   not	   all	   343,344,	   investigators	   have	   shown	   that	   development	   of	   DTH	   responses	   correlates	  
with	  clinical	  and/or	  immunological	  outcomes	  following	  vaccination.	  Differences	  in	  observations	  are	  partly	  
attributable	  to	  the	  variety	  of	  vaccination	  approaches	  and	  lack	  of	  standardised	  methods	  for	  measuring	  DTH	  
responses	  between	  studies.	  A	  more	  detailed	  analysis	  of	  antigen-­‐specific	   responses	  at	  DTH	  sites	  using	   in	  
situ	  staining	  of	  biopsy	  tissue	  with	  fluorescently	  labelled	  tetramers	  has	  been	  used	  to	  dissect	  target	  peptide	  
recognition	   by	   infiltrating	   T-­‐cells	   following	  melanoma	   vaccination345.	   Additionally,	   T-­‐cells	   were	   isolated	  
from	   biopsy	   sites	   and	   following	   a	   brief	   culture	   period,	   analysed	   for	   antigen-­‐specificity	   in	   vitro345.	   An	  
attempt	   at	   culturing	   T-­‐cells	   from	   a	   skin	   biopsy	   site	   from	   UPN	   22	   was	   made,	   but	   was	   unfortunately	  
unsuccessful.	  This	  may	  in	  part	  be	  due	  to	  the	  late	  collection	  of	  the	  skin	  biopsy	  at	  more	  than	  72	  hours	  post-­‐
vaccination,	   resulting	   in	   a	   relatively	   lower	   number	   of	   infiltrating	   lymphocytes	   available	   for	   culture.	  
However,	   high-­‐throughput	   sequencing	   of	   DNA	   obtained	   from	   these	   biopsies	   is	   planned.	   Given	   the	  
emergence	  of	  new	  T-­‐cell	   clones	   in	   the	  peripheral	  blood	  after	   the	  DTH	  response	   in	  UPN	  22,	   it	  will	  be	  of	  
great	   interest	   to	   determine	   whether	   TCRβ	   sequences	   present	   at	   biopsy	   sites	   are	   among	   those	   that	  
emerged	  and	  expanded	  in	  PB	  after	  DLI	  with	  ACV.	  	  This	  finding	  would	  suggest	  that	  leukaemia-­‐specific	  T-­‐cell	  
clones	  have	  been	  stimulated	  in	  response	  to	  therapy.	  	  
	  
Formal	  assessment	  of	  DTH	  was	  not	  described	  in	  the	  original	  trial	  protocol.	  Following	  the	  experience	  with	  
UPN	   22,	   I	   have	   written	   a	   modification	   to	   the	   clinical	   trial	   protocol	   which	   describes	   a	   planned	  
administration	   of	   2	   control	   injections	   with	   each	   vaccination	   containing	   irradiated,	   unmodified	   tumour	  
cells	   in	   one	   injection	   and	   carrier	  medium	   alone	   in	   another.	   This	   should	   distinguish	   generation	   of	   non-­‐
specific	  reactions	  against	  components	  in	  the	  medium	  from	  specific	  responses	  to	  cellular	  component.	  The	  
Medicines	  and	  Healthcare	  products	  Regulatory	  Agency	  (MHRA)	  and	  relevant	  ethical	  bodies	  have	  approved	  
this	  amendment,	  which	  will	  be	  used	  to	  assess	  patients	  recruited	  to	  the	  vaccine	  arm	  in	  future.	  
	  
Analysis	  of	  lymphocyte	  numbers	  in	  the	  trial	  subjects	  revealed	  that	  all	  3	  patients	  had	  demonstrated	  some	  
recovery	   from	   their	   lymphopenic	   states	  early	  post-­‐HSCT	  and	   that	   their	   lymphocyte	  numbers	  were	  near	  
normal,	   or	   in	   the	   normal	   range	   at	   the	   time	   of	   relapse.	   UPN22	   developed	   a	   profound	   lymphopenia	  
following	  fludarabine-­‐containing	  salvage	  chemotherapy	  that	  persisted	  at	  the	  time	  that	  ACV	  administration	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and	  DLI	  commenced.	  Immediately	  following	  recovery	  from	  the	  same	  salvage	  chemotherapy	  regimen,	  UPN	  
32	   had	   shown	   an	   increase	   in	   lymphocyte	   numbers	   to	   higher	   than	   that	   seen	   in	   healthy	   volunteers.	  
Lymphocyte	  numbers	  increased	  during	  the	  treatment	  and	  follow-­‐up	  phases	  after	  ACV	  and	  DLI	  in	  UPN	  22,	  
and	  DLI	  alone	  in	  UPN	  32	  but	  were	  unchanged	  during	  treatment	  in	  UPN	  14.	  In	  the	  absence	  of	  a	  control	  arm	  
that	  did	  not	  receive	  DLI	  in	  this	  study,	  it	  is	  not	  possible	  to	  attribute	  the	  observed	  increments	  in	  lymphocyte	  
numbers	  directly	  to	  the	  infusion	  of	  donor	  lymphocytes.	  
Lymphocyte	  subset	  analyses	  demonstrated	  that	   lymphocyte	  composition	  was	  abnormal	   in	  all	  3	  patients	  
and	  was	  not	  altered	  substantially	  by	  administration	  of	  ACV	  and/or	  DLI.	  The	  most	  marked	  deficiency	  was	  in	  
CD4+	   T-­‐cell	   numbers	   and	   frequencies,	   consistent	   with	   reports	   from	   other	   groups315,317.	   Impaired	  
reconstitution	   of	   CD4+	   T-­‐cells	   following	   lymphodepleting	   transplant	   conditioning	   regimens	   has	   been	  
attributed	   to	   the	   consequences	   of	   thymic	   atrophy	   in	   adult	   transplant	   recipients346.	   Lymphocyte	  
composition	  was	  in	  other	  respects	  more	  similar	  to	  normal	  in	  the	  two	  patients	  with	  late	  relapse	  post-­‐HSCT,	  
UPNs	  14	  and	  22.	  Both	  had	  near	  normal	  numbers	  of	  CD8+	  T-­‐cells	   throughout	   the	   trial	   follow-­‐up	  period.	  
Whilst	   UPN	   14	   also	   demonstrated	   near	   normal	   NK-­‐cell	   numbers	   at	   all	   time	   points,	   UPN	   22	   showed	  
persisting	  deficiencies	   in	  NK-­‐cell	  numbers	  during	   therapy.	  The	  high	   total	   lymphocyte	  numbers	  observed	  
throughout	   follow-­‐up	   in	   UPN	   32	   were	   due	   to	   a	   large	   and	   continuous	   expansion	   of	   CD8+	   T-­‐cells	  
(predominantly	  terminal	  effectors	  that	  may	  have	  been	  responding	  to	  a	  microbial	  stimulus	  such	  as	  herpes	  
virus	   reactivations	   or	   infection	  with	   salmonella	   spp.).	  NK-­‐cell	   numbers	   in	   this	   patient	  were	   persistently	  
lower	  than	  the	  range	  seen	  in	  the	  healthy	  volunteers.	  	  
	  
Given	  the	  previously	  published	  in	  vitro	  data	  demonstrating	  the	  ability	  of	  CD80/IL-­‐2	  modified	  AML	  cells	  to	  
activate	  leukaemia-­‐specific	  cytotoxicity	  mediated	  by	  T-­‐	  and	  NK-­‐cells121,	  analysis	  of	  these	  specific	  cell	  types	  
within	  trial	  subjects	  is	  vital.	  Although	  absolute	  numbers	  of	  CD4+	  and	  CD8+	  T-­‐cell	  numbers	  in	  UPNs	  14	  and	  
22	  were	   lower	  than	  the	  range	  seen	  in	  the	  healthy	  volunteers,	  CD4+	  and	  CD8+	  T-­‐cell	  subset	  frequencies,	  
specifically	  proportions	  of	  CD4+	  and	  CD8+	  naïve	  T-­‐cells,	  were	   close	   to	  normal	   in	   these	   two	  patients.	   In	  
view	  of	  the	  important	  role	  naïve	  T-­‐cells	  play	  in	  mediating	  alloreactive	  GvL	  responses42,300,301,	  this	  finding	  is	  
also	   of	   importance	   when	   considering	   whether	   these	   patients	   will	   be	   able	   to	   respond	   to	   therapeutic	  
vaccination.	  Crucially,	  no	  systemic	  rise	  in	  regulatory	  T-­‐cell	  numbers	  or	  frequency	  was	  observed	  in	  UPN	  22	  
during	   follow-­‐up,	   despite	   exposure	   to	   the	   IL-­‐2	   secreting	   vaccine.	   This	   suggests	   that,	   despite	   repeated	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exposure	  to	  the	  vaccine,	  induction	  of	  immunosuppressive	  T-­‐cell	  responses	  that	  could	  hamper	  leukaemia-­‐
specific	  cytotoxicity	  is	  unlikely.	  
	  
Additionally,	   using	   a	  novel	   high	   throughput	   sequencing	   approach,	   an	   evaluation	  of	   the	   TCRβ repertoire	  
during	  the	  course	  of	  therapy	  was	  made	  in	  two	  of	  the	  trial	  subjects.	  A	  modest	  rise	  in	  the	  number	  of	  unique	  
productive	  TCRβ sequences	   in	  both	  UPNs	  14	  and	  22	  consequent	  upon	  DLI	  administration	  was	  observed.	  
Secondly,	  an	  increase	  in	  TCR	  clonality	  in	  UPN	  22	  occurred	  after	  DLI	  and	  ACV	  administration.	  Expansion	  of	  
T-­‐cell	  clones	  bearing	  TCRβ	   sequences	  that	  are	  public	  clonotypes	  known	  to	  be	  expressed	  by	  EBV-­‐specific	  
CTLs	  was	  observed	   following	  DLI	  administration	   in	  UPN	  22.	  This	  observation,	   that	   responses	   to	   the	  EBV	  
immunogen	  emerged	  after	  DLI,	  lends	  support	  to	  the	  hypothesis	  that	  DLI	  boosts	  TCR	  repertoire	  diversity,	  
allowing	   response	   to	   a	   range	   of	   stimuli,	   including	   not	   only	   pathogen-­‐derived	   targets	   but	   also	   possibly	  
LAAs.	   Several	   other	   clones	   also	   emerged	   after	   DLI	   and	   ACV	   in	   UPN	   22.	   	   However,	   at	   present,	   it	   is	   not	  
possible	  to	  predict	  the	  cognate	  epitope	  from	  the	  CDR3	  amino	  acid	  sequence	  or	  to	  suggest	  recognition	  of	  
related	  peptide-­‐MHC	  (pMHC)	  complexes	  based	  on	  CDR3	  sequence	  similarity	  alone.	  This	  is	  due	  to	  the	  high	  
complexity	   of	   TCR/pMHC	   interactions	   and	   the	   difficulty	   of	   predicting	   the	   folding	   and	   physio-­‐chemical	  
properties	  of	  three-­‐dimensional	  protein	  structures.	  	  
	  
As	   yet	   there	  are	  no	   functional	  data	  directly	   assessing	  anti-­‐leukaemic	   responses	   in	  PBMCs	   isolated	   from	  
the	  three	  trial	  patients.	  These	  assays	  continue	  to	  be	  optimised	  although	  progress	  has	  been	  hampered	  by	  
the	  low	  T-­‐cell	  numbers	  in	  these	  patients	  and	  limited	  availability	  of	   leukaemic	  blasts	  for	  use	  as	  targets	   in	  
assays.	  This	  is	  particularly	  an	  issue	  for	  UPN	  22,	  whose	  stored	  leukaemic	  blasts	  were	  prioritised	  for	  vaccine	  
production.	   Antigen-­‐specific	   production	   of	   IFNγ	   and	   Granzyme	   B	   using	   Enzyme	   Linked	   Immunosorbent	  
Spot	  assay	  (ELISpot)	  will	  be	  one	  means	  to	  assess	  functional	  activity320.	  The	  potential	  to	  use	  HTS	  to	  track	  T-­‐
cell	   clones	   during	   treatment	   and	  between	   vaccination,	  marrow	  and	  PB	   sites	   is	   an	   exciting	   prospect	   for	  
future	  study.	  Only	  with	  analysis	  of	  additional	  patients,	  in	  a	  study	  powered	  to	  detect	  immune	  response	  as	  
a	   primary	   endpoint,	   might	   it	   be	   possible	   to	   confidently	   demonstrate	   evidence	   of	   vaccine-­‐induced	  
leukaemia-­‐specific	  immune	  responses.	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In	   conclusion,	   these	   findings	   illustrate	   the	   safe	   treatment	   of	   a	   patient	  with	   ACV	   and	   DLI	   and	   evidence	  
supporting	   induction	   of	   a	   response	   to	   vaccination	   in	   the	   form	   of	   a	   DTH	   reaction.	   The	   difficulties	   of	  
conducting	  such	  a	  study	  are	  highlighted,	  given	  the	  large	  number	  of	  patients	  screened	  but	  recruitment	  rate	  
of	  only	  10%.	  Given	  these	  preliminary	  safety	  data	  in	  support	  of	  the	  ACV	  and	  in	  vitro	  evidence	  of	  induction	  
of	  superior	  leukaemia-­‐specific	  cytotoxicity	  in	  the	  autologous	  setting,	  I	  have	  written	  a	  clinical	  trial	  protocol	  
to	  allow	  vaccination	  of	  AML	  patients	  who	  are	  ineligible	  for	  allogeneic	  HSCT.	  This	  complementary	  Phase	  I	  
study	  will	  run	  in	  parallel	  to	  increase	  patient	  recruitment.	  Positive	  safety	  findings	  from	  these	  studies	  should	  
allow	   progression	   to	   a	   Phase	   II	   trial	   including	   greater	   numbers	   of	   patients,	   where	   development	   of	  
immunological	  responses	  can	  be	  more	  rigorously	  evaluated.	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Chapter	  6 Summary	  and	  Future	  Work	  
6.1 Summary	  
The	   studies	   presented	   in	   this	   thesis	   examined	   two	   forms	   of	   immunotherapy	   to	   treat	   myeloid	  
malignancies,	  one	  that	  is	  in	  current	  clinical	  use	  and	  a	  second	  that	  is	  in	  development.	  	  
Firstly,	  adoptive	  transfer	  of	  unselected	  lymphocytes	  in	  the	  form	  of	  DLI,	  representing	  the	  most	  frequently	  
employed	  means	  to	  enhance	  GvL	  after	  allogeneic	  HSCT	  and	  mediated	  principally	  by	  alloreactive	  donor	  T-­‐
cells,	   was	   examined.	   Following	   disease	   recurrence	   after	   allogeneic	   HSCT,	   DLI	   has	   shown	   considerable	  
efficacy	   in	   the	   treatment	   of	   more	   indolent	   haematological	   malignancies	   such	   as	   chronic	   myeloid	  
leukaemia	  or	  lymphoma.	  	   In	  the	  context	  of	  AML	  and	  MDS,	  however,	  there	  has	  been	  limited	  evidence	  to	  
support	  DLI	  efficacy.	  The	  data	  presented	  in	  Chapter	  3	  have	  specifically	  described	  outcomes	  from	  a	  single	  
institution	   following	   therapeutic	   and	   pre-­‐emptive	  DLI	   in	   the	   setting	   of	   confirmed	  or	   impending	   relapse	  
(suggested	  by	  declining	  donor/predominantly	  recipient	  T-­‐cell	  chimerism)	  following	  TCD	  RIC	  HSCT	  for	  AML	  
or	   MDS.	   I	   have	   shown	   that	   therapeutic	   DLI	   (tDLI),	   given	   alone	   or	   following	   disease	   bulk	   reduction	   by	  
chemotherapy,	   is	   associated	  with	  an	  estimated	  5-­‐year	  overall	   survival	  of	  40%,	  exceeding	   the	   responses	  
reported	  by	  other	  groups	  that	  are	  predominantly	  in	  the	  T-­‐replete,	  myeloablative	  HSCT	  setting.	  However,	  
the	  progression/relapse	   rate	   in	   tDLI	   recipients	   at	   our	   institution	   approached	  70%	  at	   5	   years	   suggesting	  
that	  durable	  remissions	  are	  not	  currently	  being	  achieved.	  Therefore	  approaches	  to	  increase	  the	  frequency	  
and	   duration	   of	   responses	   to	   tDLI	   are	   highly	   desirable.	   The	   best	   responses	   to	   tDLI	   were	   observed	   in	  
patients	  with	   low	  disease	  burden	  prior	   to	   treatment,	  suggesting	  that	  DLI	   is	  most	  effective	  as	   therapy	   in	  
the	   context	   of	   minimal	   residual	   disease.	   Furthermore,	   administration	   of	   pre-­‐emptive	   DLI	   (pDLI)	   in	   the	  
absence	  of	  overt	  disease	  recurrence	  resulted	   in	  excellent	  5-­‐year	  overall	  and	  event-­‐free	  survivals	  of	  80%	  
and	  65%	  respectively.	  Only	  3	  patients	  with	  chimerism	  improvement	  following	  pDLI	  subsequently	  relapsed.	  
These	  outcomes	  were	  in	  direct	  contrast	  to	  the	  100%	  relapse	  rate	  for	  patients	  who	  showed	  an	  incomplete	  
chimerism	  response	  to	  pDLI.	  In	  combination,	  the	  data	  from	  both	  the	  tDLI	  and	  pDLI	  cohorts	  supports	  the	  
potential	   for	  provision	  of	  durable	  GvL	  activity	  by	   infused	   lymphocytes.	  The	   incidence	  of	  GvHD	  following	  
DLI	   was	   highest	   for	   the	   tDLI	   cohort	   (45%)	   whilst	   a	   moderate	   rate	   (31%)	   was	   observed	   in	   the	   pDLI	  
recipients,	  indicating	  the	  difficult	  challenge	  of	  separating	  effective	  GvL	  induction	  from	  unwanted	  toxicity	  
of	  GvHD.	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The	  second	  immunotherapeutic	  approach	  examined	  was	  immunisation	  that	  aims	  to	  selectively	  induce	  T-­‐
cell	  responses	  against	  leukaemic	  blasts	  and	  thus	  avoid	  GvHD.	  One	  focus	  was	  the	  well-­‐studied	  leukaemia-­‐
associated	   antigen	   WT1	   that	   has	   been	   identified	   as	   a	   high	   priority	   target	   for	   future	   studies	   of	  
immunotherapy,	   not	   only	   in	   the	   context	   of	   haematological	   malignancies	   but	   also	   in	   solid	   tumours157.	  
Phase	   I	   and	   II	   studies	   of	   vaccination	   in	  AML	   and	  MDS	  patients	   using	   a	   single	   short	   peptide	  or	  multiple	  
epitopes	   from	   this	   self-­‐antigen	   have	   shown	   promising	   expansion	   of	   functional	   WT1-­‐specific	   T-­‐cells,	  
temporally	  associated	  with	  reductions	  in	  disease	  burden	  in	  some	  cases198,199,201.	  However,	  the	  responses	  
have	  generally	  been	  short-­‐lived	  and	  of	  low	  avidity200.	  In	  Chapter	  4,	  I	  have	  described	  pre-­‐clinical	  studies	  of	  
a	   novel	   combination	   of	   adjuvants	   (CASAC)	   to	   combine	   with	   WT1	   peptide	   vaccination	   to	   induce	  WT1-­‐
specific	   T-­‐cell	   responses	   in	   C57BL/6	  mice.	   The	   inclusion	  of	   TLR	   agonists	   and	   activating	  CD40	   antibodies	  
within	   the	   vaccine	   aims	   to	   induce	   cell-­‐mediated	   immunity	   via	   activation	   of	   professional	   antigen	  
presenting	  cells	  (APCs).	  A	  number	  of	  these	  adjuvants	  are	  now	  entering	  the	  clinic.	  Repeated	  immunisations	  
were	  well	   tolerated	  by	  mice.	   In	   those	   that	   responded	  to	  vaccinations,	  expansion	  of	  WT1-­‐specific	  T-­‐cells	  
capable	  of	  potent	   in	  vivo	   cytotoxicity	  was	  observed.	   Importantly,	  T-­‐cell	   responses	  were	   induced	  against	  
the	  well	  defined	  MHC	  Class	   I	   epitope	  WT1-­‐RMF	  using	  a	   cocktail	  of	  overlapping	   long	  peptide	   sequences	  
spanning	   the	  whole	  WT1	  protein.	   If	   translated	   to	   the	  clinical	   setting,	   such	  an	  approach	  would	  have	   the	  
advantage	  of	  allowing	  a	   single	  product	   to	  be	  employed	  universally	   to	  patients	   irrespective	  of	  HLA-­‐type.	  
Furthermore,	   multiple	   Class	   I	   and	   II	   epitopes,	   including	   hitherto	   uncharacterised	   immunogenic	   WT1	  
sequences,	  may	  be	  simultaneously	  targeted.	  Vaccination	  with	  long	  peptides	  has	  the	  additional	  advantage	  
of	   directing	   presentation	   to	   professional	   rather	   than	   non-­‐professional	   APCs,	   thus	   avoiding	   potential	  
induction	   of	   T-­‐cell	   anergy214.	   However,	   while	   CASAC	   was	   shown	   to	   combine	   successfully	   with	   WT1	  
peptides	   to	   induce	   WT1-­‐specific	   T-­‐cell	   responses,	   these	   were	   inconsistently	   induced,	   with	   some	   mice	  
showing	   no	   response	   to	   vaccination	   at	   all.	   This	   suggests	   that	   further	   efforts	   are	   required	   to	   improve	  
response	  rates	  and	  magnitude.	  
	  
Given	   the	   high	   rates	   of	   disease	   recurrence	   following	   tDLI	   reported	   in	   Chapter	   3,	   a	   novel	   strategy	  
combining	  tDLI	  with	  immunisation	  to	  augment	  induction	  and	  durability	  of	  GvL	  reactions	  is	  being	  evaluated	  
in	  a	  phase	  I	  clinical	  trial.	  	  I	  described	  the	  preliminary	  results	  in	  Chapter	  5.	  The	  vaccine	  used	  was	  a	  patient-­‐
specific	  whole	  cell	  vaccine	  derived	  from	  the	  patient’s	  AML	  blasts,	   thus	  harbouring	  all	   relevant	  LAAs	  and	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mHags	   to	   that	  patient.	  A	  self-­‐inactivating	   lentiviral	  vector	  designed	   to	  maximise	  safety	  of	   this	  approach	  
and	  eliminate	  the	  risk	  of	   inducing	  replication	  competent	   lentivirus	   in	  recipients	  was	  used	  to	  successfully	  
transduce	   primary	   AML	   blasts	   collected	   from	   2	   patients	  with	   relapsed	   AML	   post-­‐allogeneic	   HSCT.	   Two	  
patients,	  UPNs	  14	  and	  32	  were	  allocated	  to	  receive	  DLI	  only	   following	  remission	  re-­‐induction	  after	  AML	  
recurrence.	  UPNs	  13	  and	  22	  were	  allocated	  to	  receive	  DLI	  along	  with	  the	  patient-­‐specific	  AML	  Cell	  Vaccine	  
(ACV).	  UPN	  13	  experienced	  a	  rapid	  relapse	  within	  weeks	  of	  treatment	  with	  the	  first	  dose	  of	  DLI	  and	  ACV.	  
UPN	  22	  was	   the	  only	   subject	   that	   received	  3	  doses	  of	   the	  ACV	  and	  DLI	   and	  experienced	  no	   immediate	  
adverse	  immune	  reactions	  and	  showed	  no	  signs	  subsequently	  of	  autoimmune	  toxicity	  or	  GvHD.	  Following	  
the	   third	   vaccination,	   a	   DTH	   reaction	   was	   observed.	   Researchers	   have	   reported	   DTH	   responses	   to	   be	  
favourably	   linked	   to	   sustained	   remissions	   following	   immunotherapy340-­‐342.	   Analysis	   of	   peripheral	   blood	  
lymphocyte	   numbers	   in	   the	   3	   trial	   subjects	   prior	   to	   and	   following	   therapy	   with	   ACV	   and/or	   DLI	  
demonstrated	  that	  these	  were	  within	  or	  near	  normal	  range	  at	  study	  entry	  and	  rose	  during	  the	  course	  of	  
treatment	   in	   2	   subjects.	   Lymphocyte	   subset	   composition	   however	   was	   abnormal	   in	   all	   3	   patients	   in	  
comparison	  with	  age-­‐matched	  volunteers.	  Divergence	  in	   lymphocyte	  subset	  composition	  from	  that	  seen	  
in	  volunteers	  was	  most	  prominent	  in	  UPN	  32,	  who	  was	  within	  six	  months	  of	  HSCT	  at	  the	  time	  of	  relapse	  
and	  entry	   to	   the	   trial,	   compared	  with	  UPNs	  14	   and	  22	  who	  were	   18	   and	  34	  months	   respectively	   post-­‐
HSCT.	   Receipt	   of	   ACV	   and/or	   DLI	   did	   not	   substantially	   alter	   lymphocyte	   subset	   composition.	   However,	  
TCRβ	   repertoire	   analyses	   revealed	   a	   dramatic	   change	   in	   one	   of	   two	   patients	   studied	   during	   therapy.	  	  
Following	  the	  third	  dose	  of	  ACV	  and	  DLI	   in	  UPN	  22,	  a	  rapid	  rise	  to	  dominance	  of	  previously	  undetected	  
TCRβ	   clonotypes	   was	   observed.	   Of	   particular	   note,	   two	   of	   the	   clonotypes	   were	   known	   sequences	  
expressed	  by	  EBV-­‐specific	  T-­‐cell	  clones	  specific	  for	  public	  HLA-­‐A*02:01	  restricted	  epitopes.	  	  UPN	  22	  is	  EBV	  
seropositive	  but	   the	  donor	   is	  EBV	  seronegative.	  Emergence	  and	  rapid	  rise	   to	  dominance	  of	  EBV	  specific	  
clonotypes	  after	  DLI	   suggests	  priming	  and	  proliferation	  of	  naïve	  T	   cells	   introduced	  by	  DLI	  has	  occurred.	  
This	   very	   promising	   finding	   suggests	   that	   infusion	   of	   donor	   T-­‐cells	   may	   expand	   the	   recipient	   T-­‐cell	  
repertoire,	   permitting	   responses	   to	   novel	   antigens,	   including	   microbial	   targets	   and	   by	   extension,	  
potentially	  leukaemia-­‐associated	  antigens.	  
	  
The	  overall	  theme	  of	  the	  studies	  presented	  has	  been	  to	  explore	  methods	  to	  boost	   leukaemia-­‐specific	  T-­‐
cell	   responses	   in	   AML	   patients.	   This	   may	   be	   achievable	   by	   infusion	   of	   naïve	   T-­‐cells	   within	   donor	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lymphocytes	  to	  induce	  responses	  to	  immunogens	  including	  LAAs.	  Vaccination	  against	  epitopes	  from	  LAAs	  
such	   as	   WT1	   may	   help	   induce	   leukaemia-­‐specific	   T-­‐cell	   responses,	   including	   cytotoxicity	   and	   cytokine	  
production.	   Preliminary	   findings	   suggest	   that	   vaccination	   using	   genetically	   modified	   AML	   blasts	   from	  
patients	   is	   feasible	  and	  safely	   combines	  with	  DLI	  administration.	  More	  patients	  need	   to	  be	   treated	  and	  
evidence	   sought	   for	  emergence	  of	   leukaemia-­‐specific	   immune	   responses	  post-­‐vaccination	  before	   safety	  
and	  efficacy	  can	  be	  clearly	  demonstrated.	  These	   issues	  are	  discussed	   in	  the	  following	  section	  describing	  
future	  investigations	  arising	  from	  the	  results	  presented.	  
	  
6.2 Future	  work	  
Data	   from	   the	   analyses	   of	   lymphocyte	   composition	   and	   the	   TCRβ	   repertoire	   in	   the	   small	   number	   of	  
RFUSIN2-­‐AML1	   trial	   subjects	   studied	   so	   far	   raise	   interesting	   questions	   concerning	   the	   immunological	  
consequences	  of	  DLI.	  Despite	  limited	  effects	  of	  DLI	  on	  lymphocyte	  subset	  composition,	  changes	  in	  T-­‐cell	  
clonal	  dominance	   following	   infusion	  of	  donor	   lymphocytes	  were	  observed	   in	  one	  of	  2	  patients	   studied.	  
The	  emergence	  and	  expansion	  of	  T-­‐cell	  clones	  specific	  for	  EBV	  only	  detectable	  after	  the	  third	  (largest)	  DLI	  
and	  ACV	  dose	  in	  UPN	  22	  suggests	  that	  naïve	  donor	  T-­‐cells	  present	  in	  the	  infused	  product	  may	  respond	  to	  
antigens	  within	  the	  recipient.	  Although	  this	  was	  in	  the	  setting	  of	  therapeutic	  DLI,	  it	  is	  likely	  that	  a	  similar	  
mechanism	   underlies	   the	   beneficial	   effects	   of	   pDLI.	   Taking	   into	   consideration	   the	   results	   of	   the	  
retrospective	  study	  of	  outcomes	  following	  pDLI	  that	  showed	  improved	  and	  sustained	  EFS	  is	  achievable	  in	  
these	   patients	   who	   are	   at	   high	   risk	   of	   relapse,	   it	   is	   hypothesised	   that	   the	   naïve	   T-­‐cell	   repertoire	   is	  
broadened	  within	  the	  DLI	  recipient	  and	  includes	  T-­‐cells	  reactive	  against	  LAA-­‐derived	  epitopes	  that	  confer	  
protection	  from	  disease	  relapse.	  Substantiation	  requires	  prospective	  study	  on	  a	  larger	  scale.	  Furthermore,	  
an	   important	   limitation	   of	   both	   the	   retrospective	   clinical	   study	   of	   pDLI	   outcomes	   and	   the	   analysis	   of	  
lymphocyte	   subset	   and	   repertoire	   analyses	   in	   trial	   subjects	   is	   the	   absence	   of	   a	   comparator	   group	   that	  
does	  not	  receive	  DLI.	  An	  earlier	  report	  from	  our	  institution	  indicated	  a	  trend	  towards	  improved	  relapse-­‐
free	   survival	   for	   recipients	   of	   pDLI	   compared	   to	   patients	   spontaneously	   achieving	   full	   donor	   chimerism	  
(FDC)	  or	  stable	  mixed	  donor	  chimerism	  following	  FBC-­‐conditioned	  allogeneic	  HSCT	  for	  AML	  and	  MDS156.	  
Those	  data,	  along	  with	  the	  impressive	  OS	  and	  low	  incidence	  of	  relapse	  in	  patients	  showing	  improvement	  
in	  donor	  T-­‐cell	  chimerism	  following	  pDLI	  reported	  in	  this	  thesis	  suggest	  that	  delayed	  add-­‐back	  of	  donor	  T-­‐
cells	  may	  confer	  protection	  from	  relapse.	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These	   hypotheses	   would	   be	  more	   clearly	   defined	   by	   a	   prospective	   investigation	   of	   lymphocyte	   subset	  
composition,	   function	   and	   TCRβ	   repertoire	   diversity	   post-­‐TCD	   RIC	  HSCT	   in	   a	   large	   number	   of	   AML	   and	  
MDS	   patients.	   In	   such	   a	   study,	   patients	   who	   do	   not	   receive	   DLI	   and	   age-­‐matched	   healthy	   volunteers	  
would	   serve	   as	   control	   groups.	   A	   detailed	   sequential	   analysis	   of	   the	   kinetics	   of	   donor	   T-­‐cell	   chimerism	  
post-­‐HSCT	  combined	  with	  analysis	  of	  lymphocyte	  composition	  and	  function	  could	  highlight	  differences	  in	  
recovery	  between	  patients	  with	   spontaneous	  development	  of	  predominant	  donor	  chimerism	  and	   those	  
with	   delayed	   attainment	   augmented	   by	   pDLI.	   Functional	   assays	   to	   assess	   anti-­‐leukaemic	   responses	   are	  
also	  required.	  These	  would	  consist	  of	  killing	  assays,	  measuring	  lysis	  of	  the	  patients’	  primary	  AML	  blasts	  by	  
matched	   patients’	   PBMCs	   after	   in	   vitro	   culture.	   Similar	   cultures	   would	   allow	   assessment	   of	   cytokine	  
production	   associated	   with	   cytotoxic	   responses,	   such	   as	   IFNγ	   and	   granzyme	   B,	   in	   ELISpot	   assays.	  
Evaluation	   of	   leukaemia-­‐specific	   responses	   in	   patients	   that	   do	   or	   do	   not	   require	   pDLI	   (and	   also	   at	  
successive	  time-­‐points	  pre-­‐and	  post-­‐pDLI)	  could	  inform	  whether	  the	  observed	  protection	  against	  relapse	  
afforded	  by	  pDLI	  correlates	  with	  enhanced	  leukaemia	  cytotoxicity	  in	  vitro.	  Serial	  measurement	  of	  minimal	  
residual	  disease,	  where	  a	  molecular	  marker	  of	  disease	  such	  as	  NPM1	  mutation	  or	  WT1	  over-­‐expression	  is	  
detected	  in	  a	  patient,	  could	  provide	  a	  sensitive	  reading	  of	  disease	  burden	  in	  the	  absence	  of	  overt	  relapse	  
in	   these	  patients.	  Given	   that	  other	  groups	  have	   reported	   the	  emergence	  of	  T-­‐cells	   specific	   for	  epitopes	  
from	  these	  2	  antigens	  following	  pDLI305,306,	  serial	  tracking	  by	  pentamer	  analyses	  could	  identify	  expansions	  
of	  these	  leukaemia-­‐specific	  T-­‐cells	  in	  patients	  at	  sequential	  time-­‐points	  during	  treatment.	  Formal	  analysis	  
of	  TCRβ	  repertoire	  diversity	  in	  a	  large	  cohort	  of	  patients	  at	  defined	  time-­‐points	  post-­‐HSCT	  in	  patients	  that	  
do,	  or	  do	  not	  receive	  pDLI	  and	  in	  comparison	  with	  results	  from	  a	  set	  of	  age-­‐matched	  healthy	  volunteers	  
would	  begin	  to	  address	  the	  question	  of	  whether	  there	  is	  restricted	  repertoire	  diversity	  following	  TCD	  RIC	  
HSCT	   for	   AML/MDS,	   how	   long	   restriction	   persists	   and	  whether	   any	   changes	   arise	   following	   T-­‐cell	   add-­‐
back.	  	  
	  
The	   above	   studies	   of	   lymphocyte	   subset	   composition	   and	   function,	   along	   with	   studies	   of	   leukaemia-­‐
specific	   T-­‐cell	   expansion	   and	   TCRβ	   repertoire	   analysis,	   could	   begin	   to	   identify	   why	   some	   but	   not	   all	  
patients	   respond	   to	  pDLI.	   In	   Chapter	   3,	   I	   observed	   that	   one	   third	  of	   patients	   did	   not	   show	  a	   sustained	  
improvement	   in	   donor	   T-­‐cell	   percentage	   following	   pDLI	   and	   ultimately	   relapsed.	   No	   factors	   were	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identified	  that	  associated	  with	  chimerism	  response.	  Although	  not	  discussed	  in	  the	  publication,	  there	  were	  
no	  observed	  differences	  in	  the	  absolute	  lymphocyte	  numbers	  immediately	  prior	  to	  pDLI	  in	  these	  2	  groups	  
(mean	   1363	   lymphocytes/µl	   [1038	   –	   1689	   lymphocytes/µl,	   CI	   95%]	   in	   responders	   and	   mean	   1206	  
lymphocytes/µl	   [696	   –	   1717	   lymphocytes/µl,	   CI	   95%]	   in	   non-­‐responders,	   p=0.6).	   This	   is	   relevant	   as	   it	  
suggests	   profound	   lymphopenia	   prior	   to	   receipt	   of	   DLI	   in	   responders,	   which	   could	   drive	   homeostatic	  
expansion	  of	  infused	  donor	  T-­‐cells,	  was	  not	  the	  reason	  for	  improved	  chimerism	  or	  protection	  from	  disease	  
in	   responding	   patients.	   Alternative	   explanations	   afforded	   by	   the	   investigations	   above	   may	   enable	  
prediction	  of	  responsiveness	  to	  pDLI.	  
	  
The	  prospective	  study	  described	  above	  would	  also	  analyse	  the	  same	  parameters	  in	  patients	  prior	  to	  and	  
following	  AML	  relapse.	  HSCT	  recipients,	  who	  have	  not	  relapsed	  or	  received	  DLI	  and	  are	  matched	  in	  terms	  
of	  the	  time	  that	  has	  elapsed	  post-­‐HSCT	  to	  the	  relapse	  cases,	  as	  well	  as	  age-­‐matched	  healthy	  volunteers,	  
could	  serve	  as	  controls.	  Large-­‐scale	  studies	  could	  identify	  any	  immune	  signatures	  predictive	  of	  relapse	  and	  
of	   responsiveness	   to	   tDLI.	   Furthermore,	   an	   in	   depth	   understanding	   of	   the	   immune	   deficits	   that	   may	  
ultimately	  allow	  leukaemic	  escape	  from	  surveillance	  and	  how	  these	  are	  corrected	  in	  those	  who	  respond	  
to	  tDLI	  would	  also	  be	  useful	  in	  the	  context	  of	  the	  AML	  Cell	  Vaccine.	  An	  unanswered	  question	  arising	  from	  
the	  preliminary	  data	  of	  vaccination	  in	  patients	  receiving	  tDLI	  post-­‐HSCT	  is	  whether	  they	  have	  “sufficient”	  
immune	  competence	  to	  respond	  to	  ACV.	  A	  clear	  definition	  of	  immune	  sufficiency	  is	  lacking	  in	  this	  setting	  
but	   could	   be	   addressed	   by	   the	   ability	   to	   mount	   NK	   and	   T-­‐cell	   responses	   following	   stimulation	   with	  
CD80/IL-­‐2	   modified	   blasts,	   given	   the	   previously	   reported	   in	   vitro	   data	   supporting	   these	   lymphocyte	  
populations	   in	  mediating	   leukaemia-­‐specific	  cytotoxicity120,121.	  Studies	  using	  T	  and	  NK-­‐cells	   isolated	  from	  
patients	  following	  tDLI	  did	  not	  however	  form	  part	  of	  these	  earlier	  reports.	  Analysis	  of	  leukaemia-­‐specific	  
cytotoxicity	   against	   primary	   AML	   blasts	   in	   vitro	   following	   co-­‐culture	   of	   T-­‐	   and	   NK-­‐cells	   isolated	   from	  
patients	   pre-­‐	   and	   post-­‐tDLI	   with	   CD80/IL-­‐2	   modified	   AML	   blasts	   could	   provide	   evidence	   of	   immune	  
competence	   to	   respond	   to	   vaccination	   and	   allow	   an	   assessment	   as	   to	   whether	   this	   is	   improved	   by	  
successive	  tDLI.	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As	  outlined	   in	  the	  discussion	   in	  Chapter	  5,	   functional	  assays	  are	  needed	  to	  complete	  the	   immunological	  
assays	   in	   patients	   from	   the	   RFUSIN2-­‐AML1	   study.	   These	   include	   measurement	   of	   leukaemia-­‐specific	  
cytotoxicity	  of	  CFSE-­‐labelled	  autologous	  AML	  blasts	  by	  PBMCs	  from	  trial	  subjects.	  To	  determine	  specificity	  
of	  the	  response,	  PHA-­‐activated	  T	  cells	  or	  EBV-­‐transformed	  B-­‐cells	  established	  from	  patients	  could	  be	  used	  
as	  autologous	  controls.	  Leukaemia	  cytotoxicity	  pre-­‐	  and	  post-­‐DLI	  with/without	  ACV	  would	  be	  compared.	  
Following	   similar	   cultures,	   ELISpot	   assays	  would	   allow	  assessment	  of	   IFNγ	   and	  Granzyme	  B	  production.	  
The	  TCRβ	  repertoire	  analyses	  in	  both	  UPNs	  14	  and	  22	  require	  completion	  for	  the	  remaining	  time	  points	  on	  
study	  follow-­‐up	  to	  continue	  to	  track	  clonotypes	  over	  time.	  This	  analysis	  also	  needs	  to	  be	  extended	  to	  the	  
other	  trial	  subjects.	   Importantly	  for	  UPN	  22,	  TCRβ	   repertoire	  analysis	  using	  the	  DTH	  biopsy	  site	  samples	  
could	   suggest	   whether	   any	   clones	   that	   dramatically	   increase	   in	   the	   peripheral	   blood	   are	   also	   highly	  
represented	   in	   the	   biopsy	   site.	   This	   could	   suggest	   expansion	   of	   leukaemia-­‐specific	   clones	   that	   are	  
attracted	   to	   the	   vaccination	   site	   at	   the	   time	   of	   the	   DTH	   reaction.	   These	   studies	   will	   also	   be	   more	  
informative	   following	   the	   protocol	   amendment	   that	   permits	   control	   vaccinations	   to	   be	   performed	   in	  
patients,	   since	   it	  would	   be	   hypothesised	   that	   any	   clonotypes	   showing	  high	   frequencies	   in	   the	  DTH	   site	  
would	  not	  be	  prominent	  in	  the	  control	  injection	  sites.	  Finally,	  another	  approach	  to	  assessing	  the	  safety	  of	  
the	  ACV	  will	  be	  to	  consider	  other	  patient	  groups	  for	  vaccination.	   I	  have	  written	  and	  submitted	  a	  clinical	  
trial	  application	  for	  a	  Phase	  I	  study	  using	  the	  ACV	  to	  maintain	  remissions	  following	  chemotherapy	  in	  AML	  
patients	  who	  are	  not	  candidates	  for	  transplant.	  This	  has	  been	  approved	  by	  the	  MHRA	  and	  relevant	  ethical	  
bodies	  and	  will	  begin	  recruitment	  at	  King’s	  College	  Hospital	  in	  the	  near	  future.	  
	  
With	   respect	   to	   the	   findings	   presented	   in	   Chapter	   4,	   the	   most	   important	   issue	   to	   address	   in	   WT1	  
vaccinations	   using	   CASAC	   will	   be	   to	   identify	   methods	   to	   increase	   the	   consistency	   and	   magnitude	   of	  
immune	  response	  induction.	  This	  would	  then	  permit	  vaccine	  efficacy	  to	  be	  evaluated	  in	  a	  tumour	  model	  
by	  challenging	   immunised	  mice	  with	  a	  murine	  syngeneic	  WT1+	  AML	  cell	   line.	  Around	  2	   in	  5	   (40%)	  non-­‐
tumour	   bearing	   mice	   showed	   expansion	   of	   WT1-­‐specific	   T-­‐cells	   following	   vaccinations	   with	   WT1	   and	  
CASAC	  within	  each	  experiment	  and	  the	  functional	  responses	  observed,	  such	  as	  lysis	  of	  WT1-­‐RMF	  loaded	  
targets,	  varied	  in	  magnitude	  between	  experiments.	  In	  some	  of	  the	  vaccination	  studies,	  no	  mice	  responded	  
to	  vaccination	  with	  WT1	  peptides	  and	  CASAC.	  Future	  studies	  should	  investigate	  this	  inconsistent	  immune	  
response	   induction.	   Optimisation	   of	   the	   immune	   readouts	   from	   these	   experiments	   is	   one	   factor	   that	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requires	   consideration.	   For	   example,	   a	   more	   sensitive	   test	   than	   pentamer	   analyses,	   such	   as	   in	   vitro	  
analysis	  of	  WT1-­‐specific	  IFNγ	  production	  by	  PBMCs	  isolated	  following	  vaccination	  rounds	  using	  an	  ELISpot	  
assay,	  might	  yield	  more	  information.	  Secondly,	  it	  would	  be	  of	  interest	  to	  determine	  whether	  there	  are	  any	  
signs	  of	  an	  exhausted	  T-­‐cell	  phenotype	  in	  non-­‐responders	  to	  vaccination	  in	  contrast	  with	  those	  mice	  that	  
show	  expansion	  of	  WT1-­‐RMF	  or	  OVA-­‐SIINF	  specific	  T-­‐cell	  responses.	  Individual	  mice	  would	  be	  ear-­‐tagged	  
to	  follow	  their	  responses.	  T-­‐cells	  isolated	  from	  peripheral	  blood	  and	  draining	  lymph	  nodes	  after	  repeated	  
vaccination	  could	  be	  assessed	  for	  expression	  of	  inhibitory	  markers	  (often	  reflective	  of	  T-­‐cell	  exhaustion),	  
such	   as	   CTLA-­‐4,	   PD-­‐1	   and	   LAG-­‐3347,348.	   An	   exhausted	   T-­‐cell	   phenotype	  might	   suggest	   a	   requirement	   for	  
further	  optimisation	  of	  dosing	  and	  timing	  of	  vaccine	  administration.	  Furthermore,	  it	  would	  be	  relevant	  to	  
determine	  whether	   there	   is	   an	   expansion	   of	   the	   Treg	   population	   in	   draining	   lymph	   nodes	   close	   to	   the	  
vaccination	   sites.	   Although	   this	   population	   was	   not	   expanded	   in	   the	   peripheral	   blood	   after	   repeated	  
vaccinations	  using	  CASAC,	  Class	  I	  and	  Class	  II	  WT1/OVA	  peptides,	  the	  lymph	  nodes	  may	  show	  contrasting	  
findings.	   Expansion	   of	   Tregs	  within	   lymph	   nodes	   could	   provide	   a	   target	   for	   inhibition	   that	  may	   enable	  
greater	  induction	  of	  immune	  responses	  (see	  below).	  
	  
The	  dissection	  of	  differences	  in	  the	  immune	  phenotype	  of	  T-­‐cells	  in	  responsive	  and	  non-­‐responsive	  mice	  
relies	   of	   course	   on	   the	   ability	   to	   induce	   WT1-­‐specific	   responses.	   The	   failure	   to	   induce	   WT1-­‐specific	  
responses	   in	   some	   experiments	   and	   the	   inconsistent	   responses	   in	   others	   suggest	   that	   manoeuvres	   to	  
boost	  induction	  of	  response	  to	  vaccination	  are	  required.	   	  Approaches	  to	  consider	  include	  (1)	  addition	  of	  
other	   stimulatory	   signals	   that	   may	   synergise	   with	   CASAC	   components	   and	   (2)	   dampening	   down	   or	  
elimination	  of	   regulatory	   signals	   that	  may	   limit	   response	   induction.	  Ways	   to	   achieve	   this	   are	  described	  
below.	   Although	   principally	   discussed	   in	   the	   context	   of	   maximising	   induction	   of	   WT1-­‐specific	   T-­‐cell	  
responses	  using	  CASAC,	  these	  strategies	  could	  equally	  be	  relevant	  to	  enhance	  leukaemia-­‐specific	  immune	  
response	  induction	  by	  other	  types	  of	  vaccination,	  such	  as	  the	  AML	  Cell	  Vaccine.	  	  
	  
Additional	   stimulatory	   signals	  within	   the	  adjuvant	   cocktail	  may	   increase	   the	   vaccination	  efficacy.	   In	   the	  
original	  studies	  by	  Wells	  et	  al	  describing	  CASAC,	  an	  agonist	  anti-­‐4-­‐1BB	  (CD137)	  antibody	  was	  delivered	  1	  
week	   after	   the	   second	   vaccination	   using	  OVA-­‐SIINF	   and	   CASAC	   to	   reduce	   the	   contraction	   phase	   of	   the	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CD8+	  T-­‐cell	  response.	  Although	  the	  size	  of	  the	  memory	  pool	  itself	  was	  unaffected	  by	  the	  inclusion	  of	  the	  
agonist	  4-­‐1BB	  antibody,	   there	  was	  evidence	  of	   a	  more	  vigorous	   recall	   response	  upon	   re-­‐challenge	  with	  
OVA-­‐SIINF	   in	  mice	  that	  received	  the	  agonist	  antibody238.	  Other	  members	  of	  the	  Tumour	  Necrosis	  Factor	  
Receptor	  (TNFR)	  family,	  such	  as	  OX40349	  and	  GITR350	  have	  not	  yet	  been	  studied	  in	  the	  context	  of	  CASAC	  for	  
priming	   and	   boosting	   of	   antigen	   specific	   responses.	   Ligation	   of	   GITR	   can	   augment	   CD28-­‐mediated	  
costimulation	  of	  T-­‐cells	  during	  priming	  whereas	  the	  effect	  of	  4-­‐1BB	  ligation	  on	  T-­‐cell	  function	  appears	  to	  
be	   greater	   on	   antigen-­‐experienced	   effector	   T-­‐cells350.	   The	   apparent	   non-­‐redundancy	   of	   these	   various	  
costimulatory	   receptor	   and	   ligand	   functions	   suggests	   that	   inclusion	   of	   agonists	   within	   CASAC	   and	  
administration	  at	  appropriate	  time-­‐points	  (during	  priming	  and/or	  boosting)	  could	  have	  an	  additive	  effect	  
to	  increase	  the	  rate	  of	  induction	  and	  avidity	  of	  LAA-­‐specific	  T-­‐cell	  responses.	  
	  
Alternatively,	  additional	  TLR	  agonists	  could	  be	  included	  in	  the	  vaccine.	  The	  use	  of	  3	  TLR	  agonists	  (ligands	  
for	  TLRs	  2,	  3	  and	  9)	   in	  the	  adjuvant	  cocktail	  has	  been	  explored	  in	  the	  context	  of	  vaccination	  against	  HIV	  
envelope	   protein	   in	   a	   mouse	   model	   and	   appeared	   to	   improve	   the	   quality	   (functional	   avidity	   of	   the	  
response	   enabling	   viral	   clearance)	   rather	   than	   the	   magnitude	   of	   the	   response351.	   The	   inclusion	   of	   an	  
additional	  TLR	  agonist	  that	  binds	  other	  receptors	  to	  synergise	  through	  alternative	  signalling	  pathways	  to	  
activate	   transcription	   is	   also	  attractive.	  TLR5	  has	  garnered	  particular	  enthusiasm	  as	  a	   target,	   as	   its	  only	  
known	   ligand	   is	   an	   exogenously-­‐derived	   microbial	   component	   (flagellin,	   derived	   from	   the	   flagellae	   of	  
microbes	  such	  as	  salmonella	  spp).	  Vaccination	  of	  mice	  with	  tumour	  cells	  genetically	  modified	  to	  express	  
flagellin	   permitted	   rejection	   of	   the	   parental	   tumour	   through	   activation	   of	   CD8+	   and	   CD4+	   T-­‐cell	  
responses.	  Flagellin	  mediated	   its	  effects	  by	  activating	  DCs	  through	   ligation	  of	  TLR5	  and	  members	  of	   the	  
Nod-­‐like	  receptor	  (NLR)	  family,	  NLRC4	  and	  NAIP5	  (neuronal	  apoptosis	  inhibitory	  protein	  5)352.	  Recently,	  a	  
modified	   version	   of	   flagellin	   administered	   intravenously	   in	   a	   murine	   model	   of	   lymphoma	   permitted	  
rejection	  of	  established	  tumour353.	  Combination	  of	  this	  product	  within	  the	  CASAC	  cocktail	  could	  synergise	  
with	  other	  TLR	  signalling	  pathways	  to	  increase	  efficacy.	  
	  
A	   further	   consideration	   is	   delivery	   of	   the	   vaccine	   components	   to	   DCs354.	   The	   study	   using	   flagellin	   in	   a	  
whole	  cell	  vaccine	  demonstrated	  that	  only	  flagellin	  within	  the	  irradiated	  tumour	  cell	  vaccine,	  as	  opposed	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to	   recombinant	   flagellin	   co-­‐administered	  with	   irradiated	   tumour	   cells,	   could	  effectively	  prolong	   survival	  
and	   elicit	   an	   adaptive	   immune	   response	   in	   mice352.	   An	   explanation	   could	   be	   requirement	   for	   the	   TLR	  
agonist	   and	   LAA(s)	   to	   be	   present	   within	   the	   same	   phagosome	   to	   signal	   through	   receptors	   within	   that	  
particular	  phagosome.	  This	  results	  in	  loading	  of	  selected	  peptides	  from	  the	  antigen	  of	  interest	  onto	  Class	  
II	  molecules	  for	  cross-­‐presentation355.	  This	  process,	  termed	  “associative	  recognition”	  of	  the	  antigen	  with	  
PAMPs,	   suggests	   that	   physical	   linking	   of	   the	   LAA	   to	   a	   TLR	  may	  be	   important	   to	   effectively	   prime	   T-­‐cell	  
responses352,355,356.	   Covalent	   linking	  of	   TLR	  agonists	   such	  as	  CpG	  ODN	   to	   immunising	  peptides	  has	  been	  
shown	   to	   improve	   immunogenicity357.	   This	   may	   be	   more	   straightforward	   to	   achieve	   in	   the	   context	   of	  
immunisation	  using	  a	  single	  epitope	  but	  more	  complex	  if	  a	  multi-­‐epitope	  vaccine	  such	  as	  the	  overlapping	  
WT1	  peptide	  pool	   is	   used	   for	   vaccination.	  Alternatively,	   delivery	   of	   peptides	   and	   adjuvant	   components	  
within	  liposomes	  may	  avoid	  the	  need	  for	  conjugation	  but	  still	  enhance	  delivery	  of	  antigen	  and	  PAMPs	  to	  
the	   same	   endosomal	   compartment358.	   More	   recent	   advances	   in	   vaccine	   design	   have	   explored	   the	  
potential	   for	   nanoparticles/microparticles	   engineered	   to	   contain	   antigen	   and	   adjuvants,	   essentially	  
mimicking	  microbial	   structures	   and	   effectively	   triggering	   DC	   activation	   following	   uptake,	  with	   resultant	  
cross-­‐presentation	  to	  T-­‐cells359.	  	  
	  
The	   strategies	   described	   above	   suggest	   ways	   to	   provide	   additional	   positive	   signals	   to	   drive	   immune	  
response	  induction	  with	  CASAC.	  Strategies	  to	  reduce	  or	  eliminate	  negative,	  regulatory	  influences	  limiting	  
immune	  response	  induction	  should	  also	  be	  studied	  in	  combination	  with	  CASAC.	  This	  may	  prove	  to	  be	  the	  
most	  effective	  means	  to	  augment	  induction	  of	  T-­‐cell	  responses	  against	  a	  self-­‐antigen	  such	  as	  WT1,	  given	  
that	   tolerance	  mechanisms	  will	  be	  present	   to	  control	  WT1-­‐specific	  T-­‐cell	   reactivity.	  As	  discussed	  above,	  
future	  studies	  should	   include	  investigation	  of	  the	  absolute	  numbers	  and	  frequencies	  of	  Tregs	  relative	  to	  
effector	   T-­‐cells	   in	   the	   draining	   lymph	   nodes	   of	   vaccination	   sites.	   Subsequent	   in	   vitro	   culture	   of	   lymph	  
node-­‐derived	   cells	  with	   immunising	  WT1	  peptides	   could	   identify	   antigen	   specific	   proliferation	   of	   Tregs.	  
Co-­‐culture	   of	   these	   Tregs	   with	   effector	   T-­‐cells	   would	   determine	   if	   they	   are	   capable	   of	   suppressing	  
proliferation	  of	  WT1-­‐specific	  T-­‐cell	  responses.	  Not	  only	  could	  repeated	  exposure	  to	  WT1	  Class	  II	  peptides	  
stimulate	  Treg	  expansion,	  there	  is	  also	  evidence	  that	  activation	  of	  DCs,	  for	  example	  by	  TLR	  agonists,	  can	  
result	  in	  their	  increased	  expression	  of	  indoleamine	  oxygenase	  (IDO)360.	  Exposure	  to	  IFNα	  and	  IFNγ	  can	  also	  
result	   in	   increased	   expression	   of	   IDO	   by	   DCs	   that	   acquire	   immunoregulatory	   function,	   suppressing	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effector	   T-­‐cells	   and	   inducing/activating	   Tregs361.	   One	   way	   to	   determine	   if	   this	   is	   the	   case	   following	  
repeated	  CASAC	  vaccination	  could	  be	  to	  quantify	  IDO	  expression	  in	  DCs	  within	  the	  draining	  lymph	  nodes	  
in	  vaccinated	   recipients	   relative	   to	  controls	   (and	   responders	  versus	  non-­‐responders)362.	   In	   combination,	  
increased	  IDO	  transcripts	  and	  Treg	  frequencies	  would	  provide	  a	  rationale	  for	   IDO	  inhibition	  and/or	  Treg	  
depletion.	  Administration	  of	  1-­‐methyl	  tryptophan	  (1-­‐MT)	  is	  being	  explored	  as	  a	  cancer	  therapy	  due	  to	  its	  
ability	  to	  inhibit	  IDO361,363.	  Co-­‐administration	  of	  1-­‐MT	  along	  with	  vaccination	  might	  therefore	  increase	  the	  
efficacy	  of	  CASAC	  vaccinations	  targeting	  WT1.	  
	  
An	   alternative	   to	   IDO	   inhibition	   is	   depletion	  of	   Tregs.	   Administration	  of	   an	   anti-­‐CD25	   antibody	  prior	   to	  
therapeutic	   vaccination	  with	   tumour	   peptide-­‐loaded	   DCs	   in	   a	  murine	   leukaemia	  model	  was	   associated	  
with	   greater	   survival,	   compared	   to	   that	   observed	   in	  mice	   immunised	  without	   anti-­‐CD25	   antibody	   pre-­‐
treatment364.	  The	  use	  of	  CD25-­‐depleting	  antibodies	  or	  low	  dose	  cyclophosphamide	  to	  diminish	  regulatory	  
T-­‐cell	   activity	   may	   be	   a	   further	   means	   to	   boost	   vaccination	   responses.	   WT1-­‐specific	   Tregs	   have	   been	  
observed	   in	   the	   peripheral	   blood	   of	   patients	   with	   AML	   and	   have	   been	   expanded	   in	   vitro	   by	   culturing	  
healthy	  donor	  PBMCs	  with	  WT1	  peptides365.	  Therefore	  in	  the	  context	  of	  CASAC	  and	  WT1	  vaccinations	  as	  
immunotherapy	   for	   AML,	   not	   only	   would	   avoidance	   of	   inducing	   WT1-­‐specific	   Tregs	   by	   repeated	  
vaccination	  be	  relevant,	  elimination	  of	  existing	  WT1-­‐specific	  Tregs	  may	  also	  be	  necessary.	  Indeed,	  higher	  
frequencies	   of	   total	   peripheral	   blood	   Tregs	   have	   been	   reported	   in	  AML	  patients	   relative	   to	   controls366,	  
suggesting	   that	   Treg	   depletion	   is	   particularly	   relevant	   for	   immunotherapy	   of	   AML	   patients367-­‐369.	   The	  
finding	  that	  low	  dose	  cyclophosphamide	  therapy	  in	  a	  murine	  breast	  cancer	  model	  facilitated	  expansion	  of	  
high	   avidity	   T-­‐cells	   specific	   for	   human	   epidermal	   growth	   factor	   receptor	   2	   (her2),	   through	   depletion	   of	  
Tregs,	  is	  particularly	  tantalising57.	  Immunisation	  could	  combine	  with	  Treg	  depletion	  to	  expand	  high	  avidity	  
tumour-­‐reactive	  T-­‐cells.	  	  
	  
Lastly,	   blocking	   antibodies	   to	   immune	   regulatory	   receptors	   such	   as	   CTLA-­‐4109	   and	   PD-­‐1370	   (or	   its	   ligand	  
PDL-­‐1371)	   have	   already	   shown	  promise	   in	   clinical	   trials	   of	   immunotherapy	   for	   a	   variety	  of	  malignancies.	  
Indeed	   dual	   blockade	   of	   CTLA-­‐4	   and	   PD-­‐1	   has	   recently	   been	   evaluated	   in	   a	   Phase	   I	   clinical	   trial	   of	  
melanoma,	  showing	  objective	  responses	  in	  over	  40%	  of	  patients	  and	  an	  acceptable	  side	  effect	  profile372.	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Whether	  cancer	  vaccinations	  may	  synergise	  with	  these	  antibodies	  to	  promote	  priming	  and	  amplification	  
of	  tumour-­‐specific	  T-­‐cell	  responses	  is	  an	  approach	  that	  is	  being	  explored	  in	  clinical	  trials373.	  In	  the	  context	  
of	   AML,	   murine	   models	   have	   already	   implicated	   PD-­‐1/PDL-­‐1	   interactions	   in	   the	   impaired	   immune	  
response	  to	  leukaemia374,375.	  Therefore	  combining	  CASAC	  vaccinations	  against	  WT1	  with	  exposure	  to	  anti-­‐
CTLA-­‐4	  and/or	  anti-­‐PD1	  antibodies	  may	  promote	   induction	  of	  WT1-­‐specific	  T-­‐cell	   responses.	  This	  should	  
be	  considered	  upon	  translation	  to	  the	  setting	  of	  therapeutic	  vaccination	  in	  a	  tumour	  model.	  The	  optimal	  
timing	   and	   sequence	   of	   exposure	   to	   the	   vaccine	   and	   anti-­‐CTLA-­‐4/anti-­‐PD1	   antibodies	   would	   need	   full	  
investigation	  in	  order	  to	  allow	  these	  approaches	  to	  synergise	  effectively.	  
	  
When	   the	   rate	   and	   magnitude	   of	   immune	   response	   induction	   in	   non-­‐tumour	   bearing	   mice	   has	   been	  
improved,	   efficacy	  of	  CASAC	  and	  WT1	  vaccinations	   should	  be	  assessed	   in	   a	  murine	  model	  of	  AML.	   The	  
C57BL/6	   derived	  WT1+	   AML	   cell	   line	   FBL-­‐3	   could	   serve	   as	   a	   suitable	   pre-­‐clinical	  model	   to	   assess	   both	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